Down	O
-	O
regulation	O
of	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
4	I-Protein
gene	O
expression	O
in	O
leukemic	O
cells	O
due	O
to	O
hypermethylation	O
of	O
CpG	O
motifs	O
in	O
the	O
promoter	O
region	O

Although	O
the	O
bcr	B-Protein
-	O
abl	B-Protein
translocation	O
has	O
been	O
shown	O
to	O
be	O
the	O
causative	O
genetic	O
aberration	O
in	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
,	O
there	O
is	O
mounting	O
evidence	O
that	O
the	O
deregulation	O
of	O
other	O
genes	O
,	O
such	O
as	O
the	O
transcription	O
factor	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
4	I-Protein
(	O
IRF	B-Protein
-	I-Protein
4	I-Protein
)	O
,	O
is	O
also	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
CML	O
.	O

Promoter	O
methylation	O
of	O
CpG	O
target	O
sites	O
or	O
direct	O
deletions	O
/	O
insertions	O
of	O
genes	O
are	O
mechanisms	O
of	O
a	O
reversible	O
or	O
permanent	O
silencing	O
of	O
gene	O
expression	O
,	O
respectively	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
or	O
mutation	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
cells	O
.	O

Whereas	O
promoter	O
mutations	O
or	O
structural	O
rearrangements	O
could	O
be	O
excluded	O
as	O
a	O
cause	O
of	O
altered	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
hematopoietic	O
cells	O
,	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
status	O
was	O
found	O
to	O
significantly	O
influence	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcription	O
.	O

First	O
,	O
treatment	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
lymphoid	O
,	O
myeloid	O
and	O
monocytic	O
cell	O
lines	O
with	O
the	O
methylation	O
-	O
inhibitor	O
5	O
-	O
aza	O
-	O
2	O
-	O
deoxycytidine	O
resulted	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
increase	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
mRNA	O
and	O
protein	O
levels	O
.	O

Second	O
,	O
using	O
a	O
restriction	O
-	O
PCR	O
-	O
assay	O
and	O
bisulfite	O
-	O
sequencing	O
we	O
identified	O
specifically	O
methylated	O
CpG	O
sites	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
but	O
not	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cells	O
.	O

Third	O
,	O
we	O
clearly	O
determined	O
promoter	O
methylation	O
as	O
a	O
mechanism	O
for	O
IRF	B-Protein
-	I-Protein
4	I-Protein
down	O
-	O
regulation	O
via	O
reporter	O
gene	O
assays	O
,	O
but	O
did	O
not	O
detect	O
an	O
association	O
of	O
methylational	O
status	O
and	O
mRNA	O
expression	O
of	O
DNA	O
methyltransferases	O
or	O
methyl	O
-	O
CpG	O
-	O
binding	O
proteins	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
CpG	O
site	O
-	O
specific	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
as	O
a	O
putative	O
mechanism	O
of	O
down	O
-	O
regulated	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
.	O

Chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
is	O
a	O
clonal	O
myeloproliferative	O
disorder	O
with	O
a	O
typical	O
three	O
phased	O
course	O
(	O
chronic	O
,	O
accelerated	O
and	O
blastic	O
phase	O
)	O
reflecting	O
the	O
loss	O
of	O
differentiation	O
and	O
malignant	O
progress	O
which	O
inevitably	O
leads	O
to	O
death	O
after	O
the	O
blastic	O
phase	O
(	O
1	O
,	O
2	O
)	O
.	O

The	O
hallmark	O
genetic	O
aberration	O
of	O
CML	O
is	O
a	O
reciprocal	O
chromosomal	O
translocation	O
t	O
(	O
9	O
;	O
22	O
)	O
leading	O
to	O
expression	O
of	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
fusion	I-Protein
gene	I-Protein
,	O
an	O
aberrant	O
activated	O
tyrosine	O
kinase	O
(	O
2	O
)	O
.	O

Treatment	O
with	O
interferon	B-Protein
alpha	I-Protein
(	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
)	O
prolongs	O
survival	O
of	O
CML	O
patients	O
and	O
is	O
associated	O
with	O
a	O
complete	O
cytogenetic	O
response	O
in	O
5	O
-	O
33	O
%	O
of	O
CML	O
patients	O
(	O
1	O
,	O
2	O
)	O
.	O

Recently	O
,	O
we	O
described	O
an	O
impaired	O
expression	O
of	O
the	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
4	I-Protein
(	O
IRF	B-Protein
-	I-Protein
4	I-Protein
)	O
in	O
CML	O
,	O
correlating	O
with	O
poor	O
response	O
to	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
treatment	O
(	O
3	O
)	O
.	O

The	O
cause	O
of	O
the	O
silencing	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
level	O
remained	O
unclear	O
.	O

Interferon	O
regulatory	O
factors	O
(	O
IRFs	O
)	O
are	O
a	O
family	O
of	O
transcriptional	O
regulators	O
defined	O
by	O
a	O
characteristic	O
homology	O
in	O
their	O
DNA	O
-	O
binding	O
domain	O
.	O

They	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
various	O
genes	O
(	O
such	O
as	O
IFNs	O
,	O
interleukins	O
,	O
MHC	O
class	O
I	O
/	O
II	O
)	O
,	O
apoptosis	O
and	O
differentiation	O
/	O
maturation	O
(	O
4	O
-	O
6	O
)	O
.	O

IRF	B-Protein
-	I-Protein
4	I-Protein
(	O
ICSAT	B-Protein
/	O
Pip	B-Protein
/	O
MUM1	B-Protein
/	O
LSIRF	B-Protein
)	O
is	O
one	O
member	O
with	O
very	O
restricted	O
expression	O
pattern	O
:	O
Predominately	O
B	O
-	O
and	O
activated	O
T	O
-	O
lymphocytes	O
are	O
IRF	B-Protein
-	I-Protein
4	I-Protein
positive	O
(	O
7	O
-	O
11	O
)	O
.	O

In	O
contrast	O
to	O
other	O
IRFs	O
,	O
expression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
cannot	O
be	O
induced	O
by	O
IFNs	O
,	O
but	O
by	O
antigen	O
stimulation	O
,	O
crosslinking	O
of	O
T	O
-	O
or	O
B	O
-	O
cell	O
receptors	O
or	O
phorbol	O
-	O
myristate	O
-	O
acetate	O
(	O
10	O
,	O
11	O
)	O
.	O

Consistent	O
with	O
the	O
restriction	O
of	O
expression	O
to	O
immunocompetent	O
cells	O
,	O
mice	O
with	O
deletion	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
failed	O
to	O
develop	O
mature	O
and	O
functionally	O
active	O
B	O
-	O
and	O
T	O
-	O
lymphocytes	O
(	O
12	O
)	O
,	O
and	O
the	O
impaired	O
expression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
in	O
CML	O
was	O
predominately	O
found	O
in	O
T	O
-	O
cells	O
(	O
3	O
)	O
.	O

These	O
data	O
suggest	O
a	O
crucial	O
role	O
for	O
IRF	B-Protein
-	I-Protein
4	I-Protein
in	O
the	O
function	O
of	O
immune	O
cells	O
.	O

Methylation	O
of	O
dinucleotide	O
cytosine	O
-	O
guanosine	O
motifs	O
(	O
CpG	O
)	O
,	O
especially	O
in	O
CpG	O
islands	O
located	O
in	O
promoter	O
regions	O
,	O
is	O
one	O
of	O
the	O
mechanisms	O
of	O
gene	O
regulation	O
in	O
mammals	O
and	O
a	O
common	O
event	O
of	O
gene	O
silencing	O
in	O
human	O
neoplasias	O
(	O
13	O
,	O
14	O
)	O
.	O

As	O
opposed	O
to	O
normal	O
cells	O
,	O
hypermethylation	O
of	O
CpG	O
islands	O
is	O
a	O
frequently	O
observed	O
phenomenon	O
in	O
every	O
cancer	O
type	O
.	O

De	O
novo	O
DNA	O
methylation	O
of	O
genes	O
such	O
as	O
cell	O
cycle	O
,	O
DNA	O
repair	O
,	O
apoptosis	O
and	O
tumor	O
suppressor	O
genes	O
is	O
therefore	O
thought	O
to	O
be	O
involved	O
in	O
tumorigenesis	O
(	O
15	O
-	O
17	O
)	O
.	O

Examples	O
for	O
such	O
aberrated	O
genes	O
are	O
MGMT	B-Protein
,	O
DAPK	B-Protein
,	O
p14ARF	B-Protein
,	O
p15INK4b	B-Protein
,	O
p16INK4a	B-Protein
,	O
BRCA1	B-Protein
,	O
CDH13	B-Protein
and	O
APAF	B-Protein
-	I-Protein
1	I-Protein
(	O
17	O
-	O
19	O
)	O
.	O

In	O
CML	O
,	O
methylation	O
is	O
known	O
to	O
regulate	O
expression	O
of	O
the	O
c	B-Protein
-	I-Protein
abl	I-Protein
,	O
the	O
bcr	B-Protein
gene	O
and	O
others	O
(	O
20	O
-	O
23	O
)	O
,	O
and	O
the	O
extent	O
of	O
methylation	O
in	O
the	O
c	B-Protein
-	I-Protein
abl	I-Protein
promoter	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
advanced	O
disease	O
(	O
24	O
)	O
.	O

Hypermethylation	O
due	O
to	O
overexpression	O
of	O
DNA	O
methyltransferases	O
(	O
DNMTs	O
)	O
remains	O
one	O
possible	O
explanation	O
for	O
de	O
novo	O
methylation	O
in	O
tumorigenesis	O
.	O

Recently	O
,	O
DNMTs	O
have	O
been	O
shown	O
to	O
be	O
up	O
-	O
regulated	O
in	O
hematopoietic	O
malignancies	O
(	O
25	O
)	O
.	O

Methyl	O
-	O
CpG	O
-	O
binding	O
proteins	O
(	O
MBPs	O
)	O
are	O
thought	O
to	O
inhibit	O
the	O
binding	O
of	O
transcriptional	O
factors	O
to	O
the	O
promoter	O
and	O
are	O
therefore	O
discussed	O
as	O
one	O
mechanism	O
of	O
transcription	O
inhibition	O
by	O
hypermethylation	O
(	O
26	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
mechanisms	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
gene	O
expression	O
silencing	O
in	O
leukemic	O
cells	O
.	O

We	O
analyzed	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
region	O
for	O
genetic	O
aberrations	O
and	O
methylational	O
status	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
hematopoietic	O
cells	O
.	O

Cell	O
lines	O

K	O
-	O
562	O
,	O
Jurkat	O
and	O
U	O
-	O
937	O
were	O
obtained	O
from	O
the	O
ATCC	O
(	O
American	O
Type	O
Culture	O
Collection	O
,	O
Rockville	O
,	O
USA	O
)	O
and	O
EM	O
-	O
2	O
,	O
LAMA	O
-	O
84	O
,	O
CML	O
-	O
T1	O
,	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
from	O
the	O
DSMZ	O
(	O
Deutsche	O
Sammlung	O
von	O
Mikroorganismen	O
und	O
Zellkulturen	O
GmbH	O
,	O
Braunschweig	O
,	O
Germany	O
)	O
.	O

All	O
cell	O
lines	O
,	O
except	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
,	O
were	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
.	O

Cell	O
culture	O
and	O
stimulation	O

All	O
cell	O
lines	O
were	O
maintained	O
at	O
5	O
%	O
CO2	O
in	O
RPMI	O
1640	O
medium	O
with	O
1	O
%	O
glutamine	O
(	O
Gibco	O
/	O
BRL	O
Eggenstein	O
,	O
Germany	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
Gibco	O
/	O
BRL	O
)	O
,	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
(	O
Biochrom	O
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

When	O
indicated	O
,	O
cells	O
were	O
treated	O
with	O
5	O
-	O
aza	O
-	O
2	O
-	O
deoxycytidine	O
(	O
AzadC	O
)	O
or	O
5	O
-	O
azacytidine	O
(	O
AzaC	O
)	O
(	O
Sigma	O
,	O
Taufkirchen	O
,	O
Germany	O
)	O
for	O
different	O
time	O
periods	O
.	O

Owing	O
to	O
their	O
chemical	O
instability	O
fresh	O
substances	O
were	O
re	O
-	O
added	O
every	O
24	O
h	O
.	O

Sequencing	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O

For	O
analysis	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
region	O
for	O
permanent	O
aberrations	O
such	O
as	O
insertions	O
/	O
deletions	O
or	O
mutation	O
,	O
we	O
PCR	O
-	O
amplified	O
two	O
fragments	O
from	O
genomic	O
DNA	O
,	O
which	O
was	O
extracted	O
from	O
depicted	O
cell	O
lines	O
with	O
a	O
commercial	O
kit	O
(	O
Qiagen	O
,	O
Hilde	O
,	O
Germany	O
)	O
as	O
recommended	O
.	O

The	O
primers	O
were	O
1	O
-	O
forward	O
:	O
5	O
'	O
-	O
TTGAGATGGAGTCTTGCTCTGT	O
-	O
3	O
'	O
,	O
1	O
-	O
reverse	O
:	O
5	O
'	O
-	O
CCAGGACCTCAGGAGGCCAGTCA	O
-	O
3	O
'	O
;	O
2	O
-	O
forward	O
:	O
5	O
'	O
-	O
AGCGGTGAAACTGAGAGTGCGAGGT	O
-	O
3	O
'	O
,	O
2	O
-	O
reverse	O
:	O
5	O
'	O
-	O
GCCACATCGCTGCAGTTTAG	O
-	O
3	O
'	O
.	O

The	O
products	O
were	O
cloned	O
with	O
the	O
'	O
TOPO	O
TA	O
cloning	O
kit	O
'	O
(	O
Invitrogen	O
,	O
Groningen	O
,	O
The	O
Netherlands	O
)	O
.	O

After	O
bacterial	O
amplification	O
of	O
the	O
cloned	O
PCR	O
fragments	O
by	O
standard	O
procedures	O
,	O
at	O
least	O
three	O
clones	O
from	O
each	O
sample	O
were	O
sequenced	O
with	O
an	O
automated	O
sequencer	O
(	O
ABI	O
Prism	O
377	O
,	O
Applied	O
Bio	O
-	O
systems	O
,	O
Foster	O
City	O
,	O
USA	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

Expression	O
analysis	O

To	O
analyze	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcriptional	O
level	O
,	O
RNA	O
was	O
extracted	O
from	O
cells	O
using	O
the	O
commercial	O
RNAzol	O
-	O
kit	O
(	O
Paesel	O
,	O
Frankfurt	O
,	O
Germany	O
)	O
.	O

An	O
aliquot	O
of	O
1	O
mug	O
total	O
RNA	O
was	O
used	O
for	O
cDNA	O
synthesis	O
as	O
described	O
previously	O
(	O
27	O
)	O
.	O

RNA	O
expression	O
analysis	O
for	O
IRF	B-Protein
-	I-Protein
4	I-Protein
and	O
the	O
reference	O
gene	O
beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
carried	O
out	O
by	O
semi	O
-	O
quantitative	O
PCR	O
as	O
described	O
previously	O
(	O
3	O
,	O
27	O
)	O
.	O

PCR	O
products	O
were	O
verified	O
by	O
automated	O
sequencing	O
.	O

PCR	O
primers	O
and	O
conditions	O
for	O
expression	O
analysis	O
of	O
DNMT	O
or	O
MBP	O
(	B-Protein
DNMT1	I-Protein
DNMT3A	B-Protein
,	O
DNMT3B	B-Protein
,	O
MeCP	B-Protein
,	O
MBD1	B-Protein
,	O
MBD2	B-Protein
and	O
MBD4	B-Protein
)	O
were	O
published	O
elsewhere	O
(	O
28	O
)	O
.	O

For	O
analysis	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
protein	O
expression	O
,	O
a	O
standard	O
immunoblotting	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
(	O
29	O
)	O
.	O

Briefly	O
,	O
protein	O
lysates	O
were	O
generated	O
by	O
incubating	O
1	O
x	O
106	O
cells	O
in	O
100	O
microl	O
RIPA	O
buffer	O
(	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
5	O
%	O
sodiumdesoxycholate	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
100	O
microg	O
/	O
ml	O
phenylmethylsulfonyl	O
fluoride	O
,	O
10	O
microl	O
/	O
ml	O
protease	O
-	O
inhibitory	O
-	O
mix	O
,	O
1	O
micromol	O
/	O
ml	O
sodiumorthovanadate	O
in	O
phosphate	O
-	O
buffered	O
saline	O
)	O
for	O
30	O
min	O
on	O
ice	O
.	O

After	O
centrifugation	O
,	O
protein	O
concentration	O
of	O
the	O
supernatant	O
was	O
determined	O
by	O
BCA	O
-	O
method	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
as	O
recommended	O
.	O

Protein	O
lysates	O
(	O
70	O
-	O
100	O
microg	O
)	O
were	O
electrophoresed	O
on	O
polyacrylamide	O
gels	O
and	O
transferred	O
to	O
a	O
PVDF	O
-	O
membrane	O
(	O
Immobilon	O
P	O
,	O
0	O
.	O
45	O
microm	O
;	O
Millipore	O
,	O
Eschborn	O
,	O
Germany	O
)	O
.	O

Membranes	O
were	O
blocked	O
with	O
2	O
.	O
5	O
%	O
blocking	O
reagent	O
(	O
Boehringer	O
Mannheim	O
,	O
Germany	O
)	O
in	O
TBST	O
buffer	O
(	O
4	O
.	O
44	O
g	O
/	O
l	O
Tris	O
-	O
HCL	O
,	O
2	O
.	O
65	O
g	O
/	O
l	O
TrisOH	O
,	O
8	O
.	O
07	O
g	O
/	O
l	O
NaCl	O
,	O
0	O
.	O
2	O
g	O
/	O
l	O
KCl	O
and	O
500	O
microl	O
/	O
l	O
Tween	O
-	O
20	O
in	O
H2O	O
)	O
and	O
subsequently	O
incubated	O
with	O
primary	O
antibody	O
as	O
indicated	O
and	O
horseradish	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibody	O
,	O
anti	O
-	O
mouse	O
or	O
anti	O
-	O
goat	O
IgG	O
(	O
DAKO	O
,	O
Hamburg	O
,	O
Germany	O
)	O
,	O
respectively	O
.	O

The	O
membranes	O
were	O
then	O
developed	O
with	O
an	O
ECL	O
detection	O
kit	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Freiburg	O
,	O
Germany	O
)	O
.	O

The	O
primary	O
antibodies	O
were	O
goat	O
anti	O
-	O
IRF	B-Protein
-	I-Protein
4	I-Protein
/	O
ICSAT	B-Protein
(	O
M	B-Protein
-	I-Protein
17	I-Protein
)	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
and	O
mouse	O
anti	O
-	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
AC	O
-	O
74	O
)	O
(	O
Sigma	O
)	O
.	O

Methylation	O
-	O
specific	O
restriction	O
-	O
PCR	O
-	O
assay	O

DNA	O
was	O
extracted	O
with	O
a	O
commercial	O
kit	O
(	O
Qiagen	O
)	O
as	O
recommended	O
.	O

Since	O
the	O
restriction	O
ability	O
of	O
several	O
endonucleases	O
is	O
inhibited	O
by	O
methylation	O
of	O
their	O
target	O
sequence	O
,	O
we	O
used	O
methylation	O
-	O
sensitive	O
enzymes	O
HpaII	O
and	O
HaeII	O
-	O
isochizomer	O
Bsp143II	O
and	O
Bsh1236I	O
(	O
MBI	O
Fermentas	O
,	O
St	O
Leon	O
-	O
Rot	O
,	O
Germany	O
)	O
(	O
20	O
,	O
24	O
)	O
.	O

As	O
control	O
the	O
methylation	O
-	O
resistant	O
enzyme	O
MspI	O
and	O
an	O
enzyme	O
with	O
no	O
recognition	O
site	O
in	O
the	O
target	O
promoter	O
,	O
EcoRI	O
,	O
were	O
used	O
.	O

DNA	O
(	O
0	O
.	O
8	O
microg	O
)	O
was	O
digested	O
by	O
40	O
U	O
the	O
respective	O
enzyme	O
for	O
6	O
h	O
and	O
,	O
to	O
ensure	O
complete	O
cleavage	O
,	O
additional	O
20	O
U	O
for	O
16	O
h	O
.	O

Thereafter	O
100	O
ng	O
of	O
digested	O
DNA	O
was	O
used	O
to	O
a	O
PCR	O
amplification	O
of	O
two	O
fragments	O
(	O
F1	O
and	O
F2	O
)	O
spanning	O
part	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
(	O
30	O
)	O
(	O
GenBank	O
U52683	O
;	O
see	O
Figure	O
3A	O
)	O
.	O

The	O
sequences	O
of	O
the	O
primers	O
were	O
F1	O
-	O
forward	O
:	O
5	O
'	O
-	O
TTGAGATGGAGTCTTGCTCTGT	O
-	O
3	O
'	O
,	O
F1	O
-	O
reverse	O
:	O
ATCACTTCCAGACTTCAGTTCACCT	O
-	O
3	O
'	O
(	O
341	O
bp	O
)	O
;	O
F2	O
-	O
forward	O
:	O
5	O
'	O
-	O
AAGGTGAACTGAAGTCTGGAAGTGA	O
-	O
3	O
'	O
,	O
F2	O
-	O
reverse	O
:	O
5	O
'	O
-	O
CCAGGACCTCAGGAGGCCAGTCA	O
-	O
3	O
'	O
(	O
474	O
bp	O
)	O
.	O

The	O
PCR	O
conditions	O
were	O
described	O
elsewhere	O
(	O
3	O
)	O
.	O

PCR	O
was	O
performed	O
with	O
an	O
annealing	O
temperature	O
of	O
62degreesC	O
and	O
35	O
cycles	O
.	O

When	O
DNA	O
was	O
methylated	O
at	O
specific	O
sites	O
,	O
the	O
sensitive	O
enzymes	O
were	O
not	O
able	O
to	O
digest	O
the	O
DNA	O
and	O
amplification	O
took	O
place	O
;	O
in	O
case	O
of	O
no	O
methylation	O
,	O
DNA	O
was	O
digested	O
and	O
no	O
product	O
was	O
generated	O
.	O

The	O
PCR	O
products	O
were	O
electrophoresed	O
on	O
a	O
3	O
%	O
agarose	O
gel	O
,	O
were	O
stained	O
with	O
ethidium	O
bromide	O
and	O
photographed	O
.	O

PCR	O
products	O
were	O
verified	O
by	O
automated	O
sequencing	O
.	O

Bisulfite	O
treatment	O

DNA	O
was	O
extracted	O
as	O
described	O
above	O
.	O

Bisulfite	O
treatment	O
of	O
DNA	O
,	O
leading	O
to	O
conversion	O
of	O
unmethylated	O
cytosine	O
to	O
uracil	O
residues	O
and	O
no	O
change	O
of	O
methylated	O
cytosine	O
residues	O
,	O
was	O
performed	O
as	O
described	O
as	O
follows	O
.	O

Briefly	O
,	O
1	O
microg	O
of	O
DNA	O
and	O
2	O
microg	O
of	O
poly	O
(	O
dA	O
-	O
dT	O
)	O
(	O
poly	O
(	O
dA	O
-	O
dT	O
)	O
copolymers	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
were	O
denaturated	O
for	O
20	O
min	O
at	O
42degreesC	O
in	O
0	O
.	O
3	O
M	O
NaOH	O
in	O
a	O
volume	O
of	O
50	O
microl	O
.	O

Fresh	O
solutions	O
of	O
30	O
microl	O
of	O
10	O
mM	O
hydrochinon	O
(	O
Sigma	O
)	O
and	O
530	O
microl	O
of	O
3	O
M	O
sodium	O
bisulfite	O
(	O
pH	O
5	O
.	O
0	O
;	O
Sigma	O
)	O
were	O
added	O
,	O
the	O
solution	O
was	O
gently	O
mixed	O
,	O
overlayed	O
with	O
mineral	O
oil	O
and	O
incubated	O
in	O
the	O
dark	O
for	O
12	O
-	O
13	O
h	O
at	O
50degreesC	O
.	O

The	O
aqueous	O
phase	O
was	O
recovered	O
using	O
the	O
'	O
Wizard	O
DNA	O
clean	O
-	O
up	O
system	O
'	O
(	O
Promega	O
,	O
Mannheim	O
,	O
Germany	O
)	O
.	O

The	O
purified	O
DNA	O
was	O
subsequently	O
mixed	O
with	O
1	O
M	O
NaOH	O
to	O
a	O
final	O
concentration	O
of	O
0	O
.	O
3	O
M	O
and	O
incubated	O
for	O
20	O
min	O
at	O
37degreesC	O
to	O
ensure	O
complete	O
desulfonisation	O
.	O

DNA	O
was	O
ethanol	O
precipitated	O
in	O
the	O
presence	O
of	O
1	O
/	O
10	O
vol	O
of	O
3	O
M	O
sodium	O
acetate	O
,	O
washed	O
with	O
70	O
%	O
ethanol	O
and	O
resuspended	O
in	O
50	O
microl	O
H2O	O
.	O

Subsequent	O
PCR	O
amplification	O
of	O
4	O
microl	O
bisulfite	O
-	O
treated	O
DNA	O
was	O
used	O
for	O
cloning	O
of	O
two	O
fragments	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
(	O
BS	O
-	O
I	O
and	O
BS	O
-	O
II	O
)	O
into	O
pCR2	O
.	O
1	O
vector	O
with	O
the	O
'	O
TOPO	O
TA	O
cloning	O
kit	O
'	O
(	O
Invitrogen	O
)	O
(	O
see	O
Figure	O
3A	O
)	O
.	O

The	O
primers	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
BS	O
-	O
I	O
and	O
BS	O
-	O
II	O
fragments	O
contain	O
the	O
putative	O
altered	O
sequence	O
of	O
the	O
sense	O
strand	O
due	O
to	O
bisulfite	O
treatment	O
(	O
converted	O
cytosine	O
residues	O
are	O
written	O
in	O
bold	O
letters	O
)	O
:	O
BS	O
-	O
I	O
-	O
forward	O
5	O
'	O
-	O
TATTTGGATTTTTAGGGAGTTTTTTTT	O
-	O
3	O
'	O
,	O
BS	O
-	O
I	O
-	O
reverse	O
5	O
'	O
-	O
ACCCAACTCCCTTAAACTATTAAACT	O
-	O
3	O
'	O
(	O
187	O
bp	O
)	O
;	O
BS	O
-	O
II	O
-	O
forward	O
5	O
'	O
-	O
AGTTTAATAGTTTAAGGGAGTTGGGT	O
-	O
3	O
'	O
,	O
BS	O
-	O
II	O
-	O
reverse	O
5	O
'	O
-	O
CTCACCCTAAACTCAAAACTAAAAAC	O
-	O
3	O
'	O
(	O
674	O
bp	O
)	O
.	O

After	O
bacterial	O
amplification	O
of	O
the	O
cloned	O
PCR	O
fragments	O
by	O
standard	O
procedures	O
,	O
eight	O
clones	O
from	O
each	O
sample	O
were	O
sequenced	O
with	O
an	O
automated	O
sequencer	O
(	O
ABI	O
Prism	O
377	O
,	O
Applied	O
Biosystems	O
)	O
.	O

In	O
vitro	O
methylation	O
and	O
reporter	O
gene	O
assays	O

The	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
-	O
reporter	O
gene	O
construct	O
was	O
generously	O
provided	O
by	O
J	O
.	O

Hiscott	O
(	O
31	O
)	O
.	O

Constructs	O
were	O
methylated	O
in	O
vitro	O
with	O
CpG	B-Protein
Methylase	I-Protein
(	O
M	B-Protein
.	I-Protein
Sss	I-Protein
I	I-Protein
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
NE	O
Biolabs	O
)	O
and	O
complete	O
methylation	O
was	O
checked	O
via	O
restriction	O
analysis	O
(	O
Figure	O
5A	O
)	O
.	O

Reporter	O
gene	O
assays	O
using	O
the	O
dual	O
luciferase	B-Protein
assay	O
(	O
Promega	O
)	O
were	O
performed	O
similar	O
to	O
previous	O
reports	O
(	O
29	O
)	O
.	O

Briefly	O
,	O
5	O
nM	O
of	O
the	O
reporter	O
construct	O
and	O
the	O
transfection	O
control	O
construct	O
expressing	O
the	O
renilla	O
luciferase	B-Protein
gene	O
were	O
transientlyco	O
-	O
expressed	O
via	O
electroporation	O
.	O

The	O
control	O
construct	O
served	O
as	O
an	O
internal	O
reference	O
for	O
transfection	O
efficiency	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
luciferase	B-Protein
activity	O
was	O
measured	O
with	O
a	O
LB	O
96	O
P	O
microlumat	O
(	O
EG	O
&	O
G	O
Berthold	O
,	O
Bad	O
Wildbad	O
,	O
Germany	O
)	O
.	O

IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
activation	O
was	O
quantified	O
as	O
a	O
ratio	O
of	O
measured	O
firefly	O
light	O
units	O
(	O
flu	O
)	O
relative	O
to	O
renilla	O
(	O
rlu	O
)	O
.	O

Each	O
experiment	O
was	O
carried	O
out	O
at	O
least	O
three	O
times	O
.	O

Absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
cells	O
is	O
not	O
due	O
to	O
promoter	O
alterations	O

We	O
have	O
previously	O
demonstrated	O
a	O
lack	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
patients	O
and	O
specifically	O
in	O
CML	O
T	O
-	O
cells	O
(	O
3	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
the	O
absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
various	O
hematopoietic	O
cell	O
lines	O
,	O
such	O
as	O
Jurkat	O
,	O
a	O
T	O
-	O
cell	O
leukemia	O
,	O
CML	O
-	O
T1	O
,	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positive	O
T	O
-	O
cell	O
line	O
,	O
K	O
-	O
562	O
,	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positve	O
erythroleukemia	O
,	O
U	O
-	O
937	O
,	O
a	O
monocytic	O
leukemia	O
,	O
EM	O
-	O
2	O
and	O
LAMA	O
-	O
84	O
,	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positve	O
myeloid	O
leukemia	O
,	O
but	O
not	O
in	O
SD	O
-	O
1	O
,	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positive	O
acute	O
lymphoblastic	O
leukemia	O
(	O
pre	O
B	O
-	O
ALL	O
)	O
,	O
RPMI	O
-	O
8226	O
,	O
a	O
multiple	O
myeloma	O
and	O
BV	O
-	O
173	O
,	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positive	O
B	O
-	O
cell	O
line	O
(	O
Figures	O
1A	O
and	O
5D	O
)	O
.	O

After	O
sequencing	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
,	O
it	O
could	O
be	O
excluded	O
that	O
absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
any	O
of	O
the	O
above	O
cell	O
lines	O
was	O
due	O
to	O
genetic	O
aberrations	O
.	O

However	O
,	O
2	O
bp	O
changes	O
(	O
nucleotide	O
-	O
1081	O
,	O
T	O
to	O
C	O
and	O
-	O
1068	O
,	O
A	O
to	O
C	O
)	O
could	O
be	O
detected	O
in	O
both	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
BV	O
-	O
173	O
and	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
LAMA	O
-	O
84	O
,	O
EM	O
-	O
2	O
and	O
K	O
-	O
562	O
(	O
Figure	O
1B	O
)	O
.	O

At	O
position	O
-	O
116	O
an	O
A	O
to	O
C	O
substitution	O
was	O
found	O
in	O
EM	O
-	O
2	O
,	O
K	O
-	O
562	O
and	O
CML	O
-	O
T1	O
,	O
whereas	O
Jurkat	O
,	O
BV	O
-	O
173	O
and	O
SD	O
-	O
1	O
exhibited	O
a	O
mixed	O
A	O
/	O
C	O
sequence	O
and	O
U	O
-	O
937	O
,	O
LAMA	O
-	O
84	O
and	O
RPMI	O
-	O
8226	O
no	O
substitution	O
at	O
all	O
(	O
Figure	O
1B	O
)	O
.	O

Consequently	O
,	O
these	O
alterations	O
are	O
unlikely	O
to	O
affect	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
.	O

Increase	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
hematopoietic	O
cells	O
after	O
demethylating	O
treatment	O

We	O
next	O
analyzed	O
whether	O
promoter	O
methylation	O
could	O
be	O
responsible	O
for	O
down	O
-	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
.	O

A	O
region	O
including	O
exon1	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
exhibited	O
a	O
large	O
number	O
of	O
CpG	O
-	O
rich	O
sequences	O
(	O
Figure	O
3A	O
)	O
.	O

Several	O
chemical	O
substances	O
such	O
as	O
5	O
-	O
aza	O
-	O
2	O
-	O
deoxycytidine	O
(	O
AzadC	O
)	O
or	O
5	O
-	O
azacytidine	O
(	O
AzaC	O
)	O
inhibit	O
de	O
novo	O
and	O
maintenance	O
methylation	O
,	O
and	O
thus	O
can	O
be	O
used	O
to	O
discern	O
promoter	O
methylation	O
(	O
32	O
,	O
33	O
)	O
.	O

We	O
used	O
AzadC	O
to	O
generate	O
unmethylated	O
DNA	O
.	O

A	O
72	O
h	O
AzadC	O
-	O
treatment	O
resulted	O
in	O
a	O
concentration	O
-	O
dependent	O
activation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcription	O
in	O
Jurkat	O
and	O
CML	O
-	O
T1	O
T	O
-	O
cells	O
as	O
well	O
as	O
in	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cell	O
lines	O
(	O
Figure	O
2A	O
)	O
.	O

IRF	B-Protein
-	I-Protein
4	I-Protein
transcription	O
was	O
induced	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
and	O
was	O
observed	O
as	O
early	O
as	O
24	O
h	O
after	O
treatment	O
with	O
AzadC	O
and	O
increased	O
over	O
time	O
until	O
72	O
h	O
(	O
Figure	O
2B	O
)	O
.	O

Time	O
and	O
strength	O
of	O
the	O
appearance	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcripts	O
varied	O
among	O
cell	O
lines	O
,	O
i	O
.	O
e	O
.	O
CML	O
-	O
T1	O
responded	O
strongest	O
to	O
AzadC	O
-	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
line	O
with	O
this	O
,	O
AzadC	O
-	O
treatment	O
of	O
CML	O
-	O
T1	O
and	O
LAMA	O
-	O
84	O
cells	O
also	O
translated	O
in	O
an	O
induction	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
protein	O
expression	O
(	O
Figure	O
2C	O
)	O
.	O

Accordingly	O
,	O
treatment	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cell	O
line	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
with	O
AzadC	O
had	O
no	O
effect	O
on	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
(	O
Figure	O
2D	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
effects	O
of	O
AzaC	O
versus	O
AzadC	O
,	O
as	O
both	O
increased	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
mRNA	O
level	O
in	O
CML	O
-	O
T1	O
cells	O
as	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
implied	O
that	O
promoter	O
methylation	O
may	O
control	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
,	O
but	O
an	O
alternative	O
explanation	O
may	O
be	O
activation	O
of	O
positive	O
transcriptional	O
regulators	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
by	O
AzadC	O
(	O
or	O
AzaC	O
)	O
.	O

Methylation	O
-	O
sensitive	O
enzymes	O
do	O
not	O
cut	O
specific	O
sites	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
in	O
hematopoietic	O
cells	O

To	O
further	O
investigate	O
promoter	O
methylation	O
as	O
a	O
regulatory	O
mechanism	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
gene	O
expression	O
,	O
restriction	O
-	O
PCR	O
-	O
assays	O
were	O
performed	O
(	O
20	O
,	O
24	O
)	O
,	O
where	O
only	O
methylated	O
DNA	O
would	O
not	O
be	O
cut	O
enabling	O
subsequent	O
PCR	O
amplification	O
and	O
vice	O
versa	O
.	O

Genomic	O
DNA	O
from	O
leukemic	O
cells	O
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
,	O
EM	O
-	O
2	O
and	O
BV	O
-	O
173	O
was	O
digested	O
with	O
the	O
methylation	O
-	O
sensitive	O
enzymes	O
HpaII	O
,	O
Bsh1236I	O
and	O
HaeII	O
-	O
isochizomer	O
Bsp143II	O
.	O

EcoRI	O
,	O
which	O
has	O
no	O
recognition	O
site	O
within	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
,	O
and	O
the	O
methylation	O
-	O
resistant	O
enzyme	O
MspI	O
served	O
as	O
controls	O
.	O

Two	O
separate	O
amplification	O
reactions	O
were	O
performed	O
,	O
generating	O
two	O
fragments	O
,	O
F1	O
and	O
F2	O
(	O
Figure	O
3A	O
)	O
.	O

After	O
digestion	O
with	O
HpaII	O
and	O
Bsp143II	O
a	O
sufficient	O
PCR	O
amplification	O
of	O
F1	O
and	O
F2	O
was	O
detected	O
in	O
DNA	O
from	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cells	O
,	O
suggesting	O
a	O
promoter	O
methylation	O
(	O
and	O
restriction	O
protection	O
)	O
at	O
the	O
respective	O
recognition	O
sites	O
(	O
Figure	O
3B	O
and	O
C	O
)	O
.	O

Notably	O
,	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
SD	O
-	O
1	O
cells	O
digestion	O
with	O
the	O
methylation	O
-	O
sensitive	O
enzymes	O
completely	O
inhibited	O
amplification	O
of	O
F1	O
and	O
F2	O
.	O

In	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
BV	O
-	O
173	O
cells	O
a	O
HpaII	O
,	O
but	O
not	O
a	O
Bsh1236I	O
digestion	O
,	O
significantly	O
reduced	O
the	O
amplifiable	O
DNA	O
message	O
of	O
F2	O
(	O
Figure	O
3C	O
)	O
,	O
whereas	O
amplification	O
of	O
F1	O
was	O
not	O
affected	O
(	O
Figure	O
3B	O
)	O
.	O

This	O
implied	O
that	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcription	O
in	O
SD	O
-	O
1	O
and	O
BV	O
-	O
173	O
cells	O
is	O
associated	O
with	O
less	O
promoter	O
methylation	O
(	O
in	O
BV	O
-	O
173	O
especially	O
at	O
HpaII	O
sites	O
)	O
as	O
compared	O
with	O
the	O
tested	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
cells	O
.	O

Specific	O
CpG	O
sites	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
are	O
methylated	O
in	O
hematopoietic	O
cells	O

In	O
order	O
to	O
exactly	O
map	O
the	O
methylation	O
sites	O
within	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
,	O
we	O
treated	O
DNA	O
of	O
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cells	O
as	O
well	O
as	O
of	O
SD	O
-	O
1	O
,	O
RPMI	O
-	O
8226	O
and	O
BV	O
-	O
173	O
control	O
cells	O
with	O
bisulfite	O
,	O
which	O
chemically	O
converts	O
unmethylated	O
cytosine	O
to	O
uracil	O
,	O
whereas	O
it	O
has	O
no	O
effect	O
on	O
methylated	O
cytosine	O
,	O
i	O
.	O
e	O
.	O
in	O
CpG	O
(	O
34	O
)	O
.	O

This	O
technique	O
is	O
especially	O
useful	O
for	O
detection	O
of	O
unknown	O
methylation	O
patterns	O
.	O

PCR	O
amplification	O
,	O
cloning	O
and	O
sequencing	O
of	O
the	O
bisulfite	O
-	O
treated	O
DNA	O
showed	O
a	O
specific	O
methylation	O
pattern	O
of	O
the	O
analyzed	O
62	O
CpG	O
sites	O
in	O
all	O
cell	O
lines	O
(	O
Figure	O
4	O
and	O
Table	O
1	O
)	O
.	O

In	O
general	O
,	O
the	O
methylational	O
status	O
ranged	O
from	O
one	O
cell	O
line	O
with	O
a	O
nearly	O
non	O
-	O
methylated	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
(	O
SD	O
-	O
1	O
,	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
)	O
to	O
a	O
completely	O
methylated	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
in	O
CML	O
-	O
T1	O
(	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
)	O
.	O

Interestingly	O
,	O
the	O
percentage	O
of	O
CpG	O
methylation	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
from	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cells	O
was	O
very	O
low	O
(	O
mean	O
24	O
%	O
)	O
as	O
compared	O
with	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
cells	O
(	O
mean	O
94	O
%	O
)	O
(	O
Figure	O
4A	O
and	O
Table	O
1	O
)	O
.	O

A	O
5	O
'	O
-	O
region	O
(	O
R1	O
)	O
with	O
13	O
hypermethylated	O
CpG	O
sites	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
5	O
.	O
5	O
of	O
8	O
with	O
77	O
%	O
methylated	O
CpGs	O
)	O
was	O
found	O
in	O
most	O
cells	O
(	O
except	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
)	O
and	O
a	O
3	O
'	O
-	O
region	O
(	O
R3	O
)	O
of	O
6	O
hypomethylated	O
CpG	O
sites	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
1	O
.	O
7	O
of	O
8	O
with	O
33	O
%	O
methylated	O
CpGs	O
)	O
was	O
found	O
in	O
most	O
cells	O
(	O
except	O
CML	O
-	O
T1	O
and	O
U	O
-	O
937	O
)	O
(	O
Figure	O
4A	O
and	O
Table	O
1	O
)	O
.	O

Intriguingly	O
,	O
a	O
stretch	O
of	O
13	O
CpG	O
sites	O
(	O
#	O
10	O
-	O
22	O
;	O
R2	O
)	O
was	O
detected	O
in	O
between	O
these	O
regions	O
,	O
which	O
were	O
highly	O
methylated	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
7	O
.	O
1	O
of	O
8	O
with	O
89	O
%	O
methylated	O
CpGs	O
)	O
but	O
totally	O
non	O
-	O
methylated	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cells	O
(	O
Figure	O
4A	O
and	O
B	O
)	O
.	O

Furthermore	O
,	O
three	O
CpG	O
sites	O
at	O
the	O
5	O
'	O
end	O
(	O
#	O
54	O
,	O
56	O
,	O
58	O
)	O
and	O
two	O
CpG	O
motifs	O
at	O
the	O
3	O
'	O
end	O
(	O
#	O
1	O
,	O
2	O
)	O
showed	O
this	O
direct	O
correlation	O
between	O
high	O
methylation	O
status	O
and	O
absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
.	O

In	O
addition	O
,	O
two	O
CpG	O
sites	O
located	O
in	O
a	O
NFkappaB	O
(	O
#	O
48	O
)	O
and	O
a	O
SP1	O
element	O
(	O
#	O
45	O
)	O
are	O
less	O
methylated	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
than	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
cells	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
:	O
1	O
/	O
8	O
versus	O
8	O
/	O
8	O
)	O
.	O

These	O
results	O
indicate	O
the	O
involvement	O
of	O
CpG	O
methylation	O
in	O
the	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemic	O
cells	O
.	O

In	O
vitro	O
methylation	O
of	O
an	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
-	O
reporter	O
construct	O
decreases	O
its	O
activity	O

To	O
provide	O
evidence	O
for	O
a	O
direct	O
effect	O
of	O
methylational	O
status	O
on	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
activity	O
we	O
performed	O
reporter	O
gene	O
assays	O
with	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
constructs	O
before	O
and	O
after	O
their	O
in	O
vitro	O
methylation	O
.	O

A	O
complete	O
methylation	O
of	O
these	O
constructs	O
was	O
checked	O
via	O
restriction	O
assays	O
with	O
methylation	O
-	O
sensitive	O
endonucleases	O
(	O
Figure	O
5A	O
)	O
.	O

Intriguingly	O
,	O
methylation	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
significantly	O
decreased	O
promoter	O
activity	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
SD	O
-	O
1	O
cells	O
by	O
85	O
.	O
0	O
%	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
silencing	O
effect	O
of	O
CpG	O
methylation	O
was	O
not	O
restricted	O
to	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cells	O
,	O
since	O
in	O
vitro	O
methylation	O
led	O
to	O
a	O
92	O
.	O
9	O
%	O
abrogation	O
of	O
promoter	O
activity	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
Jurkat	O
cells	O
(	O
Figure	O
5C	O
)	O
.	O

In	O
contrast	O
,	O
control	O
methylation	O
of	O
a	O
reporter	O
construct	O
with	O
a	O
different	O
promoter	O
(	O
FasL	B-Protein
)	O
as	O
well	O
as	O
an	O
empty	O
vector	O
had	O
no	O
effect	O
on	O
the	O
reporter	O
activity	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
proved	O
a	O
direct	O
association	O
between	O
methylation	O
and	O
activity	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
.	O

mRNA	O
expression	O
of	O
DNA	O
methyltransferases	O
and	O
methyl	O
-	O
CpG	O
-	O
binding	O
proteins	O
may	O
not	O
be	O
associated	O
with	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O

Since	O
abundance	O
of	O
DNMT	O
and	O
MBP	O
contribute	O
to	O
promoter	O
regulation	O
via	O
methylation	O
(	O
25	O
,	O
26	O
,	O
28	O
)	O
,	O
we	O
studied	O
their	O
mRNA	O
expression	O
to	O
investigate	O
a	O
possible	O
mechanism	O
for	O
the	O
observed	O
methylation	O
differences	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
.	O

To	O
this	O
end	O
,	O
we	O
did	O
not	O
detect	O
a	O
significant	O
difference	O
in	O
DNMT	O
(	O
DNMT1	B-Protein
,	O
DNMT3A	B-Protein
and	O
DNMT3B	B-Protein
)	O
or	O
MBP	O
(	O
MBD1	B-Protein
,	O
MBD2	B-Protein
,	O
MBD4	B-Protein
and	O
MeCP	B-Protein
)	O
mRNA	O
expression	O
between	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
cells	O
(	O
Figure	O
5D	O
)	O
.	O

In	O
fact	O
,	O
all	O
analyzed	O
cells	O
had	O
moderate	O
to	O
high	O
mRNA	O
levels	O
of	O
these	O
tested	O
DNMT	O
/	O
MBPs	O
and	O
differences	O
in	O
expression	O
were	O
not	O
correlated	O
with	O
IRF	B-Protein
-	I-Protein
4	I-Protein
status	O
.	O

These	O
results	O
indicate	O
a	O
distinct	O
cause	O
of	O
the	O
methylation	O
differences	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
cells	O
rather	O
than	O
changes	O
in	O
the	O
DNMT	O
and	O
MBP	O
mRNA	O
transcription	O
.	O

Many	O
genetic	O
lesions	O
are	O
known	O
to	O
influence	O
gene	O
expression	O
of	O
tumor	O
suppressor	O
genes	O
.	O

Whereas	O
mutations	O
and	O
deletions	O
or	O
insertions	O
have	O
permanent	O
effects	O
,	O
reversible	O
mechanisms	O
are	O
gene	O
methylation	O
,	O
or	O
expression	O
and	O
activation	O
of	O
transcription	O
factors	O
,	O
respectively	O
.	O

We	O
studied	O
a	O
putative	O
cause	O
for	O
absent	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
cells	O
and	O
first	O
focused	O
on	O
genetic	O
aberrations	O
of	O
the	O
promoter	O
.	O

We	O
observed	O
no	O
genetic	O
alterations	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
,	O
which	O
can	O
account	O
for	O
the	O
lack	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
:	O
The	O
detected	O
base	O
pair	O
changes	O
at	O
position	O
-	O
1081	O
(	O
T	O
to	O
C	O
substitution	O
)	O
,	O
at	O
position	O
-	O
1068	O
(	O
A	O
to	O
C	O
substitution	O
)	O
and	O
at	O
position	O
-	O
116	O
(	O
A	O
to	O
C	O
substitution	O
)	O
are	O
unlikely	O
responsible	O
for	O
absent	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
expression	O
since	O
the	O
first	O
two	O
mutations	O
were	O
found	O
both	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
cells	O
whereas	O
the	O
latter	O
change	O
was	O
not	O
detected	O
consistently	O
in	O
all	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
or	O
-	O
positive	O
cells	O
and	O
may	O
thus	O
be	O
a	O
polymorphism	O
.	O

All	O
three	O
substitutions	O
did	O
not	O
change	O
any	O
known	O
putative	O
transcription	O
factor	O
binding	O
sites	O
(	O
30	O
,	O
31	O
)	O
and	O
also	O
do	O
not	O
affect	O
any	O
restriction	O
sites	O
or	O
primer	O
binding	O
sites	O
of	O
the	O
used	O
assays	O
.	O

However	O
,	O
permanent	O
genetic	O
variations	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
coding	O
sequence	O
,	O
such	O
as	O
deletions	O
or	O
mutations	O
resulting	O
in	O
stop	O
-	O
codons	O
have	O
not	O
been	O
excluded	O
by	O
sequence	O
analysis	O
.	O

Since	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
cell	O
lines	O
and	O
CML	O
can	O
be	O
induced	O
by	O
demethylation	O
and	O
successful	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
therapy	O
(	O
3	O
)	O
,	O
respectively	O
,	O
the	O
existence	O
of	O
such	O
genetic	O
aberrations	O
seems	O
unlikely	O
.	O

We	O
then	O
investigated	O
whether	O
the	O
previously	O
described	O
down	O
-	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
human	O
myeloid	O
leukemias	O
was	O
due	O
to	O
a	O
differential	O
hypermethylation	O
of	O
the	O
promoter	O
,	O
since	O
the	O
presented	O
re	O
-	O
expression	O
due	O
to	O
AzadC	O
-	O
treatment	O
might	O
also	O
be	O
a	O
result	O
of	O
activation	O
of	O
positive	O
transcriptional	O
regulators	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
.	O

Methylation	O
of	O
CpG	O
sites	O
is	O
a	O
common	O
mechanism	O
of	O
silencing	O
genes	O
in	O
leukemia	O
and	O
has	O
also	O
been	O
shown	O
for	O
another	O
IRF	O
,	O
IRF	B-Protein
-	I-Protein
7	I-Protein
(	O
35	O
)	O
and	O
for	O
PU	B-Protein
.	I-Protein
1	I-Protein
(	O
36	O
)	O
,	O
an	O
interacting	O
partner	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
.	O

To	O
elucidate	O
the	O
relevance	O
of	O
this	O
mechanism	O
for	O
the	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
,	O
various	O
leukemic	O
cells	O
were	O
treated	O
with	O
demethylating	O
agents	O
and	O
promoters	O
were	O
sequenced	O
after	O
bisulfite	O
treatment	O
.	O

We	O
found	O
that	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
could	O
indeed	O
be	O
connected	O
to	O
the	O
methylation	O
status	O
of	O
distinct	O
CpG	O
motifs	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
.	O

In	O
Figure	O
4A	O
,	O
those	O
CpG	O
sites	O
are	O
shown	O
(	O
bottom	O
line	O
)	O
,	O
whose	O
hypermethylation	O
may	O
account	O
for	O
the	O
absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
the	O
respective	O
cells	O
.	O

One	O
of	O
them	O
(	O
#	O
54	O
)	O
is	O
adjacent	O
to	O
an	O
identified	O
regulatory	O
element	O
(	O
NFkappaB	O
-	O
site	O
)	O
,	O
indicating	O
a	O
possible	O
involvement	O
of	O
this	O
site	O
.	O

At	O
two	O
further	O
CpG	O
sites	O
(	O
#	O
48	O
,	O
45	O
)	O
the	O
methylation	O
status	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
was	O
lower	O
than	O
that	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
cells	O
.	O

These	O
CpG	O
sites	O
are	O
located	O
in	O
an	O
NFkappaB	O
and	O
an	O
SP1	O
element	O
(	O
31	O
)	O
and	O
thus	O
may	O
also	O
play	O
a	O
role	O
in	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
.	O

It	O
has	O
been	O
shown	O
that	O
NFkappaB	O
elements	O
play	O
an	O
important	O
role	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
induction	O
as	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
depends	O
on	O
binding	O
of	O
the	O
transactivator	O
c	B-Protein
-	I-Protein
Rel	I-Protein
to	O
these	O
elements	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
(	O
31	O
,	O
37	O
)	O
.	O

Furthermore	O
,	O
methylation	O
of	O
the	O
central	O
CpG	O
in	O
the	O
NFkappaB	O
element	O
inhibits	O
binding	O
of	O
the	O
NFkappaB	O
protein	O
complexes	O
(	O
38	O
)	O
,	O
promoting	O
the	O
significance	O
of	O
the	O
observed	O
methylation	O
differences	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
cells	O
.	O

Via	O
in	O
vitro	O
methylation	O
and	O
reporter	O
gene	O
assays	O
we	O
could	O
clearly	O
appoint	O
the	O
silencing	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
to	O
a	O
methylation	O
effect	O
,	O
which	O
may	O
thus	O
be	O
the	O
mechanism	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
deregulation	O
in	O
vivo	O
.	O

One	O
possible	O
cause	O
for	O
the	O
aberrant	O
methylation	O
in	O
tumorigenesis	O
is	O
an	O
increased	O
level	O
of	O
DNMTs	O
during	O
the	O
pathogenetic	O
process	O
.	O

In	O
colon	O
,	O
lung	O
and	O
hematologic	O
malignancies	O
,	O
overexpression	O
of	O
DNMT1	B-Protein
,	O
a	O
maintenance	O
DNMT	O
,	O
has	O
been	O
detected	O
(	O
39	O
-	O
41	O
)	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
shown	O
that	O
CML	O
cells	O
in	O
the	O
acute	O
phase	O
exhibited	O
elevated	O
levels	O
of	O
the	O
three	O
known	O
DNMTs	O
,	O
while	O
CML	O
cells	O
in	O
chronic	O
phase	O
expressed	O
normal	O
levels	O
of	O
DNMTs	O
if	O
compared	O
with	O
normal	O
bone	O
marrow	O
cells	O
(	O
25	O
)	O
.	O

Interestingly	O
,	O
a	O
positive	O
correlation	O
between	O
DNMT1	B-Protein
expression	O
levels	O
and	O
hypermethylation	O
of	O
p15INK4b	B-Protein
has	O
been	O
detected	O
in	O
AML	O
(	O
25	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
did	O
not	O
detect	O
significant	O
mRNA	O
expression	O
differences	O
of	O
selected	O
DNMT	O
or	O
MBP	O
,	O
making	O
it	O
an	O
unlikely	O
cause	O
for	O
the	O
observed	O
methylation	O
and	O
thus	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
differences	O
in	O
leukemia	O
cells	O
.	O

The	O
finding	O
that	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
is	O
silenced	O
by	O
promoter	O
hypermethylation	O
might	O
represent	O
a	O
mechanism	O
that	O
accounts	O
for	O
the	O
previously	O
observed	O
loss	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
CML	O
.	O

Indeed	O
,	O
several	O
clinical	O
trials	O
with	O
leukemia	O
patients	O
and	O
patients	O
with	O
myelodysplastic	O
syndromes	O
demonstrated	O
the	O
potential	O
clinical	O
benefit	O
of	O
a	O
treatment	O
with	O
demethylating	O
agents	O
(	O
42	O
-	O
45	O
)	O
.	O

The	O
expression	O
of	O
another	O
IRF	O
,	O
IFN	B-Protein
consensus	I-Protein
sequence	I-Protein
binding	I-Protein
protein	I-Protein
(	O
ICSBP	B-Protein
/	O
IRF	B-Protein
-	I-Protein
8	I-Protein
)	O
,	O
is	O
impaired	O
in	O
myeloid	O
leukemias	O
especially	O
CML	O
(	O
27	O
,	O
46	O
,	O
47	O
)	O
.	O

But	O
in	O
contrast	O
to	O
IRF	B-Protein
-	I-Protein
4	I-Protein
,	O
the	O
loss	O
of	O
this	O
IRF	O
could	O
not	O
be	O
reverted	O
in	O
ICSBP	B-Protein
-	O
negative	O
cell	O
lines	O
(	O
EM	O
-	O
2	O
,	O
CML	O
-	O
T1	O
,	O
K	O
-	O
562	O
and	O
LAMA	O
-	O
84	O
)	O
by	O
treatment	O
with	O
AzadC	O
(	O
Figure	O
6	O
)	O
and	O
AzadC	O
has	O
no	O
effect	O
on	O
ICSBP	B-Protein
levels	O
in	O
ICSBP	B-Protein
-	O
positive	O
U	O
-	O
937	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

These	O
data	O
suggest	O
a	O
distinct	O
regulatory	O
mechanism	O
for	O
these	O
two	O
IRFs	O
.	O

IRF	B-Protein
-	I-Protein
4	I-Protein
,	O
similar	O
to	O
many	O
other	O
classical	O
tumor	O
suppressor	O
genes	O
p15INK4b	B-Protein
,	O
p16INK4a	B-Protein
or	O
p53	B-Protein
,	O
may	O
thus	O
be	O
a	O
subject	O
of	O
alterations	O
in	O
the	O
promoter	O
methylation	O
status	O
leading	O
to	O
expression	O
changes	O
,	O
which	O
might	O
contribute	O
to	O
the	O
initiation	O
and	O
/	O
or	O
progression	O
of	O
cancer	O
.	O

Still	O
,	O
the	O
obvious	O
functional	O
diversity	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
remains	O
remarkable	O
and	O
cannot	O
be	O
fully	O
explained	O
by	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
status	O
.	O

For	O
example	O
,	O
IRF	B-Protein
-	I-Protein
4	I-Protein
is	O
primarily	O
known	O
for	O
its	O
oncogenic	O
features	O
.	O

In	O
multiple	O
myeloma	O
(	O
MM	O
)	O
a	O
translocation	O
on	O
chromosome	O
14q	O
was	O
reported	O
to	O
lead	O
to	O
a	O
fusion	O
gene	O
of	O
immunoglobulin	B-Protein
heavy	I-Protein
-	I-Protein
chain	I-Protein
(	O
IgH	B-Protein
)	O
and	O
IRF	B-Protein
-	I-Protein
4	I-Protein
resulting	O
in	O
a	O
subsequent	O
overexpression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
(	O
48	O
,	O
49	O
)	O
.	O

In	O
addition	O
,	O
abundant	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
was	O
found	O
to	O
be	O
a	O
marker	O
for	O
various	O
subsets	O
of	O
lymphomas	O
,	O
such	O
as	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphomas	O
,	O
primary	O
effusion	O
lymphoma	O
,	O
and	O
marginal	O
zone	O
lymphoma	O
,	O
and	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
11	O
,	O
31	O
,	O
50	O
-	O
52	O
)	O
.	O

This	O
draws	O
a	O
more	O
complex	O
picture	O
of	O
the	O
role	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
.	O

Down	O
-	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
may	O
promote	O
leukemogenesis	O
in	O
myeloid	O
cell	O
context	O
(	O
3	O
)	O
,	O
which	O
was	O
recently	O
confirmed	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
/	O
-	O
ICSBP	B-Protein
-	O
/	O
-	O
double	O
knock	O
-	O
out	O
mice	O
(	O
53	O
)	O
,	O
while	O
IRF	B-Protein
-	I-Protein
4	I-Protein
up	O
-	O
regulation	O
may	O
induce	O
a	O
growth	O
advantage	O
in	O
lymphomas	O
or	O
MM	O
(	O
48	O
)	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
regulates	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
,	O
and	O
that	O
aberrant	O
expression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
in	O
certain	O
types	O
of	O
leukemia	O
may	O
be	O
a	O
consequence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
hypermethylation	O
.	O

Foxp3	B-Protein
Represses	O
Retroviral	O
Transcription	O
by	O
Targeting	O
Both	O
NF	O
-	O
kappaB	O
and	O
CREB	O
Pathways	O

Forkhead	O
box	O
(	O
Fox	O
)	O
/	O
winged	O
-	O
helix	O
transcription	O
factors	O
regulate	O
multiple	O
aspects	O
of	O
immune	O
responsiveness	O
and	O
Foxp3	B-Protein
is	O
recognized	O
as	O
an	O
essential	O
functional	O
marker	O
of	O
regulatory	O
T	O
cells	O
.	O

Herein	O
we	O
describe	O
downstream	O
signaling	O
pathways	O
targeted	O
by	O
Foxp3	B-Protein
that	O
may	O
negatively	O
impact	O
retroviral	O
pathogenesis	O
.	O

Overexpression	O
of	O
Foxp3	B-Protein
in	O
HEK	O
293T	O
and	O
purified	O
CD4	B-Protein
+	O
T	O
cells	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
decrease	O
in	O
basal	O
levels	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
.	O

Deletion	O
of	O
the	O
carboxyl	O
-	O
terminal	O
forkhead	O
(	O
FKH	O
)	O
domain	O
,	O
critical	O
for	O
nuclear	O
localization	O
and	O
DNA	O
-	O
binding	O
activity	O
,	O
abrogated	O
the	O
ability	O
of	O
Foxp3	B-Protein
to	O
suppress	O
NF	O
-	O
kappaB	O
activity	O
in	O
HEK	O
293T	O
cells	O
,	O
but	O
not	O
in	O
Jurkat	O
or	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

We	O
further	O
demonstrate	O
that	O
Foxp3	B-Protein
suppressed	O
the	O
transcription	O
of	O
two	O
human	O
retroviral	O
promoters	O
(	O
HIV	O
-	O
1	O
and	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
[	O
HTLV	O
-	O
I	O
]	O
)	O
utilizing	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
NF	O
-	O
kappaB	O
-	O
independent	O
mechanisms	O
.	O

Examination	O
of	O
the	O
latter	O
identified	O
the	O
cAMP	O
-	O
responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
pathway	O
as	O
a	O
target	O
of	O
Foxp3	B-Protein
.	O

Finally	O
,	O
comparison	O
of	O
the	O
percent	O
Foxp3	B-Protein
+	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
to	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
asymptomatic	O
carriers	O
and	O
patients	O
with	O
HTLV	O
-	O
I	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
suggested	O
that	O
high	O
Foxp3	B-Protein
expression	O
is	O
associated	O
with	O
low	O
proviral	O
load	O
and	O
absence	O
of	O
disease	O
.	O

These	O
results	O
suggest	O
an	O
expanded	O
role	O
for	O
Foxp3	B-Protein
in	O
regulating	O
NF	O
-	O
kappaB	O
-	O
and	O
CREB	O
-	O
dependent	O
cellular	O
and	O
viral	O
gene	O
expression	O
.	O

Immunological	O
tolerance	O
to	O
self	O
-	O
antigens	O
is	O
the	O
result	O
of	O
the	O
deletion	O
of	O
self	O
-	O
reactive	O
T	O
lymphocytes	O
in	O
the	O
thymus	O
(	O
central	O
tolerance	O
)	O
and	O
suppression	O
of	O
the	O
activation	O
of	O
potentially	O
self	O
-	O
reactive	O
T	O
lymphocytes	O
in	O
the	O
periphery	O
(	O
peripheral	O
tolerance	O
)	O
[	O
1	O
]	O
.	O

Suppression	O
of	O
pathogenic	O
T	O
cell	O
responses	O
is	O
mediated	O
by	O
naturally	O
arising	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
regulatory	O
cells	O
(	O
Tregs	O
)	O
[	O
2	O
,	O
3	O
]	O
.	O

Deficiencies	O
in	O
Treg	O
development	O
and	O
function	O
have	O
been	O
linked	O
to	O
the	O
severe	O
autoimmune	O
disorder	O
known	O
as	O
immune	O
dysregulation	O
,	O
polyendocrinopathy	O
,	O
enteropathy	O
,	O
X	O
-	O
linked	O
syndrome	O
(	O
IPEX	O
)	O
[	O
4	O
]	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
have	O
provided	O
strong	O
evidence	O
that	O
dysregulation	O
of	O
Treg	O
development	O
and	O
/	O
or	O
function	O
may	O
be	O
a	O
significant	O
factor	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
multiple	O
sclerosis	O
[	O
5	O
]	O
,	O
myasthenia	O
gravis	O
[	O
6	O
]	O
,	O
and	O
type	O
1	O
diabetes	O
[	O
7	O
]	O
)	O
and	O
virus	O
-	O
induced	O
immunologic	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
human	O
T	O
lymphotropic	O
virus	O
type	O
I	O
[	O
HTLV	O
-	O
I	O
]	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
[	O
HAM	O
/	O
TSP	O
]	O
,	O
and	O
HIV	O
-	O
induced	O
AIDS	O
[	O
8	O
-	O
10	O
]	O
)	O
.	O

The	O
transcription	O
factor	O
Foxp3	B-Protein
is	O
a	O
431	O
-	O
amino	O
acid	O
(	O
48	O
-	O
kDa	O
)	O
protein	O
expressed	O
at	O
very	O
high	O
levels	O
in	O
CD4	B-Protein
+	O
CD25hi	B-Protein
T	O
cells	O
and	O
has	O
previously	O
been	O
shown	O
to	O
be	O
absolutely	O
critical	O
for	O
Treg	O
development	O
and	O
function	O
[	O
11	O
-	O
14	O
]	O
.	O

Foxp3	B-Protein
contains	O
a	O
proline	O
-	O
rich	O
amino	O
-	O
terminal	O
domain	O
reported	O
to	O
function	O
as	O
a	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
domain	O
,	O
a	O
central	O
region	O
containing	O
a	O
zinc	O
finger	O
and	O
leucine	O
zipper	O
potentially	O
important	O
for	O
protein	O
-	O
protein	O
interactions	O
,	O
and	O
a	O
carboxyl	O
-	O
terminal	O
forkhead	O
(	O
FKH	O
)	O
domain	O
required	O
for	O
nuclear	O
localization	O
and	O
DNA	O
-	O
binding	O
activity	O
[	O
14	O
-	O
16	O
]	O
.	O

Functional	O
inactivation	O
of	O
Foxp3	B-Protein
by	O
genetic	O
mutations	O
affecting	O
the	O
Foxp3	B-Protein
coding	O
region	O
,	O
as	O
demonstrated	O
in	O
IPEX	O
,	O
or	O
repression	O
of	O
Foxp3	B-Protein
expression	O
by	O
the	O
HTLV	O
-	O
I	O
-	O
encoded	O
transactivator	O
protein	O
Tax	B-Protein
,	O
as	O
recently	O
reported	O
in	O
patients	O
with	O
HAM	O
/	O
TSP	O
,	O
results	O
in	O
loss	O
of	O
regulatory	O
activity	O
in	O
CD4	B-Protein
+	O
CD25hi	B-Protein
T	O
cells	O
[	O
4	O
,	O
8	O
,	O
17	O
]	O
.	O

Although	O
it	O
is	O
clear	O
that	O
Foxp3	B-Protein
regulates	O
T	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
,	O
very	O
little	O
is	O
known	O
concerning	O
the	O
molecular	O
mechanisms	O
of	O
Foxp3	B-Protein
function	O
.	O

The	O
first	O
evidence	O
to	O
indicate	O
how	O
Foxp3	B-Protein
promotes	O
the	O
development	O
and	O
function	O
of	O
regulatory	O
T	O
cells	O
came	O
from	O
a	O
report	O
by	O
Ziegler	O
and	O
colleagues	O
[	O
16	O
]	O
,	O
which	O
suggested	O
that	O
Foxp3	B-Protein
could	O
inhibit	O
transcriptional	O
activation	O
by	O
physically	O
interacting	O
with	O
forkhead	O
binding	O
sites	O
located	O
immediately	O
adjacent	O
to	O
critical	O
cis	O
-	O
acting	O
NF	O
-	O
AT	O
binding	O
sites	O
found	O
in	O
various	O
cytokine	O
promoters	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
)	O
.	O

That	O
study	O
also	O
demonstrated	O
that	O
Foxp3	B-Protein
could	O
repress	O
activation	O
of	O
a	O
synthetic	O
reporter	O
vector	O
containing	O
an	O
SV40	O
promoter	O
and	O
three	O
tandem	O
copies	O
of	O
a	O
forkhead	O
binding	O
site	O
.	O

These	O
results	O
provided	O
additional	O
evidence	O
suggesting	O
that	O
Foxp3	B-Protein
transcriptional	O
repression	O
was	O
mediated	O
by	O
binding	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
to	O
promoters	O
containing	O
forkhead	O
binding	O
sites	O
.	O

A	O
recent	O
study	O
by	O
Bettelli	O
and	O
colleagues	O
[	O
15	O
]	O
further	O
demonstrated	O
that	O
Foxp3	B-Protein
could	O
inhibit	O
NF	O
-	O
AT	O
as	O
well	O
as	O
NF	O
-	O
kappaB	O
activation	O
,	O
although	O
the	O
mechanism	O
of	O
suppression	O
was	O
shown	O
to	O
involve	O
direct	O
protein	O
-	O
protein	O
interactions	O
between	O
NF	O
-	O
AT	O
or	O
NF	O
-	O
kappaB	O
and	O
Foxp3	B-Protein
rather	O
than	O
binding	O
of	O
Foxp3	B-Protein
to	O
promoter	O
elements	O
adjacent	O
to	O
cis	O
-	O
acting	O
NF	O
-	O
AT	O
or	O
NF	O
-	O
kappaB	O
sites	O
.	O

Collectively	O
,	O
these	O
data	O
suggested	O
that	O
Foxp3	B-Protein
may	O
function	O
as	O
a	O
transcriptional	O
repressor	O
,	O
potentially	O
through	O
the	O
formation	O
of	O
both	O
DNA	O
-	O
protein	O
and	O
protein	O
-	O
protein	O
interactions	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
expanded	O
upon	O
these	O
observations	O
by	O
defining	O
additional	O
requirements	O
of	O
Foxp3	B-Protein
-	O
mediated	O
repression	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
and	O
investigated	O
whether	O
Foxp3	B-Protein
could	O
target	O
additional	O
signaling	O
pathways	O
by	O
examining	O
transcriptional	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
NF	O
-	O
kappaB	O
-	O
independent	O
retroviral	O
pathogens	O
.	O

The	O
characterization	O
of	O
the	O
molecular	O
targets	O
of	O
Foxp3	B-Protein
and	O
the	O
mechanism	O
(	O
s	O
)	O
utilized	O
by	O
Foxp3	B-Protein
to	O
support	O
Treg	O
development	O
and	O
function	O
will	O
aid	O
in	O
our	O
understanding	O
of	O
the	O
role	O
Tregs	O
play	O
in	O
the	O
pathogenesis	O
of	O
human	O
autoimmune	O
disease	O
.	O

Foxp3	B-Protein
Suppresses	O
NF	O
-	O
kappaB	O
Dependent	O
Transcriptional	O
Activation	O

To	O
ascertain	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Foxp3	B-Protein
functions	O
to	O
promote	O
the	O
regulatory	O
function	O
of	O
CD4	B-Protein
+	O
CD25hi	B-Protein
T	O
cells	O
,	O
we	O
first	O
confirmed	O
the	O
function	O
of	O
Foxp3	B-Protein
as	O
a	O
repressor	O
of	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
previously	O
implicated	O
as	O
a	O
target	O
of	O
other	O
forkhead	O
/	O
winged	O
-	O
helix	O
family	O
transcription	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
Foxj1	B-Protein
and	O
Foxo3a	B-Protein
)	O
[	O
19	O
,	O
20	O
]	O
.	O

We	O
analyzed	O
the	O
effect	O
of	O
Foxp3	B-Protein
overexpression	O
on	O
NF	O
-	O
kappaB	O
activation	O
in	O
HEK	O
293T	O
cells	O
in	O
dose	O
-	O
response	O
and	O
time	O
course	O
analyses	O
.	O

Transfection	O
of	O
HEK	O
293T	O
cells	O
with	O
an	O
NF	O
-	O
kappaB	O
luciferase	B-Protein
reporter	O
vector	O
in	O
the	O
presence	O
or	O
absence	O
of	O
increasing	O
concentrations	O
of	O
a	O
Foxp3	B-Protein
expression	O
vector	O
or	O
a	O
control	O
vector	O
(	O
enhanced	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
[	O
EGFP	O
]	O
)	O
was	O
performed	O
,	O
and	O
cells	O
were	O
harvested	O
after	O
24	O
h	O
to	O
assay	O
for	O
luciferase	B-Protein
activity	O
and	O
Foxp3	B-Protein
mRNA	O
expression	O
.	O

Results	O
indicated	O
that	O
as	O
the	O
concentration	O
of	O
Foxp3	B-Protein
transfected	O
into	O
cells	O
increases	O
(	O
from	O
50	O
to	O
2	O
,	O
400	O
ng	O
)	O
,	O
the	O
level	O
of	O
NF	O
-	O
kappaB	O
activation	O
decreases	O
proportionally	O
(	O
Figure	O
1A	O
)	O
.	O

Foxp3	B-Protein
mRNA	O
was	O
also	O
assayed	O
to	O
monitor	O
activity	O
of	O
the	O
Foxp3	B-Protein
expression	O
vector	O
(	O
Figure	O
1B	O
)	O
.	O

Since	O
NF	O
-	O
kappaB	O
activation	O
was	O
partially	O
affected	O
by	O
transfection	O
of	O
high	O
concentrations	O
of	O
the	O
control	O
vector	O
,	O
we	O
determined	O
the	O
fold	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
Foxp3	B-Protein
compared	O
to	O
the	O
control	O
vector	O
at	O
each	O
concentration	O
(	O
Figure	O
1A	O
)	O
.	O

Fold	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
was	O
directly	O
proportional	O
to	O
the	O
level	O
of	O
Foxp3	B-Protein
mRNA	O
expression	O
detected	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

To	O
determine	O
the	O
level	O
of	O
Foxp3	B-Protein
-	O
mediated	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
over	O
time	O
,	O
HEK	O
293T	O
cells	O
were	O
transfected	O
with	O
an	O
NF	O
-	O
kappaB	O
luciferase	B-Protein
reporter	O
vector	O
and	O
an	O
expression	O
vector	O
encoding	O
Foxp3	B-Protein
or	O
EGFP	O
(	O
control	O
vector	O
)	O
and	O
harvested	O
over	O
4	O
d	O
.	O

As	O
shown	O
in	O
Figure	O
1C	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
suppressed	O
by	O
overexpression	O
of	O
Foxp3	B-Protein
at	O
all	O
time	O
points	O
.	O

Extending	O
these	O
results	O
from	O
established	O
,	O
in	O
vitro	O
HEK	O
cell	O
lines	O
to	O
primary	O
human	O
lymphocytes	O
,	O
overexpression	O
of	O
Foxp3	B-Protein
in	O
purified	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
three	O
healthy	O
donors	O
also	O
down	O
-	O
regulated	O
the	O
steady	O
-	O
state	O
level	O
of	O
NF	O
-	O
kappaB	O
activation	O
(	O
Figure	O
1D	O
)	O
.	O

These	O
results	O
recapitulate	O
those	O
from	O
Bettelli	O
and	O
colleagues	O
[	O
15	O
]	O
demonstrating	O
that	O
Foxp3	B-Protein
functions	O
,	O
in	O
part	O
,	O
to	O
block	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
human	O
cell	O
lines	O
as	O
well	O
as	O
in	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

The	O
Carboxyl	O
-	O
Terminal	O
FKH	O
Domain	O
Is	O
Not	O
Required	O
for	O
Suppression	O
of	O
NF	O
-	O
kappaB	O
Activation	O
in	O
T	O
Cells	O

To	O
define	O
the	O
requirements	O
of	O
Foxp3	B-Protein
with	O
respect	O
to	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
,	O
we	O
utilized	O
a	O
mutant	O
of	O
Foxp3	B-Protein
lacking	O
the	O
FKH	O
domain	O
(	O
Figure	O
2A	O
)	O
[	O
16	O
]	O
,	O
similar	O
to	O
the	O
scurfy	O
mutant	O
Foxp3	B-Protein
of	O
mice	O
,	O
and	O
a	O
mutant	O
Foxp3	B-Protein
protein	O
from	O
a	O
patient	O
with	O
IPEX	O
[	O
4	O
,	O
11	O
,	O
14	O
,	O
17	O
]	O
.	O

Unlike	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
which	O
localizes	O
almost	O
exclusively	O
to	O
the	O
nucleus	O
and	O
can	O
bind	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
to	O
forkhead	O
binding	O
sites	O
,	O
the	O
deltaFKH	B-Protein
mutant	I-Protein
fails	O
to	O
localize	O
to	O
the	O
nucleus	O
and	O
thus	O
cannot	O
interact	O
with	O
promoter	O
elements	O
or	O
nuclear	O
proteins	O
[	O
16	O
]	O
.	O

Therefore	O
,	O
we	O
utilized	O
the	O
deltaFKH	B-Protein
mutant	I-Protein
to	O
determine	O
whether	O
nuclear	O
localization	O
(	O
or	O
other	O
function	O
associated	O
with	O
the	O
FKH	O
domain	O
)	O
of	O
Foxp3	B-Protein
was	O
a	O
prerequisite	O
for	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Although	O
Foxp3	B-Protein
interaction	O
with	O
NF	O
-	O
kappaB	O
presumably	O
takes	O
place	O
in	O
the	O
nucleus	O
,	O
it	O
may	O
also	O
be	O
possible	O
for	O
a	O
cytoplasmic	O
Foxp3	B-Protein
protein	O
to	O
bind	O
to	O
NF	O
-	O
kappaB	O
in	O
the	O
cytoplasm	O
and	O
prevent	O
localization	O
to	O
the	O
nucleus	O
following	O
an	O
activation	O
stimulus	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
but	O
not	O
of	O
deltaFKH	B-Protein
,	O
was	O
able	O
to	O
suppress	O
activation	O
of	O
a	O
cotransfected	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
in	O
HEK	O
293T	O
cells	O
(	O
Figure	O
2B	O
)	O
.	O

Both	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
were	O
expressed	O
at	O
very	O
high	O
levels	O
following	O
transfection	O
as	O
detected	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
data	O
appear	O
to	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
is	O
critically	O
important	O
for	O
Foxp3	B-Protein
to	O
down	O
-	O
regulate	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
.	O

However	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
blocked	O
to	O
a	O
similar	O
extent	O
by	O
both	O
full	O
-	O
length	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
in	O
Jurkat	O
T	O
cells	O
(	O
Figure	O
2C	O
)	O
and	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Figure	O
2D	O
)	O
.	O

Western	O
blot	O
analysis	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
expression	O
demonstrated	O
that	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
does	O
not	O
block	O
NF	O
-	O
kappaB	O
activation	O
at	O
the	O
level	O
of	O
p65	B-Protein
protein	O
expression	O
(	O
Figure	O
2E	O
)	O
.	O

These	O
results	O
are	O
very	O
interesting	O
with	O
respect	O
to	O
Foxp3	B-Protein
function	O
,	O
because	O
they	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
,	O
and	O
possibly	O
nuclear	O
localization	O
,	O
are	O
dispensable	O
for	O
Foxp3	B-Protein
function	O
in	O
T	O
cell	O
populations	O
.	O

Alternative	O
interpretations	O
may	O
include	O
the	O
possibility	O
that	O
the	O
localization	O
of	O
deltaFKH	B-Protein
differ	O
between	O
epithelial	O
cells	O
and	O
T	O
cells	O
.	O

In	O
either	O
case	O
,	O
these	O
results	O
suggest	O
a	O
cell	O
type	O
-	O
specific	O
mechanism	O
of	O
action	O
for	O
this	O
Foxp3	B-Protein
mutant	O
.	O

Foxp3	B-Protein
Suppresses	O
HIV	O
-	O
1	O
Gene	O
Expression	O
in	O
Part	O
through	O
Blocking	O
Activation	O
of	O
NF	O
-	O
kappaB	O

If	O
Foxp3	B-Protein
functions	O
as	O
a	O
repressor	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
,	O
then	O
we	O
hypothesized	O
that	O
Foxp3	B-Protein
overexpression	O
could	O
selectively	O
down	O
-	O
regulate	O
transcription	O
from	O
promoters	O
previously	O
shown	O
to	O
be	O
responsive	O
to	O
NF	O
-	O
kappaB	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
examined	O
the	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
which	O
contains	O
two	O
tandem	O
cis	O
-	O
acting	O
NF	O
-	O
kappaB	O
binding	O
sites	O
located	O
between	O
positions	O
-	O
102	O
and	O
-	O
81	O
with	O
respect	O
to	O
the	O
transcription	O
initiation	O
site	O
[	O
21	O
]	O
.	O

NF	O
-	O
kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
gene	O
expression	O
directed	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
[	O
21	O
]	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
but	O
not	O
deltaFKH	B-Protein
,	O
in	O
HEK	O
293T	O
cells	O
was	O
able	O
to	O
inhibit	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3A	O
)	O
,	O
similar	O
to	O
what	O
was	O
previously	O
demonstrated	O
with	O
the	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
(	O
Figure	O
2B	O
)	O
.	O

Furthermore	O
,	O
HIV	O
-	O
1	O
LTR	O
activation	O
was	O
suppressed	O
by	O
full	O
-	O
length	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
in	O
Jurkat	O
T	O
cells	O
(	O
Figure	O
3B	O
)	O
.	O

To	O
demonstrate	O
that	O
Foxp3	B-Protein
-	O
mediated	O
HIV	O
-	O
1	O
LTR	O
repression	O
was	O
associated	O
with	O
interactions	O
with	O
NF	O
-	O
kappaB	O
bound	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
we	O
compared	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
or	O
an	O
identical	O
HIV	O
-	O
1	O
LTR	O
lacking	O
the	O
NF	O
-	O
kappaB	O
sites	O
located	O
between	O
-	O
102	O
and	O
-	O
81	O
(	O
HIV	O
-	O
1	O
delta	O
-	O
kappaB	O
LTR	O
)	O
(	O
Figure	O
3C	O
)	O
.	O

This	O
mutant	O
HIV	O
-	O
1	O
LTR	O
construct	O
exhibited	O
reduced	O
levels	O
of	O
transcription	O
compared	O
to	O
the	O
parental	O
HIV	O
-	O
1	O
LTR	O
in	O
purified	O
healthy	O
donor	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O

However	O
,	O
directly	O
comparing	O
the	O
effect	O
of	O
Foxp3	B-Protein
overexpression	O
on	O
the	O
activation	O
of	O
these	O
two	O
viral	O
promoters	O
demonstrated	O
that	O
Foxp3	B-Protein
was	O
more	O
capable	O
of	O
suppressing	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3D	O
)	O
compared	O
to	O
the	O
mutated	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3E	O
)	O
.	O

These	O
results	O
suggest	O
that	O
Foxp3	B-Protein
down	O
-	O
regulation	O
of	O
HIV	O
-	O
1	O
LTR	O
activation	O
was	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cis	O
-	O
acting	O
NF	O
-	O
kappaB	O
binding	O
sites	O
.	O

Residual	O
levels	O
of	O
inhibition	O
of	O
the	O
HIV	O
-	O
1	O
delta	O
-	O
kappaB	O
LTR	O
by	O
Foxp3	B-Protein
may	O
be	O
due	O
to	O
NF	O
-	O
AT	O
binding	O
sites	O
located	O
upstream	O
of	O
the	O
NF	O
-	O
kappaB	O
sites	O
within	O
the	O
HIV	O
-	O
1	O
LTR	O
[	O
22	O
,	O
23	O
]	O
.	O

The	O
Transactivation	O
Functions	O
of	O
HTLV	O
-	O
I	O
Tax	B-Protein
Are	O
Suppressed	O
by	O
Foxp3	B-Protein

Previous	O
studies	O
by	O
Bettelli	O
and	O
colleagues	O
have	O
demonstrated	O
that	O
Foxp3	B-Protein
can	O
repress	O
both	O
the	O
basal	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
as	O
well	O
as	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
[	O
15	O
]	O
.	O

Our	O
next	O
step	O
was	O
to	O
determine	O
whether	O
Foxp3	B-Protein
could	O
also	O
suppress	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
caused	O
by	O
a	O
strong	O
viral	O
transactivator	O
protein	O
.	O

HTLV	O
-	O
I	O
encodes	O
a	O
multifunctional	O
transactivator	O
protein	O
,	O
Tax	B-Protein
,	O
capable	O
of	O
activating	O
both	O
the	O
NF	O
-	O
kappaB	O
and	O
CREB	O
pathways	O
[	O
24	O
-	O
29	O
]	O
.	O

Since	O
the	O
HTLV	O
-	O
I	O
Tax	B-Protein
protein	O
can	O
function	O
at	O
multiple	O
levels	O
in	O
both	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
to	O
stimulate	O
activation	O
of	O
NF	O
-	O
kappaB	O
[	O
28	O
,	O
29	O
]	O
,	O
we	O
hypothesized	O
that	O
overexpression	O
of	O
Foxp3	B-Protein
may	O
interfere	O
with	O
this	O
process	O
.	O

However	O
,	O
since	O
Tax	B-Protein
-	O
dependent	O
HTLV	O
-	O
I	O
gene	O
expression	O
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
[	O
18	O
]	O
,	O
we	O
also	O
hypothesized	O
that	O
Foxp3	B-Protein
would	O
not	O
affect	O
Tax	B-Protein
-	O
dependent	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
overexpressed	O
HTLV	O
-	O
I	O
Tax	B-Protein
,	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
and	O
/	O
or	O
deltaFKH	B-Protein
in	O
HEK	O
293T	O
cells	O
cotransfected	O
with	O
an	O
HTLV	O
-	O
I	O
LTR	O
or	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
.	O

As	O
shown	O
in	O
Figure	O
4A	O
,	O
HTLV	O
-	O
I	O
Tax	B-Protein
strongly	O
up	O
-	O
regulated	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcriptional	O
activation	O
(	O
~	O
60	O
-	O
fold	O
)	O
.	O

Interestingly	O
,	O
overexpression	O
of	O
Foxp3	B-Protein
,	O
but	O
not	O
deltaFKH	B-Protein
,	O
suppressed	O
Tax	B-Protein
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
.	O

These	O
observations	O
further	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
is	O
required	O
for	O
inhibiting	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
presence	O
of	O
Tax	B-Protein
in	O
HEK	O
293T	O
cells	O
,	O
strikingly	O
similar	O
to	O
the	O
requirements	O
of	O
Foxp3	B-Protein
inhibition	O
of	O
basal	O
NF	O
-	O
kappaB	O
activation	O
shown	O
in	O
Figure	O
2B	O
.	O

Transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
was	O
stimulated	O
about	O
55	O
-	O
fold	O
by	O
overexpression	O
of	O
Tax	B-Protein
(	O
Figure	O
4B	O
)	O
,	O
while	O
transfection	O
of	O
Foxp3	B-Protein
suppressed	O
Tax	B-Protein
-	O
dependent	O
HTLV	O
-	O
I	O
LTR	O
activation	O
,	O
although	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
Tax	B-Protein
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
or	O
NF	O
-	O
AT	O
(	O
another	O
transcriptional	O
activator	O
known	O
to	O
interact	O
with	O
Foxp3	B-Protein
)	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
deltaFKH	B-Protein
also	O
led	O
to	O
suppression	O
of	O
HTLV	O
-	O
I	O
transactivation	O
by	O
Tax	B-Protein
to	O
a	O
similar	O
extent	O
as	O
full	O
-	O
length	O
Foxp3	B-Protein
(	O
Figure	O
4B	O
)	O
.	O

The	O
suppressive	O
effects	O
shown	O
in	O
Figure	O
4A	O
and	O
4B	O
were	O
not	O
the	O
result	O
of	O
Foxp3	B-Protein
down	O
-	O
regulating	O
the	O
expression	O
of	O
the	O
transfected	O
Tax	B-Protein
plasmid	O
as	O
determined	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
(	O
Figure	O
4C	O
)	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
Foxp3	B-Protein
interacts	O
with	O
transcriptional	O
regulators	O
in	O
addition	O
to	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
,	O
and	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
,	O
and	O
therefore	O
localization	O
to	O
the	O
nucleus	O
,	O
are	O
not	O
required	O
for	O
inhibition	O
of	O
Tax	B-Protein
-	O
mediated	O
HTLV	O
-	O
I	O
LTR	O
activation	O
(	O
even	O
in	O
HEK	O
293T	O
cells	O
)	O
.	O

To	O
determine	O
whether	O
Foxp3	B-Protein
inhibited	O
the	O
transactivation	O
functions	O
of	O
Tax	B-Protein
by	O
directly	O
associating	O
with	O
this	O
viral	O
protein	O
,	O
we	O
generated	O
an	O
expression	O
vector	O
in	O
which	O
HTLV	O
-	O
I	O
Tax	B-Protein
was	O
fused	O
in	O
-	O
frame	O
to	O
the	O
carboxyl	O
terminus	O
of	O
the	O
Gal4	B-Protein
DNA	O
-	O
binding	O
domain	O
(	O
Gal4	B-Protein
-	O
BD	O
)	O
.	O

This	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
Tax	I-Protein
fusion	O
protein	O
activated	O
transcription	O
of	O
a	O
synthetic	O
promoter	O
containing	O
five	O
Gal4	O
binding	O
sites	O
,	O
while	O
Gal4	B-Protein
-	O
BD	O
was	O
insufficient	O
to	O
stimulate	O
transcription	O
by	O
itself	O
(	O
Figure	O
4D	O
)	O
.	O

Transactivation	O
of	O
the	O
Gal4	O
-	O
resposive	O
promoter	O
by	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
Tax	I-Protein
remained	O
relatively	O
unaffected	O
by	O
overexpression	O
of	O
either	O
EGFP	O
(	O
control	O
)	O
,	O
Foxp3	B-Protein
,	O
or	O
deltaFKH	B-Protein
,	O
suggesting	O
that	O
Foxp3	B-Protein
does	O
not	O
repress	O
Tax	B-Protein
transactivation	O
by	O
directly	O
interfacing	O
with	O
the	O
HTLV	O
-	O
I	O
Tax	B-Protein
protein	O
.	O

To	O
confirm	O
that	O
Foxp3	B-Protein
had	O
a	O
direct	O
effect	O
on	O
HTLV	O
-	O
I	O
replication	O
,	O
we	O
transfected	O
HEK	O
293T	O
cells	O
with	O
a	O
well	O
-	O
characterized	O
HTLV	O
-	O
I	O
infectious	O
molecular	O
clone	O
(	O
termed	O
ACH	O
)	O
[	O
30	O
]	O
in	O
the	O
presence	O
of	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
deltaFKH	B-Protein
,	O
or	O
control	O
vector	O
.	O

ACH	O
has	O
been	O
previously	O
shown	O
to	O
direct	O
the	O
expression	O
of	O
viral	O
antigens	O
,	O
produce	O
infectious	O
virus	O
,	O
and	O
transform	O
CD4	B-Protein
+	O
T	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
31	O
,	O
32	O
]	O
.	O

After	O
24	O
h	O
,	O
the	O
amount	O
of	O
viral	O
antigen	O
expression	O
,	O
in	O
this	O
case	O
Tax	B-Protein
mRNA	O
,	O
was	O
detected	O
by	O
a	O
sensitive	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
.	O

As	O
illustrated	O
in	O
Figure	O
5	O
,	O
the	O
level	O
of	O
Tax	B-Protein
mRNA	O
synthesized	O
from	O
ACH	O
was	O
down	O
-	O
regulated	O
in	O
the	O
presence	O
of	O
Foxp3	B-Protein
compared	O
to	O
the	O
level	O
produced	O
in	O
the	O
presence	O
of	O
the	O
control	O
vector	O
.	O

deltaFKH	B-Protein
did	O
not	O
have	O
a	O
discernable	O
affect	O
on	O
Tax	B-Protein
expression	O
.	O

These	O
data	O
indicate	O
that	O
Foxp3	B-Protein
is	O
capable	O
of	O
repressing	O
the	O
expression	O
of	O
Tax	B-Protein
from	O
an	O
infectious	O
HTLV	O
-	O
I	O
molecular	O
clone	O
.	O

Increased	O
Foxp3	B-Protein
Protein	O
Expression	O
Is	O
Associated	O
with	O
Low	O
HTLV	O
-	O
I	O
Proviral	O
Load	O

Since	O
Foxp3	B-Protein
is	O
expressed	O
almost	O
exclusively	O
within	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
,	O
a	O
major	O
viral	O
reservoir	O
for	O
HTLV	O
-	O
I	O
[	O
33	O
]	O
,	O
it	O
was	O
important	O
to	O
determine	O
whether	O
there	O
was	O
an	O
association	O
between	O
Foxp3	B-Protein
and	O
HTLV	O
-	O
I	O
replication	O
in	O
infected	O
patients	O
.	O

We	O
therefore	O
quantitated	O
the	O
Foxp3	B-Protein
protein	O
expression	O
in	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
by	O
flow	O
cytometry	O
and	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
(	O
a	O
surrogate	O
marker	O
of	O
viral	O
replication	O
)	O
by	O
real	O
-	O
time	O
PCR	O
from	O
eight	O
patients	O
with	O
HAM	O
/	O
TSP	O
and	O
eight	O
asymptomatic	O
carriers	O
(	O
ACs	O
)	O
.	O

The	O
data	O
from	O
this	O
analysis	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

As	O
expected	O
,	O
patients	O
with	O
HAM	O
/	O
TSP	O
exhibited	O
significantly	O
higher	O
proviral	O
loads	O
(	O
indicated	O
as	O
HTLV	O
-	O
I	O
proviral	O
DNA	O
copies	O
/	O
100	O
cells	O
)	O
(	O
34	O
.	O
68	O
+	O
/	O
-	O
23	O
.	O
19	O
)	O
compared	O
to	O
ACs	O
(	O
4	O
.	O
75	O
+	O
/	O
-	O
5	O
.	O
47	O
)	O
(	O
p	O
=	O
0	O
.	O
0008	O
)	O
.	O

The	O
percentage	O
of	O
Foxp3	B-Protein
+	O
cells	O
within	O
the	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cell	O
population	O
was	O
significantly	O
greater	O
in	O
ACs	O
(	O
43	O
.	O
23	O
+	O
/	O
-	O
12	O
.	O
95	O
)	O
than	O
in	O
HAM	O
/	O
TSP	O
patients	O
(	O
18	O
.	O
59	O
+	O
/	O
-	O
5	O
.	O
77	O
)	O
(	O
p	O
=	O
0	O
.	O
0033	O
)	O
.	O

These	O
data	O
suggest	O
that	O
high	O
levels	O
of	O
Foxp3	B-Protein
protein	O
expression	O
are	O
associated	O
with	O
reduced	O
HTLV	O
-	O
I	O
replication	O
in	O
vivo	O
.	O

They	O
also	O
support	O
our	O
recent	O
reports	O
that	O
high	O
proviral	O
loads	O
,	O
which	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
high	O
Tax	B-Protein
mRNA	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
patients	O
,	O
are	O
associated	O
with	O
reduced	O
Foxp3	B-Protein
expression	O
[	O
8	O
,	O
34	O
]	O
.	O

CREB	O
Is	O
a	O
Target	O
for	O
Transcriptional	O
Repression	O
by	O
Foxp3	B-Protein

Although	O
Foxp3	B-Protein
could	O
down	O
-	O
regulate	O
Tax	B-Protein
-	O
dependent	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
(	O
Figure	O
4B	O
)	O
and	O
inhibit	O
Tax	B-Protein
expression	O
from	O
an	O
infectious	O
molecular	O
clone	O
(	O
Figure	O
5	O
)	O
,	O
Foxp3	B-Protein
failed	O
to	O
modulate	O
Tax	B-Protein
function	O
in	O
the	O
absence	O
of	O
the	O
viral	O
promoter	O
(	O
Figure	O
4D	O
)	O
.	O

These	O
results	O
led	O
us	O
to	O
hypothesize	O
that	O
Foxp3	B-Protein
acts	O
on	O
HTLV	O
-	O
I	O
gene	O
expression	O
by	O
interacting	O
with	O
proteins	O
important	O
for	O
driving	O
HTLV	O
-	O
I	O
LTR	O
activity	O
in	O
vivo	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
Tax	O
-	O
responsive	O
elements	O
within	O
the	O
HTLV	O
-	O
I	O
LTR	O
play	O
a	O
crucial	O
role	O
in	O
driving	O
Tax	B-Protein
-	O
mediated	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
[	O
18	O
]	O
.	O

The	O
Tax	O
-	O
responsive	O
elements	O
have	O
been	O
shown	O
to	O
resemble	O
CREB	O
binding	O
sites	O
,	O
bind	O
CREB	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
facilitate	O
HTLV	O
-	O
I	O
LTR	O
activation	O
both	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
Tax	B-Protein
[	O
35	O
,	O
36	O
]	O
.	O

Ching	O
and	O
colleagues	O
[	O
18	O
]	O
demonstrated	O
that	O
addition	O
of	O
a	O
dominant	O
-	O
negative	O
CREB	O
expression	O
vector	O
resulted	O
in	O
nearly	O
complete	O
inhibition	O
of	O
Tax	B-Protein
-	O
mediated	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
,	O
while	O
blocking	O
NF	O
-	O
kappaB	O
activation	O
by	O
addition	O
of	O
a	O
dominant	O
-	O
negative	O
IKKbeta	B-Protein
expression	O
vector	O
had	O
no	O
effect	O
on	O
Tax	B-Protein
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
Foxp3	B-Protein
may	O
inhibit	O
Tax	B-Protein
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
via	O
disruption	O
of	O
the	O
CREB	O
signaling	O
pathway	O
.	O

To	O
test	O
this	O
possibility	O
,	O
HEK	O
293T	O
cells	O
were	O
transfected	O
with	O
an	O
HTLV	O
-	O
I	O
LTR	O
or	O
synthetic	O
CREB	O
reporter	O
vector	O
along	O
with	O
a	O
control	O
expression	O
vector	O
(	O
EGFP	O
)	O
or	O
expression	O
vectors	O
encoding	O
Foxp3	B-Protein
or	O
deltaFKH	B-Protein
.	O

As	O
shown	O
in	O
Figure	O
6A	O
,	O
Foxp3	B-Protein
down	O
-	O
regulated	O
basal	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
and	O
transcription	O
of	O
a	O
synthetic	O
CREB	O
reporter	O
vector	O
,	O
suggesting	O
that	O
Foxp3	B-Protein
down	O
-	O
regulates	O
HTLV	O
-	O
I	O
LTR	O
activation	O
by	O
targeting	O
the	O
CREB	O
pathway	O
.	O

Deletion	O
of	O
the	O
FKH	O
domain	O
of	O
Foxp3	B-Protein
dampened	O
the	O
suppressive	O
effect	O
of	O
Foxp3	B-Protein
,	O
but	O
did	O
not	O
completely	O
abrogate	O
suppression	O
,	O
as	O
is	O
seen	O
with	O
NF	O
-	O
kappaB	O
-	O
responsive	O
promoters	O
in	O
HEK	O
293T	O
cells	O
.	O

Like	O
NF	O
-	O
kappaB	O
activation	O
,	O
CREB	O
transcriptional	O
activation	O
was	O
also	O
suppressed	O
by	O
expression	O
of	O
Foxp3	B-Protein
,	O
and	O
to	O
a	O
similar	O
extent	O
deltaFKH	B-Protein
,	O
in	O
healthy	O
donor	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Figure	O
6B	O
)	O
.	O

Similarly	O
,	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
also	O
repressed	O
basal	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Figure	O
6C	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
evidence	O
implicating	O
CREB	O
as	O
a	O
molecular	O
target	O
of	O
Foxp3	B-Protein
.	O

As	O
observed	O
with	O
NF	O
-	O
kappaB	O
activation	O
,	O
deltaFKH	B-Protein
was	O
a	O
more	O
potent	O
inhibitor	O
of	O
CREB	B-Protein
activation	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
than	O
in	O
HEK	O
293T	O
cells	O
,	O
further	O
indicating	O
that	O
a	O
cell	O
type	O
-	O
specific	O
mechanism	O
of	O
action	O
may	O
govern	O
the	O
function	O
of	O
this	O
Foxp3	O
mutant	O
.	O

To	O
determine	O
whether	O
Foxp3	B-Protein
functioned	O
by	O
directly	O
signaling	O
through	O
CREB	O
,	O
we	O
utilized	O
expression	O
vectors	O
encoding	O
CREB	B-Protein
-	I-Protein
1	I-Protein
or	O
c	B-Protein
-	I-Protein
Jun	I-Protein
(	O
a	O
member	O
of	O
the	O
activator	B-Protein
protein	I-Protein
1	I-Protein
family	O
of	O
transcription	O
factors	O
)	O
fused	O
in	O
-	O
frame	O
to	O
the	O
Gal4	B-Protein
-	O
BD	O
(	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
and	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
c	I-Protein
-	I-Protein
Jun	I-Protein
)	O
.	O

As	O
shown	O
in	O
Figure	O
6D	O
,	O
activation	O
of	O
a	O
Gal4	B-Protein
-	O
responsive	O
reporter	O
vector	O
by	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
was	O
down	O
-	O
regulated	O
by	O
Foxp3	B-Protein
compared	O
to	O
control	O
vector	O
(	O
EGFP	O
)	O
,	O
indicating	O
that	O
Foxp3	B-Protein
functions	O
by	O
directly	O
or	O
indirectly	O
interacting	O
with	O
CREB	B-Protein
-	I-Protein
1	I-Protein
.	O

However	O
,	O
Foxp3	B-Protein
failed	O
to	O
markedly	O
affect	O
transcriptional	O
activation	O
of	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
c	I-Protein
-	I-Protein
Jun	I-Protein
(	O
c	B-Protein
-	I-Protein
Jun	I-Protein
has	O
also	O
been	O
demonstrated	O
to	O
bind	O
to	O
the	O
HTLV	O
-	O
I	O
LTR	O
)	O
and	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
Tax	I-Protein
(	O
see	O
Figure	O
5	O
)	O
.	O

Importantly	O
,	O
the	O
mechanism	O
of	O
Foxp3	B-Protein
-	O
mediated	O
inhibition	O
of	O
CREB	O
-	O
dependent	O
transcription	O
was	O
not	O
due	O
to	O
a	O
block	O
in	O
CREB	B-Protein
-	I-Protein
1	I-Protein
protein	O
expression	O
,	O
as	O
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
Figure	O
6E	O
)	O
.	O

Although	O
these	O
results	O
demonstrate	O
that	O
Foxp3	B-Protein
functions	O
as	O
a	O
co	O
-	O
repressor	O
of	O
CREB	O
activation	O
(	O
in	O
addition	O
to	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
)	O
,	O
we	O
were	O
unable	O
to	O
detect	O
a	O
direct	O
physical	O
interaction	O
between	O
CREB	B-Protein
-	I-Protein
1	I-Protein
and	O
Foxp3	B-Protein
by	O
coimmunoprecipitation	O
or	O
mammalian	O
two	O
-	O
hybrid	O
analysis	O
(	O
unpublished	O
data	O
)	O
.	O

Therefore	O
,	O
our	O
data	O
suggest	O
that	O
Foxp3	B-Protein
may	O
interfere	O
with	O
CREB	O
signaling	O
at	O
an	O
upstream	O
event	O
,	O
such	O
as	O
phosphorylation	O
of	O
CREB	O
or	O
recruitment	O
/	O
function	O
of	O
coactivator	O
proteins	O
CREB	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CBP	B-Protein
)	O
/	O
p300	B-Protein
.	O

Foxp3	B-Protein
Antagonizes	O
CREB	O
Transcriptional	O
Activation	O
by	O
Disrupting	O
Coactivator	O
Recruitment	O

Stimulation	O
of	O
CREB	O
-	O
dependent	O
transcription	O
by	O
reagents	O
that	O
activate	O
adenylate	O
cyclase	O
and	O
increase	O
cAMP	O
levels	O
(	O
e	O
.	O
g	O
.	O
,	O
forskolin	O
)	O
increase	O
the	O
transactivation	O
potential	O
of	O
CREB	O
through	O
phosphorylation	O
of	O
serine	O
133	O
by	O
protein	O
kinase	O
A	O
,	O
which	O
permits	O
binding	O
and	O
recruitment	O
of	O
coactivators	O
CBP	B-Protein
/	O
p300	B-Protein
to	O
the	O
promoter	O
[	O
37	O
,	O
38	O
]	O
.	O

Phosphorylation	O
of	O
serine	O
133	O
does	O
not	O
,	O
however	O
,	O
affect	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
CREB	O
in	O
most	O
cases	O
[	O
39	O
-	O
41	O
]	O
.	O

Addition	O
of	O
forskolin	O
to	O
HEK	O
293T	O
cells	O
stimulated	O
activation	O
of	O
a	O
CREB	O
reporter	O
vector	O
about	O
65	O
fold	O
(	O
Figure	O
7A	O
)	O
.	O

Overexpression	O
of	O
Foxp3	B-Protein
was	O
capable	O
of	O
down	O
-	O
regulating	O
forskolin	O
-	O
induced	O
CREB	O
transcriptional	O
activation	O
.	O

The	O
functional	O
interaction	O
between	O
Foxp3	B-Protein
and	O
CREB	O
did	O
not	O
affect	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
CREB	B-Protein
-	I-Protein
1	I-Protein
,	O
but	O
did	O
show	O
a	O
modest	O
decrease	O
in	O
activating	B-Protein
transcription	I-Protein
factor	I-Protein
2	I-Protein
(	O
ATF	B-Protein
-	I-Protein
2	I-Protein
)	O
DNA	O
-	O
binding	O
activity	O
in	O
the	O
presence	O
of	O
forskolin	O
as	O
determined	O
by	O
transcription	O
factor	O
ELISA	O
(	O
Figure	O
7B	O
)	O
.	O

While	O
Foxp3	B-Protein
has	O
been	O
shown	O
to	O
bind	O
to	O
and	O
repress	O
activation	O
of	O
both	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
,	O
exactly	O
how	O
Foxp3	B-Protein
functions	O
to	O
bring	O
about	O
this	O
affect	O
has	O
not	O
been	O
elucidated	O
.	O

To	O
determine	O
how	O
Foxp3	B-Protein
blocks	O
CREB	O
-	O
dependent	O
transcription	O
,	O
we	O
examined	O
whether	O
Foxp3	B-Protein
was	O
capable	O
of	O
(	O
1	O
)	O
disrupting	O
the	O
recruitment	O
of	O
coactivator	O
proteins	O
and	O
/	O
or	O
(	O
2	O
)	O
preventing	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
(	O
which	O
is	O
a	O
prerequisite	O
for	O
coactivator	O
recruitment	O
)	O
.	O

Since	O
both	O
of	O
these	O
events	O
are	O
required	O
for	O
CREB	O
-	O
dependent	O
gene	O
expression	O
,	O
we	O
hypothesized	O
that	O
Foxp3	B-Protein
may	O
affect	O
CREB	O
activation	O
at	O
both	O
steps	O
.	O

To	O
determine	O
whether	O
Foxp3	B-Protein
can	O
disrupt	O
the	O
function	O
/	O
recruitment	O
of	O
the	O
coactivator	O
protein	O
p300	B-Protein
,	O
we	O
introduced	O
a	O
Gal4	B-Protein
reporter	O
vector	O
and	O
a	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
expression	O
vector	O
into	O
HEK	O
293T	O
cells	O
in	O
the	O
absence	O
or	O
presence	O
of	O
Foxp3	B-Protein
,	O
p300	B-Protein
,	O
and	O
/	O
or	O
control	O
expression	O
vectors	O
(	O
Figure	O
7C	O
)	O
.	O

As	O
expected	O
,	O
p300	B-Protein
overexpression	O
stimulated	O
transcription	O
of	O
the	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
fusion	O
protein	O
.	O

Foxp3	B-Protein
,	O
again	O
,	O
repressed	O
basal	O
levels	O
of	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
activation	O
by	O
more	O
than	O
2	O
-	O
fold	O
,	O
while	O
effectively	O
neutralizing	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
activation	O
in	O
the	O
presence	O
of	O
p300	B-Protein
.	O

We	O
next	O
analyzed	O
the	O
effect	O
of	O
Foxp3	B-Protein
on	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
in	O
forskolin	O
-	O
treated	O
HEK	O
293T	O
cells	O
by	O
Western	O
blot	O
analysis	O
.	O

Overexpression	O
of	O
Foxp3	B-Protein
failed	O
to	O
reduce	O
the	O
detectable	O
levels	O
of	O
CREB	O
phosphorylation	O
using	O
a	O
phosphospecific	O
antibody	O
for	O
CREB	B-Protein
-	I-Protein
1	I-Protein
(	O
unpublished	O
data	O
)	O
.	O

However	O
,	O
when	O
we	O
attempted	O
to	O
determine	O
whether	O
Foxp3	B-Protein
could	O
physically	O
interact	O
with	O
the	O
coactivator	O
protein	O
p300	B-Protein
,	O
we	O
found	O
that	O
p300	B-Protein
immunoprecipitated	O
Foxp3	B-Protein
when	O
both	O
proteins	O
were	O
overexpressed	O
in	O
HEK	O
293T	O
cells	O
(	O
Figure	O
7D	O
)	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
Foxp3	B-Protein
antagonizes	O
CREB	O
-	O
dependent	O
gene	O
expression	O
by	O
directly	O
interacting	O
with	O
coactivator	O
p300	B-Protein
and	O
interfering	O
with	O
its	O
function	O
and	O
/	O
or	O
recruitment	O
to	O
CREB	O
-	O
responsive	O
promoter	O
sequences	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
Foxp3	B-Protein
functions	O
as	O
a	O
potent	O
repressor	O
of	O
NF	O
-	O
kappaB	O
-	O
and	O
CREB	O
-	O
dependent	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
appears	O
to	O
be	O
dispensable	O
for	O
mediating	O
these	O
effects	O
,	O
at	O
least	O
in	O
T	O
cell	O
populations	O
.	O

This	O
observation	O
may	O
become	O
important	O
in	O
light	O
of	O
recent	O
reports	O
suggesting	O
that	O
Foxp3	B-Protein
expression	O
in	O
thymic	O
epithelial	O
cells	O
was	O
crucial	O
for	O
directing	O
development	O
of	O
T	O
cells	O
in	O
the	O
thymus	O
[	O
42	O
]	O
.	O

Interestingly	O
,	O
the	O
majority	O
of	O
the	O
genetic	O
mutations	O
associated	O
with	O
IPEX	O
,	O
a	O
severe	O
autoimmune	O
disorder	O
caused	O
by	O
functional	O
inactivation	O
of	O
Foxp3	B-Protein
,	O
map	O
to	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
or	O
the	O
leucine	O
zipper	O
domain	O
in	O
the	O
central	O
region	O
of	O
the	O
protein	O
.	O

Only	O
one	O
mutation	O
associated	O
with	O
IPEX	O
to	O
date	O
has	O
been	O
mapped	O
to	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
[	O
43	O
]	O
.	O

It	O
is	O
possible	O
that	O
the	O
FKH	O
domain	O
has	O
a	O
complex	O
tertiary	O
structure	O
that	O
is	O
particularly	O
sensitive	O
to	O
misfolding	O
caused	O
by	O
genetic	O
mutations	O
and	O
that	O
an	O
intact	O
FKH	O
domain	O
is	O
absolutely	O
critical	O
for	O
promoting	O
Foxp3	B-Protein
function	O
in	O
the	O
nucleus	O
,	O
whereas	O
the	O
structure	O
of	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
may	O
tolerate	O
certain	O
mutations	O
as	O
long	O
as	O
the	O
NF	O
-	O
kappaB	O
/	O
NF	O
-	O
AT	O
binding	O
motif	O
remains	O
unaltered	O
.	O

This	O
motif	O
may	O
also	O
include	O
the	O
zinc	O
finger	O
domain	O
.	O

A	O
logical	O
region	O
that	O
may	O
be	O
targeted	O
by	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
of	O
Foxp3	B-Protein
is	O
the	O
Rel	O
homology	O
domain	O
found	O
in	O
both	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
family	O
proteins	O
.	O

A	O
region	O
that	O
may	O
also	O
be	O
important	O
with	O
respect	O
to	O
Foxp3	B-Protein
function	O
is	O
the	O
leucine	O
zipper	O
domain	O
,	O
as	O
demonstrated	O
by	O
the	O
number	O
of	O
mutations	O
associated	O
with	O
IPEX	O
that	O
have	O
been	O
mapped	O
in	O
this	O
region	O
of	O
Foxp3	B-Protein
.	O

The	O
role	O
of	O
this	O
domain	O
in	O
Foxp3	B-Protein
function	O
remains	O
uncharacterized	O
,	O
but	O
may	O
play	O
a	O
role	O
in	O
dimer	O
formation	O
as	O
it	O
does	O
in	O
other	O
Foxp	O
family	O
members	O
[	O
44	O
]	O
.	O

Because	O
the	O
pathogenesis	O
of	O
a	O
number	O
of	O
retroviral	O
-	O
induced	O
immunologic	O
disorders	O
such	O
as	O
HIV	O
-	O
1	O
/	O
AIDS	O
and	O
HTLV	O
-	O
I	O
/	O
HAM	O
/	O
TSP	O
have	O
been	O
associated	O
with	O
dysregulation	O
of	O
Foxp3	B-Protein
expression	O
[	O
8	O
,	O
45	O
]	O
,	O
we	O
also	O
examined	O
the	O
role	O
of	O
Foxp3	B-Protein
in	O
retroviral	O
gene	O
expression	O
.	O

HIV	O
-	O
1	O
LTR	O
activation	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
is	O
critically	O
dependent	O
on	O
two	O
tandem	O
NF	O
-	O
kappaB	O
sites	O
located	O
between	O
nucleotide	O
positions	O
-	O
102	O
and	O
-	O
81	O
within	O
the	O
HIV	O
-	O
1	O
enhancer	O
region	O
,	O
whereas	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
HTLV	O
-	O
I	O
-	O
encoded	O
transactivator	O
protein	O
Tax	B-Protein
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
[	O
18	O
]	O
.	O

To	O
our	O
knowledge	O
for	O
the	O
first	O
time	O
,	O
Foxp3	B-Protein
was	O
shown	O
to	O
have	O
a	O
direct	O
effect	O
on	O
HIV	O
-	O
1	O
LTR	O
transcription	O
.	O

Deletion	O
of	O
the	O
NF	O
-	O
kappaB	O
sites	O
within	O
the	O
HIV	O
-	O
1	O
enhancer	O
region	O
reduced	O
the	O
responsiveness	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
to	O
Foxp3	B-Protein
-	O
mediated	O
suppression	O
.	O

In	O
addition	O
,	O
the	O
FKH	O
domain	O
of	O
Foxp3	B-Protein
was	O
required	O
for	O
this	O
inhibitory	O
effect	O
in	O
HEK	O
293T	O
cells	O
,	O
but	O
not	O
in	O
Jurkat	O
T	O
cells	O
,	O
similar	O
to	O
Foxp3	B-Protein
-	O
mediated	O
suppression	O
of	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
.	O

The	O
direct	O
effect	O
of	O
Foxp3	B-Protein
down	O
-	O
regulating	O
HIV	O
-	O
1	O
gene	O
expression	O
correlates	O
well	O
with	O
recently	O
reported	O
evidence	O
indicating	O
that	O
higher	O
regulatory	O
activity	O
of	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
from	O
HIV	O
-	O
1	O
-	O
infected	O
patients	O
was	O
associated	O
with	O
lower	O
HIV	O
-	O
1	O
viral	O
loads	O
in	O
these	O
patients	O
[	O
46	O
]	O
.	O

Foxp3	B-Protein
also	O
affected	O
two	O
well	O
-	O
known	O
functions	O
of	O
HTLV	O
-	O
I	O
Tax	B-Protein
:	O
transactivation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
and	O
,	O
most	O
surprisingly	O
,	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

Transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
by	O
Tax	B-Protein
involves	O
the	O
interaction	O
of	O
ATF	O
/	O
CREB	O
factors	O
with	O
Tax	B-Protein
in	O
the	O
nucleus	O
.	O

Binding	O
of	O
Tax	B-Protein
enhances	O
ATF	O
/	O
CREB	O
dimerization	O
and	O
promotes	O
assembly	O
of	O
Tax	B-Protein
-	O
ATF	O
/	O
CREB	O
complexes	O
onto	O
specific	O
sequences	O
in	O
the	O
viral	O
promoter	O
known	O
as	O
Tax	O
-	O
responsive	O
elements	O
.	O

This	O
series	O
of	O
steps	O
allows	O
Tax	B-Protein
to	O
recruit	O
coactivator	O
proteins	O
CBP	B-Protein
/	O
p300	B-Protein
to	O
the	O
viral	O
promoter	O
and	O
facilitate	O
a	O
high	O
level	O
of	O
viral	O
gene	O
expression	O
[	O
24	O
-	O
26	O
]	O
.	O

Transactivation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
Tax	B-Protein
was	O
inhibited	O
by	O
overexpression	O
of	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
but	O
not	O
deltaFKH	B-Protein
,	O
as	O
seen	O
with	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
in	O
HEK	O
293T	O
cells	O
.	O

However	O
,	O
Tax	B-Protein
-	O
mediated	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
was	O
inhibited	O
by	O
overexpression	O
of	O
both	O
full	O
-	O
length	O
Foxp3	B-Protein
as	O
well	O
as	O
deltaFKH	B-Protein
in	O
both	O
HEK	O
293T	O
cells	O
and	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

We	O
demonstrated	O
that	O
Foxp3	B-Protein
did	O
not	O
directly	O
affect	O
the	O
functioning	O
of	O
Tax	B-Protein
,	O
but	O
rather	O
Foxp3	B-Protein
targeted	O
the	O
transcription	O
factors	O
required	O
for	O
Tax	B-Protein
transactivation	O
(	O
i	O
.	O
e	O
.	O
,	O
NF	O
-	O
kappaB	O
and	O
a	O
then	O
-	O
unknown	O
cellular	O
factor	O
,	O
which	O
we	O
identified	O
in	O
this	O
study	O
as	O
CREB	O
)	O
.	O

The	O
negative	O
effect	O
of	O
Foxp3	B-Protein
on	O
HTLV	O
-	O
I	O
gene	O
expression	O
was	O
confirmed	O
utilizing	O
an	O
HTLV	O
-	O
I	O
infectious	O
molecular	O
clone	O
.	O

Importantly	O
,	O
we	O
demonstrated	O
that	O
HTLV	O
-	O
I	O
-	O
infected	O
individuals	O
with	O
the	O
highest	O
levels	O
of	O
Foxp3	B-Protein
protein	O
expression	O
within	O
the	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
population	O
exhibited	O
lower	O
proviral	O
loads	O
than	O
did	O
individuals	O
with	O
the	O
lowest	O
levels	O
of	O
Foxp3	B-Protein
protein	O
expression	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
directly	O
correlates	O
with	O
HTLV	O
-	O
I	O
Tax	B-Protein
mRNA	O
load	O
,	O
the	O
frequency	O
of	O
immunopathogenic	O
virus	O
-	O
specific	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
and	O
disease	O
severity	O
in	O
patients	O
with	O
HAM	O
/	O
TSP	O
[	O
47	O
]	O
.	O

These	O
results	O
have	O
important	O
implications	O
on	O
the	O
utility	O
of	O
Foxp3	B-Protein
in	O
controlling	O
viral	O
gene	O
expression	O
and	O
thus	O
pathogenesis	O
of	O
HAM	O
/	O
TSP	O
.	O

Therefore	O
,	O
Foxp3	B-Protein
becomes	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
novel	O
therapeutic	O
applications	O
directed	O
at	O
modulating	O
the	O
expression	O
of	O
this	O
important	O
regulatory	O
protein	O
,	O
especially	O
in	O
light	O
of	O
recent	O
observations	O
that	O
the	O
expression	O
of	O
Foxp3	B-Protein
can	O
also	O
be	O
down	O
-	O
regulated	O
by	O
HTLV	O
-	O
I	O
Tax	B-Protein
[	O
8	O
]	O
.	O

As	O
the	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
depends	O
primarily	O
on	O
ATF	O
/	O
CREB	O
proteins	O
(	O
whether	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
Tax	B-Protein
)	O
,	O
we	O
investigated	O
whether	O
Foxp3	B-Protein
could	O
interact	O
with	O
this	O
additional	O
cellular	O
signaling	O
pathway	O
.	O

While	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
CREB	O
is	O
,	O
in	O
most	O
cases	O
,	O
constitutive	O
,	O
the	O
transactivation	O
potential	O
of	O
CREB	O
is	O
regulated	O
by	O
the	O
phosphorylation	O
of	O
CREB	O
and	O
recruitment	O
of	O
CBP	B-Protein
/	O
p300	B-Protein
[	O
48	O
]	O
.	O

Our	O
data	O
demonstrate	O
that	O
Foxp3	B-Protein
interferes	O
with	O
the	O
latter	O
of	O
these	O
two	O
processes	O
and	O
that	O
the	O
recruitment	O
of	O
the	O
coactivator	O
protein	O
p300	B-Protein
,	O
and	O
resulting	O
transcriptional	O
activation	O
are	O
blocked	O
by	O
Foxp3	B-Protein
.	O

This	O
may	O
be	O
the	O
result	O
of	O
the	O
physical	O
interaction	O
we	O
detected	O
between	O
Foxp3	B-Protein
and	O
p300	B-Protein
.	O

With	O
respect	O
to	O
HTLV	O
-	O
I	O
LTR	O
activity	O
,	O
while	O
full	O
-	O
length	O
Foxp3	B-Protein
inhibited	O
both	O
basal	O
and	O
Tax	B-Protein
-	O
dependent	O
transcription	O
by	O
~	O
50	O
%	O
,	O
deltaFKH	B-Protein
appeared	O
less	O
effective	O
in	O
suppressing	O
basal	O
activation	O
(	O
~	O
25	O
%	O
inhibition	O
)	O
compared	O
to	O
Tax	B-Protein
-	O
dependent	O
activation	O
(	O
~	O
50	O
%	O
inhibition	O
)	O
.	O

The	O
effect	O
of	O
deltaFKH	B-Protein
on	O
basal	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
in	O
HEK	O
293T	O
cells	O
was	O
very	O
similar	O
to	O
that	O
shown	O
for	O
a	O
synthetic	O
CREB	O
reporter	O
,	O
suggesting	O
that	O
the	O
FKH	O
domain	O
of	O
Foxp3	B-Protein
is	O
important	O
at	O
some	O
level	O
.	O

As	O
observed	O
with	O
NF	O
-	O
kappaB	O
activation	O
,	O
the	O
Foxp3	B-Protein
mutant	O
lacking	O
the	O
FKH	O
domain	O
was	O
a	O
stronger	O
inhibitor	O
of	O
CREB	O
activation	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
than	O
in	O
HEK	O
293T	O
epithelial	O
cells	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
the	O
FKH	O
domain	O
is	O
dispensable	O
for	O
the	O
proper	O
functioning	O
of	O
Foxp3	B-Protein
with	O
respect	O
to	O
both	O
NF	O
-	O
kappaB	O
and	O
CREB	O
activation	O
.	O

In	O
summary	O
,	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
direct	O
evidence	O
implicating	O
a	O
role	O
for	O
the	O
Treg	O
-	O
specific	O
transcription	O
factor	O
Foxp3	B-Protein
in	O
regulating	O
retroviral	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
we	O
identify	O
the	O
CREB	O
pathway	O
as	O
a	O
molecular	O
target	O
of	O
Foxp3	B-Protein
.	O

Since	O
CREB	O
has	O
been	O
shown	O
to	O
regulate	O
multiple	O
genes	O
involved	O
in	O
transcription	O
(	O
e	O
.	O
g	O
.	O
,	O
JunD	B-Protein
,	O
c	B-Protein
-	I-Protein
Fos	I-Protein
,	O
signal	B-Protein
transducer	I-Protein
of	I-Protein
activated	I-Protein
T	I-Protein
cells	I-Protein
3	I-Protein
[	O
STAT3	B-Protein
]	O
)	O
,	O
cell	O
cycle	O
(	O
e	O
.	O
g	O
.	O
,	O
p15INK4b	B-Protein
,	O
cyclin	B-Protein
A	I-Protein
,	O
cyclin	B-Protein
D1	I-Protein
)	O
,	O
and	O
immune	O
regulation	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
T	B-Protein
-	I-Protein
cell	I-Protein
receptor	I-Protein
alpha	I-Protein
)	O
(	O
reviewed	O
in	O
[	O
48	O
]	O
)	O
,	O
the	O
findings	O
presented	O
in	O
this	O
report	O
broaden	O
the	O
potential	O
range	O
of	O
signaling	O
pathways	O
under	O
the	O
control	O
of	O
the	O
regulatory	O
protein	O
Foxp3	B-Protein
.	O

Our	O
evidence	O
stresses	O
the	O
importance	O
of	O
Foxp3	B-Protein
expression	O
and	O
Treg	O
function	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
protective	O
immunity	O
against	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
.	O

Based	O
on	O
recent	O
findings	O
,	O
Foxp3	B-Protein
may	O
limit	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
transcription	O
by	O
interfering	O
with	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
CREB	O
pathways	O
.	O

However	O
,	O
observing	O
that	O
this	O
inhibitory	O
effect	O
is	O
not	O
absolute	O
,	O
a	O
low	O
level	O
of	O
viral	O
gene	O
expression	O
may	O
persist	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
in	O
particular	O
regulatory	O
T	O
cells	O
,	O
which	O
are	O
known	O
reservoirs	O
of	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
)	O
and	O
result	O
in	O
the	O
accumulation	O
of	O
viral	O
proteins	O
that	O
either	O
stimulate	O
NF	O
-	O
kappaB	O
and	O
/	O
or	O
CREB	O
activation	O
or	O
directly	O
inhibit	O
Foxp3	B-Protein
expression	O
or	O
function	O
.	O

The	O
imbalance	O
of	O
NF	O
-	O
kappaB	O
and	O
CREB	O
activation	O
caused	O
by	O
these	O
viral	O
gene	O
products	O
may	O
be	O
a	O
crucial	O
step	O
in	O
the	O
pathogenesis	O
of	O
virus	O
-	O
induced	O
immunological	O
disorders	O
such	O
as	O
AIDS	O
and	O
HAM	O
/	O
TSP	O
.	O

Future	O
studies	O
will	O
be	O
directed	O
at	O
identifying	O
and	O
characterizing	O
cellular	O
proteins	O
that	O
interact	O
with	O
Foxp3	B-Protein
both	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
,	O
in	O
order	O
to	O
better	O
address	O
how	O
Foxp3	B-Protein
functions	O
to	O
guide	O
the	O
development	O
and	O
function	O
of	O
regulatory	O
T	O
cells	O
in	O
health	O
and	O
disease	O
.	O

Cell	O
culture	O
.	O

HEK	O
293T	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
medium	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Jurkat	O
T	O
cells	O
and	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
medium	O
(	O
Invitrogen	O
)	O
.	O

Media	O
were	O
supplemented	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
100	O
U	O
/	O
ml	O
penicillin	O
,	O
100	O
mug	O
/	O
ml	O
streptomycin	O
(	O
Cambrex	O
,	O
East	O
Rutherford	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
,	O
and	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
Atlanta	O
Biologicals	O
,	O
Norcross	O
,	O
Georgia	O
,	O
United	O
States	O
)	O
.	O

Patients	O
and	O
cell	O
preparation	O
.	O

PBMCs	O
were	O
prepared	O
by	O
centrifugation	O
over	O
Ficoll	O
-	O
Hypaque	O
gradients	O
(	O
BioWhittaker	O
,	O
Walkersville	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
from	O
eight	O
HAM	O
/	O
TSP	O
patients	O
and	O
eight	O
ACs	O
,	O
and	O
the	O
cells	O
were	O
viably	O
cryopreserved	O
in	O
liquid	O
nitrogen	O
until	O
tested	O
.	O

HAM	O
/	O
TSP	O
was	O
diagnosed	O
according	O
to	O
WHO	O
guidelines	O
[	O
49	O
]	O
.	O

HTLV	O
-	O
I	O
seropositivity	O
was	O
determined	O
by	O
ELISA	O
(	O
Abbott	O
Laboratories	O
,	O
Abbott	O
Park	O
,	O
Illinois	O
,	O
United	O
States	O
)	O
,	O
with	O
confirmation	O
by	O
Western	O
blot	O
analysis	O
(	O
Genelabs	O
Technologies	O
,	O
Redwood	O
City	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Blood	O
samples	O
were	O
obtained	O
after	O
informed	O
consent	O
as	O
part	O
of	O
a	O
clinical	O
protocol	O
reviewed	O
and	O
approved	O
by	O
the	O
NIH	O
institutional	O
review	O
panel	O
.	O

Plasmids	O
.	O

Expression	O
vectors	O
encoding	O
human	O
Foxp3	B-Protein
(	O
pCMV	O
-	O
Foxp3	B-Protein
-	O
IRES	O
-	O
EGFP	O
)	O
and	O
human	O
Foxp3	B-Protein
lacking	O
the	O
forkhead	O
(	O
FKH	O
)	O
domain	O
(	O
pCMV	O
-	O
deltaFKH	O
-	O
IRES	O
-	O
EGFP	O
)	O
were	O
generous	O
gifts	O
from	O
S	O
.	O

Ziegler	O
(	O
Benaroya	O
Research	O
Institute	O
)	O
.	O

pEGFP	O
-	O
C2	O
was	O
provided	O
by	O
I	O
.	O

Lipinski	O
(	O
NIDDK	O
/	O
NIH	O
)	O
.	O

pcDNA3	O
was	O
provided	O
by	O
K	O
.	O

T	O
.	O

Jeang	O
(	O
NIAID	O
/	O
NIH	O
)	O
.	O

pCMV4	O
-	O
Tax	B-Protein
was	O
a	O
generous	O
gift	O
from	O
W	O
.	O

Greene	O
(	O
University	O
of	O
California	O
San	O
Francisco	O
)	O
.	O

pGL4	O
-	O
luc2	O
and	O
pGL4	O
-	O
TKhRluc2	O
were	O
purchased	O
from	O
Promega	O
(	O
Madison	O
,	O
Wisconsin	O
,	O
United	O
States	O
)	O
.	O

pUC18	O
was	O
purchased	O
from	O
Stratagene	O
(	O
La	O
Jolla	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

HIV	O
-	O
1	O
wt	O
LTR	O
and	O
HIV	O
-	O
1	O
delta	O
-	O
kappaB	O
LTR	O
luciferase	B-Protein
reporter	O
vectors	O
were	O
constructed	O
by	O
cloning	O
the	O
XhoI	O
/	O
HindIII	O
LTR	O
fragments	O
from	O
pHIV	O
-	O
CAT	B-Protein
and	O
pdelta	O
-	O
kappaB	O
-	O
HIV	O
-	O
CAT	B-Protein
(	O
AIDS	O
Research	O
and	O
Reference	O
Reagent	O
Program	O
,	O
NIAID	O
/	O
NIH	O
)	O
into	O
the	O
multiple	O
cloning	O
site	O
of	O
pGL4	O
-	O
luc2	O
.	O

NF	O
-	O
kappaB	O
,	O
HTLV	O
-	O
I	O
LTR	O
,	O
and	O
CREB	O
luciferase	B-Protein
reporter	O
and	O
pCMV	O
-	O
p300	B-Protein
-	O
HA	O
expression	O
vectors	O
were	O
generously	O
provided	O
by	O
B	O
.	O

Wigdahl	O
(	O
Drexel	O
University	O
College	O
of	O
Medicine	O
)	O
.	O

HTLV	O
-	O
I	O
pACH	O
infectious	O
molecular	O
clone	O
has	O
been	O
described	O
previously	O
[	O
30	O
]	O
.	O

pFR	O
-	O
luc	O
,	O
pFA	O
-	O
CMV	O
,	O
pFA2	O
-	O
CREB	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
pFA2	O
-	O
c	B-Protein
-	I-Protein
Jun	I-Protein
were	O
purchased	O
from	O
Stratagene	O
.	O

pFA	O
-	O
Tax	B-Protein
(	O
encoding	O
a	O
fusion	O
protein	O
consisting	O
of	O
the	O
Gal4	B-Protein
DNA	O
-	O
binding	O
domain	O
fused	O
in	O
-	O
frame	O
to	O
HTLV	O
-	O
I	O
Tax	B-Protein
)	O
was	O
constructed	O
by	O
PCR	O
amplification	O
of	O
HTLV	O
-	O
I	O
Tax	B-Protein
using	O
pCMV4	O
-	O
Tax	B-Protein
as	O
a	O
template	O
and	O
BamHI	O
/	O
BglII	O
-	O
tagged	O
primers	O
.	O

The	O
amplified	O
insert	O
was	O
digested	O
and	O
ligated	O
into	O
the	O
BamHI	O
/	O
BglII	O
sites	O
of	O
pFA	O
-	O
CMV	O
.	O

Plasmid	O
contents	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

Isolation	O
of	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
were	O
isolated	O
from	O
cryopreserved	O
healthy	O
donor	O
PBMCs	O
by	O
negative	O
selection	O
with	O
the	O
CD4	B-Protein
+	O
T	O
Cell	O
Isolation	O
Kit	O
II	O
(	O
Miltenyi	O
Biotech	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
guidelines	O
.	O

Purity	O
of	O
negatively	O
selected	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
consistently	O
higher	O
than	O
96	O
%	O
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

Transient	O
expression	O
and	O
luciferase	B-Protein
assays	O
.	O

HEK	O
293T	O
cells	O
were	O
plated	O
at	O
a	O
density	O
of	O
5	O
x	O
105	O
cells	O
/	O
well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
(	O
BD	O
Biosciences	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
1	O
d	O
prior	O
to	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
~	O
2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
.	O

Jurkat	O
T	O
cells	O
were	O
plated	O
at	O
1	O
x	O
106	O
cells	O
/	O
well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
the	O
day	O
of	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
~	O
2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
.	O

Primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
2	O
x	O
106	O
)	O
were	O
nucleofected	O
with	O
the	O
specified	O
plasmid	O
DNA	O
(	O
5	O
mug	O
total	O
)	O
using	O
the	O
Human	O
T	O
Cell	O
Nucleofection	O
Kit	O
(	O
Amaxa	O
,	O
Gaithersburg	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
.	O

Forskolin	O
(	O
10	O
muM	O
;	O
Calbiochem	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
was	O
added	O
in	O
some	O
experiments	O
20	O
h	O
posttransfection	O
.	O

Cells	O
were	O
harvested	O
24	O
h	O
posttransfection	O
and	O
luciferase	B-Protein
activity	O
was	O
analyzed	O
using	O
the	O
Dual	O
-	O
luciferase	B-Protein
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
and	O
a	O
Monolight	O
2010	O
luminometer	O
(	O
Analytical	O
Luminescence	O
Laboratory	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
guidelines	O
.	O

pGL4	O
-	O
TKhRluc2	O
was	O
used	O
as	O
an	O
internal	O
control	O
to	O
normalize	O
for	O
transfection	O
efficiency	O
.	O

Nucleofected	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
also	O
monitored	O
for	O
transfection	O
efficiency	O
and	O
cell	O
viability	O
24	O
h	O
posttransfection	O
as	O
follows	O
.	O

Transfection	O
efficiency	O
was	O
routinely	O
~	O
30	O
%	O
as	O
determined	O
by	O
flow	O
cytometric	O
analysis	O
of	O
EGFP	O
expression	O
.	O

Cell	O
viability	O
,	O
determined	O
by	O
staining	O
with	O
7	O
-	O
amino	O
-	O
actinomycin	O
D	O
(	O
7	O
-	O
AAD	O
;	O
BD	O
Biosciences	O
)	O
,	O
was	O
routinely	O
~	O
70	O
%	O
.	O

Both	O
transfection	O
efficiency	O
and	O
cell	O
viability	O
in	O
nucleofected	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
independent	O
of	O
the	O
plasmids	O
used	O
.	O

Foxp3	B-Protein
and	O
HTLV	O
-	O
I	O
Tax	B-Protein
expression	O
analysis	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
Foxp3	B-Protein
and	O
HTLV	O
-	O
I	O
Tax	B-Protein
expression	O
was	O
performed	O
as	O
previously	O
described	O
[	O
8	O
,	O
47	O
]	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
extracted	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
California	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
guidelines	O
,	O
and	O
cDNA	O
was	O
synthesized	O
by	O
reverse	O
transcription	O
using	O
TaqMan	O
Gold	O
RT	O
-	O
PCR	O
Kit	O
using	O
random	O
hexamer	O
primers	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Foxp3	B-Protein
and	O
HTLV	O
-	O
I	O
Tax	B-Protein
mRNA	O
expression	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
using	O
ABI	O
PRISM	O
7700	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
normalized	O
values	O
in	O
each	O
sample	O
were	O
calculated	O
as	O
the	O
relative	O
quantity	O
of	O
Foxp3	B-Protein
or	O
HTLV	O
-	O
I	O
Tax	B-Protein
mRNA	O
expression	O
divided	O
by	O
the	O
relative	O
quantity	O
of	O
HPRT	B-Protein
mRNA	O
expression	O
.	O

The	O
values	O
were	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
normalized	O
Foxp3	B-Protein
or	O
HTLV	O
-	O
I	O
Tax	B-Protein
expression	O
=	O
2Ct	O
value	O
of	O
HPRT	B-Protein
-	O
Ct	O
value	O
of	O
Foxp3	B-Protein
or	O
HTLV	O
-	O
I	O
Tax	B-Protein
.	O

Real	O
-	O
time	O
PCR	O
.	O

Real	O
-	O
time	O
PCR	O
analysis	O
of	O
HTLV	O
-	O
I	O
(	O
Tax	B-Protein
)	O
proviral	O
load	O
was	O
performed	O
as	O
previously	O
described	O
[	O
47	O
,	O
50	O
]	O
.	O

DNA	O
was	O
extracted	O
from	O
1	O
x	O
106	O
cells	O
using	O
Puregene	O
DNA	O
Isolation	O
Kit	O
(	O
Gentra	O
,	O
Minneapolis	O
,	O
Minnesota	O
,	O
United	O
States	O
)	O
,	O
and	O
100	O
ng	O
of	O
the	O
sample	O
DNA	O
solution	O
was	O
analyzed	O
by	O
this	O
system	O
.	O

The	O
HTLV	O
-	O
I	O
proviral	O
DNA	O
load	O
was	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
copy	O
number	O
of	O
HTLV	O
-	O
I	O
(	O
pX	O
)	O
per	O
100	O
cells	O
=	O
(	O
copy	O
number	O
of	O
pX	O
)	O
/	O
(	O
copy	O
number	O
of	O
beta	B-Protein
-	I-Protein
actin	I-Protein
/	O
2	O
)	O
x	O
100	O
.	O

Western	O
blot	O
analysis	O
.	O

HEK	O
293T	O
cells	O
were	O
plated	O
at	O
a	O
density	O
of	O
5	O
x	O
105	O
cells	O
/	O
well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
(	O
BD	O
Biosciences	O
)	O
1	O
d	O
prior	O
to	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
(	O
Roche	O
)	O
.	O

Cells	O
were	O
harvested	O
24	O
h	O
posttransfection	O
for	O
whole	O
-	O
cell	O
lysates	O
in	O
RIPA	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
4	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
%	O
Igepal	O
(	O
NP	O
-	O
40	O
)	O
,	O
0	O
.	O
5	O
%	O
sodium	O
deoxycholate	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
PMSF	O
,	O
and	O
1x	O
Complete	O
Mini	O
Protease	O
Inhibitor	O
[	O
Roche	O
]	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
by	O
Lowry	O
assay	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
colorimetric	O
reactions	O
were	O
read	O
using	O
a	O
VersaMax	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
,	O
Sunnyvale	O
,	O
California	O
,	O
United	O
States	O
)	O
at	O
an	O
absorbance	O
of	O
750	O
nm	O
.	O

Size	O
fractionation	O
was	O
performed	O
on	O
20	O
mug	O
of	O
protein	O
/	O
sample	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
the	O
protein	O
was	O
transferred	O
to	O
nitrocellulose	O
or	O
PVDF	O
membranes	O
and	O
subjected	O
to	O
immunoblotting	O
using	O
the	O
indicated	O
antibodies	O
.	O

Foxp3	B-Protein
was	O
detected	O
using	O
rabbit	O
anti	O
-	O
human	O
Foxp3	B-Protein
polyclonal	O
antibody	O
(	O
ab4728	O
or	O
ab10563	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
United	O
Kingdom	O
)	O
and	O
anti	O
-	O
rabbit	O
IgG	O
-	O
HRP	O
secondary	O
antibody	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Beverly	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
.	O

NF	O
-	O
kappaB	O
p65	B-Protein
and	O
CREB	B-Protein
-	I-Protein
1	I-Protein
were	O
detected	O
using	O
rabbit	O
anti	O
-	O
human	O
polyclonal	O
(	O
p65	B-Protein
)	O
or	O
monoclonal	O
antibody	O
(	O
CREB	B-Protein
-	I-Protein
1	I-Protein
;	O
48H2	O
)	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

Beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
detected	O
using	O
a	O
mouse	O
monoclonal	O
antibody	O
(	O
AC	O
-	O
15	O
;	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
.	O

For	O
coimmunoprecipitation	O
analysis	O
,	O
cell	O
lysates	O
were	O
precleared	O
with	O
30	O
mul	O
of	O
protein	O
A	O
/	O
G	O
plus	O
-	O
agarose	O
beads	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
then	O
incubated	O
with	O
mouse	O
monoclonal	O
anti	O
-	O
HA	O
antibody	O
(	O
6E2	O
;	O
1	O
:	O
100	O
;	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
30	O
mul	O
of	O
protein	O
A	O
/	O
G	O
plus	O
-	O
agarose	O
beads	O
overnight	O
.	O

The	O
immunoprecipitates	O
were	O
washed	O
four	O
times	O
with	O
RIPA	O
buffer	O
,	O
resuspended	O
in	O
SDS	O
sample	O
buffer	O
,	O
and	O
heated	O
at	O
95	O
degreesC	O
for	O
5	O
min	O
.	O

Proteins	O
were	O
then	O
treated	O
as	O
described	O
for	O
Western	O
blot	O
analysis	O
.	O

Transcription	O
factor	O
DNA	O
-	O
binding	O
analysis	O
(	O
TF	O
-	O
ELISA	O
)	O
.	O

CREB	B-Protein
-	I-Protein
1	I-Protein
and	O
ATF	B-Protein
-	I-Protein
2	I-Protein
DNA	O
-	O
binding	O
activity	O
was	O
analyzed	O
with	O
the	O
TransFactor	O
Profiling	O
(	O
Inflammation	O
1	O
)	O
Kit	O
(	O
BD	O
Biosciences	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Nuclear	O
extracts	O
were	O
prepared	O
from	O
HEK	O
293T	O
cells	O
transfected	O
with	O
a	O
control	O
vector	O
(	O
EGFP	O
)	O
or	O
Foxp3	B-Protein
expression	O
vector	O
(	O
1	O
,	O
000	O
ng	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
forskolin	O
(	O
10	O
muM	O
for	O
4	O
h	O
)	O
using	O
the	O
TransFactor	O
Extraction	O
Kit	O
(	O
BD	O
Biosciences	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
using	O
a	O
Biophotometer	O
(	O
Eppendorf	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O

Nuclear	O
extracts	O
(	O
20	O
mug	O
)	O
were	O
incubated	O
in	O
preblocked	O
wells	O
containing	O
plate	O
-	O
bound	O
double	O
-	O
stranded	O
oligonucleotides	O
corresponding	O
to	O
an	O
ATF	O
/	O
CREB	O
consensus	O
sequence	O
(	O
.	O
.	O
.	O
TGACATCA	O
.	O
.	O
.	O
)	O
.	O

Wells	O
were	O
washed	O
,	O
incubated	O
with	O
the	O
appropriate	O
primary	O
antibody	O
,	O
washed	O
,	O
incubated	O
with	O
secondary	O
antibody	O
(	O
HRP	O
-	O
labeled	O
)	O
,	O
washed	O
again	O
,	O
and	O
finally	O
developed	O
with	O
TMB	O
substrate	O
.	O

Colorimetric	O
reactions	O
were	O
read	O
using	O
a	O
VersaMax	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
)	O
at	O
an	O
absorbance	O
of	O
655	O
nm	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
Foxp3	B-Protein
protein	O
expression	O
.	O

Cryopreserved	O
PBMCs	O
from	O
HAM	O
/	O
TSP	O
patients	O
or	O
HTLV	O
-	O
I	O
-	O
infected	O
ACs	O
were	O
thawed	O
and	O
washed	O
with	O
FACS	O
buffer	O
(	O
1x	O
PBS	O
,	O
0	O
.	O
1	O
%	O
NaN3	O
,	O
5	O
%	O
FBS	O
)	O
.	O

Cells	O
(	O
1	O
.	O
5	O
x	O
106	O
)	O
were	O
fixed	O
by	O
sequential	O
formaldehyde	O
/	O
methanol	O
fixation	O
as	O
follows	O
.	O

Cells	O
were	O
carefully	O
resuspended	O
in	O
FACS	O
buffer	O
and	O
fixed	O
with	O
100	O
mul	O
of	O
reagent	O
A	O
(	O
Fix	O
&	O
Perm	O
kit	O
;	O
Caltag	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
United	O
States	O
)	O
at	O
room	O
temperature	O
for	O
3	O
min	O
followed	O
by	O
2	O
ml	O
of	O
70	O
%	O
methanol	O
for	O
5	O
min	O
at	O
4	O
degreesC	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
permeabilized	O
with	O
100	O
mul	O
of	O
reagent	O
B	O
(	O
Fix	O
&	O
Perm	O
kit	O
)	O
and	O
stained	O
for	O
intracellular	O
Foxp3	B-Protein
with	O
mouse	O
anti	O
-	O
human	O
Foxp3	B-Protein
monoclonal	O
antibody	O
(	O
0	O
.	O
5	O
mug	O
of	O
ab22510	O
;	O
Abcam	O
)	O
or	O
the	O
appropriate	O
isotype	O
control	O
for	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
stained	O
with	O
Cy5	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
immunoglobulin	O
F	O
(	O
ab	O
'	O
)	O
2	O
secondary	O
antibody	O
(	O
Caltag	O
Laboratories	O
)	O
for	O
an	O
additional	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
stained	O
for	O
surface	O
CD4	B-Protein
expression	O
with	O
PE	O
-	O
labeled	O
anti	O
-	O
CD4	B-Protein
(	O
BD	O
)	O
and	O
CD25	B-Protein
expression	O
with	O
FITC	O
-	O
labeled	O
anti	O
-	O
CD25	B-Protein
(	O
BD	O
)	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
analyzed	O
on	O
a	O
FACSCalibur	O
(	O
BD	O
)	O
.	O

Data	O
analysis	O
was	O
performed	O
using	O
FlowJo	O
(	O
Tree	O
Star	O
,	O
Ashland	O
,	O
Oregon	O
,	O
United	O
States	O
)	O
.	O

Statistical	O
analyses	O
.	O

The	O
Mann	O
-	O
Whitney	O
U	O
test	O
was	O
used	O
to	O
compare	O
the	O
data	O
between	O
patients	O
with	O
HAM	O
/	O
TSP	O
and	O
AC	O
.	O

EBV	O
Latent	B-Protein
Membrane	I-Protein
Protein	I-Protein
1	I-Protein
Activates	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
in	O
B	O
Cell	O
Lymphomas	O

Latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
is	O
the	O
major	O
oncoprotein	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
transgenic	O
mice	O
,	O
LMP1	B-Protein
promotes	O
increased	O
lymphoma	O
development	O
by	O
12	O
mo	O
of	O
age	O
.	O

This	O
study	O
reveals	O
that	O
lymphoma	O
develops	O
in	O
B	O
-	O
1a	O
lymphocytes	O
,	O
a	O
population	O
that	O
is	O
associated	O
with	O
transformation	O
in	O
older	O
mice	O
.	O

The	O
lymphoma	O
cells	O
have	O
deregulated	O
cell	O
cycle	O
markers	O
,	O
and	O
inhibitors	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
block	O
the	O
enhanced	O
viability	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
in	O
vitro	O
.	O

Lymphoma	O
cells	O
are	O
independent	O
of	O
IL4	B-Protein
/	O
Stat6	B-Protein
signaling	O
for	O
survival	O
and	O
proliferation	O
,	O
but	O
have	O
constitutively	O
activated	O
Stat3	B-Protein
signaling	O
.	O

These	O
same	O
targets	O
are	O
also	O
deregulated	O
in	O
wild	O
-	O
type	O
B	O
-	O
1a	O
lymphomas	O
that	O
arise	O
spontaneously	O
through	O
age	O
predisposition	O
.	O

These	O
results	O
suggest	O
that	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
pathways	O
may	O
serve	O
as	O
effective	O
targets	O
in	O
the	O
treatment	O
of	O
EBV	O
-	O
associated	O
B	O
cell	O
lymphomas	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
ubiquitous	O
gamma	O
-	O
herpesvirus	O
that	O
infects	O
humans	O
predominantly	O
at	O
an	O
early	O
age	O
with	O
greater	O
than	O
90	O
%	O
of	O
the	O
adult	O
population	O
infected	O
with	O
EBV	O
[	O
1	O
]	O
.	O

EBV	O
is	O
linked	O
to	O
the	O
development	O
of	O
both	O
B	O
lymphocyte	O
and	O
epithelial	O
cell	O
malignancies	O
,	O
including	O
Burkitt	O
lymphoma	O
,	O
Hodgkin	O
disease	O
(	O
HD	O
)	O
,	O
and	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
,	O
and	O
cancers	O
linked	O
to	O
immunosuppression	O
,	O
including	O
post	O
-	O
transplant	O
lymphoma	O
and	O
AIDS	O
-	O
associated	O
lymphomas	O
[	O
2	O
,	O
3	O
]	O
.	O

In	O
vitro	O
infection	O
of	O
B	O
lymphocytes	O
with	O
EBV	O
induces	O
permanent	O
growth	O
transformation	O
,	O
and	O
this	O
ability	O
to	O
affect	O
cell	O
growth	O
regulation	O
likely	O
contributes	O
to	O
the	O
development	O
of	O
cancer	O
.	O

Many	O
of	O
the	O
viral	O
proteins	O
expressed	O
in	O
transformed	O
cells	O
,	O
including	O
the	O
EBV	O
nuclear	O
antigens	O
and	O
latent	O
membrane	O
proteins	O
,	O
have	O
profound	O
effects	O
on	O
cell	O
growth	O
regulation	O
and	O
are	O
required	O
for	O
EBV	O
latent	O
infection	O
and	O
B	O
cell	O
transformation	O
[	O
1	O
]	O
.	O

Latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
is	O
considered	O
the	O
major	O
oncoprotein	O
of	O
EBV	O
,	O
as	O
it	O
transforms	O
rodent	O
fibroblasts	O
to	O
tumorigenicity	O
in	O
nude	O
mice	O
and	O
is	O
expressed	O
in	O
HD	O
,	O
NPC	O
,	O
and	O
immunosuppression	O
-	O
associated	O
tumors	O
[	O
4	O
-	O
8	O
]	O
.	O

In	O
B	O
lymphocytes	O
,	O
LMP1	B-Protein
mimics	O
CD40	B-Protein
signaling	O
,	O
and	O
both	O
LMP1	B-Protein
and	O
CD40	B-Protein
are	O
essential	O
for	O
EBV	O
-	O
mediated	O
B	O
cell	O
transformation	O
[	O
9	O
-	O
11	O
]	O
.	O

While	O
CD40	B-Protein
interacts	O
with	O
CD40	B-Protein
ligand	I-Protein
expressed	O
on	O
activated	O
T	O
cells	O
to	O
induce	O
B	O
cell	O
activation	O
and	O
differentiation	O
,	O
LMP1	B-Protein
acts	O
as	O
a	O
constitutive	O
signal	O
through	O
ligand	O
-	O
independent	O
oligomerization	O
.	O

LMP1	B-Protein
and	O
CD40	B-Protein
interact	O
with	O
the	O
same	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	O
-	O
associated	O
factors	O
(	O
TRAFs	O
)	O
leading	O
to	O
activation	O
of	O
NFkappaB	O
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
N	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
and	O
p38	O
MAPK	O
signaling	O
pathways	O
[	O
12	O
-	O
16	O
]	O
.	O

Activation	O
of	O
NFkappaB	O
is	O
required	O
for	O
EBV	O
-	O
induced	O
B	O
cell	O
transformation	O
and	O
its	O
inhibition	O
rapidly	O
results	O
in	O
cell	O
death	O
[	O
17	O
,	O
18	O
]	O
.	O

Recent	O
studies	O
indicate	O
that	O
LMP1	B-Protein
also	O
activates	O
phosphatidylinositol	O
3	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	B-Protein
signaling	O
and	O
that	O
this	O
activation	O
is	O
required	O
for	O
LMP1	B-Protein
-	O
mediated	O
transformation	O
of	O
rodent	O
fibroblasts	O
[	O
5	O
,	O
19	O
]	O
.	O

In	O
vitro	O
,	O
primary	O
B	O
cells	O
can	O
be	O
maintained	O
by	O
CD40	B-Protein
ligation	O
in	O
combination	O
with	O
IL4	B-Protein
treatment	O
.	O

In	O
vivo	O
,	O
CD40	B-Protein
signaling	O
is	O
necessary	O
for	O
germinal	O
center	O
(	O
GC	O
)	O
formation	O
such	O
that	O
mice	O
deficient	O
for	O
CD40	B-Protein
or	O
CD40L	B-Protein
are	O
unable	O
to	O
form	O
GCs	O
in	O
response	O
to	O
T	O
cell	O
-	O
dependent	O
antigens	O
[	O
20	O
,	O
21	O
]	O
.	O

Both	O
the	O
membrane	O
proximal	O
and	O
distal	O
cytoplasmic	O
regions	O
of	O
CD40	B-Protein
that	O
bind	O
TRAF6	B-Protein
and	O
TRAFs2	B-Protein
/	O
3	B-Protein
/	O
5	B-Protein
,	O
respectively	O
,	O
are	O
necessary	O
for	O
GC	O
formation	O
,	O
but	O
either	O
region	O
is	O
sufficient	O
to	O
induce	O
extrafollicular	O
B	O
cell	O
differentiation	O
and	O
restore	O
low	O
affinity	O
antibody	O
production	O
[	O
22	O
]	O
.	O

Functionally	O
,	O
LMP1	B-Protein
can	O
rescue	O
CD40	B-Protein
-	O
deficient	O
mice	O
and	O
restore	O
immunoglobulin	O
(	O
Ig	O
)	O
class	O
switching	O
,	O
most	O
likely	O
because	O
LMP1	B-Protein
recruits	O
similar	O
TRAF	O
molecules	O
,	O
TRAFs	B-Protein
1	I-Protein
/	O
2	B-Protein
/	O
3	B-Protein
/	O
5	B-Protein
and	O
TRAF6	B-Protein
,	O
through	O
the	O
C	O
-	O
terminal	O
activation	O
regions	O
1	O
and	O
2	O
domains	O
,	O
respectively	O
.	O

However	O
,	O
LMP1	B-Protein
is	O
unable	O
to	O
restore	O
affinity	O
maturation	O
and	O
GC	O
formation	O
[	O
23	O
]	O
.	O

Several	O
EBV	O
transforming	O
proteins	O
have	O
been	O
studied	O
in	O
transgenic	O
mouse	O
models	O
,	O
however	O
,	O
only	O
LMP1	B-Protein
induces	O
tumor	O
development	O
when	O
expressed	O
under	O
the	O
control	O
of	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
[	O
24	O
-	O
26	O
]	O
.	O

The	O
LMP1	B-Protein
transgenic	O
mice	O
(	O
IgLMP1	O
)	O
express	O
LMP1	B-Protein
in	O
B	O
lymphocytes	O
,	O
and	O
in	O
mice	O
older	O
than	O
12	O
mo	O
,	O
lymphoma	O
develops	O
with	O
increased	O
incidence	O
(	O
40	O
%	O
-	O
50	O
%	O
)	O
compared	O
to	O
wild	O
-	O
type	O
control	O
mice	O
(	O
11	O
%	O
)	O
,	O
suggesting	O
that	O
LMP1	B-Protein
contributes	O
to	O
tumor	O
development	O
[	O
26	O
]	O
.	O

The	O
LMP1	B-Protein
lymphomas	O
have	O
rearranged	O
Ig	O
genes	O
and	O
have	O
activated	O
Akt	B-Protein
,	O
JNK	O
,	O
p38	O
,	O
and	O
NFkappaB	O
,	O
with	O
specific	O
activation	O
of	O
the	O
NFkappaB	O
family	O
member	O
cRel	B-Protein
[	O
27	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphomas	O
were	O
further	O
characterized	O
and	O
their	O
growth	O
properties	O
in	O
vitro	O
were	O
determined	O
.	O

To	O
obtain	O
pure	O
populations	O
of	O
malignant	O
lymphocytes	O
and	O
to	O
enable	O
more	O
detailed	O
biochemical	O
analyses	O
,	O
examples	O
of	O
primary	O
lymphomas	O
were	O
inoculated	O
and	O
passaged	O
in	O
SCID	O
mice	O
.	O

Interestingly	O
,	O
lymphoma	O
development	O
was	O
restricted	O
to	O
B	O
-	O
1a	O
lymphocytes	O
,	O
a	O
self	O
-	O
replenishing	O
population	O
of	O
cells	O
that	O
are	O
prone	O
to	O
malignancy	O
[	O
28	O
,	O
29	O
]	O
.	O

LMP1	B-Protein
transgenic	O
lymphocytes	O
had	O
increased	O
viability	O
in	O
vitro	O
and	O
viability	O
was	O
increased	O
by	O
the	O
addition	O
of	O
IL4	B-Protein
.	O

In	O
contrast	O
,	O
both	O
LMP1	B-Protein
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
were	O
independent	O
of	O
IL4	B-Protein
co	O
-	O
stimulation	O
for	O
survival	O
and	O
proliferation	O
in	O
vitro	O
with	O
a	O
complete	O
absence	O
of	O
activated	O
Stat6	B-Protein
,	O
the	O
IL4	B-Protein
target	O
.	O

The	O
lymphomas	O
were	O
also	O
distinguished	O
by	O
constitutive	O
activation	O
of	O
Stat3	B-Protein
and	O
deregulation	O
of	O
the	O
Rb	B-Protein
cell	O
cycle	O
pathway	O
.	O

Inhibition	O
of	O
the	O
PI3K	O
/	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
signaling	O
pathways	O
blocked	O
the	O
enhanced	O
growth	O
of	O
both	O
LMP1	B-Protein
transgenic	O
and	O
malignant	O
lymphocytes	O
,	O
suggesting	O
that	O
these	O
pathways	O
are	O
required	O
for	O
their	O
growth	O
and	O
survival	O
.	O

These	O
appear	O
to	O
be	O
the	O
same	O
targets	O
that	O
are	O
deregulated	O
in	O
wild	O
-	O
type	O
B	O
-	O
1a	O
lymphomas	O
that	O
arise	O
spontaneously	O
through	O
age	O
predisposition	O
.	O

This	O
study	O
reveals	O
that	O
LMP1	B-Protein
promotes	O
malignancy	O
in	O
cells	O
with	O
the	O
inherent	O
ability	O
to	O
proliferate	O
and	O
that	O
the	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
signaling	O
pathways	O
are	O
required	O
for	O
its	O
growth	O
stimulatory	O
effects	O
.	O

High	O
Levels	O
of	O
LMP1	B-Protein
Expression	O
Correlates	O
with	O
the	O
Development	O
of	O
Lymphoma	O

LMP1	B-Protein
expression	O
in	O
IgLMP1	O
mice	O
was	O
directed	O
to	O
B	O
cells	O
under	O
the	O
control	O
of	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
in	O
these	O
transgenic	O
mice	O
,	O
LMP1	B-Protein
expression	O
was	O
restricted	O
to	O
B220	O
+	O
B	O
cells	O
with	O
lymphoma	O
detected	O
in	O
greatly	O
enlarged	O
spleens	O
[	O
23	O
,	O
26	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	B-Protein
expression	O
contributes	O
to	O
lymphoma	O
development	O
,	O
B	O
cells	O
were	O
purified	O
from	O
splenocytes	O
by	O
positive	O
selection	O
using	O
anti	O
-	O
CD19	B-Protein
MACS	O
magnetic	O
beads	O
,	O
and	O
equivalent	O
amounts	O
of	O
B	O
cells	O
were	O
analyzed	O
by	O
immunoblotting	O
.	O

LMP1	B-Protein
was	O
detectable	O
in	O
LMP1	B-Protein
transgenic	O
B	O
cells	O
,	O
but	O
upon	O
development	O
of	O
lymphoma	O
,	O
LMP1	B-Protein
expression	O
was	O
stronger	O
in	O
5	O
/	O
7	O
lymphomas	O
analyzed	O
with	O
concomitant	O
appearance	O
of	O
degradation	O
products	O
(	O
Figure	O
1A	O
)	O
.	O

To	O
determine	O
whether	O
the	O
higher	O
level	O
of	O
LMP1	B-Protein
detected	O
was	O
due	O
to	O
an	O
expansion	O
of	O
malignant	O
lymphocytes	O
,	O
expression	O
of	O
LMP1	B-Protein
in	O
the	O
spleen	O
was	O
further	O
evaluated	O
by	O
immunohistochemical	O
staining	O
.	O

Immunohistochemistry	O
analysis	O
of	O
spleen	O
sections	O
detected	O
LMP1	B-Protein
in	O
the	O
plasma	O
membrane	O
of	O
cells	O
in	O
both	O
the	O
follicular	O
white	O
pulp	O
and	O
circulating	O
lymphocytes	O
in	O
the	O
red	O
pulp	O
(	O
Figure	O
1B	O
)	O
.	O

LMP1	B-Protein
expression	O
was	O
heterogeneous	O
with	O
strong	O
LMP1	B-Protein
staining	O
interspersed	O
amongst	O
a	O
background	O
of	O
cells	O
staining	O
weakly	O
for	O
LMP1	B-Protein
.	O

Upon	O
development	O
to	O
lymphoma	O
,	O
LMP1	B-Protein
expression	O
was	O
more	O
abundantly	O
detected	O
with	O
multiple	O
foci	O
of	O
intense	O
LMP1	B-Protein
staining	O
.	O

This	O
demonstrates	O
that	O
the	O
increased	O
LMP1	B-Protein
detected	O
by	O
immunoblotting	O
upon	O
malignant	O
progression	O
reflects	O
an	O
increase	O
in	O
LMP1	B-Protein
expression	O
and	O
an	O
accumulation	O
of	O
cells	O
expressing	O
high	O
levels	O
of	O
LMP1	B-Protein
.	O

This	O
correlation	O
between	O
high	O
LMP1	B-Protein
expression	O
and	O
the	O
development	O
of	O
lymphoma	O
suggests	O
that	O
progression	O
to	O
lymphoma	O
results	O
from	O
increased	O
levels	O
of	O
LMP1	B-Protein
.	O

LMP1	B-Protein
Promotes	O
B	O
-	O
1a	O
Lymphomas	O
That	O
Can	O
Escape	O
Allelic	O
Exclusion	O

To	O
determine	O
if	O
LMP1	B-Protein
signaling	O
affects	O
B	O
cell	O
differentiation	O
and	O
to	O
immunophenotype	O
the	O
lymphomas	O
that	O
arise	O
from	O
LMP1	B-Protein
expression	O
,	O
surface	O
Ig	O
expression	O
of	O
heavy	O
chains	O
(	O
IgM	O
,	O
IgG	O
,	O
IgD	O
)	O
and	O
light	O
chains	O
(	O
kappa	O
,	O
lambda	O
)	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

Similar	O
numbers	O
of	O
naive	O
(	O
IgM	O
+	O
IgD	O
+	O
IgG	O
-	O
)	O
splenic	O
B	O
cells	O
with	O
a	O
strong	O
bias	O
towards	O
kappa	O
light	O
chain	O
were	O
detected	O
from	O
wild	O
-	O
type	O
or	O
LMP1	B-Protein
transgenic	O
mice	O
,	O
indicating	O
that	O
LMP1	B-Protein
signaling	O
does	O
not	O
affect	O
B	O
cell	O
maturation	O
(	O
unpublished	O
data	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
of	O
the	O
SCID	O
-	O
passaged	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
revealed	O
an	O
IgMhighIgDlow	O
phenotype	O
(	O
Figure	O
2A	O
)	O
,	O
indicative	O
of	O
marginal	O
zone	O
,	O
B	O
-	O
1	O
,	O
or	O
memory	O
B	O
cells	O
.	O

B	O
-	O
1	O
cells	O
are	O
further	O
separated	O
into	O
CD5	B-Protein
+	O
(	O
B	O
-	O
1a	O
)	O
and	O
CD5	B-Protein
-	O
(	O
B	O
-	O
1b	O
)	O
subsets	O
.	O

To	O
differentiate	O
between	O
these	O
cell	O
types	O
,	O
lymphoma	O
cells	O
were	O
further	O
analyzed	O
for	O
the	O
B	O
-	O
1a	O
marker	O
CD5	B-Protein
.	O

All	O
(	O
5	O
/	O
5	O
)	O
of	O
the	O
tested	O
LMP1	B-Protein
transgenic	O
lymphomas	O
displayed	O
an	O
IgMhighIgDlowCD5	B-Protein
+	O
phenotype	O
(	O
Figure	O
2A	O
)	O
,	O
an	O
expression	O
pattern	O
that	O
distinguishes	O
B	O
-	O
1a	O
cells	O
.	O

Interestingly	O
,	O
a	O
spontaneous	O
wild	O
-	O
type	O
lymphoma	O
also	O
developed	O
in	O
B	O
-	O
1a	O
cells	O
(	O
Figure	O
2A	O
)	O
.	O

These	O
cells	O
are	O
an	O
interesting	O
population	O
that	O
is	O
self	O
replenishing	O
with	O
an	O
increased	O
likelihood	O
to	O
become	O
malignant	O
in	O
aged	O
mice	O
[	O
30	O
]	O
.	O

Analysis	O
of	O
LMP1	B-Protein
transgenic	O
mice	O
before	O
the	O
development	O
of	O
lymphoma	O
showed	O
similar	O
numbers	O
of	O
splenic	O
B	O
-	O
1a	O
(	O
CD19	B-Protein
+	O
CD5	B-Protein
+	O
)	O
and	O
B	O
-	O
1b	O
or	O
B	O
-	O
2	O
populations	O
(	O
CD19	B-Protein
+	O
CD5	B-Protein
-	O
)	O
,	O
indicating	O
that	O
LMP1	B-Protein
does	O
not	O
affect	O
B	O
cell	O
differentiation	O
(	O
Figure	O
2B	O
)	O
.	O

Due	O
to	O
allelic	O
exclusion	O
,	O
mature	O
B	O
cells	O
that	O
have	O
been	O
exposed	O
to	O
antigen	O
will	O
typically	O
express	O
only	O
one	O
heavy	O
chain	O
isotype	O
(	O
IgG	O
,	O
IgE	O
,	O
or	O
IgA	O
)	O
and	O
either	O
a	O
kappa	O
or	O
lambda	O
light	O
chain	O
.	O

Interestingly	O
,	O
2	O
/	O
5	O
LMP1	B-Protein
transgenic	O
lymphomas	O
analyzed	O
(	O
lymphomas	O
2	O
and	O
4	O
)	O
were	O
doubly	O
positive	O
for	O
low	O
levels	O
of	O
both	O
kappa	O
and	O
lambda	O
light	O
chains	O
(	O
Figure	O
2A	O
)	O
.	O

Previous	O
characterization	O
of	O
the	O
LMP1	B-Protein
lymphomas	O
had	O
revealed	O
that	O
the	O
lymphomas	O
were	O
clonal	O
as	O
determined	O
by	O
Ig	O
heavy	O
chain	O
rearrangement	O
[	O
26	O
]	O
,	O
and	O
analysis	O
of	O
kappa	O
chain	O
rearrangement	O
(	O
Figure	O
S1	O
)	O
of	O
the	O
samples	O
analyzed	O
in	O
this	O
study	O
confirmed	O
clonality	O
.	O

To	O
further	O
assess	O
light	O
chain	O
expression	O
,	O
the	O
passaged	O
samples	O
were	O
tested	O
by	O
immunoblotting	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
(	O
Figure	O
2C	O
)	O
.	O

Interestingly	O
,	O
very	O
low	O
levels	O
of	O
expression	O
of	O
both	O
light	O
chains	O
were	O
detected	O
by	O
flow	O
cytometry	O
.	O

The	O
low	O
levels	O
of	O
expression	O
may	O
reflect	O
a	O
limitation	O
of	O
the	O
total	O
number	O
of	O
light	O
chains	O
that	O
can	O
be	O
expressed	O
on	O
the	O
surface	O
of	O
a	O
B	O
cell	O
.	O

In	O
agreement	O
with	O
the	O
flow	O
cytometry	O
analysis	O
,	O
LMP1	B-Protein
transgenic	O
lymphomas	O
2	O
and	O
4	O
were	O
also	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
by	O
immunoblot	O
analysis	O
(	O
Figure	O
2C	O
)	O
,	O
confirming	O
that	O
these	O
lymphomas	O
express	O
both	O
light	O
chains	O
.	O

A	O
previous	O
study	O
of	O
mice	O
that	O
developed	O
leukemia	O
due	O
to	O
an	O
expansion	O
of	O
self	O
-	O
reactive	O
B	O
-	O
1a	O
cells	O
determined	O
that	O
the	O
B	O
-	O
1a	O
leukemias	O
were	O
also	O
doubly	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
[	O
31	O
]	O
.	O

These	O
findings	O
indicate	O
that	O
expression	O
of	O
LMP1	B-Protein
in	O
B	O
-	O
1a	O
cells	O
promotes	O
the	O
development	O
of	O
malignancy	O
and	O
can	O
result	O
in	O
the	O
aberrant	O
escape	O
from	O
allelic	O
exclusion	O
.	O

LMP1	B-Protein
Promotes	O
B	O
Cell	O
Survival	O
and	O
Proliferation	O
In	O
Vitro	O

Primary	O
B	O
cell	O
cultures	O
can	O
be	O
maintained	O
through	O
CD40	B-Protein
ligation	O
and	O
supplementation	O
with	O
IL4	B-Protein
[	O
32	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	B-Protein
affects	O
primary	O
B	O
cell	O
survival	O
and	O
proliferation	O
,	O
splenocytes	O
were	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL4	B-Protein
and	O
analyzed	O
by	O
MTS	O
as	O
a	O
metabolic	O
marker	O
,	O
by	O
ethidium	O
monoazide	O
(	O
EMA	O
)	O
exclusion	O
for	O
viability	O
,	O
and	O
by	O
5	O
-	O
bromo	O
-	O
2	O
'	O
-	O
deoxy	O
-	O
uridine	O
(	O
BrdU	O
)	O
incorporation	O
for	O
proliferation	O
.	O

In	O
the	O
MTS	O
assay	O
,	O
as	O
expected	O
,	O
splenocytes	O
from	O
wild	O
-	O
type	O
mice	O
did	O
not	O
survive	O
even	O
with	O
the	O
addition	O
of	O
IL4	B-Protein
due	O
to	O
a	O
lack	O
of	O
CD40	B-Protein
ligation	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
LMP1	B-Protein
splenocytes	O
had	O
increased	O
metabolism	O
even	O
in	O
the	O
absence	O
of	O
IL4	B-Protein
,	O
which	O
was	O
further	O
enhanced	O
upon	O
addition	O
of	O
IL4	B-Protein
.	O

Wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
had	O
high	O
levels	O
of	O
MTS	O
activity	O
even	O
in	O
the	O
absence	O
of	O
IL4	B-Protein
(	O
Figure	O
3A	O
)	O
.	O

The	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
had	O
approximately	O
4	O
-	O
fold	O
higher	O
MTS	O
activity	O
than	O
the	O
normal	O
transgenic	O
lymphocytes	O
and	O
were	O
at	O
least	O
2	O
-	O
fold	O
higher	O
than	O
the	O
control	O
lymphoma	O
.	O

As	O
previously	O
published	O
,	O
lymphoma	O
usually	O
develops	O
in	O
mice	O
over	O
12	O
mo	O
of	O
age	O
and	O
all	O
mice	O
are	O
sacrificed	O
by	O
18	O
-	O
20	O
mo	O
.	O

The	O
ages	O
of	O
the	O
transgenic	O
mice	O
with	O
or	O
without	O
lymphoma	O
ranged	O
between	O
6	O
and	O
20	O
mo	O
old	O
.	O

There	O
was	O
no	O
correlation	O
between	O
age	O
and	O
MTS	O
activity	O
.	O

EMA	O
exclusion	O
of	O
CD19	B-Protein
+	O
gated	O
B	O
cells	O
prepared	O
from	O
two	O
wild	O
-	O
type	O
and	O
two	O
LMP1	B-Protein
transgenic	O
mice	O
indicated	O
a	O
2	O
-	O
fold	O
increase	O
in	O
viability	O
in	O
the	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
compared	O
to	O
wild	O
-	O
type	O
lymphocytes	O
.	O

Two	O
examples	O
of	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
had	O
greatly	O
increased	O
viability	O
that	O
was	O
not	O
increased	O
by	O
IL4	B-Protein
treatment	O
,	O
indicating	O
that	O
the	O
lymphoma	O
cells	O
are	O
independent	O
of	O
IL4	B-Protein
co	O
-	O
stimulation	O
(	O
Figure	O
3B	O
)	O
.	O

Enhancement	O
in	O
MTS	O
activity	O
was	O
observed	O
in	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
by	O
the	O
addition	O
of	O
IL4	B-Protein
;	O
however	O
,	O
EMA	O
exclusion	O
did	O
not	O
reveal	O
a	O
similar	O
increase	O
.	O

This	O
could	O
reflect	O
a	O
difference	O
for	O
IL4	B-Protein
requirement	O
in	O
the	O
metabolic	O
activity	O
versus	O
the	O
viability	O
of	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
.	O

Although	O
expression	O
of	O
LMP1	B-Protein
could	O
enhance	O
survival	O
of	O
non	O
-	O
malignant	O
primary	O
lymphocytes	O
,	O
BrdU	O
incorporation	O
revealed	O
that	O
LMP1	B-Protein
expression	O
alone	O
was	O
not	O
sufficient	O
to	O
induce	O
proliferation	O
in	O
culture	O
(	O
unpublished	O
data	O
)	O
.	O

Only	O
lymphoma	O
cells	O
had	O
detectable	O
levels	O
of	O
BrdU	O
incorporation	O
detected	O
by	O
flow	O
cytometry	O
(	O
Figure	O
3C	O
)	O
.	O

Interestingly	O
,	O
LMP1	B-Protein
lymphoma	O
cells	O
had	O
significantly	O
higher	O
levels	O
of	O
proliferation	O
in	O
comparison	O
to	O
the	O
spontaneous	O
lymphoma	O
that	O
developed	O
in	O
an	O
LMP1	B-Protein
-	O
negative	O
littermate	O
(	O
25	O
%	O
versus	O
4	O
%	O
)	O
.	O

This	O
higher	O
level	O
of	O
proliferation	O
was	O
observed	O
in	O
lymphomas	O
that	O
express	O
both	O
high	O
(	O
Table	O
1	O
,	O
LMP1	B-Protein
-	O
L2	O
and	O
LMP1	B-Protein
-	O
L3	O
)	O
and	O
low	O
(	O
Table	O
1	O
,	O
LMP1	B-Protein
-	O
L5	O
)	O
levels	O
of	O
LMP1	B-Protein
,	O
suggesting	O
that	O
even	O
small	O
amounts	O
of	O
LMP1	B-Protein
is	O
sufficient	O
to	O
induce	O
dramatic	O
effects	O
in	O
proliferation	O
.	O

The	O
level	O
of	O
proliferation	O
was	O
not	O
enhanced	O
upon	O
IL4	B-Protein
addition	O
,	O
confirming	O
the	O
IL4	B-Protein
independence	O
observed	O
in	O
the	O
viability	O
studies	O
(	O
Figure	O
3C	O
;	O
Table1	O
)	O
.	O

Wild	O
-	O
Type	O
and	O
LMP1	B-Protein
Transgenic	O
Lymphoma	O
Cells	O
Do	O
Not	O
Require	O
IL4	B-Protein
and	O
Stat6	B-Protein
Signaling	O

To	O
investigate	O
whether	O
IL4	B-Protein
independence	O
was	O
due	O
to	O
endogenous	O
IL4	B-Protein
expression	O
,	O
IL4	B-Protein
transcription	O
was	O
assessed	O
by	O
an	O
Rnase	O
protection	O
assay	O
(	O
RPA	O
)	O
.	O

IL4	B-Protein
transcription	O
was	O
detectable	O
with	O
control	O
RNA	O
and	O
faintly	O
in	O
the	O
mouse	O
lymphoma	O
cell	O
line	O
K46mu	O
(	O
Figure	O
4A	O
)	O
.	O

However	O
,	O
IL4	B-Protein
transcription	O
was	O
not	O
detectable	O
in	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
from	O
wild	O
-	O
type	O
lymphocytes	O
(	O
unpublished	O
data	O
)	O
,	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
,	O
or	O
lymphoma	O
cells	O
,	O
although	O
the	O
GAPDH	B-Protein
and	O
L32	B-Protein
controls	O
were	O
effectively	O
protected	O
(	O
Figure	O
4A	O
)	O
.	O

Activated	O
Stat6	B-Protein
(	O
pStat6	B-Protein
)	O
,	O
a	O
target	O
of	O
the	O
IL4	B-Protein
receptor	I-Protein
pathway	O
,	O
was	O
detected	O
in	O
the	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
(	O
Figure	O
4B	O
)	O
.	O

In	O
contrast	O
,	O
pStat6	O
was	O
barely	O
detected	O
in	O
either	O
the	O
wild	O
-	O
type	O
or	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
.	O

However	O
,	O
the	O
pathway	O
was	O
not	O
disabled	O
,	O
as	O
treatment	O
of	O
the	O
lymphoma	O
cells	O
with	O
IL4	B-Protein
induced	O
Stat6	B-Protein
phosphorylation	O
(	O
Figure	O
4C	O
)	O
.	O

Although	O
wild	O
-	O
type	O
lymphocytes	O
cannot	O
be	O
maintained	O
in	O
culture	O
with	O
IL4	B-Protein
supplementation	O
alone	O
(	O
Figure	O
3A	O
)	O
,	O
slight	O
enhancement	O
in	O
MTS	O
activity	O
could	O
be	O
detected	O
if	O
the	O
cells	O
were	O
analyzed	O
at	O
an	O
earlier	O
time	O
point	O
,	O
at	O
1	O
d	O
(	O
Figure	O
4D	O
)	O
versus	O
3	O
d	O
(	O
Figure	O
3A	O
)	O
post	O
-	O
harvest	O
.	O

The	O
enhancement	O
of	O
MTS	O
activity	O
induced	O
by	O
IL4	B-Protein
in	O
wild	O
-	O
type	O
lymphocytes	O
could	O
be	O
neutralized	O
by	O
the	O
addition	O
of	O
IL4	B-Protein
antibody	O
(	O
Figure	O
4D	O
)	O
.	O

However	O
,	O
neutralizing	O
antibodies	O
to	O
IL4	B-Protein
did	O
not	O
affect	O
the	O
MTS	O
activity	O
of	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
(	O
Figure	O
4E	O
)	O
.	O

In	O
summary	O
,	O
the	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
grew	O
independently	O
of	O
IL4	B-Protein
treatment	O
and	O
did	O
not	O
require	O
Stat6	B-Protein
signaling	O
.	O

LMP1	B-Protein
Upregulates	O
IL10	B-Protein
and	O
Constitutively	O
Activates	O
Stat3	B-Protein

To	O
identify	O
cytokines	O
that	O
may	O
contribute	O
to	O
the	O
increased	O
survival	O
and	O
growth	O
of	O
lymphomas	O
,	O
the	O
expression	O
levels	O
of	O
a	O
panel	O
of	O
cytokines	O
were	O
screened	O
on	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
,	O
using	O
an	O
RPA	O
probe	O
set	O
for	O
IL4	B-Protein
,	O
IL5	B-Protein
,	O
IL10	B-Protein
,	O
IL13	B-Protein
,	O
IL15	B-Protein
,	O
IL9	B-Protein
,	O
IL2	B-Protein
,	O
IL6	B-Protein
,	O
and	O
IFNgamma	B-Protein
.	O

Expression	O
levels	O
were	O
quantified	O
with	O
a	O
phosphorimager	O
and	O
normalized	O
to	O
the	O
ribosomal	O
housekeeping	O
gene	O
L32	B-Protein
.	O

None	O
of	O
the	O
tested	O
cytokines	O
were	O
detected	O
in	O
wild	O
-	O
type	O
lymphocytes	O
,	O
therefore	O
cytokine	O
:	O
L32	B-Protein
ratios	O
were	O
set	O
to	O
1	O
in	O
the	O
mouse	O
B	O
cell	O
lymphoma	O
line	O
967	O
.	O

Transcription	O
of	O
IL10	B-Protein
,	O
IL15	B-Protein
,	O
and	O
IFNgamma	B-Protein
were	O
reproducibly	O
detected	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
and	O
was	O
higher	O
than	O
in	O
the	O
B	O
cell	O
lymphoma	O
cell	O
lines	O
967	O
and	O
K46mu	O
(	O
Figure	O
5A	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
expression	O
of	O
IL15	B-Protein
and	O
IFNgamma	B-Protein
between	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	B-Protein
cells	I-Protein
,	O
suggesting	O
that	O
upregulation	O
of	O
IL15	B-Protein
and	O
IFNgamma	B-Protein
is	O
induced	O
by	O
LMP1	B-Protein
expression	O
in	O
healthy	O
lymphocytes	O
but	O
is	O
not	O
a	O
unique	O
property	O
of	O
malignant	O
lymphocytes	O
.	O

Strikingly	O
,	O
IL10	B-Protein
,	O
a	O
B	O
lymphocyte	O
stimulatory	O
cytokine	O
,	O
was	O
increased	O
1	O
.	O
5	O
-	O
to	O
5	O
-	O
fold	O
in	O
the	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
compared	O
to	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
(	O
Figure	O
5A	O
)	O
.	O

Production	O
of	O
IL15	B-Protein
and	O
IFNgamma	B-Protein
has	O
been	O
associated	O
with	O
induction	O
of	O
cytotoxic	O
effector	O
responses	O
in	O
cells	O
latently	O
infected	O
with	O
EBV	O
[	O
33	O
,	O
34	O
]	O
.	O

However	O
,	O
transformation	O
and	O
growth	O
properties	O
induced	O
by	O
EBV	O
are	O
associated	O
with	O
the	O
upregulation	O
of	O
IL10	B-Protein
[	O
35	O
-	O
38	O
]	O
;	O
hence	O
,	O
the	O
effects	O
of	O
IL10	B-Protein
upregulation	O
on	O
the	O
growth	O
properties	O
of	O
the	O
lymphoma	O
cells	O
were	O
further	O
examined	O
.	O

Immunoblot	O
analysis	O
indicated	O
that	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
had	O
corresponding	O
increased	O
levels	O
of	O
phosphorylated	O
alpha	O
and	O
beta	O
isoforms	O
of	O
activated	O
Stat3	B-Protein
,	O
a	O
target	O
of	O
the	O
IL10	B-Protein
receptor	O
(	O
Figure	O
5B	O
)	O
.	O

However	O
,	O
when	O
comparing	O
the	O
same	O
lymphomas	O
,	O
there	O
was	O
no	O
correlation	O
between	O
the	O
levels	O
of	O
IL10	B-Protein
induction	O
and	O
the	O
levels	O
of	O
Stat3	B-Protein
activation	O
.	O

This	O
suggests	O
that	O
the	O
activation	O
of	O
Stat3	B-Protein
is	O
not	O
solely	O
induced	O
by	O
IL10	B-Protein
or	O
that	O
Stat3	B-Protein
activation	O
may	O
be	O
constitutive	O
.	O

Additionally	O
,	O
there	O
was	O
no	O
correlation	O
between	O
the	O
levels	O
of	O
LMP1	B-Protein
expression	O
and	O
the	O
levels	O
of	O
IL10	B-Protein
induction	O
(	O
Figures	O
1A	O
and	O
5A	O
)	O
.	O

This	O
indicates	O
that	O
the	O
induction	O
of	O
IL10	B-Protein
is	O
a	O
general	O
property	O
associated	O
with	O
enhanced	O
survival	O
and	O
may	O
only	O
be	O
indirectly	O
affected	O
by	O
LMP1	B-Protein
.	O

Neutralizing	O
antibodies	O
to	O
IL10	B-Protein
did	O
not	O
affect	O
the	O
survival	O
of	O
lymphoma	O
cells	O
as	O
determined	O
by	O
the	O
MTS	O
assay	O
(	O
unpublished	O
data	O
)	O
,	O
suggesting	O
constitutive	O
activation	O
of	O
Stat3	B-Protein
.	O

This	O
was	O
confirmed	O
by	O
immunoblot	O
analysis	O
such	O
that	O
in	O
the	O
presence	O
of	O
anti	O
-	O
IL10	B-Protein
neutralizing	O
antibodies	O
,	O
pStat3	B-Protein
levels	O
remained	O
activated	O
in	O
lymphoma	O
cells	O
isolated	O
from	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
(	O
Figure	O
5C	O
)	O
.	O

Exogenous	O
addition	O
of	O
IL10	B-Protein
enhanced	O
pStat3	B-Protein
activation	O
above	O
constitutive	O
levels	O
,	O
indicating	O
that	O
lymphoma	O
cells	O
are	O
responsive	O
to	O
IL10	B-Protein
treatment	O
(	O
Figure	O
5C	O
)	O
.	O

This	O
means	O
that	O
although	O
the	O
lymphoma	O
cells	O
have	O
constitutive	O
Stat3	B-Protein
activation	O
,	O
it	O
may	O
be	O
further	O
enhanced	O
by	O
IL10	B-Protein
induction	O
.	O

The	O
neutralizing	O
effect	O
of	O
the	O
anti	O
-	O
IL10	B-Protein
antibody	O
was	O
confirmed	O
by	O
pre	O
-	O
incubation	O
of	O
IL10	B-Protein
with	O
anti	O
-	O
IL10	B-Protein
antibody	O
compared	O
to	O
a	O
rat	O
IgG1	O
isotype	O
control	O
(	O
Figure	O
5C	O
)	O
.	O

Nuclear	O
translocation	O
of	O
pStat3	B-Protein
is	O
a	O
consequence	O
of	O
activation	O
,	O
and	O
nuclear	O
pStat3	B-Protein
was	O
not	O
detected	O
by	O
immunohistochemistry	O
staining	O
of	O
spleen	O
sections	O
from	O
control	O
mice	O
.	O

However	O
,	O
nuclear	O
pStat3	B-Protein
was	O
detectable	O
in	O
LMP1	B-Protein
transgenic	O
mice	O
and	O
wild	O
-	O
type	O
lymphomas	O
and	O
was	O
detected	O
more	O
homogeneously	O
in	O
LMP1	B-Protein
transgenic	O
lymphomas	O
(	O
Figure	O
5D	O
)	O
.	O

The	O
constitutive	O
activation	O
of	O
pStat3	B-Protein
and	O
abundant	O
nuclear	O
Stat3	B-Protein
suggests	O
that	O
Stat3	B-Protein
signaling	O
contributes	O
to	O
LMP1	B-Protein
-	O
mediated	O
lymphoma	O
development	O
.	O

LMP1	B-Protein
Activates	O
Akt	B-Protein
Signaling	O
and	O
Deregulates	O
the	O
Rb	B-Protein
Cell	O
Cycle	O
Pathway	O

LMP1	B-Protein
transformation	O
of	O
rodent	O
fibroblasts	O
requires	O
activation	O
of	O
PI3K	O
and	O
Akt	B-Protein
[	O
5	O
]	O
.	O

Additionally	O
,	O
activated	O
pAkt	B-Protein
is	O
frequently	O
detected	O
in	O
NPC	O
and	O
the	O
neoplastic	O
Reed	O
-	O
Sternberg	O
cells	O
of	O
classical	O
HD	O
[	O
39	O
,	O
40	O
]	O
.	O

To	O
determine	O
if	O
Akt	B-Protein
signaling	O
is	O
activated	O
in	O
LMP1	B-Protein
transgenic	O
mice	O
,	O
pAkt	B-Protein
and	O
several	O
of	O
its	O
targets	O
were	O
assessed	O
by	O
immunoblotting	O
of	O
splenic	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
.	O

LMP1	B-Protein
transgenic	O
B	O
cells	O
had	O
increased	O
levels	O
of	O
pAkt	B-Protein
compared	O
to	O
wild	O
-	O
type	O
lymphocytes	O
;	O
however	O
,	O
progression	O
to	O
lymphoma	O
in	O
both	O
LMP1	B-Protein
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
did	O
not	O
further	O
increase	O
pAkt	B-Protein
levels	O
.	O

The	O
Akt	B-Protein
target	O
glycogen	B-Protein
synthase	I-Protein
kinase	I-Protein
3	I-Protein
(	O
GSK3	B-Protein
)	O
is	O
inactivated	O
by	O
phosphorylation	O
;	O
however	O
,	O
increased	O
phosphorylated	O
GSK3	B-Protein
was	O
not	O
detected	O
in	O
the	O
transgenic	O
lymphocytes	O
and	O
was	O
almost	O
absent	O
in	O
the	O
lymphoma	O
samples	O
(	O
Figure	O
6A	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
GSK3	B-Protein
is	O
not	O
a	O
target	O
of	O
activated	O
Akt	B-Protein
in	O
the	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
.	O

Similarly	O
,	O
activation	O
of	O
Akt	B-Protein
without	O
phosphorylation	O
of	O
GSK3	B-Protein
has	O
been	O
previously	O
shown	O
in	O
EBV	O
-	O
positive	O
HD	O
[	O
40	O
]	O
.	O

In	O
contrast	O
,	O
the	O
wild	O
-	O
type	O
lymphocytes	O
lacked	O
activated	O
Akt	B-Protein
but	O
did	O
have	O
detectable	O
phosphorylated	O
GSK3	B-Protein
.	O

This	O
further	O
suggests	O
that	O
additional	O
pathways	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
GSK3	B-Protein
.	O

To	O
identify	O
other	O
potential	O
Akt	B-Protein
targets	O
,	O
immunoblot	O
analysis	O
for	O
p	B-Protein
-	I-Protein
mTOR	I-Protein
was	O
performed	O
.	O

Activated	O
p	B-Protein
-	I-Protein
mTOR	I-Protein
was	O
not	O
increased	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
,	O
indicating	O
that	O
this	O
pathway	O
is	O
not	O
affected	O
by	O
LMP1	B-Protein
-	O
induced	O
Akt	B-Protein
activation	O
and	O
does	O
not	O
contribute	O
to	O
lymphoma	O
development	O
(	O
Figure	O
6B	O
)	O
.	O

Akt	B-Protein
is	O
also	O
known	O
to	O
phosphorylate	O
and	O
induce	O
the	O
degradation	O
of	O
the	O
pro	O
-	O
apoptotic	O
Forkhead	O
family	O
of	O
transcription	O
factors	O
,	O
leading	O
to	O
cell	O
cycle	O
progression	O
and	O
survival	O
in	O
some	O
human	O
tumors	O
[	O
41	O
,	O
42	O
]	O
.	O

Immunoblot	O
analysis	O
of	O
splenic	O
B	O
cells	O
did	O
not	O
consistently	O
detect	O
p	O
-	O
FoxO1	B-Protein
levels	O
,	O
a	O
signal	O
that	O
targets	O
FoxO1	B-Protein
for	O
degradation	O
.	O

Hence	O
,	O
degradation	O
of	O
FoxO1	B-Protein
was	O
assessed	O
by	O
detection	O
of	O
total	O
FoxO1	B-Protein
levels	O
.	O

Immunoblot	O
analysis	O
indicated	O
that	O
total	O
FoxO1	B-Protein
levels	O
were	O
greatly	O
decreased	O
in	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
(	O
Figure	O
6B	O
)	O
,	O
suggesting	O
that	O
inhibition	O
of	O
the	O
Forkhead	O
signaling	O
pathway	O
is	O
an	O
important	O
target	O
of	O
Akt	B-Protein
in	O
lymphoma	O
development	O
.	O

However	O
,	O
considering	O
that	O
Akt	B-Protein
activation	O
did	O
not	O
induce	O
FoxO1	B-Protein
degradation	O
in	O
LMP1	B-Protein
transgenic	O
B	O
cells	O
,	O
Akt	B-Protein
may	O
not	O
be	O
the	O
sole	O
regulator	O
of	O
FoxO1	B-Protein
,	O
and	O
it	O
may	O
be	O
that	O
progression	O
to	O
lymphoma	O
requires	O
modulation	O
of	O
multiple	O
pathways	O
.	O

The	O
Forkhead	O
family	O
of	O
transcription	O
factors	O
is	O
known	O
to	O
induce	O
the	O
expression	O
of	O
the	O
Cdk	O
inhibitor	O
p27	B-Protein
[	O
43	O
,	O
44	O
]	O
.	O

LMP1	B-Protein
-	O
transformed	O
rodent	O
fibroblasts	O
have	O
decreased	O
expression	O
of	O
p27	B-Protein
,	O
upregulation	O
of	O
Cdk2	B-Protein
,	O
and	O
subsequent	O
phosphorylation	O
and	O
inactivation	O
of	O
the	O
tumor	O
suppressor	O
gene	O
Rb	B-Protein
[	O
45	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	B-Protein
affected	O
cell	O
cycle	O
regulation	O
through	O
the	O
Rb	B-Protein
pathway	O
in	O
B	O
cells	O
,	O
immunoblot	O
analyses	O
for	O
pRb	B-Protein
,	O
Cdk2	B-Protein
,	O
and	O
p27	B-Protein
were	O
performed	O
on	O
splenic	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
.	O

LMP1	B-Protein
transgenic	O
B	O
cells	O
had	O
enhanced	O
levels	O
of	O
pRb	B-Protein
with	O
concomitant	O
stabilization	O
of	O
total	O
Rb	B-Protein
levels	O
and	O
Cdk2	B-Protein
compared	O
to	O
wild	O
-	O
type	O
B	O
lymphocytes	O
(	O
Figure	O
6C	O
)	O
.	O

Progression	O
to	O
lymphoma	O
in	O
both	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
led	O
to	O
increased	O
levels	O
of	O
Rb	B-Protein
,	O
correspondingly	O
high	O
levels	O
of	O
Cdk2	B-Protein
,	O
and	O
decreased	O
levels	O
of	O
p27	B-Protein
(	O
Figure	O
6C	O
)	O
.	O

These	O
data	O
indicate	O
that	O
the	O
Rb	B-Protein
pathway	O
is	O
deregulated	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
that	O
lymphoma	O
cells	O
are	O
distinguished	O
by	O
loss	O
of	O
FoxO1	B-Protein
and	O
decreased	O
p27	B-Protein
.	O

LMP1	B-Protein
Promotes	O
Tumor	O
Growth	O
and	O
Survival	O
through	O
Activation	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
Pathways	O

To	O
explore	O
which	O
pathways	O
were	O
required	O
for	O
the	O
enhanced	O
growth	O
and	O
survival	O
of	O
LMP1	B-Protein
-	O
induced	O
lymphomas	O
,	O
splenocytes	O
from	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
inhibitors	O
for	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
Stat3	B-Protein
,	O
mTOR	B-Protein
,	O
or	O
MAPK	O
and	O
assayed	O
for	O
growth	O
and	O
survival	O
by	O
the	O
MTS	O
assay	O
.	O

As	O
previously	O
shown	O
,	O
wild	O
-	O
type	O
lymphocytes	O
were	O
not	O
viable	O
in	O
culture	O
and	O
could	O
not	O
be	O
tested	O
with	O
the	O
inhibitors	O
.	O

However	O
,	O
the	O
enhanced	O
viability	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
was	O
effectively	O
blocked	O
by	O
treatment	O
with	O
triciribine	O
,	O
BAY11	O
-	O
7085	O
,	O
cucurbitacin	O
I	O
,	O
and	O
slightly	O
with	O
SB203580	O
,	O
but	O
not	O
by	O
treatment	O
with	O
rapamycin	O
,	O
U0126	O
,	O
or	O
AG490	O
(	O
Figure	O
7	O
)	O
.	O

Triciribine	O
inhibits	O
the	O
activation	O
of	O
Akt	B-Protein
and	O
at	O
20	O
muM	O
has	O
been	O
shown	O
to	O
induce	O
growth	O
arrest	O
in	O
cancer	O
cells	O
with	O
aberrant	O
Akt	B-Protein
activity	O
[	O
46	O
]	O
.	O

The	O
effects	O
of	O
triciribine	O
on	O
cell	O
growth	O
of	O
the	O
transgenic	O
lymphocytes	O
and	O
lymphomas	O
were	O
apparent	O
as	O
low	O
as	O
1	O
muM	O
,	O
suggesting	O
that	O
activation	O
of	O
Akt	B-Protein
is	O
required	O
for	O
the	O
survival	O
and	O
growth	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

The	O
effects	O
of	O
the	O
inhibitors	O
were	O
assessed	O
by	O
identifying	O
phosphorylated	O
Akt	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
total	O
levels	O
of	O
IkappaBalpha	B-Protein
(	O
Figure	O
8	O
)	O
.	O

Treatment	O
with	O
triciribine	O
effectively	O
blocked	O
phosphorylation	O
of	O
Akt	B-Protein
,	O
and	O
phosphorylated	O
Akt	B-Protein
was	O
no	O
longer	O
detected	O
past	O
5	O
muM	O
.	O

Phosphorylated	O
Stat3	B-Protein
and	O
IkappaBalpha	B-Protein
were	O
still	O
present	O
at	O
25	O
muM	O
.	O

These	O
findings	O
suggest	O
that	O
triciribine	O
specifically	O
targets	O
Akt	B-Protein
and	O
that	O
Akt	B-Protein
activation	O
is	O
required	O
for	O
the	O
enhanced	O
viability	O
of	O
the	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
.	O

Inhibition	O
of	O
NFkappaB	O
signaling	O
rapidly	O
induces	O
cell	O
death	O
of	O
EBV	O
-	O
transformed	O
lymphocytes	O
[	O
17	O
,	O
18	O
]	O
.	O

BAY11	O
-	O
7085	O
,	O
an	O
inhibitor	O
of	O
NFkappaB	O
signaling	O
,	O
also	O
greatly	O
decreased	O
the	O
viability	O
of	O
the	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
at	O
doses	O
as	O
low	O
as	O
1	O
muM	O
,	O
and	O
at	O
5	O
muM	O
the	O
cells	O
were	O
completely	O
nonviable	O
(	O
Figure	O
7	O
)	O
.	O

This	O
is	O
well	O
within	O
the	O
reported	O
IC50	O
of	O
10	O
muM	O
.	O

Phosphorylated	O
Akt	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
total	O
IkappaBalpha	B-Protein
were	O
still	O
present	O
up	O
to	O
treatment	O
with	O
15	O
muM	O
and	O
then	O
were	O
no	O
longer	O
detected	O
(	O
Figure	O
8	O
)	O
.	O

This	O
finding	O
suggests	O
that	O
inhibition	O
of	O
NFkappaB	O
can	O
induce	O
cell	O
death	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
without	O
significant	O
effects	O
on	O
activation	O
of	O
Akt	B-Protein
or	O
Stat3	B-Protein
.	O

Cucurbitacin	O
I	O
inhibits	O
activation	O
of	O
Stat3	B-Protein
by	O
suppressing	O
the	O
activation	O
of	O
its	O
kinase	O
JAK2	B-Protein
.	O

It	O
has	O
been	O
shown	O
to	O
selectively	O
inhibit	O
the	O
growth	O
of	O
tumors	O
with	O
constitutively	O
activated	O
Stat3	B-Protein
[	O
47	O
]	O
.	O

Similarly	O
,	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
were	O
susceptible	O
to	O
cucurbitacin	O
I	O
treatment	O
starting	O
at	O
0	O
.	O
1	O
muM	O
,	O
a	O
dose	O
that	O
corresponds	O
closely	O
to	O
the	O
reported	O
IC50	O
of	O
500	O
nM	O
(	O
Figure	O
7	O
)	O
[	O
47	O
]	O
.	O

Phosphorylated	O
Akt	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
total	O
IkappaBalpha	B-Protein
were	O
not	O
detectable	O
past	O
1	O
muM	O
and	O
at	O
higher	O
doses	O
all	O
protein	O
levels	O
were	O
greatly	O
decreased	O
,	O
indicative	O
of	O
the	O
total	O
loss	O
of	O
viability	O
(	O
Figure	O
8	O
)	O
.	O

A	O
second	O
reported	O
inhibitor	O
of	O
Stat3	B-Protein
,	O
AG490	O
,	O
had	O
no	O
effect	O
on	O
growth	O
(	O
Figure	O
7	O
)	O
,	O
but	O
activation	O
of	O
Akt	B-Protein
,	O
Stat3	B-Protein
,	O
or	O
levels	O
of	O
IkappaBalpha	B-Protein
were	O
also	O
not	O
affected	O
(	O
Figure	O
8	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
inhibition	O
of	O
Stat3	B-Protein
can	O
induce	O
cell	O
death	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
,	O
but	O
Stat3	B-Protein
inhibition	O
also	O
has	O
considerable	O
crossover	O
effects	O
on	O
Akt	B-Protein
and	O
NFkappaB	O
signaling	O
.	O

LMP1	B-Protein
has	O
also	O
been	O
shown	O
to	O
activate	O
JNK	O
and	O
p38	O
MAPK	O
pathways	O
[	O
13	O
,	O
48	O
]	O
,	O
and	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
were	O
mildly	O
susceptible	O
to	O
growth	O
inhibition	O
by	O
SB202190	O
,	O
an	O
inhibitor	O
of	O
p38	O
MAPK	O
,	O
but	O
not	O
U0126	O
,	O
an	O
inhibitor	O
of	O
MEK1	B-Protein
/	O
2	B-Protein
activity	O
.	O

However	O
,	O
effects	O
of	O
SB202190	O
were	O
only	O
apparent	O
at	O
high	O
doses	O
(	O
>	O
10	O
muM	O
)	O
,	O
much	O
higher	O
than	O
the	O
reported	O
IC50	O
of	O
0	O
.	O
35	O
muM	O
,	O
suggesting	O
that	O
p38	O
MAPK	O
does	O
not	O
significantly	O
contribute	O
to	O
the	O
enhanced	O
viability	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

Interestingly	O
,	O
both	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
were	O
similarly	O
susceptible	O
to	O
triciribine	O
,	O
BAY11	O
-	O
7085	O
,	O
and	O
cucurbitacin	O
I	O
treatments	O
,	O
but	O
not	O
SB202190	O
,	O
AG490	O
,	O
or	O
U0126	O
treatment	O
,	O
suggesting	O
that	O
activation	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
but	O
not	O
MAPK	O
pathways	O
are	O
characteristics	O
associated	O
with	O
malignant	O
transformation	O
(	O
Figure	O
7	O
)	O
.	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
mTOR	B-Protein
,	O
did	O
not	O
affect	O
the	O
viability	O
of	O
the	O
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
,	O
confirming	O
that	O
mTOR	B-Protein
is	O
not	O
targeted	O
by	O
Akt	B-Protein
activation	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
or	O
malignant	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

This	O
study	O
defines	O
the	O
oncogenic	O
properties	O
of	O
LMP1	B-Protein
in	O
promoting	O
B	O
cell	O
lymphomagenesis	O
.	O

LMP1	B-Protein
transgenic	O
mice	O
have	O
a	O
higher	O
incidence	O
of	O
lymphoma	O
[	O
26	O
]	O
and	O
the	O
progression	O
to	O
lymphoma	O
correlates	O
with	O
higher	O
expression	O
levels	O
of	O
LMP1	B-Protein
(	O
Figure	O
1A	O
and	O
1B	O
)	O
,	O
suggesting	O
that	O
LMP1	B-Protein
is	O
directly	O
involved	O
in	O
tumor	O
development	O
.	O

Table	O
1	O
summarizes	O
the	O
biological	O
and	O
molecular	O
properties	O
that	O
were	O
identified	O
in	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
.	O

Although	O
many	O
of	O
the	O
molecular	O
properties	O
studied	O
were	O
similar	O
between	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
,	O
there	O
were	O
distinguishing	O
biological	O
properties	O
,	O
namely	O
the	O
ability	O
of	O
LMP1	B-Protein
transgenic	O
lymphomas	O
to	O
induce	O
higher	O
levels	O
of	O
survival	O
and	O
proliferation	O
.	O

Interestingly	O
,	O
although	O
LMP1	B-Protein
transgenic	O
mice	O
develop	O
lymphomas	O
in	O
the	O
same	O
B	O
-	O
1a	O
cell	O
type	O
as	O
spontaneous	O
wild	O
-	O
type	O
lymphomas	O
(	O
Figure	O
2	O
)	O
,	O
some	O
signaling	O
effects	O
induced	O
by	O
LMP1	B-Protein
may	O
explain	O
the	O
enhanced	O
promotion	O
to	O
lymphomagenesis	O
.	O

Since	O
CD40	B-Protein
-	O
deficient	O
mice	O
have	O
decreased	O
numbers	O
of	O
IgMhighIgDlow	O
cells	O
,	O
a	O
phenotype	O
associated	O
with	O
B	O
-	O
1	O
,	O
marginal	O
zone	O
,	O
and	O
memory	O
B	O
cells	O
,	O
the	O
mimicry	O
of	O
CD40	B-Protein
signaling	O
by	O
LMP1	B-Protein
could	O
possibly	O
contribute	O
to	O
the	O
expansion	O
of	O
B	O
-	O
1	O
cells	O
[	O
20	O
]	O
.	O

It	O
is	O
noteworthy	O
that	O
expression	O
of	O
LMP1	B-Protein
in	O
transgenic	O
mice	O
has	O
been	O
shown	O
to	O
inhibit	O
the	O
formation	O
of	O
GCs	O
[	O
23	O
,	O
49	O
]	O
,	O
preventing	O
typical	O
B	O
-	O
2	O
cells	O
from	O
antigen	O
-	O
driven	O
selection	O
and	O
expansion	O
.	O

The	O
lack	O
of	O
GC	O
reactions	O
may	O
contribute	O
to	O
the	O
bias	O
of	O
LMP1	B-Protein
transgenic	O
mice	O
towards	O
B	O
-	O
1	O
cell	O
lymphomas	O
.	O

Interestingly	O
,	O
LMP2	B-Protein
signaling	O
also	O
favors	O
development	O
of	O
B	O
-	O
1	O
cells	O
,	O
but	O
this	O
occurs	O
in	O
the	O
absence	O
of	O
transformation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
mimicry	O
of	O
B	O
cell	O
receptor	O
signaling	O
by	O
LMP2	B-Protein
promotes	O
B	O
-	O
1	O
cell	O
differentiation	O
but	O
not	O
transformation	O
[	O
24	O
,	O
50	O
,	O
51	O
]	O
.	O

This	O
promotion	O
of	O
B	O
-	O
1	O
differentiation	O
may	O
account	O
for	O
the	O
ability	O
of	O
LMP2	B-Protein
to	O
exacerbate	O
autoimmunity	O
and	O
bypass	O
anergy	O
induction	O
[	O
52	O
,	O
53	O
]	O
.	O

In	O
contrast	O
,	O
the	O
preponderance	O
of	O
tumors	O
of	O
B	O
-	O
1a	O
origin	O
does	O
not	O
reflect	O
effects	O
of	O
LMP1	B-Protein
signaling	O
on	O
B	O
cell	O
differentiation	O
,	O
as	O
splenic	O
B	O
cells	O
from	O
healthy	O
LMP1	B-Protein
transgenic	O
mice	O
contain	O
similar	O
numbers	O
of	O
B	O
-	O
1	O
and	O
B	O
-	O
2	O
cells	O
as	O
wild	O
-	O
type	O
mice	O
.	O

In	O
support	O
of	O
this	O
lack	O
of	O
effect	O
,	O
the	O
differentiation	O
of	O
B	O
-	O
1	O
versus	O
B	O
-	O
2	O
cells	O
is	O
thought	O
to	O
be	O
independent	O
of	O
CD40	B-Protein
signaling	O
[	O
54	O
]	O
.	O

B	O
-	O
1	O
cells	O
constitute	O
the	O
predominant	O
lymphocyte	O
population	O
in	O
the	O
peritoneal	O
and	O
pleuropericardial	O
cavities	O
,	O
while	O
B	O
-	O
2	O
cells	O
are	O
mainly	O
found	O
in	O
the	O
spleen	O
,	O
lymph	O
node	O
,	O
and	O
peripheral	O
blood	O
.	O

B	O
-	O
1	O
cells	O
produce	O
the	O
main	O
source	O
of	O
IgM	O
and	O
IgA	O
antibodies	O
in	O
serum	O
,	O
which	O
are	O
involved	O
in	O
T	O
cell	O
-	O
independent	O
responses	O
to	O
common	O
microbial	O
antigens	O
.	O

Importantly	O
,	O
B	O
-	O
1	O
cells	O
have	O
the	O
unique	O
capacity	O
to	O
self	O
replenish	O
and	O
are	O
also	O
predisposed	O
to	O
transformation	O
[	O
28	O
,	O
29	O
]	O
.	O

Clonal	O
expansion	O
of	O
B	O
-	O
1	O
cells	O
can	O
be	O
detected	O
in	O
aging	O
mice	O
above	O
18	O
mo	O
of	O
age	O
,	O
and	O
B	O
-	O
1	O
cells	O
are	O
thought	O
to	O
be	O
the	O
murine	O
progenitor	O
of	O
B	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
[	O
30	O
]	O
.	O

The	O
data	O
presented	O
in	O
this	O
study	O
indicate	O
that	O
although	O
LMP1	B-Protein
is	O
expressed	O
in	O
all	O
B	O
lymphocytes	O
in	O
the	O
transgenic	O
mice	O
,	O
malignancy	O
develops	O
in	O
this	O
specific	O
subset	O
of	O
B	O
cells	O
.	O

The	O
elevated	O
expression	O
of	O
LMP1	B-Protein
in	O
B	O
-	O
1a	O
cells	O
and	O
the	O
activation	O
of	O
specific	O
pathways	O
apparently	O
induce	O
malignant	O
growth	O
.	O

These	O
same	O
pathways	O
can	O
also	O
become	O
sporadically	O
activated	O
in	O
aged	O
mice	O
and	O
also	O
result	O
in	O
lymphoma	O
development	O
.	O

This	O
is	O
similar	O
to	O
EBV	O
-	O
associated	O
cancers	O
in	O
vivo	O
,	O
where	O
pathways	O
that	O
are	O
activated	O
by	O
LMP1	B-Protein
are	O
also	O
activated	O
in	O
the	O
less	O
prevalent	O
EBV	O
-	O
negative	O
forms	O
of	O
the	O
cancers	O
[	O
40	O
,	O
55	O
-	O
58	O
]	O
.	O

Thus	O
,	O
the	O
contribution	O
of	O
EBV	O
and	O
LMP1	B-Protein
to	O
tumor	O
development	O
is	O
apparently	O
the	O
continuous	O
activation	O
of	O
pathways	O
that	O
can	O
also	O
be	O
sporadically	O
activated	O
and	O
contribute	O
to	O
tumor	O
development	O
.	O

The	O
lymphomas	O
were	O
marked	O
by	O
the	O
upregulation	O
of	O
IL10	B-Protein
,	O
constitutive	O
activation	O
of	O
Stat3	B-Protein
signaling	O
,	O
and	O
a	O
requirement	O
for	O
activation	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
pathways	O
(	O
Figures	O
5	O
and	O
7	O
)	O
.	O

Induction	O
of	O
IL10	B-Protein
is	O
associated	O
with	O
the	O
transformation	O
of	O
B	O
-	O
1	O
lymphomas	O
in	O
mice	O
[	O
59	O
,	O
60	O
]	O
and	O
is	O
frequently	O
associated	O
with	O
EBV	O
-	O
positive	O
B	O
cell	O
malignancies	O
acting	O
as	O
a	O
B	O
cell	O
growth	O
factor	O
[	O
35	O
-	O
38	O
]	O
.	O

In	O
addition	O
,	O
LMP1	B-Protein
has	O
been	O
shown	O
to	O
stimulate	O
IL10	B-Protein
expression	O
in	O
Burkitt	O
lymphoma	O
cell	O
lines	O
[	O
61	O
,	O
62	O
]	O
.	O

This	O
suggests	O
that	O
although	O
Stat3	B-Protein
is	O
constitutively	O
activated	O
in	O
the	O
lymphoma	O
cells	O
,	O
the	O
induction	O
of	O
IL10	B-Protein
may	O
further	O
enhance	O
Stat3	B-Protein
activation	O
or	O
may	O
contribute	O
to	O
other	O
IL10	B-Protein
-	O
responsive	O
signaling	O
pathways	O
.	O

LMP1	B-Protein
activates	O
both	O
the	O
canonical	O
and	O
non	O
-	O
canonical	O
pathways	O
of	O
NFkappaB	O
signaling	O
[	O
14	O
,	O
63	O
-	O
65	O
]	O
,	O
and	O
inhibition	O
of	O
NFkappaB	O
blocked	O
the	O
survival	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
LMP1	B-Protein
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
.	O

NFkappaB	O
and	O
PI3K	O
signaling	O
are	O
crucial	O
for	O
CD40	B-Protein
-	O
induced	O
proliferation	O
,	O
and	O
mice	O
deficient	O
for	O
cRel	B-Protein
or	O
the	O
p85	B-Protein
regulatory	O
subunit	O
of	O
PI3K	O
are	O
unresponsive	O
to	O
mitogenic	O
stimuli	O
,	O
including	O
CD40	B-Protein
ligation	O
[	O
66	O
-	O
68	O
]	O
.	O

We	O
have	O
previously	O
shown	O
that	O
cRel	B-Protein
is	O
specifically	O
activated	O
in	O
both	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
,	O
suggesting	O
that	O
activation	O
of	O
cRel	B-Protein
is	O
associated	O
with	O
B	O
cell	O
transformation	O
[	O
27	O
]	O
.	O

Our	O
observations	O
suggest	O
that	O
similar	O
to	O
CD40	B-Protein
-	O
induced	O
proliferation	O
,	O
LMP1	B-Protein
induces	O
proliferation	O
through	O
PI3K	O
-	O
mediated	O
activation	O
of	O
Akt	B-Protein
and	O
activation	O
of	O
NFkappaB	O
components	O
such	O
as	O
cRel	B-Protein
.	O

CD40	B-Protein
also	O
induces	O
downregulation	O
of	O
the	O
cell	O
cycle	O
inhibitor	O
p27	B-Protein
through	O
a	O
PI3K	O
-	O
dependent	O
manner	O
,	O
and	O
the	O
LMP1	B-Protein
lymphoma	O
cells	O
also	O
had	O
decreased	O
levels	O
of	O
p27	B-Protein
with	O
phosphorylation	O
of	O
Rb	B-Protein
and	O
increased	O
Cdk2	B-Protein
(	O
Figure	O
6C	O
)	O
[	O
66	O
]	O
.	O

Although	O
LMP1	B-Protein
has	O
been	O
shown	O
to	O
deregulate	O
the	O
Rb	B-Protein
pathway	O
in	O
epithelial	O
cells	O
[	O
69	O
]	O
,	O
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
demonstration	O
of	O
this	O
property	O
in	O
B	O
lymphocytes	O
.	O

The	O
requirement	O
for	O
Akt	B-Protein
activation	O
was	O
confirmed	O
by	O
the	O
striking	O
inhibition	O
of	O
lymphoma	O
viability	O
by	O
triciribine	O
,	O
an	O
Akt	B-Protein
inhibitor	O
.	O

However	O
,	O
the	O
activated	O
pAkt	B-Protein
did	O
not	O
lead	O
to	O
phosphorylation	O
and	O
inactivation	O
of	O
the	O
downstream	O
target	O
GSK3	B-Protein
(	O
Figure	O
6A	O
)	O
.	O

This	O
effect	O
has	O
also	O
been	O
described	O
in	O
EBV	O
-	O
positive	O
HD	O
biopsies	O
[	O
40	O
]	O
.	O

In	O
contrast	O
,	O
rapamycin	O
,	O
U0126	O
,	O
and	O
SB202190	O
did	O
not	O
affect	O
the	O
survival	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
or	O
the	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
(	O
Figure	O
7A	O
,	O
7C	O
,	O
and	O
7E	O
)	O
.	O

This	O
lack	O
of	O
effect	O
by	O
rapamycin	O
confirmed	O
the	O
absence	O
of	O
activated	O
p	B-Protein
-	I-Protein
mTOR	I-Protein
levels	O
(	O
Figure	O
6B	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
other	O
Akt	B-Protein
targets	O
contribute	O
to	O
malignant	O
progression	O
.	O

One	O
key	O
target	O
is	O
likely	O
the	O
inhibition	O
of	O
the	O
Fox01	B-Protein
transcription	O
factors	O
.	O

Repression	O
of	O
the	O
pro	O
-	O
apoptotic	O
transcription	O
factor	O
FoxO1	B-Protein
in	O
a	O
PI3K	O
-	O
dependent	O
manner	O
can	O
inhibit	O
expression	O
of	O
bcl6	B-Protein
,	O
a	O
transcription	O
factor	O
necessary	O
for	O
GC	O
formation	O
[	O
49	O
,	O
70	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
overstimulation	O
of	O
CD40	B-Protein
signaling	O
with	O
agonistic	O
antibodies	O
inhibits	O
GC	O
formation	O
[	O
71	O
]	O
.	O

Similarly	O
,	O
due	O
to	O
mimicry	O
of	O
CD40	B-Protein
signaling	O
,	O
transgenic	O
LMP1	B-Protein
mice	O
are	O
also	O
defective	O
in	O
GC	O
formation	O
[	O
23	O
,	O
49	O
]	O
.	O

The	O
constitutive	O
signaling	O
by	O
LMP1	B-Protein
likely	O
blocks	O
GC	O
formation	O
through	O
downregulation	O
of	O
bcl6	B-Protein
.	O

Interestingly	O
,	O
clinical	O
studies	O
indicate	O
that	O
expression	O
of	O
LMP1	B-Protein
and	O
bcl6	B-Protein
are	O
mutually	O
exclusive	O
in	O
non	O
-	O
HD	O
and	O
classical	O
HD	O
[	O
72	O
,	O
73	O
]	O
.	O

Thus	O
,	O
the	O
LMP1	B-Protein
transgenic	O
lymphomas	O
mirror	O
aspects	O
of	O
EBV	O
-	O
induced	O
HD	O
.	O

Although	O
the	O
activation	O
of	O
Akt	B-Protein
and	O
the	O
lack	O
of	O
Fox01	B-Protein
in	O
the	O
lymphoma	O
cells	O
suggest	O
that	O
LMP1	B-Protein
affects	O
bcl6	B-Protein
and	O
GC	O
formation	O
through	O
this	O
pathway	O
,	O
regulation	O
of	O
other	O
Forkhead	O
targets	O
involved	O
in	O
cell	O
cycle	O
progression	O
,	O
such	O
as	O
p27	B-Protein
and	O
CyclinD2	B-Protein
,	O
likely	O
contribute	O
to	O
malignant	O
transformation	O
.	O

Indeed	O
,	O
loss	O
of	O
FoxO1	B-Protein
expression	O
in	O
lymphoma	O
cells	O
correlated	O
with	O
a	O
loss	O
of	O
p27	B-Protein
(	O
Figure	O
6B	O
and	O
6C	O
)	O
.	O

CyclinD2	B-Protein
has	O
also	O
been	O
shown	O
to	O
be	O
upregulated	O
by	O
LMP1	B-Protein
through	O
release	O
of	O
FoxO1	B-Protein
-	O
mediated	O
repression	O
[	O
70	O
]	O
.	O

In	O
summary	O
,	O
in	O
this	O
transgenic	O
model	O
of	O
lymphomagenesis	O
,	O
LMP1	B-Protein
promotes	O
malignancy	O
in	O
B	O
-	O
1a	O
cells	O
,	O
a	O
population	O
that	O
is	O
predisposed	O
to	O
clonal	O
expansion	O
with	O
age	O
.	O

The	O
malignant	O
lymphocytes	O
were	O
distinguished	O
by	O
constitutively	O
active	O
Stat3	B-Protein
signaling	O
,	O
decreased	O
p27	B-Protein
,	O
and	O
activated	O
Akt	B-Protein
and	O
NFkappaB	O
pathways	O
,	O
properties	O
that	O
are	O
associated	O
with	O
promoting	O
the	O
growth	O
and	O
survival	O
of	O
B	O
lymphocytes	O
.	O

Importantly	O
,	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
pathways	O
were	O
critically	O
required	O
for	O
the	O
growth	O
and	O
survival	O
of	O
malignant	O
lymphocytes	O
as	O
well	O
as	O
healthy	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
.	O

The	O
growth	O
of	O
EBV	O
-	O
transformed	O
lymphocytes	O
also	O
requires	O
activation	O
of	O
NFkappaB	O
,	O
and	O
these	O
studies	O
provide	O
insight	O
into	O
how	O
LMP1	B-Protein
contributes	O
to	O
EBV	O
-	O
associated	O
transformation	O
.	O

The	O
transgenic	O
lymphomas	O
mirror	O
multiple	O
aspects	O
of	O
EBV	O
-	O
induced	O
tumors	O
and	O
suggest	O
that	O
in	O
vivo	O
these	O
properties	O
of	O
LMP1	B-Protein
are	O
major	O
factors	O
in	O
the	O
development	O
of	O
cancer	O
.	O

Transgenic	O
mice	O
.	O

Generation	O
of	O
LMP1	B-Protein
mice	O
under	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
have	O
been	O
described	O
previously	O
and	O
were	O
maintained	O
as	O
heterozygotes	O
on	O
a	O
Balbc	O
background	O
[	O
26	O
]	O
.	O

LMP1	B-Protein
mice	O
were	O
genotyped	O
by	O
Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
tail	O
DNA	O
as	O
described	O
previously	O
[	O
26	O
]	O
.	O

Spleen	O
and	O
liver	O
sections	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
and	O
embedded	O
in	O
paraffin	O
,	O
and	O
5	O
-	O
mum	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
for	O
histopathological	O
analysis	O
.	O

Lymphomas	O
were	O
passaged	O
by	O
intraperitoneal	O
injection	O
of	O
1	O
x	O
108	O
splenocytes	O
into	O
SCID	O
mice	O
and	O
sacrificed	O
upon	O
development	O
of	O
an	O
extended	O
abdomen	O
.	O

Animals	O
were	O
housed	O
in	O
the	O
Association	O
for	O
Assessment	O
and	O
Accreditation	O
for	O
Animal	O
Care	O
-	O
approved	O
animal	O
facility	O
at	O
the	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
.	O

All	O
protocols	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O

Isolation	O
and	O
growth	O
of	O
B	O
cells	O
.	O

Splenocytes	O
were	O
prepared	O
by	O
homogenizing	O
spleen	O
tissue	O
with	O
two	O
frosted	O
slides	O
and	O
debris	O
was	O
filtered	O
through	O
a	O
100	O
-	O
mum	O
cell	O
strainer	O
.	O

Erythrocytes	O
were	O
lysed	O
using	O
0	O
.	O
8	O
%	O
ammonium	O
chloride	O
solution	O
(	O
StemCell	O
Technologies	O
)	O
for	O
10	O
min	O
on	O
ice	O
and	O
washed	O
twice	O
with	O
PBS	O
.	O

B	O
cells	O
were	O
isolated	O
using	O
CD19	B-Protein
-	O
MACS	O
beads	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Miltenyi	O
Biotec	O
)	O
and	O
grown	O
in	O
Iscove	O
'	O
s	O
medium	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
antibiotic	O
/	O
antimycotic	O
(	O
GIBCO	O
)	O
.	O

Splenocytes	O
isolated	O
from	O
SCID	O
-	O
passaged	O
lymphomas	O
consisted	O
of	O
80	O
%	O
-	O
90	O
%	O
B	O
cells	O
as	O
determined	O
by	O
flow	O
cytometry	O
,	O
and	O
were	O
hence	O
not	O
further	O
purified	O
with	O
CD19	B-Protein
-	O
MACS	O
beads	O
.	O

Splenocytes	O
were	O
seeded	O
at	O
1	O
.	O
25	O
x	O
106	O
cells	O
/	O
ml	O
and	O
where	O
applicable	O
,	O
recombinant	O
mouse	O
IL4	B-Protein
was	O
added	O
at	O
100	O
ng	O
/	O
ml	O
,	O
recombinant	O
mouse	O
IL10	B-Protein
at	O
10	O
ng	O
/	O
ml	O
,	O
and	O
rat	O
IgG1	O
anti	O
-	O
mouse	O
IL10	B-Protein
and	O
rat	O
IgG1	O
isotype	O
control	O
at	O
10	O
mug	O
/	O
ml	O
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
BrdU	O
incorporation	O
assays	O
,	O
splenocytes	O
were	O
pulsed	O
for	O
24	O
h	O
with	O
10	O
muM	O
BrdU	O
1	O
d	O
post	O
-	O
harvest	O
.	O

MTS	O
assay	O
.	O

The	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
5	O
-	O
(	O
3	O
-	O
carboxymethoxyphenyl	O
)	O
-	O
2	O
-	O
(	O
4	O
-	O
sulfophenyl	O
)	O
-	O
2H	O
-	O
tetrazolium	O
inner	O
salt	O
(	O
MTS	O
)	O
cell	O
cytotoxicity	O
/	O
proliferation	O
assays	O
were	O
performed	O
using	O
the	O
CellTiter	O
96	O
aqueous	O
one	O
-	O
solution	O
cell	O
proliferation	O
assay	O
(	O
Promega	O
)	O
,	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O

For	O
IL4	B-Protein
studies	O
,	O
splenocytes	O
were	O
cultured	O
for	O
3	O
d	O
in	O
the	O
presence	O
or	O
absence	O
of	O
100	O
ng	O
/	O
ml	O
IL4	B-Protein
.	O

Cells	O
were	O
seeded	O
on	O
day	O
3	O
in	O
triplicate	O
in	O
a	O
96	O
-	O
well	O
plate	O
at	O
2	O
.	O
5	O
x	O
106	O
cells	O
/	O
ml	O
at	O
100	O
mul	O
per	O
well	O
.	O

MTS	O
reagent	O
was	O
added	O
for	O
4	O
h	O
and	O
absorbance	O
was	O
read	O
at	O
540	O
nm	O
;	O
values	O
plotted	O
were	O
subtracted	O
from	O
blanks	O
.	O

For	O
neutralization	O
assays	O
,	O
splenocytes	O
were	O
seeded	O
at	O
5	O
x	O
106	O
cells	O
/	O
ml	O
at	O
100	O
mul	O
per	O
well	O
on	O
day	O
of	O
harvest	O
and	O
IL4	B-Protein
,	O
rat	O
IgG1	O
anti	O
-	O
mouse	O
IL4	B-Protein
,	O
or	O
rat	O
IgG1	O
isotype	O
control	O
(	O
R	O
&	O
D	O
Systems	O
)	O
were	O
added	O
at	O
the	O
concentrations	O
indicated	O
in	O
the	O
figures	O
.	O

Cultures	O
were	O
pulsed	O
for	O
4	O
h	O
with	O
MTS	O
reagent	O
1	O
d	O
post	O
-	O
seeding	O
.	O

For	O
inhibitor	O
studies	O
,	O
splenocytes	O
were	O
seeded	O
at	O
1	O
x	O
107	O
cells	O
/	O
ml	O
at	O
100	O
mul	O
per	O
well	O
on	O
day	O
of	O
harvest	O
,	O
and	O
inhibitors	O
were	O
added	O
at	O
the	O
concentrations	O
indicated	O
in	O
the	O
figures	O
.	O

The	O
inhibitors	O
BAY11	O
-	O
7085	O
,	O
rapamycin	O
,	O
triciribine	O
,	O
U0126	O
,	O
SB202190	O
,	O
and	O
cucurbitacin	O
I	O
were	O
purchased	O
from	O
EMD	O
Biosciences	O
.	O

For	O
non	O
-	O
malignant	O
splenocyte	O
cultures	O
,	O
B	O
cell	O
activation	O
was	O
induced	O
with	O
10	O
mug	O
/	O
ml	O
of	O
goat	O
F	O
(	O
ab	O
'	O
)	O
anti	O
-	O
mouse	O
IgM	O
(	O
Jackson	O
ImmunoResearch	O
)	O
.	O

Cultures	O
were	O
pulsed	O
for	O
4	O
h	O
with	O
MTS	O
reagent	O
1	O
d	O
post	O
-	O
seeding	O
.	O

Immunohistochemistry	O
.	O

Paraffin	O
-	O
embedded	O
spleen	O
sections	O
were	O
deparaffinized	O
in	O
Histoclear	O
(	O
National	O
Diagnostics	O
)	O
and	O
rehydrated	O
in	O
graded	O
ethanol	O
.	O

Sections	O
were	O
antigen	O
retrieved	O
by	O
microwaving	O
in	O
citrate	O
buffer	O
(	O
pH	O
6	O
.	O
0	O
)	O
for	O
15	O
min	O
(	O
LMP1	B-Protein
staining	O
)	O
and	O
10	O
min	O
(	O
pStat3	O
staining	O
)	O
.	O

For	O
LMP1	B-Protein
staining	O
,	O
sections	O
were	O
blocked	O
with	O
1	O
%	O
BSA	O
and	O
0	O
.	O
1	O
%	O
cold	O
fish	O
skin	O
gelatin	O
followed	O
with	O
streptavidin	O
/	O
biotin	O
block	O
(	O
Vector	O
Labs	O
)	O
.	O

Rat	O
IgG	O
anti	O
-	O
LMP1	B-Protein
(	O
clones	O
8G3	O
and	O
1G6	O
,	O
Ascenion	O
)	O
were	O
used	O
at	O
1	O
:	O
10	O
dilution	O
from	O
tissue	O
culture	O
supernatants	O
,	O
followed	O
with	O
8	O
mug	O
/	O
ml	O
biotinylated	O
mouse	O
F	O
(	O
ab	O
'	O
)	O
anti	O
-	O
rat	O
IgG	O
(	O
H	O
+	O
L	O
)	O
pre	O
-	O
adsorbed	O
to	O
mouse	O
serum	O
(	O
Jackson	O
ImmunoResearch	O
)	O
and	O
2	O
mug	O
/	O
ml	O
streptavidin	O
-	O
alkaline	O
phosphatase	O
conjugate	O
(	O
Jackson	O
ImmunoResearch	O
)	O
.	O

Stains	O
were	O
developed	O
with	O
BCIP	O
/	O
NBT	O
and	O
counterstained	O
in	O
Nuclear	O
Fast	O
Red	O
(	O
Dako	O
)	O
.	O

Phospho	O
-	O
Stat3	B-Protein
was	O
detected	O
with	O
4	O
mug	O
/	O
ml	O
of	O
pStat3	O
antibody	O
(	O
Tyr705	O
,	O
Cell	O
Signaling	O
)	O
and	O
detected	O
with	O
anti	O
-	O
rabbit	O
Poly	O
-	O
HRP	O
IHC	O
detection	O
kit	O
(	O
Chemicon	O
)	O
.	O

Flow	O
cytometry	O
.	O

One	O
million	O
splenocytes	O
were	O
stained	O
with	O
the	O
appropriate	O
primary	O
antibody	O
unconjugated	O
or	O
conjugated	O
to	O
FITC	O
,	O
PE	O
,	O
or	O
APC	O
diluted	O
in	O
stain	O
buffer	O
(	O
PBS	O
with	O
3	O
%	O
FBS	O
)	O
.	O

For	O
BrdU	O
detection	O
,	O
the	O
FITC	O
-	O
BrdU	O
flow	O
kit	O
was	O
used	O
as	O
instructed	O
by	O
the	O
manufacturer	O
(	O
BD	O
Bioscience	O
)	O
.	O

Briefly	O
,	O
cells	O
were	O
exposed	O
to	O
EMA	O
(	O
Molecular	O
Probes	O
)	O
for	O
exclusion	O
of	O
dead	O
cells	O
,	O
stained	O
for	O
surface	O
antigens	O
,	O
fixed	O
in	O
paraformaldehyde	O
,	O
and	O
permeabilized	O
with	O
saponin	O
.	O

To	O
expose	O
BrdU	O
epitopes	O
,	O
cells	O
were	O
treated	O
with	O
Dnase	O
and	O
stained	O
with	O
FITC	O
-	O
conjugated	O
anti	O
-	O
BrdU	O
antibody	O
.	O

Flow	O
cytometry	O
was	O
performed	O
on	O
FACScalibur	O
using	O
the	O
CellQuest	O
program	O
(	O
Becton	O
Dickinson	O
)	O
.	O

Further	O
analysis	O
was	O
conducted	O
on	O
the	O
Summit	O
v4	O
.	O
2	O
program	O
(	O
Dako	O
)	O
.	O

Rnase	O
protection	O
assay	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
using	O
the	O
Rneasy	O
midi	O
purification	O
kit	O
with	O
Dnase	O
treatment	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Qiagen	O
)	O
.	O

The	O
mCK	O
-	O
1	O
probe	O
template	O
set	O
(	O
BD	O
Biosciences	O
)	O
was	O
labeled	O
using	O
the	O
In	O
Vitro	O
Transcription	O
Kit	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
BD	O
Biosciences	O
)	O
.	O

Briefly	O
,	O
50	O
ng	O
of	O
mCK	O
-	O
1	O
probe	O
set	O
was	O
labeled	O
with	O
[	O
alpha	O
-	O
32P	O
]	O
UTP	O
using	O
T7	O
RNA	O
polymerase	O
and	O
purified	O
using	O
Sephadex	O
G	O
-	O
50	O
columns	O
(	O
NucAway	O
Spin	O
column	O
,	O
Ambion	O
)	O
.	O

The	O
labeled	O
probe	O
was	O
quantitated	O
using	O
a	O
scintillation	O
counter	O
,	O
and	O
6	O
x	O
105	O
cherenkov	O
cpm	O
was	O
used	O
to	O
hybridize	O
to	O
4	O
mug	O
of	O
total	O
RNA	O
using	O
the	O
RPA	O
kit	O
(	O
BD	O
Biosciences	O
)	O
.	O

Samples	O
were	O
denatured	O
at	O
90	O
degreesC	O
and	O
hybridized	O
at	O
56	O
degreesC	O
overnight	O
.	O

Single	O
-	O
stranded	O
RNA	O
was	O
digested	O
with	O
a	O
mixture	O
of	O
Rnase	B-Protein
A	I-Protein
and	O
T1	B-Protein
,	O
and	O
precipitated	O
using	O
isopropanol	O
.	O

Protected	O
probes	O
were	O
resolved	O
on	O
a	O
denaturing	O
4	O
.	O
75	O
%	O
acrylamide	O
gel	O
,	O
dried	O
,	O
and	O
imaged	O
using	O
a	O
phosphorImager	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Densitometry	O
was	O
performed	O
using	O
the	O
ImageQuant	O
TL	O
v2005	O
software	O
(	O
GE	O
Healthcare	O
)	O
.	O

PCR	O
analysis	O
of	O
kappa	O
chain	O
rearrangement	O
.	O

DNA	O
was	O
isolated	O
from	O
splenocytes	O
using	O
the	O
Dneasy	O
Tissue	O
Kit	O
(	O
Qiagen	O
)	O
,	O
with	O
Rnase	O
treatment	O
.	O

PCR	O
reactions	O
contained	O
100	O
ng	O
of	O
genomic	O
DNA	O
,	O
0	O
.	O
2	O
muM	O
each	O
primer	O
,	O
0	O
.	O
2	O
mM	O
dNTPs	O
,	O
and	O
2	O
.	O
5	O
U	O
Taq	B-Protein
DNA	I-Protein
polymerase	I-Protein
(	O
NEB	O
)	O
performed	O
in	O
1X	O
ThermoPol	O
buffer	O
(	O
NEB	O
)	O
.	O

Primers	O
used	O
were	O
Vkappacon	O
and	O
Jkappa5	O
-	O
1degrees	O
and	O
have	O
been	O
described	O
previously	O
[	O
74	O
]	O
.	O

PCR	O
conditions	O
were	O
94	O
degreesC	O
for	O
2	O
min	O
,	O
40	O
cycles	O
of	O
94	O
degreesC	O
for	O
30	O
s	O
,	O
63	O
degreesC	O
for	O
90	O
s	O
,	O
and	O
72	O
degreesC	O
for	O
1	O
min	O
,	O
followed	O
by	O
1	O
cycle	O
of	O
72	O
degreesC	O
for	O
5	O
min	O
.	O

Immunoblot	O
analysis	O
.	O

Whole	O
cell	O
lysates	O
were	O
prepared	O
in	O
radioimmunoprecipitation	O
assay	O
(	O
RIPA	O
)	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
0	O
.	O
1	O
%	O
sodium	O
deoxycholate	O
)	O
supplemented	O
with	O
2	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
,	O
1	O
mM	O
Na3VO4	O
,	O
and	O
1	O
:	O
100	O
protease	O
/	O
phosphatase	O
inhibitor	O
cocktails	O
(	O
Sigma	O
)	O
.	O

Crude	O
lysates	O
were	O
centrifuged	O
at	O
13	O
,	O
000	O
rpm	O
for	O
10	O
min	O
at	O
4	O
degreesC	O
and	O
the	O
supernatants	O
were	O
collected	O
for	O
further	O
analysis	O
.	O

Protein	O
concentrations	O
were	O
determined	O
with	O
the	O
Bio	O
-	O
Rad	O
DC	O
protein	O
assay	O
system	O
.	O

Lysates	O
were	O
boiled	O
in	O
the	O
presence	O
of	O
2	O
.	O
5	O
%	O
beta	O
-	O
mecaptoethanol	O
,	O
separated	O
by	O
denaturing	O
SDS	O
-	O
PAGE	O
,	O
and	O
transferred	O
to	O
0	O
.	O
45	O
-	O
mum	O
Optitran	O
membranes	O
(	O
Schleicher	O
&	O
Schuell	O
)	O
in	O
a	O
Bio	O
-	O
Rad	O
transfer	O
unit	O
.	O

Membranes	O
were	O
immunoblotted	O
with	O
the	O
appropriate	O
primary	O
antibody	O
followed	O
by	O
horseradish	O
peroxidase	B-Protein
-	O
tagged	O
secondary	O
antibodies	O
(	O
Amersham	O
Biosciences	O
and	O
Dako	O
)	O
and	O
detected	O
with	O
the	O
SuperSignal	O
West	O
Pico	O
System	O
(	O
Pierce	O
)	O
.	O

Antibodies	O
.	O

FITC	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgM	O
,	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
IgD	O
(	O
clone	O
11	O
-	O
26	O
)	O
,	O
rat	O
IgG1kappa	O
anti	O
-	O
mouse	O
kappa	O
(	O
clone	O
187	O
.	O
1	O
)	O
,	O
rat	O
IgG2bkappa	O
anti	O
-	O
mouse	O
lambda	O
(	O
clone	O
JC5	O
-	O
1	O
)	O
;	O
PE	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG	O
;	O
un	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
kappa	O
and	O
anti	O
-	O
mouse	O
lambda	O
were	O
purchased	O
from	O
Southern	O
Biotech	O
.	O

APC	O
-	O
conjugated	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
CD19	B-Protein
(	O
clone	O
6D5	O
)	O
,	O
PE	O
-	O
conjugated	O
mouse	O
IgG2akappa	O
anti	O
-	O
LMP1	B-Protein
(	O
clone	O
S12	O
)	O
,	O
un	O
-	O
conjugated	O
mouse	O
IgG2a	O
anti	O
-	O
Rb	B-Protein
(	O
clone	O
2	O
)	O
,	O
and	O
anti	O
-	O
Cdk2	B-Protein
(	O
clone	O
55	O
)	O
were	O
purchased	O
from	O
BD	O
Bioscience	O
.	O

PE	O
-	O
conjugated	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
CD5	B-Protein
(	O
clone	O
53	O
-	O
7	O
.	O
3	O
)	O
was	O
purchased	O
from	O
eBioscience	O
.	O

Rat	O
anti	O
-	O
LMP1	B-Protein
(	O
clones	O
8G3	O
,	O
1G6	O
,	O
7E10	O
,	O
and	O
7G8	O
)	O
was	O
purchased	O
from	O
Ascenion	O
.	O

Rabbit	O
anti	O
-	O
pAkt	B-Protein
(	O
Ser473	O
)	O
,	O
anti	O
-	O
pGSK3alpha	B-Protein
/	O
beta	B-Protein
(	O
Ser21	O
/	O
9	O
)	O
,	O
anti	O
-	O
pStat3	B-Protein
(	O
Tyr705	O
)	O
,	O
anti	O
-	O
pStat6	B-Protein
(	O
Tyr641	O
)	O
,	O
anti	O
-	O
pmTOR	B-Protein
(	O
Ser2448	O
)	O
,	O
anti	O
-	O
Stat6	B-Protein
,	O
anti	O
-	O
Akt	B-Protein
,	O
anti	O
-	O
FoxO1	B-Protein
,	O
and	O
anti	O
-	O
p27	B-Protein
were	O
purchased	O
from	O
Cell	O
Signaling	O
.	O

Rabbit	O
anti	O
-	O
Stat3	B-Protein
(	O
H	O
-	O
190	O
)	O
,	O
anti	O
-	O
IkappaBalpha	B-Protein
(	O
C	O
-	O
21	O
)	O
,	O
and	O
goat	O
anti	O
-	O
beta	B-Protein
actin	I-Protein
(	O
I	O
-	O
19	O
)	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
.	O

Mouse	O
IgG1kappa	O
anti	O
-	O
GSK3	B-Protein
was	O
purchased	O
from	O
Upstate	O
Biotechnology	O
.	O

Rabbit	O
anti	O
-	O
pRb	B-Protein
(	O
Thr373	O
)	O
was	O
purchased	O
from	O
EMD	O
Biosciences	O
.	O

High	O
LMP1	B-Protein
Expression	O
Correlates	O
with	O
the	O
Development	O
of	O
Lymphoma	O

LMP1	B-Protein
expression	O
is	O
shown	O
by	O
(	O
A	O
)	O
immunoblotting	O
of	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
and	O
(	O
B	O
)	O
immunohistochemistry	O
staining	O
of	O
spleen	O
tissue	O
from	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
.	O

(	O
A	O
)	O
Lymphomas	O
are	O
identified	O
with	O
a	O
number	O
(	O
1	O
-	O
7	O
)	O
.	O

Arrows	O
indicate	O
the	O
LMP1	B-Protein
-	O
specific	O
band	O
and	O
its	O
degradation	O
products	O
as	O
well	O
as	O
a	O
non	O
-	O
specific	O
band	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
B	O
)	O
White	O
and	O
red	O
pulps	O
are	O
shown	O
,	O
but	O
this	O
architecture	O
is	O
lost	O
upon	O
development	O
of	O
lymphoma	O
.	O

Scale	O
bar	O
,	O
20	O
mum	O
.	O

LMP1	B-Protein
Promotes	O
B	O
-	O
1a	O
Lymphomas	O
That	O
Can	O
Escape	O
Allelic	O
Exclusion	O

(	O
A	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
splenocytes	O
from	O
a	O
WT	O
or	O
LMP1	B-Protein
transgenic	O
lymphoma	O
for	O
the	O
pan	O
-	O
B	O
cell	O
(	O
CD19	B-Protein
)	O
,	O
B	O
-	O
1a	O
cell	O
(	O
CD5	B-Protein
)	O
,	O
and	O
Ig	O
heavy	O
chain	O
(	O
IgM	O
and	O
IgD	O
)	O
and	O
light	O
chain	O
(	O
kappa	O
and	O
lambda	O
)	O
markers	O
.	O

Shown	O
are	O
the	O
results	O
from	O
WT	O
lymphoma	O
1	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
4	O
.	O

This	O
analysis	O
was	O
repeated	O
on	O
four	O
other	O
LMP1	B-Protein
transgenic	O
lymphomas	O
(	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
)	O
showing	O
a	O
similar	O
B	O
-	O
1a	O
phenotype	O
,	O
of	O
which	O
lymphomas	O
2	O
and	O
4	O
were	O
also	O
doubly	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
.	O

(	O
B	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
WT	O
or	O
LMP1	B-Protein
transgenic	O
splenocytes	O
for	O
B	O
-	O
1a	O
(	O
CD19	B-Protein
+	O
CD5	B-Protein
+	O
)	O
and	O
B	O
-	O
1b	O
or	O
B2	O
subsets	O
(	O
CD19	B-Protein
+	O
CD5	B-Protein
-	O
)	O
.	O

Percentages	O
of	O
B	O
-	O
1a	O
and	O
B	O
-	O
1b	O
or	O
B2	O
subsets	O
are	O
shown	O
in	O
each	O
quadrant	O
.	O

This	O
analysis	O
was	O
repeated	O
on	O
three	O
other	O
WT	O
and	O
two	O
other	O
LMP1	B-Protein
transgenic	O
mice	O
with	O
similar	O
results	O
.	O

(	O
C	O
)	O
Immunoblot	O
analysis	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
of	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
purified	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

LMP1	B-Protein
Promotes	O
B	O
Cell	O
Survival	O
and	O
Proliferation	O
In	O
Vitro	O

(	O
A	O
)	O
MTS	O
assay	O
of	O
splenocytes	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
.	O

Splenocytes	O
were	O
cultured	O
in	O
the	O
presence	O
(	O
grey	O
bars	O
)	O
or	O
absence	O
(	O
black	O
bars	O
)	O
of	O
IL4	B-Protein
for	O
3	O
d	O
.	O

The	O
results	O
are	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
averaged	O
from	O
multiple	O
mice	O
where	O
"	O
n	O
"	O
the	O
number	O
of	O
mice	O
analyzed	O
is	O
as	O
follows	O
:	O
n	O
=	O
2	O
for	O
WT	O
lymphocytes	O
and	O
WT	O
lymphomas	O
,	O
n	O
=	O
11	O
for	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
,	O
and	O
n	O
=	O
13	O
for	O
LMP1	B-Protein
transgenic	O
lymphomas	O
.	O

(	O
B	O
)	O
EMA	O
exclusion	O
of	O
CD19	B-Protein
+	O
gated	O
splenocytes	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
showing	O
percentage	O
of	O
viable	O
B	O
cells	O
cultured	O
with	O
(	O
white	O
bars	O
)	O
or	O
without	O
(	O
black	O
bars	O
)	O
IL4	B-Protein
for	O
2	O
d	O
.	O

(	O
C	O
)	O
Flow	O
cytometry	O
analysis	O
for	O
incorporated	O
BrdU	O
in	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
cultured	O
with	O
or	O
without	O
IL4	B-Protein
for	O
2	O
d	O
.	O

Shown	O
are	O
the	O
results	O
from	O
WT	O
lymphoma	O
1	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
2	O
.	O

Percentages	O
of	O
cells	O
in	O
each	O
quadrant	O
are	O
shown	O
.	O

Wild	O
-	O
Type	O
and	O
LMP1	B-Protein
Transgenic	O
Lymphoma	O
Cells	O
Survive	O
Independently	O
of	O
IL4	B-Protein
/	O
Stat6	B-Protein
Signaling	O
in	O
Culture	O

(	O
A	O
)	O
Rnase	O
protection	O
assay	O
for	O
IL4	B-Protein
mRNA	O
from	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
splenocytes	O
.	O

The	O
L32	B-Protein
and	O
GAPDH	B-Protein
housekeeping	O
genes	O
were	O
used	O
as	O
a	O
loading	O
control	O
.	O

Arrow	O
indicates	O
the	O
position	O
of	O
the	O
protected	O
probe	O
.	O

(	O
B	O
and	O
C	O
)	O
Immunoblot	O
analysis	O
of	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
for	O
activated	O
pStat6	B-Protein
in	O
(	O
B	O
)	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
at	O
the	O
time	O
of	O
harvest	O
or	O
in	O
(	O
C	O
)	O
whole	O
splenocytes	O
cultured	O
with	O
or	O
without	O
IL4	B-Protein
.	O

(	O
B	O
)	O
Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
,	O
and	O
the	O
white	O
line	O
indicates	O
that	O
intervening	O
lanes	O
have	O
been	O
spliced	O
out	O
.	O

(	O
D	O
and	O
E	O
)	O
MTS	O
assay	O
of	O
(	O
D	O
)	O
WT	O
lymphocytes	O
and	O
(	O
E	O
)	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
cultured	O
with	O
IL4	B-Protein
,	O
a	O
neutralizing	O
antibody	O
to	O
IL4	B-Protein
,	O
or	O
a	O
rat	O
IgG	O
isotype	O
control	O
at	O
the	O
indicated	O
concentrations	O
.	O

Shown	O
are	O
the	O
results	O
from	O
LMP1	B-Protein
transgenic	O
lymphoma	O
3	O
.	O

The	O
results	O
are	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
from	O
a	O
single	O
representative	O
experiment	O
that	O
was	O
repeated	O
twice	O
with	O
similar	O
results	O
.	O

LMP1	B-Protein
Upregulates	O
IL10	B-Protein
Expression	O
and	O
Constitutively	O
Activates	O
Stat3	B-Protein

(	O
A	O
)	O
Relative	O
expression	O
of	O
IL10	B-Protein
,	O
IL15	B-Protein
,	O
and	O
IFNgamma	B-Protein
mRNA	O
in	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
,	O
as	O
detected	O
with	O
an	O
Rnase	O
protection	O
assay	O
.	O

Mouse	O
lymphoma	O
cell	O
lines	O
967	O
and	O
K46mu	O
were	O
used	O
as	O
controls	O
.	O

Expression	O
levels	O
were	O
quantified	O
with	O
a	O
phosphorimager	O
and	O
values	O
were	O
normalized	O
to	O
the	O
ribosomal	O
housekeeping	O
gene	O
L32	B-Protein
.	O

The	O
cytokine	O
:	O
L32	B-Protein
ratio	O
was	O
set	O
to	O
1	O
in	O
the	O
mouse	O
B	O
cell	O
lymphoma	O
line	O
967	O
.	O

(	O
B	O
and	O
C	O
)	O
Immunoblot	O
analysis	O
of	O
activated	O
pStat3	B-Protein
in	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
(	O
B	O
)	O
at	O
the	O
time	O
of	O
harvest	O
,	O
and	O
(	O
C	O
)	O
4	O
h	O
after	O
culture	O
with	O
or	O
without	O
IL10	B-Protein
,	O
a	O
neutralizing	O
antibody	O
to	O
IL10	B-Protein
,	O
or	O
a	O
rat	O
IgG1	O
isotype	O
control	O
.	O

(	O
C	O
)	O
Shown	O
are	O
the	O
results	O
for	O
WT	O
lymphoma	O
1	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
1	O
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
the	O
alpha	O
and	O
beta	O
isoforms	O
of	O
Stat3	B-Protein
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
D	O
)	O
Immunohistochemistry	O
detection	O
of	O
activated	O
nuclear	O
pStat3	B-Protein
in	O
the	O
spleens	O
of	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
.	O

Scale	O
bar	O
,	O
20	O
mum	O
.	O

LMP1	B-Protein
Activates	O
Akt	B-Protein
Signaling	O
and	O
Deregulates	O
the	O
Rb	B-Protein
Cell	O
Cycle	O
Pathway	O

(	O
A	O
and	O
B	O
)	O
Immunoblot	O
analysis	O
of	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
from	O
the	O
spleens	O
of	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
for	O
Akt	B-Protein
signaling	O
,	O
probing	O
for	O
(	O
A	O
)	O
activated	O
pAkt	B-Protein
and	O
downstream	O
targets	O
,	O
including	O
inactivated	O
pGSK3alpha	B-Protein
/	O
beta	B-Protein
,	O
and	O
(	O
B	O
)	O
activated	O
p	B-Protein
-	I-Protein
mTOR	I-Protein
,	O
and	O
total	O
levels	O
of	O
FoxO1	B-Protein
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
alpha	O
and	O
beta	O
isoforms	O
of	O
GSK3	B-Protein
.	O

The	O
white	O
line	O
indicates	O
that	O
intervening	O
lanes	O
have	O
been	O
spliced	O
out	O
.	O

(	O
C	O
)	O
Immunoblot	O
analysis	O
for	O
cell	O
cycle	O
proteins	O
regulating	O
the	O
Rb	B-Protein
pathway	O
,	O
probing	O
for	O
activated	O
pRb	B-Protein
,	O
and	O
total	O
levels	O
of	O
Cdk2	B-Protein
and	O
the	O
Cdk	O
inhibitor	O
p27	B-Protein
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
Signaling	O
Are	O
Required	O
for	O
the	O
Growth	O
and	O
Survival	O
of	O
Lymphoma	O
Cells	O

MTS	O
assay	O
of	O
splenocytes	O
from	O
(	O
A	O
and	O
B	O
)	O
WT	O
or	O
(	O
C	O
and	O
D	O
)	O
LMP1	B-Protein
transgenic	O
lymphomas	O
and	O
(	O
E	O
and	O
F	O
)	O
LMP1	B-Protein
transgenic	O
lymphoctyes	O
.	O

Splenocytes	O
were	O
cultured	O
with	O
or	O
without	O
inhibitors	O
of	O
NFkappaB	O
(	O
BAY11	O
)	O
,	O
mTOR	B-Protein
(	O
rapamycin	O
)	O
,	O
Akt	B-Protein
(	O
triciribine	O
)	O
,	O
MEK1	B-Protein
/	O
2	B-Protein
(	O
U0126	O
)	O
,	O
p38	O
(	O
SB202190	O
)	O
,	O
or	O
Stat3	B-Protein
(	O
cucurbitacin	O
I	O
and	O
AG490	O
)	O
at	O
the	O
indicated	O
concentrations	O
.	O

The	O
results	O
are	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
.	O

Shown	O
are	O
the	O
results	O
for	O
(	O
A	O
and	O
B	O
)	O
WT	O
lymphoma	O
1	O
,	O
(	O
C	O
and	O
D	O
)	O
LMP1	B-Protein
transgenic	O
lymphoma	O
2	O
,	O
and	O
(	O
E	O
and	O
F	O
)	O
one	O
out	O
of	O
two	O
LMP1	B-Protein
transgenic	O
mice	O
analyzed	O
.	O

This	O
analysis	O
was	O
repeated	O
with	O
LMP1	B-Protein
transgenic	O
lymphoma	O
4	O
yielding	O
similar	O
results	O
.	O

Analysis	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
Pathways	O
in	O
Contribution	O
to	O
the	O
Growth	O
and	O
Survival	O
of	O
Lymphoma	O
Cells	O

(	O
A	O
-	O
D	O
)	O
Immunoblot	O
analysis	O
of	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
for	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
signaling	O
after	O
treatment	O
with	O
(	O
A	O
)	O
an	O
Akt	B-Protein
inhibitor	O
,	O
triciribine	O
,	O
(	O
B	O
)	O
an	O
NFkappaB	O
inhibitor	O
,	O
BAY11	O
-	O
7085	O
,	O
and	O
the	O
Stat3	B-Protein
inhibitors	O
(	O
C	O
)	O
cucurbitacin	O
I	O
and	O
(	O
D	O
)	O
AG490	O
,	O
at	O
the	O
indicated	O
concentrations	O
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
alpha	O
and	O
beta	O
isoforms	O
of	O
Stat3	B-Protein
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

Summary	O
of	O
Analysis	O
Performed	O
on	O
Wild	O
-	O
Type	O
and	O
LMP1	B-Protein
Transgenic	O
Lymphomas	O

Runx3	B-Protein
and	O
T	O
-	O
box	O
proteins	O
cooperate	O
to	O
establish	O
the	O
transcriptional	O
program	O
of	O
effector	O
CTLs	O

Activation	O
of	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
with	O
antigen	O
induces	O
their	O
differentiation	O
into	O
effector	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
.	O

CTLs	O
lyse	O
infected	O
or	O
aberrant	O
target	O
cells	O
by	O
exocytosis	O
of	O
lytic	O
granules	O
containing	O
the	O
pore	O
-	O
forming	O
protein	O
perforin	B-Protein
and	O
a	O
family	O
of	O
proteases	O
termed	O
granzymes	O
.	O

We	O
show	O
that	O
effector	O
CTL	O
differentiation	O
occurs	O
in	O
two	O
sequential	O
phases	O
in	O
vitro	O
,	O
characterized	O
by	O
early	O
induction	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
late	O
induction	O
of	O
Eomesodermin	B-Protein
(	O
Eomes	B-Protein
)	O
,	O
T	O
-	O
box	O
transcription	O
factors	O
that	O
regulate	O
the	O
early	O
and	O
late	O
phases	O
of	O
interferon	B-Protein
(	I-Protein
IFN	I-Protein
)	I-Protein
gamma	I-Protein
expression	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
a	O
critical	O
role	O
for	O
the	O
transcription	O
factor	O
Runx3	B-Protein
in	O
CTL	O
differentiation	O
.	O

Runx3	B-Protein
regulates	O
Eomes	B-Protein
expression	O
as	O
well	O
as	O
expression	O
of	O
three	O
cardinal	O
markers	O
of	O
the	O
effector	O
CTL	O
program	O
:	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
perforin	B-Protein
,	O
and	O
granzyme	B-Protein
B	I-Protein
.	O

Our	O
data	O
point	O
to	O
the	O
existence	O
of	O
an	O
elaborate	O
transcriptional	O
network	O
in	O
which	O
Runx3	B-Protein
initially	O
induces	O
and	O
then	O
cooperates	O
with	O
T	O
-	O
box	O
transcription	O
factors	O
to	O
regulate	O
gene	O
transcription	O
in	O
differentiating	O
CTLs	O
.	O

Naive	O
CD8	B-Protein
+	O
T	O
cells	O
differentiate	O
into	O
effector	O
CTLs	O
with	O
the	O
ability	O
to	O
lyse	O
antigen	O
-	O
bearing	O
target	O
cells	O
by	O
exocytosis	O
of	O
lytic	O
granules	O
containing	O
perforin	B-Protein
and	O
granzymes	O
,	O
and	O
to	O
produce	O
inflammatory	O
cytokines	O
such	O
as	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
TNF	B-Protein
upon	O
restimulation	O
through	O
the	O
TCR	O
(	O
1	O
,	O
2	O
)	O
.	O

In	O
vivo	O
experiments	O
have	O
elucidated	O
many	O
critical	O
parameters	O
governing	O
the	O
development	O
and	O
evolution	O
of	O
primary	O
CTL	O
responses	O
(	O
3	O
,	O
4	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
in	O
vitro	O
systems	O
such	O
as	O
those	O
developed	O
to	O
study	O
CD4	B-Protein
+	O
T	O
cell	O
differentiation	O
to	O
define	O
the	O
molecular	O
basis	O
of	O
effector	O
CTL	O
differentiation	O
(	O
5	O
,	O
6	O
)	O
.	O
The	O
T	O
-	O
box	O
transcription	O
factors	O
Eomesodermin	B-Protein
(	O
Eomes	B-Protein
)	O
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
are	O
needed	O
for	O
important	O
aspects	O
of	O
effector	O
and	O
memory	O
CTL	O
differentiation	O
(	O
7	O
)	O
.	O

In	O
uninfected	O
mice	O
,	O
compound	O
deletion	O
of	O
theTbx21	B-Protein
(	O
encoding	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
andeomesodermingenes	B-Protein
is	O
associated	O
with	O
a	O
selective	O
loss	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
with	O
an	O
IL	B-Protein
-	I-Protein
2Rbeta	I-Protein
-	O
high	O
,	O
memory	O
phenotype	O
(	O
8	O
)	O
.	O

Mice	O
deficient	O
for	O
both	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
in	O
T	O
cells	O
have	O
impaired	O
expression	O
of	O
cytolytic	O
mediators	O
,	O
manifest	O
poor	O
cytolytic	O
activity	O
,	O
and	O
fail	O
to	O
control	O
acute	O
lymphocytic	O
choriomeningitis	O
virus	O
infection	O
(	O
9	O
)	O
.	O

Nevertheless	O
,	O
the	O
specific	O
roles	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
in	O
clonal	O
expansion	O
and	O
CTL	O
differentiation	O
have	O
not	O
yet	O
been	O
resolved	O
:	O
in	O
particular	O
,	O
it	O
is	O
not	O
known	O
whether	O
these	O
transcription	O
factors	O
function	O
redundantly	O
to	O
control	O
effector	O
CD8	B-Protein
+	O
T	O
cell	O
differentiation	O
,	O
and	O
whether	O
they	O
do	O
so	O
directly	O
by	O
targeting	O
specific	O
effector	O
cytokine	O
and	O
cytolytic	O
genes	O
.	O
Runx	O
proteins	O
,	O
a	O
family	O
of	O
three	O
DNA	O
-	O
binding	O
transcription	O
factors	O
,	O
control	O
thymocyte	O
differentiation	O
and	O
the	O
CD4	B-Protein
/	O
CD8	B-Protein
lineage	O
decision	O
(	O
10	O
-	O
13	O
)	O
.	O

Runx3	B-Protein
and	O
perforin	B-Protein
mRNA	O
are	O
expressed	O
by	O
double	O
-	O
positive	O
(	O
DP	O
)	O
thymocytes	O
and	O
CD8	B-Protein
+	O
single	O
-	O
positive	O
(	O
SP	O
)	O
thymocytes	O
but	O
not	O
in	O
CD4	B-Protein
+	O
SP	O
cells	O
(	O
14	O
)	O
.	O

Although	O
Runx3	B-Protein
is	O
not	O
expressed	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
its	O
expression	O
is	O
up	O
-	O
regulated	O
during	O
Th1	O
cell	O
differentiation	O
,	O
and	O
Runx3	B-Protein
influences	O
Th1	O
cell	O
differentiation	O
and	O
function	O
through	O
direct	O
regulation	O
of	O
theIl4andIfngcytokine	B-Protein
genes	O
(	O
15	O
,	O
16	O
)	O
.	O

In	O
contrast	O
,	O
all	O
three	O
Runx	O
proteins	O
are	O
expressed	O
in	O
mature	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
10	O
,	O
12	O
)	O
,	O
and	O
Runx3	B-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
show	O
reduced	O
cytolytic	O
activity	O
(	O
12	O
,	O
13	O
)	O
.	O

We	O
therefore	O
tested	O
whether	O
Runx3	B-Protein
influenced	O
cytolytic	O
T	O
cell	O
differentiation	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
Runx3	B-Protein
and	O
T	O
-	O
box	O
factors	O
synergistically	O
regulate	O
CTL	O
differentiation	O
and	O
function	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
is	O
induced	O
quickly	O
upon	O
TCR	O
stimulation	O
and	O
is	O
required	O
for	O
early	O
programming	O
of	O
cytokine	O
production	O
(	O
17	O
)	O
,	O
whereas	O
Eomes	B-Protein
is	O
induced	O
later	O
during	O
differentiation	O
and	O
sustains	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

Runx3	B-Protein
is	O
required	O
for	O
Eomes	B-Protein
and	O
perforin	B-Protein
expression	O
,	O
and	O
both	O
Eomes	B-Protein
and	O
Runx3	B-Protein
bind	O
at	O
thePrf1locus	B-Protein
;	O
in	O
contrast	O
,	O
perforin	B-Protein
expression	O
is	O
unaffected	O
in	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
cells	O
.	O

T	O
cells	O
lacking	O
Runx3	B-Protein
show	O
decreased	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
Runx3	B-Protein
also	O
binds	O
the	O
promoter	O
regions	O
of	O
theIfngandGzmbgenes	B-Protein
.	O

Collectively	O
,	O
these	O
results	O
provide	O
evidence	O
for	O
a	O
complex	O
transcriptional	O
network	O
in	O
which	O
Runx3	B-Protein
is	O
a	O
primary	O
regulator	O
ofGzmbexpression	B-Protein
but	O
synergizes	O
with	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
,	O
respectively	O
,	O
to	O
promote	O
transcription	O
of	O
theIfngandPrf1genes	B-Protein
.	O

A	O
cell	O
culture	O
system	O
to	O
monitor	O
effector	O
CTL	O
differentiation	O

We	O
used	O
a	O
simple	O
cell	O
culture	O
system	O
to	O
examine	O
the	O
kinetics	O
of	O
effector	O
gene	O
expression	O
during	O
CD8	B-Protein
+	O
T	O
cell	O
differentiation	O
.	O

Naive	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
P14	O
TCR	O
transgenic	O
mice	O
were	O
activated	O
for	O
2	O
d	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
or	O
with	O
splenic	O
APCs	O
in	O
the	O
presence	O
of	O
Gp33	O
peptide	O
,	O
and	O
were	O
cultured	O
in	O
media	O
containing	O
100	O
U	O
/	O
ml	O
of	O
recombinant	O
human	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
rhIL	B-Protein
-	I-Protein
2	I-Protein
)	O
.	O

We	O
used	O
TCR	O
transgenic	O
mice	O
for	O
these	O
experiments	O
because	O
they	O
provide	O
a	O
reliable	O
source	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
that	O
are	O
truly	O
naive	O
;	O
however	O
,	O
we	O
chose	O
not	O
to	O
stimulate	O
cells	O
with	O
antigen	O
in	O
most	O
experiments	O
so	O
as	O
to	O
avoid	O
contamination	O
with	O
proteins	O
and	O
nucleic	O
acids	O
derived	O
from	O
APCs	O
.	O

There	O
were	O
only	O
minor	O
differences	O
in	O
gene	O
expression	O
during	O
differentiation	O
induced	O
by	O
antigen	O
/	O
APC	O
versus	O
anti	O
-	O
CD3	B-Protein
/	O
anti	O
-	O
CD28	B-Protein
,	O
and	O
the	O
major	O
conclusions	O
presented	O
in	O
this	O
report	O
are	O
the	O
same	O
for	O
both	O
activating	O
conditions	O
.	O

Under	O
our	O
culture	O
conditions	O
,	O
activated	O
CD8	B-Protein
+	O
T	O
cells	O
expanded	O
exponentially	O
and	O
accumulated	O
for	O
>	O
8	O
d	O
.	O

We	O
limited	O
our	O
analysis	O
to	O
the	O
first	O
6	O
-	O
8	O
d	O
after	O
activation	O
,	O
a	O
period	O
that	O
coincides	O
with	O
clonal	O
expansion	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
after	O
activation	O
in	O
vivo	O
.	O

Distinct	O
expression	O
kinetics	O
of	O
perforin	B-Protein
and	O
granzyme	B-Protein
B	I-Protein
during	O
CTL	O
development	O
in	O
culture	O

Our	O
experiments	O
revealed	O
clear	O
differences	O
in	O
the	O
kinetics	O
of	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
cytokine	O
expression	O
during	O
CD8	B-Protein
+	O
T	O
cell	O
activation	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Naive	O
T	O
cells	O
showed	O
detectable	O
expression	O
of	O
perforin	B-Protein
mRNA	O
as	O
well	O
as	O
perforin	B-Protein
protein	O
(	O
Fig	O
.	O
1	O
,	O
A	O
-	O
D	O
)	O
.	O

Relative	O
to	O
its	O
expression	O
in	O
naive	O
T	O
cells	O
,	O
perforin	B-Protein
(	O
Prf1	B-Protein
)	O
mRNA	O
expression	O
did	O
not	O
increase	O
appreciably	O
at	O
day	O
2	O
but	O
showed	O
a	O
reproducible	O
decrease	O
at	O
day	O
4	O
,	O
followed	O
by	O
robust	O
reexpression	O
between	O
days	O
4	O
and	O
8	O
(	O
Fig	O
.	O
1	O
,	O
A	O
-	O
D	O
)	O
.	O

In	O
contrast	O
,	O
granzyme	B-Protein
B	I-Protein
(	O
Gzmb	B-Protein
)	O
mRNA	O
was	O
low	O
or	O
undetectable	O
in	O
naive	O
T	O
cells	O
but	O
was	O
strongly	O
up	O
-	O
regulated	O
by	O
day	O
2	O
after	O
stimulation	O
and	O
increased	O
progressively	O
until	O
day	O
6	O
(	O
Fig	O
.	O
1	O
,	O
A	O
and	O
B	O
)	O
;	O
similarly	O
,	O
granzyme	B-Protein
B	I-Protein
protein	O
was	O
expressed	O
by	O
day	O
4	O
and	O
remained	O
high	O
until	O
day	O
6	O
(	O
Fig	O
.	O
1	O
E	O
)	O
.	O

As	O
expected	O
,	O
a	O
small	O
fraction	O
of	O
naive	O
T	O
cells	O
expressed	O
the	O
cytokines	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
TNF	B-Protein
in	O
response	O
to	O
stimulation	O
,	O
and	O
this	O
capacity	O
increased	O
significantly	O
in	O
differentiated	O
cells	O
(	O
Fig	O
.	O
1	O
E	O
;	O
see	O
also	O
Fig	O
.	O
2	O
A	O
)	O
.	O

We	O
evaluated	O
antigen	O
-	O
dependent	O
cytolytic	O
function	O
in	O
a	O
short	O
-	O
term	O
assay	O
in	O
which	O
target	O
cell	O
death	O
was	O
measured	O
within	O
2	O
h	O
(	O
Fig	O
.	O
1	O
F	O
)	O
.	O

By	O
limiting	O
the	O
duration	O
of	O
TCR	O
stimulation	O
,	O
this	O
strategy	O
minimizes	O
cytolysis	O
secondary	O
to	O
new	O
gene	O
expression	O
during	O
the	O
period	O
of	O
the	O
assay	O
.	O

Naive	O
T	O
cells	O
did	O
not	O
display	O
significant	O
cytolytic	O
function	O
in	O
this	O
short	O
-	O
term	O
assay	O
(	O
unpublished	O
data	O
)	O
,	O
most	O
likely	O
because	O
they	O
express	O
immature	O
(	O
unprocessed	O
)	O
forms	O
of	O
perforin	B-Protein
and	O
lack	O
the	O
capacity	O
to	O
degranulate	O
(	O
18	O
,	O
19	O
)	O
.	O

Even	O
after	O
activation	O
for	O
2	O
or	O
4	O
d	O
,	O
the	O
cells	O
showed	O
poor	O
cytolytic	O
activity	O
(	O
Fig	O
.	O
1	O
F	O
)	O
,	O
in	O
striking	O
contrast	O
to	O
their	O
capacity	O
for	O
efficient	O
cytokine	O
production	O
(	O
Fig	O
.	O
1	O
E	O
)	O
.	O

Only	O
cells	O
cultured	O
until	O
day	O
6	O
displayed	O
robust	O
cytotoxicity	O
,	O
as	O
judged	O
by	O
their	O
ability	O
to	O
induce	O
apoptosis	O
in	O
a	O
large	O
number	O
of	O
target	O
cells	O
(	O
Fig	O
.	O
1	O
F	O
)	O
.	O

These	O
results	O
show	O
that	O
after	O
a	O
strong	O
priming	O
stimulus	O
through	O
TCRs	O
and	O
co	O
-	O
stimulatory	O
receptors	O
in	O
vitro	O
,	O
granzyme	B-Protein
B	I-Protein
expression	O
and	O
the	O
ability	O
to	O
produce	O
effector	O
cytokines	O
are	O
programmed	O
early	O
,	O
whereas	O
perforin	B-Protein
expression	O
and	O
cytolytic	O
function	O
are	O
induced	O
later	O
,	O
during	O
the	O
phase	O
of	O
clonal	O
expansion	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Therefore	O
,	O
the	O
two	O
major	O
effector	O
functions	O
of	O
CTL	O
,	O
cytokine	O
production	O
and	O
cytolytic	O
activity	O
,	O
are	O
not	O
intrinsically	O
coregulated	O
.	O

Distinct	O
kinetics	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
expression	O
during	O
CTL	O
differentiation	O

The	O
T	O
-	O
box	O
transcription	O
factors	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
have	O
been	O
linked	O
to	O
the	O
regulation	O
of	O
genes	O
encoding	O
effector	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
,	O
Ifng	B-Protein
)	O
and	O
genes	O
important	O
for	O
cytolytic	O
function	O
(	O
e	O
.	O
g	O
.	O
,	O
Prf1	B-Protein
and	O
GzmB	B-Protein
)	O
(	O
20	O
)	O
.	O

We	O
investigated	O
the	O
kinetics	O
of	O
expression	O
of	O
these	O
transcription	O
factors	O
in	O
our	O
in	O
vitro	O
cultures	O
(	O
Fig	O
.	O
1	O
,	O
A	O
-	O
D	O
)	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
mRNA	O
and	O
protein	O
were	O
not	O
detectable	O
in	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
but	O
were	O
strongly	O
induced	O
upon	O
TCR	O
priming	O
(	O
day	O
2	O
)	O
and	O
remained	O
expressed	O
through	O
day	O
6	O
of	O
differentiation	O
(	O
Fig	O
.	O
1	O
,	O
A	O
and	O
C	O
;	O
quantified	O
in	O
Fig	O
.	O
1	O
,	O
B	O
and	O
D	O
)	O
.	O

In	O
contrast	O
,	O
Eomes	B-Protein
expression	O
was	O
low	O
or	O
undetectable	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
and	O
TCR	O
priming	O
in	O
culture	O
had	O
only	O
a	O
modest	O
effect	O
on	O
its	O
expression	O
at	O
day	O
2	O
(	O
Fig	O
.	O
1	O
,	O
A	O
and	O
C	O
)	O
.	O

Strong	O
induction	O
of	O
Eomes	B-Protein
mRNA	O
and	O
protein	O
was	O
only	O
observed	O
at	O
day	O
4	O
and	O
later	O
(	O
Fig	O
.	O
1	O
,	O
A	O
and	O
C	O
)	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
mRNA	O
expression	O
slightly	O
preceded	O
the	O
expression	O
of	O
GzmB	B-Protein
mRNA	O
;	O
similarly	O
,	O
Eomes	B-Protein
mRNA	O
and	O
protein	O
were	O
expressed	O
~	O
1	O
d	O
ahead	O
of	O
the	O
reexpression	O
of	O
perforin	B-Protein
mRNA	O
and	O
protein	O
,	O
respectively	O
(	O
Fig	O
.	O
1	O
,	O
B	O
and	O
D	O
)	O
.	O

This	O
detailed	O
kinetic	O
analysis	O
suggested	O
that	O
,	O
under	O
our	O
culture	O
conditions	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
contribute	O
to	O
distinct	O
aspects	O
of	O
gene	O
transcription	O
during	O
CTL	O
differentiation	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
is	O
required	O
early	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
,	O
and	O
our	O
data	O
suggested	O
that	O
Eomes	B-Protein
might	O
not	O
function	O
during	O
this	O
early	O
period	O
but	O
rather	O
might	O
contribute	O
later	O
to	O
the	O
control	O
of	O
perforin	B-Protein
expression	O
.	O

Our	O
data	O
seemed	O
most	O
consistent	O
with	O
a	O
model	O
in	O
which	O
TCR	O
signals	O
induce	O
T	B-Protein
-	I-Protein
bet	I-Protein
,	O
which	O
in	O
turn	O
induces	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
17	O
)	O
and	O
possibly	O
granzyme	B-Protein
B	I-Protein
;	O
subsequently	O
,	O
Eomes	B-Protein
is	O
induced	O
during	O
the	O
period	O
of	O
clonal	O
expansion	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
activates	O
perforin	B-Protein
expression	O
.	O

Perforin	B-Protein
and	O
granzyme	B-Protein
B	I-Protein
expression	O
are	O
not	O
appreciably	O
regulated	O
by	O
T	B-Protein
-	I-Protein
bet	I-Protein

To	O
test	O
the	O
model	O
outlined	O
in	O
the	O
previous	O
paragraph	O
directly	O
,	O
we	O
compared	O
the	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
perforin	B-Protein
,	O
and	O
granzyme	B-Protein
B	I-Protein
in	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
WT	O
and	O
Tbx21	B-Protein
(	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
-	O
deficient	O
mice	O
.	O

As	O
expected	O
(	O
17	O
,	O
21	O
)	O
,	O
naive	O
Tbx21	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
produced	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
poorly	O
upon	O
activation	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O

Notably	O
,	O
this	O
deleterious	O
effect	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
deficiency	O
was	O
only	O
observed	O
in	O
differentiating	O
CD8	B-Protein
+	O
T	O
cells	O
until	O
day	O
4	O
of	O
culture	O
but	O
was	O
almost	O
completely	O
mitigated	O
by	O
day	O
6	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O

This	O
most	O
likely	O
reflected	O
compensation	O
by	O
Eomes	B-Protein
,	O
which	O
was	O
strongly	O
induced	O
between	O
days	O
4	O
and	O
6	O
(	O
Fig	O
.	O
1	O
)	O
.	O

In	O
contrast	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
T	O
cells	O
cultured	O
for	O
6	O
d	O
showed	O
no	O
defect	O
in	O
perforin	B-Protein
mRNA	O
expression	O
(	O
Fig	O
.	O
2	O
B	O
,	O
compare	O
lanes	O
1	O
and	O
4	O
)	O
.	O

We	O
consistently	O
observed	O
a	O
modest	O
reduction	O
in	O
GzmB	B-Protein
mRNA	O
in	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
T	O
cells	O
(	O
Fig	O
.	O
2	O
B	O
,	O
compare	O
lanes	O
1	O
and	O
4	O
)	O
,	O
which	O
did	O
not	O
translate	O
into	O
a	O
decrease	O
in	O
expression	O
of	O
granzyme	B-Protein
B	I-Protein
protein	O
(	O
Fig	O
.	O
2	O
C	O
)	O
.	O

To	O
examine	O
the	O
role	O
of	O
Eomes	B-Protein
,	O
we	O
transduced	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
WT	O
and	O
Tbx21	B-Protein
-	O
/	O
-	O
mice	O
with	O
retroviruses	O
containing	O
internal	O
ribosome	O
entry	O
site	O
(	O
IRES	O
)	O
-	O
GFP	B-Protein
that	O
were	O
either	O
empty	O
or	O
encoded	O
a	O
strongly	O
transactivating	O
version	O
of	O
Eomes	B-Protein
(	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
)	O
(	O
8	O
)	O
,	O
and	O
expanded	O
them	O
for	O
6	O
d	O
under	O
our	O
culture	O
conditions	O
.	O

Eo	B-Protein
-	I-Protein
VP16	I-Protein
,	O
but	O
not	O
the	O
empty	O
GFP	B-Protein
retrovirus	O
,	O
increased	O
perforin	B-Protein
expression	O
in	O
both	O
WT	O
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
2	O
B	O
,	O
lanes	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
6	O
)	O
.	O

As	O
expected	O
,	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
also	O
rescued	O
the	O
early	O
defect	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
observed	O
in	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
2	O
D	O
)	O
.	O

However	O
,	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
did	O
not	O
induce	O
GzmB	B-Protein
mRNA	O
expression	O
in	O
either	O
WT	O
or	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
cells	O
;	O
thus	O
,	O
the	O
partial	O
T	B-Protein
-	I-Protein
bet	I-Protein
dependence	O
of	O
GzmB	B-Protein
mRNA	O
expression	O
cannot	O
be	O
compensated	O
for	O
by	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
.	O

Runx3	B-Protein
controls	O
multiple	O
aspects	O
of	O
the	O
CTL	O
differentiation	O
program	O
,	O
in	O
part	O
through	O
induction	O
of	O
Eomes	B-Protein

Because	O
Runx3	B-Protein
is	O
highly	O
expressed	O
in	O
peripheral	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
and	O
because	O
of	O
the	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
Runx3	B-Protein
cooperation	O
we	O
observed	O
earlier	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
15	O
)	O
,	O
we	O
examined	O
the	O
role	O
of	O
Runx3	B-Protein
in	O
effector	O
CTL	O
differentiation	O
.	O

We	O
isolated	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
(	O
KO	O
)	O
mice	O
of	O
the	O
outbred	O
ICR	O
background	O
and	O
their	O
WT	O
Runx3	B-Protein
+	O
/	O
+	O
littermates	O
by	O
positive	O
selection	O
with	O
anti	O
-	O
CD8	B-Protein
magnetic	O
beads	O
(	O
Figs	O
.	O
S1	O
and	O
S2	O
,	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
jem	O
.	O
org	O
/	O
cgi	O
/	O
content	O
/	O
full	O
/	O
jem	O
.	O
20081242	O
/	O
DC1	O
)	O
.	O

Strikingly	O
,	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
strongly	O
impaired	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
effector	O
CTLs	O
,	O
as	O
judged	O
by	O
expression	O
of	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Fig	O
.	O
3	O
)	O
.	O

Compared	O
with	O
WT	O
T	O
cells	O
,	O
perforin	B-Protein
mRNA	O
and	O
protein	O
expression	O
were	O
essentially	O
undetectable	O
in	O
Runx3	B-Protein
-	O
/	O
-	O
T	O
cells	O
at	O
day	O
6	O
of	O
culture	O
(	O
Fig	O
.	O
3	O
,	O
A	O
and	O
B	O
)	O
.	O

Runx3	B-Protein
-	O
/	O
-	O
T	O
cells	O
also	O
had	O
no	O
detectable	O
Eomes	B-Protein
expression	O
;	O
in	O
contrast	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
expression	O
was	O
unimpaired	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

Furthermore	O
,	O
Runx3	B-Protein
was	O
required	O
for	O
maximal	O
production	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
but	O
not	O
TNF	B-Protein
or	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
by	O
CD8	B-Protein
+	O
T	O
cells	O
restimulated	O
at	O
day	O
6	O
(	O
Fig	O
.	O
3	O
C	O
)	O
.	O

We	O
previously	O
reported	O
that	O
Th1	O
cell	O
differentiation	O
was	O
regulated	O
through	O
a	O
feed	O
-	O
forward	O
loop	O
in	O
which	O
T	B-Protein
-	I-Protein
bet	I-Protein
is	O
up	O
-	O
regulated	O
early	O
and	O
induces	O
Runx3	B-Protein
,	O
after	O
which	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Runx3	B-Protein
cooperate	O
to	O
induce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
silence	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
thus	O
promoting	O
stable	O
differentiation	O
toward	O
the	O
Th1	O
lineage	O
(	O
15	O
,	O
22	O
)	O
.	O

Because	O
(	O
a	O
)	O
Runx3	B-Protein
appeared	O
necessary	O
for	O
Eomes	B-Protein
induction	O
(	O
Fig	O
.	O
3	O
A	O
)	O
,	O
(	O
b	O
)	O
the	O
kinetics	O
of	O
Eomes	B-Protein
expression	O
paralleled	O
those	O
of	O
perforin	B-Protein
expression	O
(	O
Fig	O
.	O
2	O
)	O
,	O
and	O
(	O
c	O
)	O
overexpression	O
of	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
in	O
either	O
WT	O
or	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
T	O
cells	O
led	O
to	O
an	O
increase	O
in	O
both	O
perforin	B-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
(	O
Fig	O
.	O
2	O
,	O
B	O
and	O
D	O
)	O
,	O
we	O
asked	O
whether	O
CTL	O
differentiation	O
was	O
also	O
potentially	O
regulated	O
by	O
a	O
feed	O
-	O
forward	O
loop	O
involving	O
these	O
same	O
two	O
classes	O
of	O
Runx	O
and	O
T	O
-	O
box	O
transcription	O
factors	O
.	O

Specifically	O
,	O
we	O
asked	O
whether	O
Runx3	B-Protein
,	O
which	O
was	O
necessary	O
for	O
Eomes	B-Protein
induction	O
,	O
then	O
cooperated	O
with	O
Eomes	B-Protein
to	O
regulate	O
transcription	O
of	O
the	O
effector	O
CTL	O
markers	O
perforin	B-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
granzyme	B-Protein
B	I-Protein
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
used	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
to	O
ask	O
whether	O
Eomes	B-Protein
and	O
Runx3	B-Protein
bound	O
regulatory	O
regions	O
of	O
the	O
Prf1	B-Protein
,	O
Ifng	B-Protein
,	O
and	O
Gzmb	B-Protein
genes	O
(	O
Fig	O
.	O
3	O
D	O
)	O
.	O

Both	O
proteins	O
associated	O
with	O
gene	O
regulatory	O
regions	O
in	O
differentiated	O
CTLs	O
.	O

Runx3	B-Protein
bound	O
to	O
the	O
Prf1	B-Protein
and	O
Gzmb	B-Protein
transcription	O
start	O
sites	O
(	O
TSS	O
)	O
;	O
to	O
a	O
known	O
IL	O
-	O
2	O
responsive	O
enhancer	O
located	O
near	O
-	O
1	O
kb	O
of	O
the	O
Prf1	B-Protein
gene	O
(	O
23	O
)	O
;	O
to	O
the	O
distal	O
CTL	O
-	O
specific	O
DNase	O
I	O
hypersensitive	O
site	O
9	O
in	O
the	O
Prf1	B-Protein
locus	O
(	O
24	O
)	O
;	O
to	O
the	O
Ifng	B-Protein
promoter	O
near	O
the	O
TSS	O
,	O
as	O
previously	O
reported	O
for	O
Th1	O
cells	O
(	O
10	O
)	O
;	O
and	O
to	O
several	O
DNase	O
I	O
hypersensitive	O
sites	O
in	O
the	O
Ifng	B-Protein
locus	O
(	O
Fig	O
.	O
3	O
D	O
and	O
not	O
depicted	O
)	O
(	O
25	O
)	O
.	O

Eomes	B-Protein
bound	O
primarily	O
to	O
the	O
Prf1	B-Protein
TSS	O
and	O
the	O
-	O
1	O
kb	O
enhancer	O
;	O
this	O
binding	O
was	O
substantially	O
greater	O
than	O
that	O
observed	O
at	O
the	O
promoter	O
of	O
the	O
Il2rb	B-Protein
gene	O
,	O
a	O
known	O
direct	O
target	O
of	O
Eomes	B-Protein
(	O
8	O
)	O
,	O
and	O
comparable	O
to	O
that	O
observed	O
at	O
the	O
Ifng	B-Protein
TSS	O
,	O
a	O
known	O
target	O
of	O
T	O
-	O
box	O
proteins	O
in	O
both	O
Th1	O
and	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
3	O
D	O
)	O
(	O
17	O
)	O
.	O

To	O
determine	O
whether	O
Runx3	B-Protein
controlled	O
the	O
expression	O
of	O
CTL	O
effector	O
genes	O
through	O
its	O
induction	O
of	O
Eomes	B-Protein
,	O
we	O
retrovirally	O
expressed	O
Runx3	B-Protein
and	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
in	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
.	O

Because	O
of	O
the	O
limited	O
number	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
in	O
these	O
mice	O
,	O
and	O
because	O
we	O
saw	O
no	O
difference	O
between	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
CD4	B-Protein
-	O
SP	O
and	O
CD8	B-Protein
+	O
CD4	B-Protein
+	O
DP	O
cells	O
in	O
our	O
previous	O
experiments	O
,	O
we	O
used	O
total	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
without	O
further	O
fractionation	O
as	O
recipients	O
for	O
retroviral	O
transduction	O
.	O

Reconstitution	O
of	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
with	O
Runx3	B-Protein
restored	O
expression	O
of	O
Eomes	B-Protein
as	O
well	O
as	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Fig	O
.	O
4	O
,	O
A	O
and	O
B	O
)	O
.	O

In	O
addition	O
,	O
Runx3	B-Protein
-	O
/	O
-	O
T	O
cells	O
showed	O
a	O
compensatory	O
up	O
-	O
regulation	O
of	O
Runx1	B-Protein
,	O
which	O
was	O
suppressed	O
upon	O
reconstitution	O
with	O
Runx3	B-Protein
,	O
indicating	O
that	O
Runx1	B-Protein
is	O
a	O
target	O
of	O
repression	O
by	O
Runx3	B-Protein
.	O

Notably	O
,	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
did	O
not	O
up	O
-	O
regulate	O
perforin	B-Protein
expression	O
when	O
expressed	O
in	O
Runx3	B-Protein
-	O
/	O
-	O
cells	O
,	O
even	O
though	O
it	O
restored	O
the	O
capacity	O
to	O
induce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
upon	O
TCR	O
restimulation	O
(	O
Fig	O
.	O
4	O
,	O
A	O
and	O
B	O
)	O
.	O

This	O
result	O
suggests	O
strongly	O
that	O
perforin	B-Protein
expression	O
requires	O
Runx3	B-Protein
and	O
Eomes	B-Protein
.	O

As	O
expected	O
from	O
their	O
defect	O
in	O
perforin	B-Protein
and	O
granzyme	B-Protein
B	I-Protein
expression	O
,	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
showed	O
defective	O
cytolytic	O
activity	O
in	O
a	O
mixed	O
lymphocyte	O
reaction	O
(	O
12	O
)	O
.	O

However	O
,	O
TCR	O
-	O
stimulated	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
cells	O
were	O
as	O
effective	O
as	O
WT	O
cells	O
in	O
killing	O
tumor	O
cells	O
in	O
a	O
redirected	O
CTL	O
assay	O
(	O
12	O
)	O
.	O

Furthermore	O
,	O
CD8	B-Protein
+	O
cells	O
from	O
the	O
peritoneal	O
cavity	O
of	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
immunized	O
with	O
certain	O
tumor	O
cells	O
effectively	O
killed	O
these	O
targets	O
(	O
13	O
)	O
.	O

Therefore	O
,	O
although	O
activation	O
of	O
the	O
perforin	B-Protein
/	O
granzyme	B-Protein
B	I-Protein
machinery	O
is	O
defective	O
in	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
cells	O
,	O
these	O
cells	O
are	O
not	O
entirely	O
devoid	O
of	O
cytolytic	O
activity	O
and	O
could	O
still	O
effectively	O
kill	O
targets	O
,	O
possibly	O
by	O
alternative	O
mechanisms	O
such	O
as	O
the	O
Fas	B-Protein
-	O
Fas	B-Protein
ligand	I-Protein
pathway	O
.	O

Runx3	B-Protein
and	O
T	O
-	O
box	O
factors	O
control	O
a	O
complex	O
program	O
of	O
transcriptional	O
regulation	O
during	O
CTL	O
differentiation	O

Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
that	O
Runx3	B-Protein
,	O
together	O
with	O
T	O
-	O
box	O
factors	O
,	O
orchestrates	O
a	O
complex	O
program	O
of	O
transcriptional	O
regulation	O
in	O
differentiating	O
CTL	O
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

Runx3	B-Protein
is	O
present	O
in	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
before	O
activation	O
(	O
12	O
)	O
.	O

It	O
represses	O
Runx1	B-Protein
and	O
has	O
a	O
positive	O
role	O
in	O
the	O
induction	O
of	O
Eomes	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
perforin	B-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O

Runx3	B-Protein
binds	O
to	O
promoters	O
and	O
putative	O
regulatory	O
regions	O
of	O
the	O
latter	O
three	O
genes	O
,	O
suggesting	O
a	O
direct	O
effect	O
on	O
gene	O
expression	O
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
determine	O
whether	O
Eomes	B-Protein
and	O
Runx1	B-Protein
are	O
also	O
direct	O
target	O
genes	O
of	O
Runx3	B-Protein
.	O

Surprisingly	O
,	O
Runx3	B-Protein
contributed	O
to	O
the	O
optimal	O
expression	O
of	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
at	O
day	O
4	O
(	O
Fig	O
.	O
S2	O
)	O
.	O

For	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
the	O
requirement	O
for	O
Runx3	B-Protein
subsides	O
by	O
day	O
6	O
(	O
Fig	O
.	O
3	O
C	O
)	O
,	O
possibly	O
because	O
of	O
compensation	O
by	O
Runx1	B-Protein
,	O
which	O
is	O
derepressed	O
in	O
Runx3	B-Protein
-	O
/	O
-	O
cells	O
(	O
Fig	O
.	O
4	O
A	O
)	O
.	O

Runx3	B-Protein
continues	O
to	O
be	O
required	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
even	O
at	O
day	O
6	O
,	O
perhaps	O
because	O
of	O
its	O
role	O
in	O
the	O
induction	O
of	O
Eomes	B-Protein
expression	O
(	O
Fig	O
.	O
4	O
A	O
)	O
.	O

An	O
unexpected	O
finding	O
was	O
that	O
the	O
two	O
T	O
-	O
box	O
transcription	O
factors	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
,	O
are	O
up	O
-	O
regulated	O
with	O
very	O
different	O
kinetics	O
in	O
CD8	B-Protein
+	O
T	O
cells	O
under	O
our	O
culture	O
conditions	O
and	O
have	O
nonredundant	O
roles	O
in	O
the	O
subsequent	O
expression	O
of	O
key	O
effector	O
proteins	O
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
is	O
needed	O
early	O
to	O
confer	O
on	O
activated	O
CD8	B-Protein
+	O
T	O
cells	O
the	O
competence	O
to	O
produce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
upon	O
restimulation	O
,	O
but	O
its	O
function	O
is	O
less	O
important	O
at	O
later	O
times	O
.	O

Eomes	B-Protein
,	O
which	O
is	O
induced	O
late	O
and	O
functions	O
downstream	O
of	O
Runx3	B-Protein
,	O
may	O
substitute	O
for	O
T	B-Protein
-	I-Protein
bet	I-Protein
in	O
promoting	O
the	O
acute	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
restimulated	O
CTLs	O
(	O
8	O
)	O
.	O

Indeed	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
both	O
contribute	O
to	O
perforin	B-Protein
expression	O
in	O
NK	O
cells	O
(	O
8	O
,	O
26	O
)	O
,	O
and	O
Eomes	B-Protein
induces	O
granzyme	B-Protein
B	I-Protein
as	O
effectively	O
as	O
T	B-Protein
-	I-Protein
bet	I-Protein
in	O
developing	O
Th2	O
cells	O
(	O
7	O
)	O
;	O
thus	O
,	O
the	O
relative	O
roles	O
of	O
these	O
T	O
-	O
box	O
transcription	O
factors	O
vary	O
depending	O
on	O
cell	O
type	O
.	O

Surprisingly	O
,	O
however	O
,	O
Eomes	B-Protein
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
appeared	O
nonredundant	O
in	O
their	O
ability	O
to	O
induce	O
two	O
other	O
markers	O
of	O
CTL	O
function	O
,	O
Prf1	B-Protein
and	O
Gzmb	B-Protein
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

Rather	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
were	O
involved	O
in	O
regulating	O
granzyme	B-Protein
B	I-Protein
and	O
perforin	B-Protein
expression	O
,	O
respectively	O
:	O
up	O
-	O
regulation	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
mRNA	O
and	O
protein	O
closely	O
preceded	O
up	O
-	O
regulation	O
of	O
Gzmb	B-Protein
and	O
Prf1	B-Protein
mRNA	O
and	O
protein	O
,	O
respectively	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
had	O
no	O
role	O
in	O
perforin	B-Protein
expression	O
under	O
our	O
culture	O
conditions	O
,	O
and	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
did	O
not	O
affect	O
granzyme	B-Protein
B	I-Protein
expression	O
when	O
expressed	O
in	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
/	O
-	O
or	O
Runx3	B-Protein
-	O
/	O
-	O
cells	O
.	O

Because	O
conventional	O
Eomes	B-Protein
-	O
deficient	O
mice	O
die	O
before	O
precursor	O
cells	O
can	O
be	O
isolated	O
for	O
bone	O
marrow	O
transfers	O
(	O
27	O
)	O
and	O
because	O
T	O
cells	O
conditionally	O
deficient	O
in	O
Eomes	B-Protein
have	O
only	O
recently	O
been	O
described	O
(	O
9	O
)	O
,	O
we	O
were	O
unable	O
to	O
introduce	O
Runx3	B-Protein
into	O
Eomes	B-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
to	O
test	O
formally	O
whether	O
Eomes	B-Protein
cooperated	O
with	O
Runx3	B-Protein
to	O
induce	O
perforin	B-Protein
expression	O
.	O

Collectively	O
,	O
our	O
data	O
are	O
consistent	O
with	O
a	O
transcriptional	O
network	O
in	O
which	O
preexisting	O
Runx3	B-Protein
cooperates	O
with	O
the	O
induced	O
T	O
-	O
box	O
factors	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
and	O
IL	B-Protein
-	I-Protein
2Rbeta	I-Protein
signals	O
(	O
unpublished	O
data	O
)	O
to	O
orchestrate	O
CTL	O
differentiation	O
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

Our	O
data	O
recall	O
the	O
"	O
feed	O
-	O
forward	O
"	O
interaction	O
between	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Runx3	B-Protein
that	O
we	O
previously	O
described	O
in	O
CD4	B-Protein
+	O
(	O
Th1	O
)	O
T	O
cells	O
(	O
15	O
)	O
but	O
are	O
distinct	O
in	O
two	O
respects	O
:	O
in	O
differentiating	O
Th1	O
cells	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
is	O
induced	O
by	O
TCR	O
signals	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
in	O
turn	O
induces	O
Runx3	B-Protein
(	O
15	O
)	O
,	O
whereas	O
in	O
differentiating	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
preexisting	O
Runx3	B-Protein
is	O
required	O
to	O
induce	O
the	O
T	O
-	O
box	O
transcription	O
factor	O
Eomes	B-Protein
.	O

Whole	O
-	O
genome	O
experiments	O
in	O
these	O
and	O
other	O
systems	O
will	O
be	O
required	O
to	O
establish	O
whether	O
cooperation	O
between	O
T	O
-	O
box	O
and	O
Runx	O
family	O
transcription	O
factors	O
is	O
a	O
general	O
feature	O
of	O
cellular	O
differentiation	O
programs	O
.	O

Antibodies	O
and	O
reagents	O
.	O

The	O
following	O
antibodies	O
used	O
for	O
intracellular	O
or	O
surface	O
stains	O
were	O
obtained	O
from	O
eBioscience	O
:	O
anti	O
-	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
anti	O
-	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
anti	O
-	O
TNF	B-Protein
,	O
anti	O
-	O
granzyme	B-Protein
B	I-Protein
,	O
anti	O
-	O
CD8	B-Protein
,	O
anti	O
-	O
CD25	B-Protein
,	O
and	O
anti	O
-	O
CD44	B-Protein
.	O

Anti	O
-	O
CD69	B-Protein
was	O
purchased	O
from	O
BD	O
.	O

For	O
ChIP	O
experiments	O
,	O
the	O
anti	O
-	O
Eomes	B-Protein
antibody	O
was	O
obtained	O
from	O
Abcam	O
and	O
the	O
anti	O
-	O
Runx3	B-Protein
antibody	O
was	O
produced	O
by	O
the	O
Groner	O
laboratory	O
.	O

The	O
following	O
antibodies	O
were	O
used	O
for	O
immunoblotting	O
:	O
antiperforin	B-Protein
(	O
Abcam	O
)	O
,	O
anti	O
-	O
Eomes	B-Protein
(	O
Abcam	O
)	O
,	O
and	O
anti	O
-	O
Pol	O
-	O
II	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
.	O

The	O
T	B-Protein
-	I-Protein
bet	I-Protein
antibody	O
was	O
provided	O
by	O
L	O
.	O

Glimcher	O
(	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
Boston	O
,	O
MA	O
)	O
.	O

The	O
following	O
reagents	O
were	O
used	O
for	O
the	O
experiments	O
presented	O
in	O
this	O
report	O
:	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
Apoptosis	O
Detection	O
Kit	O
(	O
BD	O
)	O
,	O
CD8	B-Protein
Negative	O
Isolation	O
Kit	O
(	O
Invitrogen	O
)	O
,	O
CD8	B-Protein
MicroBeads	O
(	O
Miltenyi	O
Biotec	O
)	O
,	O
and	O
SYBR	O
Green	O
PCR	O
Core	O
Reagents	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
Gp33	O
peptide	O
(	O
KAVYNFATC	O
)	O
was	O
synthesized	O
by	O
the	O
Tufts	O
University	O
Core	O
Facility	O
,	O
and	O
10	O
mM	O
of	O
stock	O
solutions	O
was	O
prepared	O
in	O
DMSO	O
.	O

Isolation	O
and	O
culture	O
of	O
primary	O
CD8	O
+	O
T	O
cells	O
.	O

CD8	B-Protein
+	O
T	O
cells	O
from	O
4	O
-	O
8	O
-	O
wk	O
-	O
old	O
Tcra	B-Protein
-	O
/	O
-	O
x	O
P14	O
TCR	O
transgenic	O
(	O
Taconic	O
)	O
,	O
C57BL	O
/	O
6J	O
WT	O
,	O
or	O
Tbx21	B-Protein
-	O
/	O
-	O
(	O
The	O
Jackson	O
Laboratory	O
)	O
mice	O
were	O
purified	O
(	O
>	O
95	O
%	O
purity	O
)	O
by	O
negative	O
selection	O
(	O
Invitrogen	O
)	O
from	O
pooled	O
spleen	O
and	O
lymph	O
node	O
cells	O
.	O

CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
on	O
the	O
ICR	O
background	O
were	O
purified	O
by	O
positive	O
selection	O
(	O
Miltenyi	O
Biotec	O
)	O
.	O

All	O
mice	O
were	O
maintained	O
in	O
specific	O
pathogen	O
-	O
free	O
barrier	O
facilities	O
and	O
used	O
according	O
to	O
protocols	O
approved	O
by	O
the	O
Immune	O
Disease	O
Institute	O
and	O
the	O
Harvard	O
Medical	O
School	O
Animal	O
Care	O
and	O
Use	O
Committees	O
.	O

For	O
stimulation	O
,	O
purified	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
cultured	O
at	O
106	O
cells	O
/	O
ml	O
(	O
10	O
ml	O
)	O
in	O
T25	O
flasks	O
coated	O
with	O
1	O
mug	O
/	O
ml	O
each	O
of	O
anti	O
-	O
CD3	B-Protein
(	O
clone	O
2C11	O
)	O
and	O
anti	O
-	O
CD28	B-Protein
(	O
clone	O
37	O
.	O
51	O
)	O
by	O
pretreatment	O
with	O
300	O
mug	O
/	O
ml	O
goat	O
anti	O
-	O
hamster	O
IgG	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
removed	O
from	O
the	O
TCR	O
stimulation	O
and	O
recultured	O
at	O
a	O
concentration	O
of	O
5	O
x	O
105	O
cells	O
/	O
ml	O
in	O
media	O
supplemented	O
with	O
100	O
U	O
/	O
ml	O
rhIL	O
-	O
2	O
.	O

Every	O
24	O
h	O
,	O
viable	O
cells	O
were	O
counted	O
and	O
readjusted	O
to	O
5	O
x	O
105	O
cells	O
/	O
ml	O
with	O
fresh	O
media	O
containing	O
the	O
corresponding	O
amount	O
of	O
rhIL	B-Protein
-	I-Protein
2	I-Protein
.	O

Isolation	O
of	O
CD8	O
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
.	O

Runx3	B-Protein
-	O
deficient	O
T	O
cells	O
fail	O
to	O
silence	O
CD4	B-Protein
expression	O
normally	O
(	O
Fig	O
.	O
S1	O
)	O
(	O
12	O
,	O
13	O
)	O
.	O

We	O
therefore	O
further	O
fractionated	O
the	O
positively	O
selected	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
KO	O
mice	O
into	O
CD8	B-Protein
+	O
CD4	B-Protein
-	O
SP	O
or	O
CD8	B-Protein
+	O
CD4	B-Protein
+	O
DP	O
cells	O
by	O
separation	O
using	O
anti	O
-	O
CD4	B-Protein
magnetic	O
beads	O
.	O

This	O
yielded	O
a	O
Runx3	B-Protein
KO	O
SP	O
"	O
enriched	O
"	O
population	O
that	O
contained	O
75	O
%	O
CD8	B-Protein
+	O
CD4	B-Protein
-	O
cells	O
and	O
a	O
KO	O
DP	O
enriched	O
population	O
that	O
contained	O
85	O
%	O
CD8	B-Protein
+	O
CD4	B-Protein
+	O
cells	O
(	O
Fig	O
.	O
S1	O
)	O
.	O

The	O
cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Protein
+	O
anti	O
-	O
CD28	B-Protein
for	O
2	O
d	O
before	O
removing	O
them	O
from	O
the	O
TCR	O
stimulus	O
and	O
culturing	O
them	O
in	O
media	O
containing	O
100	O
U	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

As	O
previously	O
reported	O
,	O
TCR	O
-	O
induced	O
proliferation	O
of	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
was	O
severely	O
impaired	O
,	O
irrespective	O
of	O
CD4	B-Protein
expression	O
(	O
Fig	O
.	O
S1	O
)	O
(	O
12	O
,	O
13	O
)	O
.	O

However	O
,	O
the	O
Runx3	B-Protein
-	O
/	O
-	O
cells	O
showed	O
cell	O
-	O
surface	O
expression	O
patterns	O
indicative	O
of	O
activated	O
cells	O
,	O
including	O
up	O
-	O
regulation	O
of	O
CD25	B-Protein
and	O
CD69	B-Protein
(	O
Fig	O
.	O
S1	O
)	O
.	O

As	O
expected	O
from	O
their	O
ability	O
to	O
up	O
-	O
regulate	O
CD25	B-Protein
,	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
responded	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
supplementation	O
after	O
day	O
2	O
and	O
efficiently	O
expanded	O
until	O
day	O
6	O
of	O
the	O
culture	O
period	O
,	O
albeit	O
at	O
slower	O
rates	O
compared	O
with	O
WT	O
cells	O
(	O
Fig	O
.	O
S1	O
)	O
.	O

Although	O
a	O
fraction	O
of	O
the	O
KO	O
DP	O
cells	O
silenced	O
CD4	B-Protein
expression	O
after	O
activation	O
,	O
the	O
ratio	O
of	O
SP	O
/	O
DP	O
cells	O
in	O
each	O
enriched	O
population	O
remained	O
constant	O
thereafter	O
,	O
and	O
we	O
did	O
not	O
observe	O
any	O
major	O
differences	O
between	O
these	O
two	O
populations	O
throughout	O
the	O
culture	O
period	O
,	O
indicating	O
that	O
in	O
terms	O
of	O
effector	O
CTL	O
differentiation	O
and	O
under	O
our	O
culture	O
conditions	O
,	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
that	O
also	O
coexpress	O
CD4	B-Protein
are	O
indistinguishable	O
from	O
those	O
that	O
do	O
not	O
.	O

The	O
data	O
presented	O
in	O
Fig	O
.	O

S2	O
are	O
from	O
Runx3	B-Protein
KO	O
SP	O
cells	O
,	O
whereas	O
those	O
shown	O
in	O
Figs	O
.	O

3	O
and	O
4	O
are	O
from	O
total	O
Runx3	B-Protein
KO	O
CD8	B-Protein
cells	O
.	O

FACS	O
-	O
based	O
cytotoxicity	O
assay	O
.	O

To	O
measure	O
cytotoxicity	O
,	O
EL4	O
thymoma	O
target	O
cells	O
were	O
loaded	O
with	O
0	O
or	O
1	O
muM	O
Gp33	O
peptide	O
for	O
2	O
h	O
before	O
a	O
2	O
-	O
h	O
coincubation	O
with	O
P14	O
CD8	B-Protein
+	O
T	O
cells	O
at	O
the	O
effector	O
-	O
to	O
-	O
target	O
ratios	O
indicated	O
in	O
the	O
figures	O
in	O
96	O
-	O
well	O
round	O
-	O
bottom	O
plates	O
.	O

After	O
the	O
coincubation	O
period	O
,	O
cells	O
were	O
stained	O
with	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
anti	O
-	O
CD8	B-Protein
-	O
allophycocyanin	O
.	O

Data	O
analysis	O
was	O
performed	O
with	O
FlowJo	O
software	O
(	O
Tree	O
Star	O
,	O
Inc	O
.	O
)	O
;	O
EL4	O
target	O
cells	O
(	O
CD8	B-Protein
-	O
negative	O
events	O
)	O
were	O
gated	O
,	O
and	O
the	O
percentage	O
of	O
Annexin	B-Protein
V	I-Protein
+	O
target	O
cells	O
was	O
determined	O
.	O

Cytokine	O
and	O
surface	O
marker	O
staining	O
.	O

To	O
assess	O
cytokine	O
production	O
,	O
cells	O
were	O
restimulated	O
with	O
10	O
nM	O
PMA	O
+	O
1	O
muM	O
ionomycin	O
for	O
6	O
h	O
(	O
unless	O
indicated	O
otherwise	O
in	O
the	O
figures	O
)	O
,	O
and	O
intracellular	O
cytokine	O
stains	O
were	O
performed	O
as	O
previously	O
described	O
(	O
28	O
)	O
.	O

To	O
detect	O
expression	O
of	O
surface	O
molecules	O
,	O
cells	O
were	O
washed	O
in	O
PBS	O
,	O
resuspended	O
in	O
FACS	O
wash	O
buffer	O
(	O
3	O
%	O
FBS	O
,	O
0	O
.	O
1	O
%	O
sodium	O
azide	O
,	O
30	O
mM	O
Hepes	O
,	O
1x	O
PBS	O
)	O
containing	O
the	O
antibodies	O
indicated	O
in	O
the	O
figures	O
at	O
previously	O
optimized	O
concentrations	O
,	O
incubated	O
for	O
15	O
min	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
,	O
washed	O
,	O
and	O
resuspended	O
in	O
2	O
%	O
formaldehyde	O
fixative	O
solution	O
before	O
acquisition	O
on	O
a	O
FACSCalibur	O
(	O
BD	O
)	O
.	O

Retroviral	O
transduction	O
of	O
primary	O
CD8	O
+	O
T	O
cells	O
.	O

For	O
transduction	O
experiments	O
,	O
viral	O
supernatants	O
were	O
generated	O
by	O
calcium	O
phosphate	O
transfection	O
of	O
Phoenix	O
cells	O
and	O
concentration	O
by	O
overnight	O
centrifugation	O
at	O
6	O
,	O
000	O
g	O
.	O

At	O
~	O
42	O
h	O
after	O
the	O
initial	O
TCR	O
activation	O
of	O
106	O
CD8	B-Protein
+	O
T	O
cells	O
per	O
well	O
in	O
12	O
-	O
well	O
plates	O
,	O
the	O
culture	O
media	O
was	O
removed	O
and	O
replaced	O
with	O
complete	O
media	O
supplemented	O
with	O
8	O
mug	O
/	O
ml	O
polybrene	O
containing	O
fresh	O
plus	O
concentrated	O
virus	O
.	O

The	O
plates	O
were	O
centrifuged	O
at	O
700	O
g	O
for	O
1	O
h	O
at	O
RT	O
before	O
returning	O
to	O
37degreesC	O
for	O
an	O
additional	O
5	O
h	O
.	O

Retroviral	O
constructs	O
for	O
Eomes	B-Protein
-	I-Protein
VP16	I-Protein
and	O
the	O
MIG	O
control	O
empty	O
vector	O
were	O
a	O
gift	O
from	O
S	O
.	O
L	O
.	O

Reiner	O
(	O
University	O
of	O
Pennsylvania	O
,	O
Philadelphia	O
,	O
PA	O
)	O
(	O
8	O
)	O
.	O

ChIP	O
and	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

20	O
x	O
106	O
CD8	B-Protein
+	O
T	O
cells	O
per	O
immunoprecipitation	O
were	O
fixed	O
by	O
adding	O
a	O
1	O
/	O
10th	O
volume	O
of	O
fixation	O
solution	O
(	O
11	O
.	O
1	O
%	O
formaldehyde	O
,	O
100	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
EGTA	O
,	O
50	O
mM	O
Hepes	O
)	O
to	O
1	O
volume	O
of	O
culture	O
media	O
and	O
were	O
incubated	O
for	O
10	O
or	O
30	O
min	O
at	O
RT	O
.	O

Fixation	O
was	O
stopped	O
with	O
120	O
mM	O
glycine	O
on	O
ice	O
for	O
5	O
min	O
.	O

Fixed	O
cells	O
were	O
washed	O
2x	O
with	O
cold	O
PBS	O
,	O
1x	O
with	O
cold	O
solution	O
I	O
(	O
10	O
mM	O
Tris	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
10	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
EGTA	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
)	O
,	O
and	O
1x	O
with	O
cold	O
solution	O
II	O
(	O
10	O
mM	O
Tris	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
EGTA	O
,	O
200	O
mM	O
NaCl	O
)	O
.	O

After	O
washes	O
,	O
cell	O
pellets	O
were	O
resuspended	O
at	O
40	O
x	O
106	O
cells	O
/	O
ml	O
in	O
ChIP	O
lysis	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
25	O
mM	O
Tris	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
0	O
.	O
5	O
%	O
deoxycholate	O
plus	O
protease	O
and	O
phosphatase	O
inhibitors	O
)	O
,	O
and	O
chromatin	O
was	O
sheared	O
with	O
a	O
sonicator	O
to	O
yield	O
0	O
.	O
5	O
-	O
1	O
-	O
kb	O
DNA	O
fragments	O
.	O

After	O
preclearing	O
the	O
sheared	O
chromatin	O
with	O
protein	O
A	O
-	O
sepharose	O
beads	O
and	O
removing	O
5	O
%	O
as	O
input	O
chromatin	O
,	O
immunoprecipitation	O
was	O
performed	O
by	O
adding	O
optimized	O
antibody	O
amounts	O
(	O
per	O
20	O
x	O
106	O
cell	O
equivalents	O
:	O
2	O
.	O
5	O
mug	O
anti	O
-	O
Eomes	B-Protein
,	O
1	O
:	O
100	O
dilution	O
anti	O
-	O
Runx3	B-Protein
)	O
,	O
followed	O
by	O
overnight	O
incubation	O
at	O
4degreesC	O
;	O
protein	O
A	O
-	O
sepharose	O
beads	O
were	O
added	O
for	O
the	O
last	O
3	O
h	O
of	O
the	O
incubation	O
period	O
.	O

Beads	O
were	O
washed	O
2x	O
with	O
RIPA	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
8	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
0	O
.	O
5	O
%	O
deoxycholate	O
)	O
,	O
1x	O
with	O
high	O
salt	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
8	O
]	O
,	O
500	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
1	O
%	O
SDS	O
)	O
,	O
and	O
1x	O
with	O
TE	O
buffer	O
.	O

After	O
the	O
last	O
wash	O
,	O
DNA	O
was	O
eluted	O
by	O
resuspending	O
the	O
beads	O
in	O
elution	O
buffer	O
(	O
1	O
%	O
SDS	O
,	O
100	O
mM	O
NaHCO3	O
)	O
.	O

Both	O
input	O
and	O
ChIP	O
chromatin	O
were	O
then	O
treated	O
with	O
RNase	O
A	O
(	O
5	O
mug	O
total	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
,	O
followed	O
by	O
the	O
addition	O
of	O
proteinase	O
K	O
(	O
100	O
mug	O
total	O
)	O
and	O
overnight	O
incubation	O
at	O
65degreesC	O
to	O
reverse	O
cross	O
-	O
linking	O
.	O

DNA	O
was	O
then	O
purified	O
with	O
QIAquick	O
columns	O
(	O
Gel	O
Extraction	O
Kit	O
;	O
QIAGEN	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
resuspended	O
in	O
a	O
50	O
-	O
mul	O
volume	O
.	O

For	O
real	O
-	O
time	O
PCR	O
detection	O
of	O
immunoprecipitated	O
targets	O
using	O
the	O
SYBR	O
Green	O
PCR	O
Kit	O
,	O
a	O
standard	O
curve	O
was	O
obtained	O
with	O
serial	O
dilutions	O
of	O
input	O
DNA	O
for	O
each	O
sample	O
,	O
and	O
1	O
mul	O
ChIP	O
DNA	O
was	O
used	O
per	O
PCR	O
reaction	O
(	O
performed	O
in	O
duplicates	O
)	O
.	O

Melt	O
curves	O
and	O
agarose	O
gels	O
were	O
analyzed	O
to	O
ensure	O
amplification	O
of	O
specific	O
target	O
sequences	O
.	O

Refer	O
to	O
Table	O
S1	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
jem	O
.	O
org	O
/	O
cgi	O
/	O
content	O
/	O
full	O
/	O
jem	O
.	O
20081242	O
/	O
DC1	O
)	O
for	O
a	O
list	O
of	O
primer	O
sets	O
.	O

The	O
data	O
are	O
presented	O
as	O
the	O
number	O
of	O
immunoprecipitated	O
target	O
sequences	O
relative	O
to	O
input	O
chromatin	O
,	O
assuming	O
two	O
copies	O
of	O
target	O
sequence	O
per	O
cell	O
equivalent	O
used	O
for	O
the	O
ChIP	O
.	O

Northern	O
and	O
Western	O
blot	O
analyses	O
.	O

RNA	O
isolation	O
and	O
Northern	O
blot	O
analysis	O
was	O
performed	O
as	O
previously	O
described	O
(	O
29	O
)	O
.	O

In	O
brief	O
,	O
10	O
mug	O
of	O
total	O
RNA	O
was	O
loaded	O
per	O
lane	O
and	O
transferred	O
to	O
positively	O
charged	O
nylon	O
membranes	O
(	O
Hybond	O
-	O
N	O
+	O
;	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
confirmed	O
by	O
ethidium	O
bromide	O
staining	O
of	O
ribosomal	O
RNA	O
species	O
on	O
the	O
membrane	O
.	O

Membranes	O
were	O
hybridized	O
with	O
1	O
ng	O
/	O
ml	O
alpha	O
-	O
[	O
32P	O
]	O
dCTP	O
-	O
labeled	O
trichloroacetic	O
acid	O
precipitable	O
probe	O
in	O
ExpressHyb	O
hybridization	O
buffer	O
(	O
Clontech	O
Laboratories	O
,	O
Inc	O
.	O
)	O
.	O

All	O
cDNA	O
probes	O
were	O
confirmed	O
to	O
have	O
the	O
appropriate	O
single	O
-	O
copy	O
specificity	O
under	O
these	O
conditions	O
using	O
genomic	O
Southern	O
blot	O
analysis	O
.	O

Band	O
intensities	O
were	O
acquired	O
by	O
phosphorimaging	O
analysis	O
.	O

For	O
Western	O
analysis	O
,	O
whole	O
-	O
cell	O
protein	O
lysates	O
were	O
obtained	O
from	O
CD8	B-Protein
+	O
T	O
cells	O
at	O
the	O
time	O
points	O
indicated	O
in	O
the	O
figures	O
during	O
clonal	O
expansion	O
in	O
100	O
U	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
with	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
10	O
%	O
glycerol	O
,	O
5	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
)	O
by	O
resuspending	O
samples	O
in	O
10	O
mul	O
per	O
106	O
cells	O
and	O
incubating	O
on	O
ice	O
for	O
30	O
min	O
in	O
the	O
presence	O
of	O
protease	O
inhibitors	O
.	O

Immunoblot	O
analysis	O
was	O
performed	O
with	O
the	O
antibodies	O
indicated	O
in	O
the	O
figures	O
after	O
SDS	O
-	O
PAGE	O
(	O
10	O
-	O
30	O
mug	O
of	O
total	O
protein	O
was	O
loaded	O
per	O
well	O
)	O
.	O

Quantification	O
of	O
detected	O
protein	O
was	O
performed	O
with	O
an	O
Intelligent	O
Dark	O
Box	O
unit	O
(	O
LAS	O
-	O
3000	O
;	O
Fujifilm	O
)	O
and	O
normalized	O
for	O
loading	O
with	O
the	O
amount	O
of	O
RNA	O
Pol	O
-	O
II	O
detected	O
in	O
each	O
lane	O
.	O

Online	O
supplemental	O
material	O
.	O

Fig	O
.	O

S1	O
shows	O
the	O
characterization	O
of	O
peripheral	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
.	O

Fig	O
.	O

S2	O
shows	O
effector	O
protein	O
expression	O
by	O
Runx3	B-Protein
WT	O
and	O
KO	O
cells	O
at	O
day	O
4	O
of	O
in	O
vitro	O
culture	O
.	O

Primer	O
sequences	O
used	O
for	O
ChIP	O
experiments	O
are	O
shown	O
in	O
Table	O
S1	O
.	O

Online	O
supplemental	O
material	O
is	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
jem	O
.	O
org	O
/	O
cgi	O
/	O
content	O
/	O
full	O
/	O
jem	O
.	O
20081242	O
/	O
DC1	O
.	O

Kinetics	O
of	O
gene	O
expression	O
during	O
CD8	B-Protein
+	O
T	O
cell	O
differentiation	O
.	O

(	O
A	O
)	O
Kinetics	O
of	O
Prf1	B-Protein
,	O
Gzmb	B-Protein
,	O
Tbx21	B-Protein
(	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
,	O
and	O
Eomes	B-Protein
mRNA	O
expression	O
in	O
differentiating	O
P14	O
CD8	B-Protein
+	O
T	O
cells	O
analyzed	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
day	O
7	O
Th1	O
cells	O
was	O
used	O
as	O
a	O
control	O
.	O

Sizes	O
of	O
mRNA	O
transcripts	O
are	O
indicated	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
relative	O
mRNA	O
amounts	O
by	O
phosphorimager	O
analysis	O
.	O

(	O
C	O
)	O
Kinetics	O
of	O
protein	O
expression	O
in	O
differentiating	O
P14	O
CD8	B-Protein
+	O
T	O
cells	O
analyzed	O
by	O
immunoblotting	O
.	O

Sizes	O
of	O
protein	O
bands	O
are	O
indicated	O
.	O

(	O
D	O
)	O
Relative	O
protein	O
amounts	O
quantified	O
from	O
the	O
Western	O
blots	O
.	O

(	O
E	O
)	O
Intracellular	O
staining	O
for	O
granzyme	B-Protein
B	I-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
TNF	B-Protein
.	O

Granzyme	B-Protein
B	I-Protein
staining	O
was	O
specific	O
relative	O
to	O
an	O
isotype	O
control	O
(	O
not	O
depicted	O
)	O
.	O

Cells	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
4	O
h	O
.	O

(	O
F	O
)	O
FACS	O
-	O
based	O
assay	O
to	O
measure	O
cytolytic	O
activity	O
of	O
P14	O
CD8	B-Protein
+	O
T	O
cells	O
against	O
EL4	O
targets	O
loaded	O
with	O
0	O
(	O
-	O
)	O
or	O
1	O
(	O
+	O
)	O
muM	O
Gp33	O
peptide	O
(	O
effector	O
-	O
to	O
-	O
target	O
ratio	O
=	O
5	O
:	O
1	O
)	O
.	O

Percentage	O
of	O
Annexin	B-Protein
V	I-Protein
+	O
(	O
apoptotic	O
)	O
target	O
cells	O
in	O
the	O
CD8	B-Protein
-	O
negative	O
EL4	O
target	O
population	O
(	O
dot	O
plots	O
)	O
was	O
determined	O
(	O
histograms	O
)	O
.	O

Cytolytic	O
activity	O
was	O
blocked	O
by	O
incubation	O
with	O
2	O
mM	O
EGTA	O
(	O
not	O
depicted	O
)	O
,	O
confirming	O
involvement	O
of	O
the	O
granule	O
exocytosis	O
(	O
perforin	B-Protein
-	O
granzyme	B-Protein
B	I-Protein
)	O
pathway	O
.	O

Data	O
are	O
representative	O
of	O
at	O
least	O
five	O
(	O
A	O
-	O
E	O
)	O
or	O
three	O
(	O
F	O
)	O
independent	O
experiments	O
.	O

Regulation	O
of	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
by	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
in	O
differentiating	O
CTLs	O
.	O

(	O
A	O
)	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
by	O
WT	O
(	O
Tbx21	B-Protein
+	O
/	O
+	O
)	O
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
(	O
Tbx21	B-Protein
-	O
/	O
-	O
)	O
T	O
cells	O
.	O

Naive	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
or	O
cells	O
activated	O
and	O
cultured	O
for	O
4	O
or	O
6	O
d	O
,	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
6	O
h	O
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
was	O
assessed	O
by	O
intracellular	O
staining	O
.	O

Numbers	O
show	O
the	O
percentage	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
+	O
cells	O
.	O

(	O
B	O
)	O
Northern	O
blot	O
analysis	O
of	O
Prf1	B-Protein
and	O
GzmB	B-Protein
mRNA	O
expression	O
in	O
WT	O
or	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
activated	O
and	O
either	O
left	O
uninfected	O
(	O
uninf	O
)	O
or	O
transduced	O
with	O
retroviruses	O
expressing	O
Eomes	B-Protein
-	I-Protein
VP16	I-Protein
(	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
)	O
or	O
an	O
empty	O
IRES	O
-	O
GFP	B-Protein
cassette	O
(	O
GFP	O
)	O
.	O

Total	O
cellular	O
RNA	O
was	O
analyzed	O
on	O
day	O
6	O
of	O
culture	O
.	O

The	O
frequency	O
of	O
transduced	O
cells	O
in	O
the	O
cultures	O
was	O
equivalent	O
for	O
both	O
constructs	O
(	O
~	O
65	O
-	O
70	O
%	O
GFP	O
+	O
cells	O
;	O
not	O
depicted	O
)	O
.	O

(	O
C	O
)	O
Granzyme	B-Protein
B	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
by	O
Tbx21	B-Protein
+	O
/	O
+	O
and	O
Tbx21	B-Protein
-	O
/	O
-	O
T	O
cells	O
analyzed	O
in	O
restimulated	O
cells	O
that	O
had	O
been	O
cultured	O
for	O
5	O
d	O
.	O

(	O
D	O
)	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
by	O
cells	O
transduced	O
with	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
or	O
control	O
(	O
GFP	B-Protein
)	O
retroviruses	O
(	O
RV	O
)	O
measured	O
on	O
day	O
4	O
after	O
6	O
h	O
of	O
restimulation	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Numbers	O
show	O
the	O
percentage	O
of	O
GFP	B-Protein
+	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
+	O
cells	O
.	O

Results	O
are	O
representative	O
of	O
three	O
(	O
A	O
and	O
C	O
)	O
or	O
two	O
(	O
B	O
and	O
D	O
)	O
independent	O
experiments	O
.	O

Key	O
role	O
for	O
Runx3	B-Protein
in	O
effector	O
CTL	O
differentiation	O
.	O

(	O
A	O
)	O
Western	O
analysis	O
of	O
Runx3	B-Protein
,	O
Eomes	B-Protein
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
,	O
and	O
perforin	B-Protein
expression	O
in	O
Runx3	B-Protein
+	O
/	O
+	O
versus	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
SP	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

beta	B-Protein
-	I-Protein
Actin	I-Protein
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
B	O
)	O
Northern	O
blot	O
analysis	O
of	O
Prf1	B-Protein
mRNA	O
expression	O
in	O
Runx3	B-Protein
+	O
/	O
+	O
versus	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

beta	B-Protein
-	I-Protein
Actin	I-Protein
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
C	O
)	O
Expression	O
of	O
granzyme	B-Protein
B	I-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
TNF	B-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
by	O
resting	O
or	O
restimulated	O
(	O
6	O
h	O
)	O
Runx3	B-Protein
+	O
/	O
+	O
versus	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
SP	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

The	O
vertical	O
gray	O
line	O
indicates	O
the	O
granzyme	B-Protein
B	I-Protein
MFI	O
for	O
WT	O
GFP	B-Protein
+	O
cells	O
.	O

Results	O
in	O
A	O
-	O
C	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O

(	O
D	O
)	O
ChIP	O
analysis	O
of	O
binding	O
of	O
endogenous	O
Runx3	B-Protein
and	O
Eomes	B-Protein
to	O
the	O
Prf1	B-Protein
locus	O
.	O

Enrichment	O
of	O
the	O
indicated	O
genomic	O
regions	O
was	O
evaluated	O
by	O
real	O
-	O
time	O
PCR	O
of	O
DNA	O
from	O
immunoprecipitated	O
and	O
input	O
chromatin	O
.	O

The	O
data	O
are	O
the	O
means	O
of	O
duplicate	O
measurements	O
from	O
two	O
chromatin	O
preparations	O
from	O
two	O
independent	O
CD8	B-Protein
+	O
T	O
cell	O
differentiations	O
.	O

The	O
efficiency	O
of	O
recovery	O
of	O
input	O
for	O
the	O
-	O
1	O
-	O
kb	O
region	O
of	O
Prf1	B-Protein
was	O
0	O
.	O
97	O
%	O
for	O
the	O
Runx3	B-Protein
ChIP	O
and	O
0	O
.	O
5	O
%	O
for	O
the	O
Eomes	B-Protein
ChIP	O
.	O

Runx3	B-Protein
controls	O
Eomes	B-Protein
,	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
in	O
effector	O
CTLs	O
.	O

Runx3	B-Protein
+	O
/	O
+	O
or	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
activated	O
and	O
transduced	O
with	O
retroviruses	O
bearing	O
an	O
empty	O
IRES	O
-	O
GFP	B-Protein
cassette	O
(	O
GFP	O
)	O
or	O
also	O
encoding	O
Eomes	B-Protein
-	I-Protein
VP16	I-Protein
(	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
)	O
or	O
Myc	B-Protein
-	O
Runx3	B-Protein
(	O
Runx3	B-Protein
)	O
.	O

The	O
frequency	O
of	O
transduced	O
cells	O
in	O
the	O
cultures	O
was	O
equivalent	O
for	O
all	O
constructs	O
(	O
~	O
75	O
-	O
90	O
%	O
GFP	O
+	O
cells	O
;	O
not	O
depicted	O
)	O
.	O

(	O
A	O
)	O
Protein	O
expression	O
in	O
whole	O
-	O
cell	O
extracts	O
(	O
day	O
6	O
)	O
was	O
analyzed	O
by	O
immunoblotting	O
.	O

Overexpression	O
of	O
Eomes	B-Protein
-	I-Protein
VP16	I-Protein
cannot	O
be	O
detected	O
with	O
the	O
Eomes	B-Protein
antibody	O
,	O
as	O
the	O
C	O
-	O
terminal	O
epitope	O
is	O
within	O
the	O
region	O
that	O
has	O
been	O
replaced	O
with	O
the	O
VP16	B-Protein
transactivation	O
domain	O
.	O

(	O
B	O
)	O
Expression	O
of	O
granzyme	B-Protein
B	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
after	O
culture	O
for	O
6	O
d	O
and	O
restimulation	O
for	O
4	O
h	O
with	O
PMA	O
and	O
ionomycin	O
was	O
determined	O
by	O
intracellular	O
staining	O
.	O

The	O
percentage	O
of	O
positively	O
stained	O
cells	O
is	O
shown	O
above	O
the	O
gate	O
;	O
the	O
mean	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
granzyme	B-Protein
B	I-Protein
staining	O
for	O
the	O
total	O
population	O
is	O
shown	O
below	O
the	O
gate	O
.	O

The	O
vertical	O
gray	O
lines	O
indicate	O
the	O
MFI	O
for	O
WT	O
GFP	B-Protein
+	O
cells	O
.	O

Results	O
are	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
Schematic	O
diagram	O
of	O
the	O
transcriptional	O
network	O
involving	O
Runx3	B-Protein
and	O
T	O
-	O
box	O
factors	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
is	O
induced	O
by	O
TCR	O
signals	O
and	O
is	O
essential	O
for	O
early	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

Runx3	B-Protein
is	O
present	O
in	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
and	O
represses	O
Runx1	B-Protein
and	O
induces	O
Eomes	B-Protein
,	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

Eomes	B-Protein
may	O
participate	O
in	O
sustaining	O
late	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
,	O
whereas	O
Runx3	B-Protein
and	O
Eomes	B-Protein
(	O
but	O
not	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
may	O
cooperate	O
to	O
activate	O
perforin	B-Protein
expression	O
.	O

The	O
dotted	O
line	O
indicates	O
the	O
partial	O
effect	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
deficiency	O
on	O
Gzmb	B-Protein
mRNA	O
but	O
not	O
granzyme	B-Protein
B	I-Protein
protein	O
expression	O
.	O

Insights	O
into	O
the	O
Regulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
Production	O
in	O
Human	O
Mononuclear	O
Cells	O
:	O
The	O
Effects	O
of	O
Non	O
-	O
Specific	O
Phosphodiesterase	O
Inhibition	O

OBJECTIVE	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
nonspecific	O
phosphodiesterase	O
inhibition	O
on	O
transcription	O
factor	O
activation	O
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
production	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
human	O
mononuclear	O
cells	O
.	O

INTRODUCTION	O

The	O
production	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
following	O
LPS	O
stimulation	O
is	O
one	O
of	O
the	O
key	O
steps	O
in	O
bacterial	O
sepsis	O
and	O
inflammation	O
.	O

The	O
mechanism	O
by	O
which	O
phosphodiesterase	O
inhibition	O
alters	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
the	O
presence	O
of	O
LPS	O
remains	O
unclear	O
.	O

METHODS	O

Human	O
mononuclear	O
cells	O
were	O
stimulated	O
with	O
LPS	O
(	O
1	O
mug	O
/	O
mL	O
)	O
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
Pentoxifylline	O
(	O
PTX	O
;	O
20	O
mM	O
)	O
,	O
a	O
nonspecific	O
phosphodiesterase	O
inhibitor	O
.	O

Western	O
blotting	O
of	O
phosphorylated	O
cytoplasmic	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
,	O
nuclear	O
factor	O
-	O
kappaB	O
p65	B-Protein
(	O
NF	O
-	O
kappaB	O
)	O
,	O
and	O
nuclear	O
cAMP	O
-	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
was	O
performed	O
.	O

DNA	O
binding	O
of	O
NF	O
-	O
kappaB	O
and	O
CREB	O
was	O
verified	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
levels	O
were	O
determined	O
in	O
the	O
supernatant	O
of	O
stimulated	O
cells	O
in	O
the	O
presence	O
and	O
absence	O
Protein	O
kinase	O
A	O
inhibition	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

RESULTS	O

PTX	O
was	O
demonstrated	O
to	O
significantly	O
reduce	O
cytoplasmic	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
,	O
nuclear	O
p65	B-Protein
phosphorylation	O
,	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
contrast	O
,	O
PTX	O
markedly	O
enhanced	O
the	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
CREB	O
.	O

Cells	O
concomitantly	O
treated	O
with	O
PTX	O
and	O
LPS	O
secreted	O
similar	O
levels	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
the	O
presence	O
and	O
absence	O
Protein	O
kinase	O
A	O
inhibition	O
.	O

DISCUSSION	O

The	O
increased	O
level	O
of	O
cAMP	O
that	O
results	O
from	O
phosphodiesterase	O
inhibition	O
affects	O
cytoplasmic	O
and	O
nuclear	O
events	O
,	O
resulting	O
in	O
the	O
attenuation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
activation	O
of	O
CREB	O
transcriptional	O
DNA	O
binding	O
through	O
pathways	O
that	O
are	O
partially	O
Protein	O
kinase	O
A	O
-	O
independent	O
.	O

CONCLUSION	O

PTX	O
-	O
mediated	O
phosphodiesterase	O
inhibition	O
occurs	O
partially	O
through	O
a	O
Protein	O
kinase	O
A	O
-	O
independent	O
pathway	O
and	O
may	O
serve	O
as	O
a	O
useful	O
tool	O
in	O
the	O
attenuation	O
of	O
LPS	O
-	O
induced	O
inflammation	O
.	O

The	O
bacterial	O
membrane	O
component	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
capable	O
of	O
initiating	O
phosphorylation	O
and	O
activation	O
of	O
multiple	O
host	O
intracellular	O
protein	O
kinases	O
and	O
transcription	O
factors	O
.	O

Transcription	O
factor	O
activation	O
,	O
which	O
results	O
in	O
the	O
modulation	O
of	O
gene	O
transcription	O
and	O
protein	O
synthesis	O
,	O
is	O
a	O
critical	O
element	O
in	O
the	O
defense	O
mechanism	O
of	O
the	O
host	O
immune	O
system	O
.	O
1	O
,	O
2	O

LPS	O
-	O
induced	O
transcription	O
factor	O
activation	O
has	O
been	O
shown	O
to	O
be	O
a	O
key	O
regulator	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
production	O
.	O
3	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
a	O
potent	O
pro	O
-	O
inflammatory	O
cytokine	O
involved	O
in	O
a	O
wide	O
spectrum	O
of	O
cellular	O
responses	O
.	O

Furthermore	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
synthesis	O
can	O
be	O
attenuated	O
in	O
immune	O
cells	O
exposed	O
to	O
phosphodiesterase	O
(	O
PDE	O
)	O
inhibition	O
after	O
challenge	O
by	O
a	O
variety	O
of	O
pro	O
-	O
inflammatory	O
stimulants	O
.	O
4	O
The	O
signaling	O
mechanisms	O
affected	O
by	O
PDE	O
inhibition	O
,	O
which	O
ultimately	O
lead	O
to	O
the	O
downregulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
,	O
have	O
not	O
been	O
well	O
characterized	O
in	O
inflammatory	O
cells	O
.	O

Classically	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
PDE	O
inhibition	O
results	O
in	O
the	O
intracellular	O
accumulation	O
of	O
the	O
second	O
messenger	O
cyclic	O
adenosine	O
-	O
3	O
,	O
5	O
-	O
monophosphate	O
(	O
cAMP	O
)	O
and	O
subsequent	O
activation	O
of	O
Protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O
5	O
PKA	O
activation	O
then	O
leads	O
to	O
the	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
cAMP	O
-	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
,	O
transmission	O
of	O
signals	O
into	O
the	O
nucleus	O
,	O
and	O
the	O
subsequent	O
modulation	O
of	O
gene	O
transcription	O
.	O
6	O
This	O
apparently	O
simple	O
linear	O
cascade	O
does	O
not	O
fully	O
explain	O
the	O
mechanism	O
by	O
which	O
an	O
elevation	O
in	O
the	O
intracellular	O
cAMP	O
level	O
exerts	O
wide	O
-	O
ranging	O
effects	O
on	O
multiple	O
cellular	O
functions	O
.	O

There	O
is	O
a	O
growing	O
body	O
of	O
evidence	O
suggesting	O
that	O
cAMP	O
may	O
function	O
through	O
both	O
PKA	O
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O
6	O
-	O
8	O

LPS	O
-	O
induced	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
has	O
also	O
been	O
the	O
focus	O
of	O
a	O
great	O
deal	O
of	O
research	O
.	O

It	O
has	O
been	O
clearly	O
demonstrated	O
that	O
agents	O
that	O
increase	O
intracellular	O
cAMP	O
also	O
inhibit	O
NF	O
-	O
kappaB	O
-	O
dependent	O
pro	O
-	O
inflammatory	O
gene	O
transcription	O
,	O
particularly	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
.	O
9	O

Controversy	O
exists	O
regarding	O
the	O
exact	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
PDE	O
inhibition	O
down	O
-	O
regulates	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
.	O

Possibilities	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
,	O
downregulation	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
,	O
increased	O
CREB	O
activation	O
,	O
and	O
competition	O
between	O
NF	O
-	O
kappaB	O
and	O
CREB	O
for	O
common	O
co	O
-	O
activators	O
such	O
as	O
CREB	O
binding	O
protein	O
(	O
CBP	O
)	O
.	O

It	O
is	O
also	O
not	O
known	O
whether	O
these	O
processes	O
rely	O
solely	O
upon	O
the	O
activation	O
of	O
PKA	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
the	O
present	O
study	O
is	O
to	O
determine	O
the	O
effects	O
of	O
nonspecific	O
PDE	O
inhibition	O
with	O
1	O
-	O
[	O
5	O
-	O
oxohexyl	O
]	O
-	O
3	O
,	O
7	O
-	O
dimethylxanthine	O
(	O
Pentoxifylline	O
;	O
PTX	O
)	O
on	O
NF	O
-	O
kappaB	O
and	O
CREB	O
activation	O
in	O
vitro	O
in	O
human	O
mononuclear	O
cells	O
.	O

With	O
the	O
use	O
of	O
specific	O
inhibitors	O
,	O
we	O
also	O
investigated	O
the	O
role	O
of	O
PKA	O
in	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Human	O
Research	O
Protections	O
Program	O
and	O
the	O
Institutional	O
Review	O
Board	O
.	O

Written	O
consent	O
to	O
participate	O
in	O
the	O
study	O
was	O
obtained	O
from	O
all	O
volunteers	O
prior	O
to	O
blood	O
donation	O
.	O
Heparinized	O
Vacutainers	O
were	O
purchased	O
from	O
Becton	O
Dickinson	O
(	O
San	O
Jose	O
,	O
CA	O
)	O
.	O

1	O
.	O
5	O
-	O
mL	O
Eppendorf	O
centrifuge	O
tubes	O
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburg	O
,	O
PA	O
)	O
.	O

Hank	O
'	O
s	O
balanced	O
salt	O
solution	O
(	O
HBSS	O
)	O
and	O
RPMI	O
1640	O
were	O
obtained	O
from	O
Irvine	O
Scientific	O
(	O
Santa	O
Ana	O
,	O
CA	O
)	O
.	O

LPS	O
fromEscherichia	O
coliserotype	O
0111	O
:	O
B4	O
and	O
PTX	O
were	O
purchased	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

The	O
PKA	O
inhibitor	O
,	O
N	O
-	O
[	O
2	O
-	O
(	O
(	O
p	O
-	O
bromocinnamyl	O
)	O
amino	O
)	O
ethyl	O
]	O
-	O
5	O
-	O
isoguinolinesulfonamide	O
-	O
2HCl	O
]	O
(	O
H89	O
)	O
,	O
was	O
purchased	O
from	O
Calbiochem	O
(	O
La	O
Jolla	O
,	O
CA	O
)	O
.	O

Antibodies	O
for	O
phosphorylated	O
CREB	B-Protein
(	O
serine	O
133	O
)	O
,	O
phosphorylated	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
(	O
serines	O
32	O
and	O
36	O
)	O
,	O
phosphorylated	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
(	O
serine	O
276	O
)	O
,	O
and	O
secondary	O
antibodies	O
were	O
purchased	O
from	O
Cell	O
Signaling	O
(	O
Beverly	O
,	O
MA	O
)	O
.	O
Dextran	O
T500	O
and	O
Percoll	O
were	O
received	O
from	O
GE	O
Healthcare	O
/	O
Amersham	O
Biosciences	O
(	O
Piscataway	O
,	O
NJ	O
)	O
.	O

The	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
obtained	O
from	O
Quantikine	O
R	O
&	O
D	O
Systems	O
(	O
Minneapolis	O
,	O
MN	O
)	O
.	O
Tris	O
-	O
glycine	O
and	O
DNA	O
retardation	O
gels	O
,	O
nitrocellulose	O
membranes	O
,	O
and	O
western	O
blot	O
running	O
buffers	O
were	O
obtained	O
from	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O

NE	O
-	O
PER	O
(	O
R	O
)	O
nuclear	O
and	O
cytoplasmic	O
extraction	O
reagents	O
,	O
the	O
BCA	O
protein	O
reagent	O
kit	O
,	O
the	O
Supersignal	O
West	O
Pico	O
Chemiluminescent	O
Kit	O
,	O
and	O
the	O
LightShift	O
Chemiluminescent	O
EMSA	O
Kit	O
were	O
purchased	O
from	O
Pierce	O
(	O
Rockland	O
,	O
IL	O
)	O
.	O

CREB	O
and	O
NF	O
-	O
kappaB	O
DNA	O
oligonucleotide	O
probes	O
were	O
synthesized	O
by	O
IDT	O
(	O
Coralville	O
,	O
IA	O
)	O
.	O

Nylon	O
membranes	O
were	O
purchased	O
from	O
Roche	O
Applied	O
Sciences	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

Western	O
blot	O
band	O
quantification	O
was	O
performed	O
with	O
the	O
UN	O
-	O
SCAN	O
-	O
IT	O
Gel	O
Digitizing	O
software	O
(	O
Silk	O
Scientific	O
,	O
Orem	O
,	O
UT	O
)	O
.	O

Human	O
Peripheral	O
Blood	O
Mononuclear	O
Cell	O
Isolation	O
and	O
Stimulation	O

Human	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
the	O
peripheral	O
blood	O
of	O
four	O
healthy	O
human	O
volunteers	O
.	O

The	O
sample	O
size	O
was	O
chosen	O
from	O
our	O
previously	O
published	O
work	O
,	O
which	O
demonstrated	O
reliable	O
results	O
.	O
10	O
Cell	O
isolation	O
and	O
all	O
subsequent	O
experiments	O
were	O
conducted	O
under	O
sterile	O
and	O
pyrogen	O
-	O
free	O
conditions	O
.	O

Blood	O
collected	O
in	O
heparin	O
tubes	O
was	O
incubated	O
with	O
Dextran	O
T500	O
and	O
the	O
red	O
cells	O
were	O
sedimented	O
for	O
40	O
minutes	O
at	O
room	O
temperature	O
.	O

The	O
resultant	O
serum	O
was	O
then	O
washed	O
with	O
HBSS	O
and	O
separated	O
by	O
Percoll	O
gradient	O
centrifugation	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cell	O
viability	O
was	O
assessed	O
by	O
trypan	O
blue	O
dye	O
exclusion	O
,	O
with	O
purity	O
of	O
greater	O
than	O
95	O
%	O
.	O

Isolated	O
cells	O
were	O
resuspended	O
in	O
RPMI	O
1640	O
supplemented	O
with	O
10	O
%	O
FBS	O
and	O
5	O
mM	O
HEPES	O
at	O
a	O
concentration	O
of	O
1	O
x	O
107cells	O
/	O
mL	O
.	O

Each	O
subsequent	O
experiment	O
listed	O
below	O
was	O
conducted	O
on	O
samples	O
of	O
5	O
x	O
106	O
cells	O
per	O
treatment	O
group	O
.	O

Isolated	O
cells	O
were	O
stimulated	O
with	O
either	O
HBSS	O
as	O
a	O
negative	O
control	O
,	O
LPS	O
(	O
1	O
mug	O
/	O
mL	O
)	O
,	O
PTX	O
(	O
20	O
mM	O
)	O
,	O
or	O
concomitant	O
LPS	O
/	O
PTX	O
,	O
at	O
the	O
above	O
-	O
mentioned	O
concentrations	O
,	O
for	O
30	O
minutes	O
at	O
37degreesC	O
.	O

Cells	O
were	O
placed	O
on	O
ice	O
for	O
10	O
minutes	O
to	O
stop	O
the	O
reaction	O
and	O
the	O
samples	O
were	O
then	O
stored	O
at	O
-	O
70degreesC	O
for	O
further	O
analysis	O
.	O

The	O
stimulation	O
times	O
and	O
concentrations	O
of	O
LPS	O
and	O
PTX	O
utilized	O
in	O
this	O
study	O
were	O
determined	O
in	O
previous	O
pilot	O
studies	O
done	O
in	O
our	O
laboratory	O
,	O
which	O
examined	O
the	O
effects	O
of	O
increasing	O
concentrations	O
of	O
PTX	O
on	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
.	O

LPS	O
at	O
a	O
concentration	O
of	O
1	O
mug	O
/	O
mL	O
and	O
PTX	O
at	O
a	O
concentration	O
of	O
20	O
mM	O
were	O
the	O
minimum	O
concentrations	O
necessary	O
to	O
produce	O
a	O
reproducible	O
and	O
reliable	O
up	O
-	O
regulation	O
and	O
down	O
-	O
regulation	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
,	O
respectively	O
,	O
in	O
quantitative	O
assays	O
(	O
data	O
not	O
shown	O
)	O
.	O

Effect	O
of	O
PTX	O
on	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
mononuclear	O
cells	O

The	O
concentration	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
quantitatively	O
determined	O
by	O
ELISA	O
in	O
the	O
media	O
of	O
cells	O
exposed	O
to	O
the	O
treatments	O
described	O
above	O
after	O
stimulation	O
for	O
up	O
to	O
a	O
maximum	O
of	O
18	O
hours	O
,	O
at	O
3	O
-	O
hour	O
intervals	O
.	O

The	O
results	O
are	O
expressed	O
in	O
pg	O
/	O
mL	O
.	O

SDS	O
-	O
PAGE	O
and	O
Immunoblotting	O
(	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
,	O
and	O
CREB	B-Protein
)	O

Following	O
stimulation	O
,	O
PBMCs	O
were	O
washed	O
with	O
ice	O
-	O
cold	O
PBS	O
and	O
centrifuged	O
to	O
collect	O
a	O
cell	O
pellet	O
.	O

The	O
pellet	O
was	O
resuspended	O
in	O
ice	O
-	O
cold	O
SDS	O
sample	O
buffer	O
supplemented	O
with	O
100	O
mM	O
dithiothreitol	O
.	O

Cytoplasmic	O
and	O
nuclear	O
extracts	O
were	O
isolated	O
with	O
NE	O
-	O
PER	O
nuclear	O
and	O
cytoplasmic	O
extraction	O
reagents	O
with	O
1x	O
Halt	O
Protease	O
Inhibitor	O
Cocktail	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Protein	O
concentrations	O
were	O
determined	O
with	O
the	O
BCA	O
protein	O
reagent	O
kit	O
for	O
each	O
sample	O
according	O
to	O
a	O
standardized	O
curve	O
for	O
albumin	O
.	O

Cell	O
lysates	O
were	O
collected	O
by	O
boiling	O
the	O
samples	O
in	O
a	O
100degreesC	O
water	O
bath	O
for	O
5	O
minutes	O
.	O

Ten	O
mug	O
of	O
protein	O
per	O
sample	O
was	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
through	O
8	O
-	O
16	O
%	O
tris	O
-	O
glycine	O
polyacrylamide	O
gradient	O
gels	O
and	O
transferred	O
to	O
nitrocellulose	O
membranes	O
.	O

The	O
membranes	O
were	O
blocked	O
with	O
5	O
%	O
milk	O
in	O
Tris	O
-	O
buffered	O
saline	O
/	O
Tween	O
20	O
(	O
Fischer	O
Scientific	O
,	O
Pittsburgh	O
,	O
PA	O
)	O
for	O
1	O
hour	O
.	O

Cytoplasmic	O
extracts	O
were	O
incubated	O
with	O
phosphorylated	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
antibody	O
(	O
1	O
:	O
200	O
)	O
,	O
while	O
nuclear	O
extracts	O
were	O
incubated	O
with	O
either	O
phosphorylated	O
NF	O
-	O
kappaB	O
p65	B-Protein
antibody	O
(	O
1	O
:	O
500	O
)	O
or	O
phosphorylated	O
CREB	O
antibody	O
(	O
1	O
:	O
500	O
)	O
overnight	O
at	O
4degreesC	O
in	O
separate	O
experiments	O
.	O

The	O
membranes	O
were	O
washed	O
with	O
Tris	O
-	O
buffered	O
saline	O
/	O
Tween	O
20	O
and	O
incubated	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
with	O
the	O
secondary	O
antibody	O
,	O
horseradish	O
peroxidase	O
-	O
linked	O
anti	O
-	O
rabbit	O
IgG	O
diluted	O
1	O
:	O
2000	O
in	O
blocking	O
solution	O
.	O

After	O
repeated	O
washing	O
of	O
the	O
membrane	O
,	O
the	O
Supersignal	O
West	O
Pico	O
Chemiluminescent	O
Kit	O
was	O
applied	O
for	O
antibody	O
detection	O
per	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Western	O
blot	O
data	O
is	O
presented	O
as	O
a	O
percentage	O
of	O
LPS	O
stimulation	O
.	O

The	O
percentage	O
of	O
LPS	O
stimulation	O
was	O
calculated	O
by	O
dividing	O
the	O
mean	O
band	O
pixel	O
total	O
for	O
each	O
treatment	O
arm	O
divided	O
by	O
the	O
mean	O
pixel	O
total	O
of	O
samples	O
stimulated	O
with	O
LPS	O
and	O
multiplying	O
by	O
100	O
.	O

Thus	O
,	O
LPS	O
stimulation	O
is	O
reported	O
as	O
100	O
%	O
and	O
each	O
of	O
the	O
treatment	O
arms	O
is	O
reported	O
as	O
a	O
percent	O
of	O
LPS	O
stimulation	O
.	O

NF	O
-	O
kappaB	O
and	O
CREB	O
Electrophoretic	O
Mobility	O
Shift	O
Assay	O
(	O
EMSA	O
)	O

The	O
non	O
-	O
radioactive	O
LightShift	O
Chemiluminescent	O
EMSA	O
Kit	O
was	O
used	O
to	O
detect	O
DNA	O
-	O
protein	O
interactions	O
.	O

The	O
NF	O
-	O
kappaB	O
3	O
'	O
biotin	O
end	O
-	O
labeled	O
DNA	O
oligonucleotide	O
used	O
as	O
a	O
probe	O
for	O
the	O
EMSA	O
was	O
a	O
42	O
-	O
bp	O
double	O
stranded	O
construct	O
(	O
5	O
'	O
-	O
TTGTTACAA	O
-	O
GGGGACTTTCCGCTGGGGACTTTCCAGGGAGGC	O
-	O
3	O
'	O
)	O
containing	O
two	O
tandemly	O
repeated	O
NF	O
-	O
kappaB	O
binding	O
sites	O
(	O
underlined	O
)	O
.	O

Specificity	O
was	O
determined	O
by	O
a	O
competition	O
assay	O
with	O
the	O
addition	O
of	O
200	O
molar	O
excess	O
of	O
unlabeled	O
double	O
stranded	O
NF	O
-	O
kappaB	O
oligonucleotide	O
.	O

The	O
CREB	O
3	O
'	O
biotin	O
end	O
-	O
labeled	O
DNA	O
oligonucleotide	O
used	O
as	O
a	O
probe	O
for	O
the	O
EMSA	O
was	O
a	O
23	O
-	O
bp	O
double	O
stranded	O
construct	O
(	O
5	O
'	O
-	O
TTT	O
TCG	O
AGC	O
TCTGACGTCAGA	O
-	O
GC	O
-	O
3	O
'	O
)	O
containing	O
the	O
CRE	O
consensus	O
sequence	O
(	O
underlined	O
)	O
.	O

Specificity	O
was	O
determined	O
by	O
a	O
competition	O
assay	O
with	O
the	O
addition	O
of	O
200	O
molar	O
excess	O
of	O
unlabeled	O
double	O
stranded	O
CREB	O
oligonucleotide	O
.	O

Nuclear	O
extracts	O
(	O
10	O
mug	O
)	O
were	O
incubated	O
with	O
5	O
nM	O
NF	O
-	O
kappaB	O
or	O
CREB	O
probe	O
(	O
NF	O
-	O
kB	O
:	O
1x	O
binding	O
buffer	O
,	O
50	O
mM	O
KCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
1	O
%	O
NP40	O
,	O
10	O
%	O
glycerol	O
,	O
and	O
50	O
ng	O
/	O
mul	O
poly	O
dI	O
-	O
dC	O
,	O
CREB	O
:	O
1x	O
binding	O
buffer	O
,	O
20	O
mM	O
Tris	O
,	O
pH	O
7	O
.	O
5	O
,	O
50	O
mM	O
KCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
10	O
%	O
NP40	O
,	O
6	O
%	O
glycerol	O
,	O
0	O
.	O
1	O
mg	O
/	O
mL	O
BSA	O
and	O
50	O
ng	O
/	O
mul	O
poly	O
dI	O
-	O
dC	O
)	O
and	O
were	O
then	O
electrophoresed	O
through	O
a	O
6	O
%	O
DNA	O
retardation	O
gel	O
at	O
100V	O
for	O
90	O
minutes	O
.	O

The	O
gels	O
were	O
electrophoretically	O
transferred	O
at	O
380mA	O
for	O
1	O
hour	O
on	O
ice	O
to	O
a	O
positively	O
charged	O
nylon	O
membrane	O
and	O
immediately	O
cross	O
-	O
linked	O
for	O
15	O
minutes	O
with	O
a	O
UV	O
transilluminator	O
equipped	O
with	O
a	O
312	O
nm	O
bulb	O
.	O

Streptavidin	O
-	O
horseradish	O
peroxidase	O
conjugate	O
and	O
the	O
LightShift	O
Chemiluminescent	O
Substrate	O
were	O
used	O
to	O
detect	O
the	O
biotin	O
end	O
-	O
labeled	O
DNA	O
.	O

The	O
nylon	O
membranes	O
were	O
exposed	O
to	O
x	O
-	O
ray	O
film	O
for	O
1	O
-	O
3	O
minutes	O
for	O
detection	O
.	O

Role	O
of	O
PKA	O
on	O
LPS	O
-	O
induced	O
mononuclear	O
cell	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O

To	O
evaluate	O
the	O
role	O
of	O
PKA	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
mononuclear	O
cells	O
and	O
its	O
involvement	O
in	O
the	O
attenuation	O
of	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
observed	O
following	O
PTX	O
treatment	O
,	O
H89	O
,	O
a	O
specific	O
PKA	O
inhibitor	O
,	O
was	O
utilized	O
.	O

Isolated	O
mononuclear	O
cells	O
were	O
incubated	O
according	O
to	O
the	O
treatment	O
groups	O
described	O
above	O
in	O
the	O
presence	O
and	O
absence	O
of	O
pretreatment	O
with	O
H89	O
(	O
10	O
muM	O
)	O
for	O
1	O
hour	O
at	O
37degreesC	O
.	O

The	O
dose	O
of	O
H89	O
was	O
chosen	O
based	O
on	O
previous	O
work	O
which	O
demonstrated	O
specific	O
and	O
complete	O
inhibition	O
of	O
PKA	O
at	O
this	O
concentration	O
.	O
10	O
Since	O
the	O
activity	O
of	O
this	O
inhibitor	O
is	O
both	O
specific	O
and	O
consistent	O
at	O
this	O
specified	O
dose	O
,	O
we	O
did	O
not	O
include	O
experiments	O
with	O
additional	O
PKA	O
inhibitors	O
with	O
this	O
set	O
of	O
experiments	O
.	O

The	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
concentration	O
in	O
the	O
supernatant	O
was	O
measured	O
quantitatively	O
by	O
ELISA	O
.	O

The	O
results	O
are	O
expressed	O
in	O
pg	O
/	O
mL	O
.	O

Statistical	O
Analysis	O

The	O
experimental	O
results	O
obtained	O
in	O
this	O
study	O
were	O
derived	O
from	O
four	O
separate	O
experiments	O
with	O
healthy	O
volunteer	O
donors	O
.	O

Each	O
assay	O
was	O
performed	O
in	O
duplicate	O
or	O
triplicate	O
where	O
appropriate	O
.	O

Data	O
is	O
presented	O
as	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

Statistical	O
differences	O
between	O
groups	O
were	O
determined	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
with	O
a	O
Bonferroni	O
correction	O
.	O

Statistical	O
significance	O
was	O
defined	O
as	O
P	O
<	O
0	O
.	O
05	O
.	O

The	O
effects	O
of	O
PTX	O
on	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O

To	O
determine	O
the	O
duration	O
of	O
PDE	O
inhibition	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
after	O
LPS	O
stimulation	O
,	O
time	O
course	O
studies	O
were	O
conducted	O
.	O

In	O
accordance	O
with	O
prior	O
work	O
,	O
PTX	O
had	O
a	O
rapid	O
and	O
sustained	O
effect	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
vitro	O
(	O
Figure	O
1	O
)	O
.	O

PTX	O
decreases	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O

Since	O
phosphorylation	O
leads	O
to	O
ubiquitination	O
and	O
degradation	O
of	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
and	O
subsequent	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
,	O
we	O
first	O
examined	O
the	O
effects	O
of	O
PTX	O
on	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
.	O

Cytoplasmic	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
was	O
markedly	O
increased	O
following	O
LPS	O
stimulation	O
when	O
compared	O
to	O
control	O
(	O
100	O
+	O
/	O
-	O
0	O
vs	O
.	O
20	O
+	O
/	O
-	O
18	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
addition	O
of	O
PTX	O
significantly	O
downregulated	O
LPS	O
-	O
induced	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
(	O
P	O
=	O
0	O
.	O
02	O
;	O
Figure	O
2	O
)	O

In	O
a	O
similar	O
fashion	O
,	O
nuclear	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
was	O
increased	O
following	O
LPS	O
stimulation	O
(	O
100	O
+	O
/	O
-	O
0	O
vs	O
.	O
38	O
+	O
/	O
-	O
20	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

PTX	O
similarly	O
decreased	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
p65	B-Protein
nuclear	O
phosphorylation	O
,	O
a	O
marker	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
nuclear	O
translocation	O
(	O
100	O
+	O
/	O
-	O
0	O
vs	O
.	O
40	O
+	O
/	O
-	O
6	O
;	O
P	O
=	O
0	O
.	O
03	O
;	O
Figure	O
3A	O
)	O
.	O

EMSAs	O
were	O
then	O
performed	O
to	O
verify	O
the	O
PTX	O
-	O
induced	O
alterations	O
in	O
nuclear	O
phosphorylation	O
resulted	O
in	O
similar	O
effects	O
on	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
addition	O
of	O
PTX	O
to	O
LPS	O
-	O
stimulated	O
mononuclear	O
cells	O
resulted	O
in	O
comparable	O
downregulation	O
of	O
DNA	O
binding	O
activity	O
,	O
similar	O
to	O
the	O
observed	O
downregulation	O
of	O
NF	O
-	O
kappaB	O
phosphorylation	O
(	O
Figure	O
3B	O
)	O
.	O

PTX	O
upregulates	O
CREB	O
phosphorylation	O
and	O
activation	O
after	O
LPS	O
stimulation	O

Phosphorylation	O
of	O
nuclear	O
CREB	O
was	O
used	O
as	O
a	O
marker	O
for	O
CREB	O
activation	O
.	O

LPS	O
stimulation	O
caused	O
a	O
negligible	O
increase	O
in	O
CREB	O
phosphorylation	O
when	O
compared	O
to	O
control	O
(	O
Figure	O
4A	O
)	O
.	O

PTX	O
alone	O
caused	O
a	O
marked	O
increase	O
in	O
CREB	O
phosphorylation	O
(	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O
HBSS	O
)	O
.	O

When	O
LPS	O
and	O
PTX	O
exposure	O
occurred	O
simultaneously	O
,	O
CREB	O
phosphorylation	O
was	O
significantly	O
higher	O
than	O
with	O
LPS	O
stimulation	O
alone	O
(	O
543	O
+	O
/	O
-	O
92	O
vs	O
.	O
100	O
+	O
/	O
-	O
0	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
addition	O
,	O
the	O
amount	O
of	O
CREB	O
phosphorylation	O
seen	O
with	O
concomitant	O
LPS	O
and	O
PTX	O
treatment	O
was	O
less	O
than	O
that	O
seen	O
with	O
PTX	O
alone	O
,	O
although	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

To	O
determine	O
if	O
CREB	O
-	O
DNA	O
binding	O
was	O
affected	O
by	O
PTX	O
in	O
a	O
manner	O
similar	O
to	O
CREB	O
phosphorylation	O
,	O
an	O
EMSA	O
was	O
performed	O
.	O

Exposure	O
of	O
LPS	O
-	O
stimulated	O
cells	O
to	O
PTX	O
similarly	O
increased	O
CREB	B-Protein
DNA	O
-	O
binding	O
compared	O
to	O
LPS	O
alone	O
(	O
Figure	O
4B	O
)	O
.	O

Effect	O
of	O
PTX	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
the	O
presence	O
of	O
PKA	O
inhibition	O

The	O
role	O
of	O
PKA	O
in	O
PTX	O
-	O
induced	O
downregulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
LPS	O
-	O
stimulated	O
mononuclear	O
cells	O
was	O
assessed	O
by	O
treating	O
mononuclear	O
cells	O
with	O
H89	O
,	O
a	O
PKA	O
inhibitor	O
,	O
prior	O
to	O
LPS	O
and	O
PTX	O
exposure	O
.	O

The	O
addition	O
PTX	O
to	O
LPS	O
-	O
stimulated	O
cells	O
resulted	O
in	O
a	O
reduction	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
similar	O
to	O
that	O
observed	O
in	O
our	O
previous	O
experiments	O
(	O
529	O
pg	O
/	O
mL	O
+	O
/	O
-	O
112	O
vs	O
.	O
37	O
pg	O
/	O
mL	O
+	O
/	O
-	O
10	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Pre	O
-	O
incubation	O
of	O
cells	O
with	O
H89	O
prior	O
to	O
LPS	O
and	O
PTX	O
exposure	O
did	O
not	O
result	O
in	O
any	O
significant	O
modulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
when	O
compared	O
to	O
that	O
demonstrated	O
with	O
PTX	O
alone	O
(	O
P	O
=	O
0	O
.	O
2	O
;	O
Figure	O
5	O
)	O
.	O

These	O
results	O
suggest	O
that	O
downregulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
PTX	O
in	O
LPS	O
-	O
stimulated	O
mononuclear	O
cells	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
PKA	O
-	O
independent	O
.	O

The	O
exposure	O
of	O
inflammatory	O
cells	O
to	O
a	O
variety	O
of	O
extracellular	O
stimuli	O
results	O
in	O
the	O
initiation	O
of	O
transcriptional	O
and	O
posttranscriptional	O
events	O
,	O
which	O
culminate	O
in	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
.	O
11	O
-	O
14	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
released	O
very	O
early	O
following	O
shock	O
and	O
is	O
considered	O
an	O
important	O
mediator	O
of	O
the	O
inflammatory	O
cascade	O
,	O
since	O
it	O
regulates	O
the	O
synthesis	O
of	O
several	O
other	O
critical	O
cytokines	O
and	O
chemokines	O
.	O
15	O
A	O
clear	O
relationship	O
between	O
increased	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
synthesis	O
and	O
the	O
development	O
of	O
shock	O
and	O
multiple	O
organ	O
dysfunction	O
has	O
been	O
observed	O
in	O
animal	O
models	O
of	O
sepsis	O
.	O
15	O
-	O
17	O

Because	O
of	O
its	O
importance	O
in	O
orchestrating	O
multiple	O
steps	O
of	O
the	O
inflammatory	O
response	O
,	O
strategies	O
aimed	O
at	O
decreasing	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
levels	O
or	O
attenuating	O
its	O
production	O
seem	O
attractive	O
.	O

PDE	O
inhibitors	O
have	O
been	O
shown	O
to	O
downregulate	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
distinct	O
human	O
cell	O
populations	O
.	O

We	O
have	O
previously	O
shown	O
that	O
,	O
in	O
general	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
levels	O
continue	O
to	O
increase	O
after	O
LPS	O
exposure	O
and	O
that	O
concomitant	O
infusion	O
of	O
phosphodiesterase	O
inhibitors	O
can	O
markedly	O
decrease	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
levels	O
.	O
18	O
-	O
19	O
In	O
this	O
in	O
vitro	O
study	O
,	O
we	O
verified	O
the	O
sustained	O
attenuation	O
of	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
over	O
time	O
in	O
an	O
isolated	O
human	O
mononuclear	O
cell	O
population	O
.	O

The	O
mechanisms	O
by	O
which	O
PTX	O
,	O
a	O
non	O
-	O
specific	O
phosphodiesterase	O
inhibitor	O
,	O
significantly	O
and	O
consistently	O
decreases	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
have	O
not	O
been	O
completely	O
elucidated	O
.	O

It	O
has	O
been	O
postulated	O
that	O
drugs	O
that	O
increase	O
intracellular	O
cAMP	O
exert	O
their	O
anti	O
-	O
inflammatory	O
effects	O
through	O
the	O
activation	O
of	O
PKA	O
.	O

This	O
classic	O
pathway	O
has	O
been	O
challenged	O
as	O
the	O
sole	O
mechanism	O
involved	O
in	O
the	O
modulation	O
of	O
inflammation	O
by	O
cAMP	O
-	O
enhancing	O
drugs	O
,	O
and	O
alternative	O
mechanisms	O
involving	O
PKA	O
-	O
independent	O
pathways	O
have	O
been	O
proposed	O
.	O
6	O
-	O
8	O
In	O
this	O
series	O
of	O
experiments	O
,	O
we	O
observed	O
a	O
significant	O
attenuation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
LPS	O
-	O
stimulated	O
human	O
mononuclear	O
cells	O
following	O
PTX	O
administration	O
,	O
independent	O
of	O
PKA	O
activation	O
.	O

We	O
used	O
a	O
nonspecific	O
phosphodiesterase	O
inhibitor	O
,	O
PTX	O
,	O
in	O
the	O
present	O
study	O
because	O
it	O
has	O
been	O
used	O
clinically	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
which	O
inflammation	O
is	O
an	O
important	O
component	O
of	O
the	O
pathophysiology	O
of	O
the	O
disease	O
process	O
.	O
19	O
Additionally	O
,	O
the	O
use	O
of	O
PTX	O
in	O
sepsis	O
as	O
an	O
adjunct	O
to	O
other	O
treatments	O
to	O
maintain	O
adequate	O
organ	O
function	O
has	O
been	O
explored	O
based	O
upon	O
its	O
effects	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
synthesis	O
.	O

However	O
,	O
the	O
reported	O
beneficial	O
effects	O
of	O
PTX	O
are	O
not	O
only	O
related	O
to	O
the	O
downregulation	O
of	O
TNF	B-Protein
-	I-Protein
alphabut	I-Protein
also	O
to	O
PTX	O
'	O
s	O
hemorrheologic	O
properties	O
,	O
its	O
ability	O
to	O
reduce	O
neutrophil	O
activation	O
,	O
and	O
its	O
beneficial	O
effects	O
on	O
microcirculation	O
,	O
cardiac	O
performance	O
,	O
and	O
organ	O
injury	O
.	O
20	O
-	O
25	O
Herein	O
,	O
we	O
demonstrated	O
that	O
the	O
downregulatory	O
effects	O
of	O
PTX	O
in	O
human	O
mononuclear	O
cells	O
involves	O
modulation	O
of	O
pathways	O
that	O
involve	O
NF	O
-	O
kappaB	O
and	O
CREB	O
,	O
two	O
major	O
transcription	O
factors	O
involved	O
in	O
the	O
inflammatory	O
cascade	O
.	O

NF	O
-	O
kappaB	O
/	O
Rel	O
constitutes	O
a	O
family	O
of	O
transcriptional	O
factors	O
involved	O
in	O
the	O
regulation	O
of	O
numerous	O
cytokine	O
genes	O
and	O
immune	O
responses	O
in	O
different	O
cell	O
populations	O
.	O

The	O
most	O
abundant	O
form	O
of	O
NF	O
-	O
kappaB	O
is	O
the	O
p50	B-Protein
-	O
p65	B-Protein
heterodimer	O
.	O
26	O
The	O
inactive	O
form	O
of	O
NF	O
-	O
kappaB	O
exists	O
in	O
the	O
cytoplasm	O
bound	O
to	O
an	O
inhibitory	O
complex	O
containing	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
.	O

Following	O
cellular	O
stimulation	O
with	O
LPS	O
and	O
chemotactic	O
factors	O
,	O
NF	O
-	O
kappaB	O
inducible	O
kinase	O
phosphorylates	O
and	O
activates	O
the	O
I	O
-	O
kappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
consisting	O
of	O
IKK	B-Protein
-	I-Protein
1	I-Protein
and	O
IKK	B-Protein
-	I-Protein
2	I-Protein
,	O
which	O
in	O
turn	O
phosphorylates	O
the	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
subunit	O
.	O

Phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
subsequent	O
degradation	O
of	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
results	O
in	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
.	O

This	O
allows	O
the	O
transcription	O
factor	O
to	O
bind	O
to	O
promoter	O
regions	O
of	O
specific	O
pro	O
-	O
inflammatory	O
genes	O
and	O
influence	O
transcription	O
.	O
27	O
,	O
28	O
Because	O
a	O
number	O
of	O
potential	O
kappaB	O
sites	O
are	O
present	O
in	O
the	O
nucleotide	O
sequences	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
,	O
NF	O
-	O
kappaB	O
is	O
considered	O
to	O
be	O
a	O
critical	O
transcriptional	O
factor	O
involved	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
expression	O
and	O
protein	O
synthesis	O
.	O
29	O
,	O
30	O

In	O
this	O
set	O
of	O
experiments	O
,	O
we	O
demonstrated	O
that	O
PTX	O
downregulates	O
cytoplasmic	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
,	O
nuclear	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
/	O
translocation	O
,	O
as	O
well	O
as	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
after	O
LPS	O
stimulation	O
,	O
suggesting	O
that	O
PTX	O
exerts	O
its	O
function	O
proximal	O
to	O
or	O
at	O
the	O
level	O
of	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
.	O

Previous	O
studies	O
that	O
have	O
evaluated	O
the	O
effects	O
of	O
cAMP	O
-	O
elevating	O
drugs	O
on	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
and	O
NF	O
-	O
kappaB	O
have	O
reported	O
conflicting	O
results	O
.	O

Haddad	O
et	O
al	O
.	O
reported	O
results	O
similar	O
to	O
ours	O
with	O
respect	O
to	O
the	O
effects	O
of	O
PTX	O
on	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
and	O
NF	O
-	O
kappaB	O
in	O
pulmonary	O
epithelial	O
cells	O
.	O
31	O
Conversely	O
,	O
Neumann	O
et	O
al	O
.	O
proposed	O
that	O
increased	O
intracellular	O
cAMP	O
stabilizes	O
the	O
interaction	O
between	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
and	O
NF	O
-	O
kappaB	O
,	O
therefore	O
reducing	O
NF	O
-	O
kappaB	O
activation	O
.	O
32	O
In	O
contrast	O
,	O
Takahashi	O
et	O
al	O
.	O
showed	O
no	O
difference	O
in	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
degradation	O
in	O
Jurkat	O
T	O
-	O
lymphocytes	O
in	O
the	O
presence	O
and	O
absence	O
of	O
forskolin	O
,	O
an	O
alternative	O
cAMP	O
inducing	O
compound	O
.	O

This	O
group	O
also	O
demonstrated	O
that	O
forskolin	O
did	O
not	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
that	O
CREB	O
was	O
not	O
involved	O
in	O
forskolin	O
-	O
induced	O
decrease	O
in	O
p65	B-Protein
transcriptional	O
activity	O
.	O
33	O
Similar	O
results	O
were	O
reported	O
by	O
Ollivier	O
et	O
al	O
.	O
using	O
THP	O
-	O
1	O
cells	O
and	O
endothelial	O
cells	O
treated	O
with	O
forskolin	O
or	O
dibutyryl	O
cAMP	O
,	O
two	O
agents	O
known	O
to	O
function	O
through	O
cAMP	O
elevation	O
and	O
subsequent	O
PKA	O
activation	O
.	O
9	O
The	O
differences	O
between	O
our	O
results	O
and	O
those	O
mentioned	O
above	O
may	O
be	O
explained	O
by	O
the	O
use	O
of	O
different	O
cell	O
types	O
and	O
exogenous	O
stimulants	O
.	O

It	O
is	O
also	O
possible	O
that	O
PTX	O
exerts	O
its	O
anti	O
-	O
inflammatory	O
effects	O
on	O
the	O
NF	O
-	O
kappaB	O
pathway	O
independent	O
of	O
PKA	O
,	O
as	O
suggested	O
by	O
the	O
continued	O
attenuation	O
of	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
PTX	O
in	O
the	O
presence	O
or	O
absence	O
of	O
PKA	O
inhibition	O
observed	O
in	O
this	O
study	O
.	O

This	O
hypothesis	O
is	O
currently	O
under	O
investigation	O
in	O
our	O
laboratory	O
.	O

Furthermore	O
,	O
we	O
utilized	O
a	O
broad	O
PKA	O
inhibitor	O
in	O
this	O
study	O
in	O
addition	O
to	O
H89	O
,	O
but	O
did	O
not	O
examine	O
the	O
effect	O
of	O
specific	O
inhibition	O
of	O
various	O
PKA	O
isoforms	O
.	O

This	O
information	O
may	O
yield	O
more	O
insight	O
into	O
the	O
mechanism	O
by	O
which	O
PTX	O
exerts	O
its	O
down	O
-	O
regulatory	O
effects	O
.	O

PDE	O
inhibitors	O
may	O
also	O
downregulate	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
by	O
altering	O
the	O
competitive	O
binding	O
of	O
CREB	O
and	O
NF	O
-	O
kappaB	O
to	O
the	O
promoter	O
regions	O
of	O
pro	O
-	O
inflammatory	O
genes	O
.	O

Herein	O
,	O
we	O
showed	O
that	O
the	O
activation	O
and	O
DNA	O
binding	O
activity	O
of	O
CREB	O
is	O
upregulated	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
PTX	O
.	O

Of	O
note	O
,	O
the	O
increase	O
in	O
CREB	O
activity	O
was	O
slightly	O
alleviated	O
by	O
the	O
addition	O
of	O
LPS	O
,	O
suggesting	O
competition	O
between	O
PTX	O
-	O
induced	O
CREB	O
-	O
associated	O
gene	O
transcription	O
and	O
those	O
factors	O
,	O
such	O
as	O
NF	O
-	O
kappaB	O
,	O
which	O
may	O
be	O
upregulated	O
by	O
LPS	O
exposure	O
.	O

This	O
competition	O
has	O
been	O
postulated	O
to	O
involve	O
the	O
recruitment	O
of	O
the	O
co	O
-	O
activator	O
CBP	B-Protein
and	O
its	O
homologue	O
p30034	B-Protein
,	O
suggesting	O
an	O
alternative	O
mechanism	O
that	O
may	O
be	O
involved	O
in	O
the	O
anti	O
-	O
inflammatory	O
actions	O
of	O
PTX	O
.	O

Future	O
studies	O
are	O
planned	O
to	O
delineate	O
the	O
validity	O
of	O
this	O
potential	O
mechanism	O
.	O

The	O
effects	O
of	O
PTX	O
on	O
other	O
transcription	O
factors	O
,	O
such	O
as	O
AP	O
-	O
1	O
,	O
c	B-Protein
-	I-Protein
fos	I-Protein
,	O
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
,	O
cannot	O
be	O
ruled	O
out	O
by	O
our	O
experiments	O
.	O

Activation	O
of	O
AP	O
-	O
1	O
and	O
its	O
components	O
(	O
c	B-Protein
-	I-Protein
fos	I-Protein
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
)	O
by	O
agents	O
that	O
enhance	O
mononuclear	O
cell	O
activity	O
has	O
been	O
implicated	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
.	O

Moreover	O
,	O
AP	O
-	O
1	O
and	O
CREB	O
recognize	O
a	O
similar	O
DNA	O
binding	O
sequence	O
in	O
the	O
promoter	O
region	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene35	O
.	O

Given	O
these	O
relationships	O
,	O
it	O
is	O
conceivable	O
that	O
PTX	O
may	O
exert	O
some	O
of	O
its	O
anti	O
-	O
inflammatory	O
actions	O
by	O
affecting	O
AP	O
-	O
1	O
activation	O
and	O
favoring	O
CREB	O
binding	O
,	O
thus	O
inhibiting	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
transcription	O
.	O

Additional	O
studies	O
are	O
necessary	O
to	O
elucidate	O
the	O
complex	O
interactions	O
between	O
CREB	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
AP	O
-	O
1	O
following	O
LPS	O
exposure	O
and	O
PDE	O
inhibition	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
PTX	O
on	O
the	O
cGMP	O
pathway	O
after	O
LPS	O
stimulation	O
has	O
not	O
been	O
explored	O
,	O
although	O
we	O
plan	O
to	O
do	O
so	O
in	O
the	O
future	O
.	O

In	O
summary	O
,	O
we	O
have	O
demonstrated	O
that	O
PDE	O
inhibition	O
of	O
human	O
mononuclear	O
cells	O
downregulates	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
a	O
PKA	O
-	O
independent	O
mechanism	O
.	O

In	O
addition	O
,	O
PTX	O
attenuates	O
the	O
activity	O
of	O
NF	O
-	O
B	O
while	O
upregulating	O
CREB	O
activation	O
after	O
LPS	O
stimulation	O
,	O
which	O
may	O
result	O
in	O
modulation	O
of	O
pro	O
-	O
inflammatory	O
mediator	O
synthesis	O
.	O

Therefore	O
,	O
PTX	O
may	O
serve	O
as	O
a	O
potential	O
adjunct	O
therapeutic	O
for	O
the	O
treatment	O
of	O
conditions	O
in	O
which	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
plays	O
a	O
significant	O
role	O
.	O

Interleukin	B-Protein
-	I-Protein
10	I-Protein
Production	O
by	O
Th1	O
Cells	O
Requires	O
Interleukin	B-Protein
-	I-Protein
12	I-Protein
-	O
Induced	O
STAT4	B-Protein
Transcription	O
Factor	O
and	O
ERK	B-Protein
MAP	O
Kinase	O
Activation	O
by	O
High	O
Antigen	O
Dose	O

Summary	O

CD4	B-Protein
+	O
T	O
cells	O
producing	O
interleukin	B-Protein
-	I-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
and	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
are	O
reported	O
in	O
chronic	O
infections	O
.	O

However	O
,	O
the	O
signals	O
that	O
direct	O
the	O
development	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
T	O
helper	O
1	O
(	O
Th1	O
)	O
cells	O
are	O
undefined	O
.	O

We	O
showed	O
that	O
development	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
required	O
high	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
ligation	O
,	O
sustained	O
ERK1	B-Protein
and	O
ERK2	B-Protein
MAP	O
kinases	O
phosphorylation	O
,	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
transcription	O
factor	O
activation	O
.	O

Repeated	O
TCR	O
triggering	O
led	O
to	O
enhanced	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
,	O
and	O
continued	O
IL	B-Protein
-	I-Protein
12	I-Protein
action	O
and	O
high	O
-	O
dose	O
TCR	O
signaling	O
were	O
required	O
for	O
the	O
development	O
and	O
maintenance	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
.	O

Although	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
require	O
the	O
activation	O
of	O
distinct	O
STATs	O
for	O
their	O
differentiation	O
,	O
activation	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
was	O
a	O
common	O
requirement	O
for	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
all	O
Th	O
cell	O
subsets	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
also	O
correlated	O
with	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
.	O

Despite	O
having	O
distinct	O
functions	O
in	O
protection	O
against	O
pathogens	O
,	O
all	O
Th	O
cells	O
share	O
the	O
important	O
task	O
of	O
controlling	O
overexuberant	O
immune	O
responses	O
by	O
means	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
.	O

Interleukin	B-Protein
-	I-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
is	O
a	O
cytokine	O
with	O
broad	O
anti	O
-	O
inflammatory	O
properties	O
that	O
inhibits	O
macrophage	O
and	O
dendritic	O
cell	O
(	O
DC	O
)	O
function	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
limits	O
the	O
immune	O
and	O
inflammatory	O
responses	O
to	O
pathogens	O
and	O
gut	O
flora	O
and	O
prevents	O
damage	O
to	O
the	O
host	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
;	O
O	O
'	O
Garra	O
and	O
Vieira	O
,	O
2004	O
)	O
,	O
but	O
when	O
dysregulated	O
may	O
result	O
in	O
chronic	O
infection	O
(	O
Brooks	O
et	O
al	O
.	O
,	O
2006	O
;	O
Ejrnaes	O
et	O
al	O
.	O
,	O
2006	O
;	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
is	O
expressed	O
by	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
B	O
cells	O
,	O
DCs	O
,	O
and	O
macrophages	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
and	O
also	O
by	O
Th1	O
cells	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
;	O
Assenmacher	O
et	O
al	O
.	O
,	O
1994	O
;	O
Del	O
Prete	O
et	O
al	O
.	O
,	O
1993	O
;	O
Gerosa	O
et	O
al	O
.	O
,	O
1996	O
;	O
Jankovic	O
et	O
al	O
.	O
,	O
2007	O
;	O
Pohl	O
-	O
Koppe	O
et	O
al	O
.	O
,	O
1998	O
)	O
and	O
(	O
reviewed	O
in	O
O	O
'	O
Garra	O
and	O
Vieira	O
,	O
2007	O
;	O
Trinchieri	O
,	O
2007	O
)	O
,	O
certain	O
regulatory	O
(	O
Treg	O
)	O
T	O
cells	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
;	O
O	O
'	O
Garra	O
and	O
Vieira	O
,	O
2004	O
;	O
Roncarolo	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
and	O
Th17	O
cells	O
(	O
Awasthi	O
et	O
al	O
.	O
,	O
2007	O
;	O
Fitzgerald	O
et	O
al	O
.	O
,	O
2007	O
;	O
McGeachy	O
et	O
al	O
.	O
,	O
2007	O
;	O
Stumhofer	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

In	O
vitro	O
human	O
CD4	B-Protein
+	O
and	O
CD8	B-Protein
+	O
T	O
cell	O
clones	O
,	O
or	O
mouse	O
CD4	B-Protein
+	O
T	O
cells	O
that	O
produce	O
both	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
can	O
be	O
differentiated	O
by	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
stimulation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Gerosa	O
et	O
al	O
.	O
,	O
1996	O
;	O
Jeannin	O
et	O
al	O
.	O
,	O
1996	O
;	O
Meyaard	O
et	O
al	O
.	O
,	O
1996	O
;	O
Windhagen	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O

Furthermore	O
,	O
Th1	O
cell	O
clones	O
coproducing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
have	O
been	O
isolated	O
from	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
of	O
active	O
pulmonary	O
tuberculosis	O
(	O
TB	O
)	O
patients	O
(	O
Gerosa	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
was	O
also	O
reported	O
in	O
animals	O
infected	O
with	O
Toxoplasma	O
gondii	O
(	O
Jankovic	O
et	O
al	O
.	O
,	O
2002	O
;	O
Shaw	O
et	O
al	O
.	O
,	O
2006	O
)	O
or	O
with	O
Leishmania	O
major	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
)	O
and	O
shown	O
to	O
be	O
required	O
for	O
regulation	O
of	O
the	O
immune	O
response	O
in	O
these	O
infections	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
;	O
Jankovic	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

The	O
relative	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
produced	O
by	O
Th1	O
cells	O
may	O
influence	O
the	O
balance	O
between	O
clearance	O
and	O
persistent	O
infection	O
with	O
certain	O
pathogens	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
;	O
Trinchieri	O
,	O
2007	O
)	O
,	O
thus	O
determining	O
whether	O
chronic	O
infection	O
or	O
immunopathology	O
ensues	O
.	O

Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
responses	O
differentiate	O
along	O
distinct	O
signaling	O
pathways	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Ivanov	O
et	O
al	O
.	O
,	O
2007	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
.	O

Th1	O
cell	O
development	O
requires	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
(	I-Protein
STAT	I-Protein
)	I-Protein
1	I-Protein
activation	O
,	O
induced	O
by	O
type	B-Protein
I	I-Protein
IFN	I-Protein
or	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
the	O
transcription	O
factor	O
T	B-Protein
-	I-Protein
box	I-Protein
21	I-Protein
(	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
,	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
signaling	O
,	O
which	O
can	O
couple	O
with	O
IL	B-Protein
-	I-Protein
18	I-Protein
-	O
induced	O
IRAK	B-Protein
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
to	O
drive	O
the	O
high	O
amounts	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
required	O
to	O
eradicate	O
intracellular	O
pathogens	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
)	O
.	O

Th2	O
cell	O
development	O
,	O
with	O
expression	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
,	O
requires	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
STAT6	B-Protein
,	O
and	O
the	O
transcription	O
factor	O
GATA	B-Protein
binding	I-Protein
protein	I-Protein
(	I-Protein
GATA	I-Protein
)	I-Protein
-	I-Protein
3	I-Protein
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
)	O
.	O

The	O
development	O
of	O
Th17	O
cells	O
requires	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
and	O
the	O
STAT3	B-Protein
-	O
dependent	O
expression	O
of	O
the	O
transcription	O
factor	O
RORgammat	B-Protein
(	O
Ivanov	O
et	O
al	O
.	O
,	O
2007	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
.	O

Th1	O
and	O
Th2	O
cell	O
responses	O
can	O
also	O
be	O
induced	O
by	O
varying	O
the	O
dose	O
of	O
antigen	O
presented	O
to	O
the	O
naive	O
T	O
cell	O
by	O
the	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
.	O

Whereas	O
high	O
doses	O
of	O
antigen	O
,	O
with	O
sustained	O
TCR	O
signaling	O
and	O
extracellular	O
-	O
signal	O
regulated	O
(	O
ERK	O
)	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
phosphorylation	O
,	O
result	O
in	O
Th1	O
cells	O
producing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
via	O
an	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
independent	O
mechanism	O
,	O
low	O
doses	O
of	O
antigen	O
,	O
with	O
transient	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
,	O
favor	O
Th2	O
responses	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
secretion	O
(	O
Constant	O
et	O
al	O
.	O
,	O
1995	O
;	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
;	O
Jorritsma	O
et	O
al	O
.	O
,	O
2003	O
;	O
Yamane	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Because	O
Th1	O
and	O
Th2	O
cells	O
cross	O
regulate	O
each	O
other	O
'	O
s	O
development	O
and	O
function	O
and	O
can	O
suppress	O
Th17	O
cell	O
responses	O
,	O
and	O
all	O
differentiate	O
along	O
distinct	O
signaling	O
pathways	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
produced	O
by	O
all	O
these	O
Th	O
cells	O
may	O
thus	O
act	O
as	O
a	O
feedback	O
regulator	O
to	O
control	O
the	O
pathology	O
associated	O
with	O
an	O
overexuberant	O
,	O
albeit	O
efficacious	O
,	O
inflammatory	O
response	O
.	O

Whether	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
these	O
different	O
Th	O
cell	O
subsets	O
is	O
induced	O
by	O
independent	O
and	O
/	O
or	O
common	O
mechanisms	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
showed	O
that	O
in	O
vitro	O
differentiation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
from	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
required	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
signaling	O
,	O
strong	O
TCR	O
activation	O
(	O
high	O
antigen	O
dose	O
)	O
,	O
and	O
sustained	O
ERK1	B-Protein
and	O
ERK2	B-Protein
phosphorylation	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
activation	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
is	O
a	O
requirement	O
for	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
subsets	O
.	O

This	O
common	O
but	O
highly	O
regulated	O
pathway	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
induction	O
and	O
maintenance	O
ensures	O
its	O
function	O
as	O
a	O
feedback	O
loop	O
to	O
control	O
damage	O
to	O
the	O
host	O
and	O
also	O
allows	O
a	O
protective	O
response	O
to	O
ensue	O
as	O
opposed	O
to	O
chronic	O
infection	O
.	O

IL	B-Protein
-	I-Protein
12	I-Protein
and	O
High	O
Doses	O
of	O
Antigen	O
Induce	O
the	O
Development	O
of	O
Th1	O
Cells	O
Producing	O
IL	B-Protein
-	I-Protein
10	I-Protein

To	O
study	O
the	O
differentiation	O
of	O
Th1	O
cells	O
coproducing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
we	O
cultured	O
purified	O
TCR	O
-	O
transgenic	O
DO11	O
.	O
10	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
purified	O
DCs	O
as	O
APCs	O
and	O
increasing	O
doses	O
of	O
ovalbumin	B-Protein
peptide	O
323	O
-	O
339	O
(	O
OVA	B-Protein
)	O
.	O

Culture	O
with	O
high	O
doses	O
of	O
antigen	O
for	O
7	O
days	O
gave	O
rise	O
to	O
Th1	O
cells	O
expressing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
upon	O
restimulation	O
(	O
Constant	O
et	O
al	O
.	O
,	O
1995	O
;	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
)	O
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Figure	O
S1A	O
available	O
online	O
)	O
.	O

Culture	O
with	O
low	O
antigen	O
doses	O
under	O
the	O
same	O
conditions	O
led	O
to	O
the	O
differentiation	O
of	O
Th2	O
cells	O
,	O
which	O
expressed	O
both	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
upon	O
restimulation	O
(	O
Figure	O
S1A	O
)	O
.	O

Culture	O
of	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
an	O
APC	O
-	O
free	O
system	O
by	O
stimulation	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
antibodies	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
resulted	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
producing	O
Th1	O
cells	O
,	O
a	O
proportion	O
of	O
which	O
coproduced	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
as	O
did	O
Th2	O
cells	O
resulting	O
from	O
culture	O
in	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
Figure	O
S1B	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
lack	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
produced	O
by	O
Th1	O
cells	O
resulted	O
from	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
DCs	O
and	O
high	O
antigen	O
dose	O
or	O
alternatively	O
required	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
we	O
cultured	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
increasing	O
doses	O
of	O
antigen	O
presented	O
by	O
DC	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

At	O
low	O
doses	O
of	O
antigen	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
abrogated	O
the	O
development	O
of	O
Th2	O
cells	O
and	O
induced	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
but	O
only	O
low	O
levels	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
,	O
suggesting	O
that	O
IL	B-Protein
-	I-Protein
12	I-Protein
per	O
se	O
was	O
not	O
sufficient	O
to	O
induce	O
significant	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
in	O
Th1	O
cells	O
(	O
Figure	O
1A	O
)	O
.	O

Strikingly	O
,	O
as	O
the	O
antigen	O
dose	O
was	O
increased	O
,	O
Th1	O
populations	O
driven	O
with	O
IL	B-Protein
-	I-Protein
12	I-Protein
now	O
contained	O
higher	O
numbers	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
cells	O
(	O
Figure	O
1A	O
)	O
and	O
produced	O
more	O
IL	B-Protein
-	I-Protein
10	I-Protein
protein	O
upon	O
restimulation	O
(	O
Figures	O
1A	O
and	O
1B	O
)	O
.	O

Thus	O
,	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
required	O
both	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
high	O
doses	O
of	O
antigen	O
.	O

Th1	O
cells	O
differentiated	O
to	O
produce	O
large	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
lost	O
their	O
capacity	O
to	O
produce	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
Figure	O
1B	O
)	O
.	O

Because	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
reduced	O
the	O
proliferation	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
at	O
both	O
high	O
and	O
low	O
antigen	O
doses	O
(	O
Table	O
S1	O
)	O
,	O
and	O
only	O
the	O
former	O
showed	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
,	O
the	O
development	O
of	O
high	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
cells	O
is	O
most	O
likely	O
not	O
related	O
to	O
limited	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Naive	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
DO11	O
.	O
10	O
/	O
recombination	B-Protein
-	I-Protein
activating	I-Protein
gene	I-Protein
1	I-Protein
(	O
Rag1	B-Protein
)	O
-	O
deficient	O
animals	O
,	O
cultured	O
with	O
high	O
doses	O
of	O
antigen	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
also	O
resulted	O
in	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
Th1	O
cells	O
,	O
showing	O
that	O
this	O
expression	O
was	O
not	O
dependent	O
on	O
the	O
presence	O
of	O
effector	O
or	O
memory	O
T	O
cells	O
or	O
Treg	O
cells	O
(	O
Figure	O
S2	O
)	O
.	O

Although	O
it	O
has	O
been	O
suggested	O
that	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
can	O
induce	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Kitani	O
et	O
al	O
.	O
,	O
2003	O
;	O
Schiott	O
et	O
al	O
.	O
,	O
2000	O
)	O
,	O
we	O
found	O
that	O
in	O
developing	O
Th1	O
and	O
Th2	O
cells	O
this	O
was	O
not	O
the	O
case	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
fact	O
,	O
neutralization	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
led	O
to	O
increased	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
both	O
T	O
cell	O
subsets	O
(	O
Figure	O
S3	O
)	O
.	O

Thus	O
,	O
the	O
development	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
only	O
depended	O
on	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
together	O
with	O
high	O
antigen	O
dose	O
and	O
not	O
on	O
other	O
soluble	O
factors	O
such	O
as	O
IL	B-Protein
-	I-Protein
2	I-Protein
or	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
or	O
on	O
the	O
presence	O
of	O
other	O
T	O
cell	O
types	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
by	O
Th1	O
Cells	O
Is	O
Dependent	O
on	O
STAT4	B-Protein
but	O
Not	O
on	O
STAT6	B-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
Signaling	O

To	O
further	O
elucidate	O
the	O
mechanisms	O
required	O
for	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
we	O
investigated	O
the	O
role	O
of	O
STAT4	B-Protein
,	O
one	O
of	O
the	O
signaling	O
pathways	O
activated	O
by	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Murphy	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

Naive	O
CD4	B-Protein
+	O
D011	O
.	O
10	O
T	O
cells	O
deficient	O
in	O
STAT4	B-Protein
(	O
Ouyang	O
et	O
al	O
.	O
,	O
1998	O
)	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
OVA	B-Protein
.	O

Again	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
were	O
differentiated	O
at	O
the	O
high	O
antigen	O
dose	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
in	O
DO11	O
.	O
10	O
T	O
cells	O
(	O
Figure	O
2A	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
absence	O
of	O
STAT4	B-Protein
,	O
the	O
percentage	O
of	O
cells	O
expressing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
was	O
dramatically	O
diminished	O
as	O
expected	O
and	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
cells	O
expressing	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Figure	O
2A	O
)	O
,	O
suggesting	O
that	O
STAT4	B-Protein
contributes	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
Th1	O
cells	O
.	O

Because	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
is	O
associated	O
with	O
an	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
induced	O
Th2	O
cell	O
phenotype	O
,	O
we	O
investigated	O
whether	O
the	O
differentiation	O
of	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
depended	O
on	O
signaling	O
through	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
receptor	O
via	O
STAT6	B-Protein
activation	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Murphy	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

The	O
absence	O
of	O
STAT6	B-Protein
did	O
not	O
impair	O
the	O
differentiation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
OVA	B-Protein
(	O
Figure	O
2A	O
)	O
.	O

In	O
fact	O
,	O
a	O
higher	O
percentage	O
of	O
STAT6	B-Protein
-	O
deficient	O
cells	O
compared	O
with	O
WT	O
cells	O
produced	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Figure	O
2A	O
)	O
,	O
which	O
may	O
be	O
the	O
result	O
of	O
the	O
loss	O
of	O
Th2	O
cell	O
control	O
over	O
a	O
Th1	O
cell	O
response	O
.	O

As	O
expected	O
,	O
lack	O
of	O
STAT6	B-Protein
abrogated	O
both	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
T	O
cells	O
developed	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
or	O
with	O
low	O
antigen	O
dose	O
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
STAT4	B-Protein
signaling	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
production	O
by	O
Th2	O
cells	O
was	O
if	O
anything	O
increased	O
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
what	O
was	O
observed	O
under	O
Th1	O
conditions	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
Th2	O
cells	O
depended	O
on	O
STAT6	B-Protein
,	O
but	O
not	O
on	O
STAT4	B-Protein
,	O
signaling	O
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
inability	O
of	O
STAT4	B-Protein
-	O
deficient	O
T	O
cells	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
might	O
be	O
due	O
to	O
the	O
absence	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
as	O
suggested	O
before	O
(	O
Shaw	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
we	O
differentiated	O
DO11	O
.	O
10	O
or	O
DO11	O
.	O
10	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
deficient	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
increasing	O
doses	O
of	O
OVA	B-Protein
.	O

The	O
secretion	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
as	O
induced	O
by	O
high	O
antigen	O
dose	O
,	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
was	O
not	O
affected	O
by	O
an	O
absence	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Figure	O
2D	O
)	O
,	O
showing	O
that	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
is	O
independent	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O

In	O
the	O
absence	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
secreted	O
IL	B-Protein
-	I-Protein
4	I-Protein
as	O
expected	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
also	O
tested	O
for	O
any	O
potential	O
role	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
in	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
culturing	O
DO11	O
.	O
10	O
or	O
DO11	O
.	O
10	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
deficient	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
increasing	O
doses	O
of	O
antigen	O
.	O

As	O
observed	O
in	O
the	O
absence	O
of	O
STAT6	B-Protein
(	O
Figure	O
2A	O
)	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
deficiency	O
had	O
no	O
effect	O
on	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Figure	O
2E	O
)	O
,	O
but	O
compromised	O
the	O
development	O
of	O
Th2	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Figure	O
2F	O
)	O
.	O

Thus	O
,	O
our	O
data	O
suggested	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
or	O
Th2	O
cells	O
was	O
dependent	O
on	O
the	O
specific	O
signaling	O
pathways	O
required	O
for	O
their	O
differentiation	O
,	O
given	O
that	O
STAT4	B-Protein
is	O
required	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
and	O
STAT6	B-Protein
for	O
Th2	O
cells	O
.	O

High	O
Antigen	O
Doses	O
and	O
STAT4	B-Protein
Are	O
Required	O
for	O
the	O
In	O
Vivo	O
Generation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
Producing	O
Th1	O
Cells	O

To	O
address	O
the	O
mechanisms	O
regulating	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
in	O
vivo	O
,	O
we	O
transferred	O
DO11	O
.	O
10	O
cells	O
into	O
BALB	O
/	O
c	O
recipient	O
mice	O
and	O
immunized	O
the	O
recipients	O
with	O
very	O
high	O
doses	O
of	O
OVA	B-Protein
-	O
protein	O
with	O
or	O
without	O
added	O
lipopolysacharide	O
(	O
LPS	O
)	O
.	O

T	O
cells	O
were	O
recovered	O
from	O
the	O
inguinal	O
lymph	O
nodes	O
3	O
days	O
after	O
priming	O
and	O
restimulated	O
in	O
vitro	O
with	O
OVA	B-Protein
peptide	O
for	O
48	O
hr	O
.	O

This	O
in	O
vivo	O
immunization	O
induced	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
,	O
and	O
the	O
amount	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
was	O
enhanced	O
by	O
addition	O
of	O
LPS	O
in	O
the	O
immunization	O
(	O
Figure	O
3A	O
)	O
and	O
with	O
higher	O
doses	O
of	O
OVA	B-Protein
(	O
3	O
muM	O
versus	O
1	O
muM	O
,	O
data	O
not	O
shown	O
)	O
.	O

To	O
test	O
the	O
role	O
of	O
STAT4	B-Protein
and	O
STAT6	B-Protein
signaling	O
in	O
the	O
in	O
vivo	O
development	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
,	O
we	O
transferred	O
STAT4	B-Protein
-	O
or	O
STAT6	B-Protein
-	O
deficient	O
or	O
WT	O
DO11	O
.	O
10	O
cells	O
into	O
recipient	O
BALB	O
/	O
c	O
mice	O
and	O
immunized	O
with	O
OVA	B-Protein
-	O
protein	O
plus	O
LPS	O
as	O
before	O
.	O

In	O
vivo	O
expression	O
of	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
was	O
markedly	O
reduced	O
but	O
not	O
completely	O
abrogated	O
in	O
the	O
absence	O
of	O
STAT4	B-Protein
signaling	O
(	O
Figures	O
3B	O
and	O
3C	O
)	O
,	O
suggesting	O
the	O
existence	O
of	O
compensatory	O
mechanisms	O
that	O
were	O
absent	O
in	O
the	O
in	O
vitro	O
system	O
.	O

Signaling	O
through	O
STAT6	B-Protein
had	O
no	O
effect	O
on	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
as	O
shown	O
by	O
intracellular	O
cytokine	O
staining	O
(	O
ICS	O
)	O
and	O
by	O
immunoassay	O
in	O
STAT6	B-Protein
-	O
deficient	O
T	O
cells	O
(	O
Figures	O
3B	O
and	O
3C	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
Is	O
Maintained	O
by	O
High	O
TCR	O
Signal	O
Strength	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein

We	O
next	O
investigated	O
whether	O
repeated	O
strong	O
TCR	O
activation	O
is	O
a	O
compensatory	O
signal	O
for	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
signaling	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
Th1	O
cells	O
.	O

For	O
this	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
differentiated	O
for	O
2	O
consecutive	O
weeks	O
with	O
high	O
antigen	O
doses	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
throughout	O
(	O
Figures	O
4A	O
-	O
4D	O
)	O
.	O

High	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
cooperated	O
to	O
induce	O
maximal	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
(	O
Figures	O
4A	O
and	O
4B	O
)	O
,	O
given	O
that	O
this	O
combination	O
resulted	O
in	O
the	O
highest	O
numbers	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
.	O

Repeated	O
high	O
antigen	O
dose	O
stimulation	O
in	O
the	O
absence	O
of	O
exogenously	O
added	O
IL	B-Protein
-	I-Protein
12	I-Protein
resulted	O
in	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
,	O
suggesting	O
that	O
repeated	O
strong	O
TCR	O
triggering	O
may	O
overcome	O
the	O
need	O
for	O
IL	B-Protein
-	I-Protein
12	I-Protein
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
induction	O
(	O
Figures	O
4C	O
and	O
4D	O
)	O
.	O

However	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
induction	O
under	O
these	O
conditions	O
was	O
abrogated	O
when	O
IL	B-Protein
-	I-Protein
12p40	I-Protein
-	O
deficient	O
DCs	O
were	O
used	O
as	O
APCs	O
(	O
Figure	O
4E	O
)	O
.	O

Thus	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
is	O
essential	O
during	O
both	O
primary	O
and	O
secondary	O
antigenic	O
stimulation	O
for	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
.	O

To	O
determine	O
the	O
requirements	O
for	O
stability	O
of	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
,	O
we	O
differentiated	O
CD4	B-Protein
+	O
T	O
cells	O
for	O
1	O
week	O
with	O
high	O
antigen	O
doses	O
with	O
or	O
without	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figures	O
4A	O
and	O
4C	O
)	O
,	O
washed	O
them	O
,	O
and	O
then	O
restimulated	O
them	O
for	O
an	O
additional	O
week	O
with	O
a	O
low	O
antigen	O
dose	O
,	O
in	O
the	O
absence	O
or	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figure	O
4F	O
)	O
.	O

Th1	O
cells	O
induced	O
in	O
the	O
first	O
week	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
culture	O
with	O
high	O
antigen	O
doses	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
lost	O
their	O
ability	O
to	O
express	O
IL	B-Protein
-	I-Protein
10	I-Protein
when	O
recultured	O
with	O
low	O
doses	O
of	O
OVA	B-Protein
,	O
which	O
could	O
be	O
compensated	O
for	O
,	O
to	O
some	O
extent	O
,	O
by	O
addition	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
to	O
the	O
secondary	O
cultures	O
(	O
Figure	O
4F	O
)	O
,	O
again	O
suggesting	O
that	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
signals	O
cooperate	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Finally	O
,	O
DO11	O
.	O
10	O
CD4	B-Protein
+	O
cells	O
that	O
were	O
exposed	O
to	O
low	O
doses	O
of	O
antigen	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
during	O
the	O
primary	O
differentiation	O
phase	O
produced	O
high	O
amounts	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
but	O
little	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
but	O
they	O
could	O
be	O
induced	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
when	O
both	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
were	O
present	O
during	O
the	O
recall	O
phase	O
(	O
Figure	O
S4	O
)	O
.	O

Thus	O
,	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
are	O
required	O
for	O
sustaining	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
by	O
Th1	O
Cells	O
Requires	O
ERK1	B-Protein
and	O
ERK2	B-Protein
Activation	O

Our	O
data	O
showed	O
that	O
the	O
maintenance	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
induction	O
in	O
Th1	O
cells	O
required	O
stimulation	O
with	O
high	O
antigen	O
dose	O
,	O
which	O
to	O
some	O
extent	O
could	O
be	O
compensated	O
for	O
by	O
the	O
addition	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

Signaling	O
through	O
the	O
TCR	O
with	O
high	O
doses	O
of	O
antigen	O
induced	O
stronger	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
than	O
that	O
induced	O
by	O
low	O
antigen	O
dose	O
,	O
not	O
only	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
data	O
not	O
shown	O
)	O
as	O
previously	O
demonstrated	O
(	O
Jorritsma	O
et	O
al	O
.	O
,	O
2003	O
)	O
but	O
also	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
restimulated	O
with	O
the	O
same	O
high	O
and	O
low	O
antigen	O
doses	O
(	O
Figure	O
5A	O
)	O
.	O

Although	O
the	O
apparent	O
peak	O
and	O
amount	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
varied	O
slightly	O
between	O
experiments	O
,	O
a	O
consistent	O
finding	O
was	O
that	O
high	O
antigen	O
dose	O
differentiated	O
Th1	O
cells	O
always	O
showed	O
enhanced	O
and	O
prolonged	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
regardless	O
of	O
whether	O
they	O
were	O
restimulated	O
with	O
high	O
or	O
low	O
antigen	O
dose	O
(	O
Figure	O
5B	O
)	O
.	O

We	O
then	O
investigated	O
whether	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
was	O
required	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
Th1	O
cells	O
by	O
using	O
U0126	O
(	O
Figure	O
5C	O
)	O
,	O
a	O
compound	O
that	O
blocks	O
downstream	O
ERK	O
activation	O
.	O

To	O
ensure	O
that	O
only	O
T	O
cell	O
signaling	O
was	O
being	O
affected	O
by	O
U0126	O
,	O
we	O
used	O
an	O
APC	O
-	O
free	O
system	O
in	O
which	O
the	O
T	O
cells	O
were	O
differentiated	O
in	O
the	O
presence	O
of	O
increasing	O
doses	O
of	O
anti	O
-	O
CD3	B-Protein
and	O
a	O
constant	O
amount	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

As	O
in	O
the	O
APC	O
-	O
driven	O
cultures	O
,	O
stronger	O
TCR	O
stimulation	O
together	O
with	O
IL	B-Protein
-	I-Protein
12	I-Protein
led	O
to	O
higher	O
percentages	O
of	O
cells	O
producing	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
after	O
1	O
week	O
of	O
culture	O
(	O
Figure	O
5C	O
)	O
.	O

Addition	O
of	O
U0126	O
to	O
the	O
cultures	O
abrogated	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
at	O
all	O
doses	O
of	O
anti	O
-	O
CD3	B-Protein
(	O
Figure	O
5C	O
)	O
.	O

Because	O
U0126	O
inhibits	O
the	O
MEK5	B-Protein
-	O
catalyzed	O
activation	O
of	O
ERK5	B-Protein
,	O
as	O
well	O
as	O
the	O
MEK1	B-Protein
-	O
and	O
MEK2	B-Protein
-	O
catalyzed	O
activation	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
(	O
Bain	O
et	O
al	O
.	O
,	O
2007	O
;	O
Mody	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
we	O
also	O
used	O
the	O
more	O
specific	O
,	O
structurally	O
unrelated	O
MEK1	B-Protein
and	O
MEK2	B-Protein
inhibitor	O
PD184352	O
at	O
concentrations	O
in	O
which	O
it	O
inhibits	O
MEK1	B-Protein
and	O
MEK2	B-Protein
but	O
not	O
MEK5	B-Protein
(	O
Bain	O
et	O
al	O
.	O
,	O
2007	O
;	O
Mody	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

PD184352	O
caused	O
a	O
similar	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
(	O
Figure	O
5D	O
and	O
Figure	O
S5A	O
)	O
.	O

Upon	O
addition	O
of	O
inhibitors	O
to	O
other	O
signaling	O
pathways	O
,	O
including	O
a	O
p38	B-Protein
MAPK	I-Protein
inhibitor	O
,	O
SB203580	O
,	O
or	O
the	O
GSK3beta	B-Protein
inhibitor	O
,	O
CT99021	O
(	O
Bain	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
no	O
effect	O
on	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
was	O
observed	O
(	O
Figure	O
S5B	O
)	O
.	O

Our	O
data	O
thus	O
suggested	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
in	O
response	O
to	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
requires	O
ERK1	B-Protein
and	O
ERK2	B-Protein
signaling	O
,	O
but	O
not	O
the	O
activation	O
of	O
the	O
p38	B-Protein
or	O
the	O
GSK3beta	B-Protein
pathways	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
by	O
Th2	O
and	O
Th17	O
Cells	O
Also	O
Requires	O
ERK1	B-Protein
and	O
ERK2	B-Protein
Activation	O

To	O
address	O
whether	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th2	O
and	O
Th17	O
cells	O
was	O
also	O
dependent	O
on	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
,	O
we	O
differentiated	O
these	O
cells	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
in	O
the	O
absence	O
of	O
APCs	O
(	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2009	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
MEK	B-Protein
inhibitor	O
(	O
PD184352	O
)	O
.	O

We	O
showed	O
that	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
is	O
a	O
common	O
pathway	O
required	O
for	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
different	O
Th	O
cell	O
subsets	O
because	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
both	O
Th2	O
and	O
Th17	O
cells	O
was	O
markedly	O
inhibited	O
in	O
the	O
presence	O
of	O
the	O
MEK	B-Protein
inhibitor	O
(	O
PD184352	O
)	O
(	O
Figure	O
5D	O
and	O
Figure	O
S5B	O
)	O
.	O

In	O
contrast	O
,	O
inhibitors	O
of	O
p38	B-Protein
MAPK	I-Protein
or	O
of	O
GSK	B-Protein
-	I-Protein
3beta	I-Protein
activation	O
did	O
not	O
affect	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
these	O
subsets	O
(	O
Figure	O
S5B	O
)	O
.	O

Activation	O
of	O
the	O
ERK1	B-Protein
and	O
ERK2	B-Protein
signaling	O
pathway	O
is	O
therefore	O
a	O
common	O
requirement	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
.	O

c	B-Protein
-	I-Protein
maf	I-Protein
Expression	O
Correlates	O
with	O
IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
in	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
Cells	O

To	O
investigate	O
further	O
the	O
downstream	O
factors	O
involved	O
in	O
regulating	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
,	O
we	O
differentiated	O
DO11	O
.	O
10	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
increasing	O
doses	O
of	O
OVA	B-Protein
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
and	O
quantified	O
the	O
expression	O
of	O
cytokines	O
and	O
transcription	O
factors	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Low	O
-	O
dose	O
antigen	O
resulted	O
in	O
transcription	O
of	O
Il4	B-Protein
and	O
this	O
was	O
abrogated	O
by	O
both	O
high	O
antigen	O
doses	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figure	O
6A	O
)	O
.	O

A	O
low	O
amount	O
of	O
transcription	O
of	O
Ifngamma	B-Protein
was	O
induced	O
by	O
IL	B-Protein
-	I-Protein
12	I-Protein
when	O
cells	O
were	O
differentiated	O
with	O
low	O
antigen	O
dose	O
,	O
but	O
this	O
effect	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
was	O
markedly	O
upregulated	O
with	O
increasing	O
doses	O
of	O
antigen	O
(	O
Figure	O
6A	O
)	O
.	O

A	O
low	O
amount	O
of	O
Il10	B-Protein
transcription	O
was	O
observed	O
at	O
low	O
doses	O
of	O
antigen	O
accompanying	O
Il4	B-Protein
expression	O
(	O
Th2	O
cell	O
response	O
)	O
,	O
and	O
this	O
was	O
abrogated	O
by	O
increased	O
doses	O
of	O
antigen	O
as	O
was	O
Il4	B-Protein
expression	O
(	O
Figure	O
6A	O
)	O
.	O

At	O
low	O
doses	O
of	O
antigen	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
had	O
little	O
effect	O
to	O
increase	O
IL	B-Protein
-	I-Protein
10	I-Protein
mRNA	O
expression	O
(	O
Figure	O
6A	O
)	O
in	O
keeping	O
with	O
the	O
protein	O
data	O
(	O
Figure	O
1A	O
)	O
.	O

However	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
induced	O
a	O
high	O
amount	O
of	O
Il10	B-Protein
transcription	O
as	O
well	O
as	O
Ifngamma	B-Protein
expression	O
with	O
increased	O
antigen	O
doses	O
(	O
Figure	O
6A	O
)	O
,	O
again	O
in	O
keeping	O
with	O
the	O
protein	O
data	O
(	O
Figure	O
1A	O
)	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
differentiated	O
with	O
increasing	O
doses	O
of	O
antigen	O
did	O
not	O
express	O
high	O
amounts	O
of	O
Tbx	B-Protein
-	I-Protein
21	I-Protein
(	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
mRNA	O
,	O
unless	O
they	O
were	O
cocultured	O
with	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figure	O
6B	O
)	O
.	O

In	O
contrast	O
,	O
high	O
amounts	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
mRNA	O
expression	O
were	O
only	O
observed	O
under	O
Th2	O
cell	O
differentiation	O
conditions	O
(	O
low	O
-	O
dose	O
antigen	O
)	O
(	O
Figure	O
6B	O
)	O
,	O
and	O
this	O
expression	O
was	O
markedly	O
downregulated	O
by	O
both	O
increasing	O
antigen	O
dose	O
and	O
coculture	O
in	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figure	O
6B	O
)	O
.	O

Differentiation	O
of	O
T	O
cells	O
under	O
low	O
antigen	O
dose	O
led	O
to	O
expression	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
,	O
in	O
keeping	O
with	O
the	O
Th2	O
cell	O
profile	O
(	O
Ho	O
et	O
al	O
.	O
,	O
1996	O
)	O
,	O
which	O
was	O
almost	O
completely	O
abrogated	O
by	O
increasing	O
doses	O
of	O
antigen	O
(	O
Figure	O
6B	O
)	O
.	O

Interestingly	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
sustained	O
the	O
high	O
expression	O
of	O
c	B-Protein
-	I-Protein
Maf	I-Protein
mRNA	O
even	O
at	O
the	O
highest	O
antigen	O
dose	O
(	O
Figure	O
6B	O
)	O
.	O

Moreover	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
maintenance	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
required	O
STAT4	B-Protein
activation	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
Th17	O
cells	O
that	O
expressed	O
IL	B-Protein
-	I-Protein
17a	I-Protein
as	O
well	O
as	O
IL	B-Protein
-	I-Protein
10	I-Protein
mRNA	O
(	O
Figure	O
6C	O
)	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
GATA	B-Protein
-	I-Protein
3	I-Protein
mRNA	O
were	O
undetectable	O
(	O
data	O
not	O
shown	O
)	O
,	O
whereas	O
that	O
of	O
ROR	B-Protein
-	I-Protein
gammat	I-Protein
was	O
high	O
(	O
Figure	O
6C	O
)	O
(	O
Ivanov	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Th17	O
cells	O
also	O
expressed	O
high	O
amounts	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
(	O
Figure	O
6C	O
)	O
,	O
confirming	O
a	O
recent	O
report	O
(	O
Bauquet	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

c	B-Protein
-	I-Protein
Maf	I-Protein
is	O
therefore	O
expressed	O
in	O
all	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
expressing	O
T	O
cell	O
populations	O
tested	O
(	O
Figures	O
6B	O
and	O
6C	O
)	O
and	O
may	O
not	O
be	O
just	O
a	O
Th2	O
cell	O
-	O
specific	O
transcription	O
factor	O
as	O
originally	O
thought	O
(	O
Ho	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O

We	O
showed	O
also	O
that	O
like	O
Il10	B-Protein
expression	O
,	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
was	O
inhibited	O
in	O
Th1	O
and	O
Th17	O
cells	O
in	O
the	O
presence	O
of	O
the	O
MEK1	B-Protein
and	O
MEK2	B-Protein
inhibitor	O
(	O
PD184352	O
)	O
,	O
whereas	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
RORgammat	B-Protein
expression	O
was	O
hardly	O
affected	O
(	O
Figure	O
6D	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
systems	O
reflects	O
the	O
importance	O
of	O
this	O
cytokine	O
in	O
the	O
tight	O
regulation	O
of	O
the	O
immune	O
response	O
,	O
to	O
minimize	O
pathology	O
during	O
infection	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
Th1	O
cells	O
has	O
been	O
reported	O
to	O
regulate	O
the	O
immune	O
response	O
in	O
leishmaniasis	O
and	O
toxoplasmosis	O
.	O

However	O
,	O
in	O
many	O
situations	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
is	O
not	O
produced	O
by	O
Th1	O
cells	O
in	O
response	O
to	O
antigenic	O
stimulation	O
.	O

Our	O
goal	O
was	O
to	O
address	O
the	O
molecular	O
signals	O
that	O
determine	O
whether	O
Th1	O
cells	O
develop	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Trinchieri	O
,	O
2007	O
)	O
.	O

Here	O
,	O
we	O
showed	O
that	O
Th1	O
cells	O
required	O
high	O
-	O
antigen	O
-	O
dose	O
-	O
induced	O
ERK1	B-Protein
and	O
ERK2	B-Protein
phosphorylation	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT	B-Protein
-	I-Protein
4	I-Protein
activation	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Our	O
findings	O
that	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
was	O
a	O
common	O
pathway	O
required	O
for	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
subsets	O
,	O
which	O
differentiate	O
along	O
distinct	O
pathways	O
,	O
such	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
provides	O
a	O
highly	O
regulated	O
feedback	O
loop	O
to	O
avoid	O
the	O
extremes	O
of	O
excessive	O
inflammation	O
or	O
chronic	O
infections	O
and	O
also	O
allow	O
a	O
protective	O
response	O
to	O
diverse	O
pathogens	O
.	O

In	O
certain	O
viral	O
or	O
parasitic	O
infections	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
;	O
Brooks	O
et	O
al	O
.	O
,	O
2006	O
;	O
Ejrnaes	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
high	O
amounts	O
of	O
stimulation	O
may	O
lead	O
to	O
the	O
chronic	O
nonhealing	O
infection	O
shown	O
to	O
be	O
regulated	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

During	O
the	O
course	O
of	O
infection	O
,	O
after	O
initial	O
triggering	O
with	O
antigen	O
,	O
T	O
cells	O
migrate	O
to	O
the	O
tissue	O
encountering	O
high	O
doses	O
of	O
antigen	O
and	O
factors	O
produced	O
by	O
the	O
innate	O
immune	O
response	O
.	O

Under	O
these	O
conditions	O
,	O
we	O
speculate	O
that	O
Th1	O
cells	O
will	O
be	O
induced	O
to	O
express	O
high	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
in	O
keeping	O
with	O
reports	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
were	O
found	O
in	O
CD4	B-Protein
+	O
clones	O
isolated	O
from	O
BAL	O
but	O
not	O
blood	O
of	O
TB	O
patients	O
(	O
Gerosa	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Similarly	O
,	O
the	O
immune	O
response	O
to	O
a	O
clinical	O
isolate	O
of	O
L	O
.	O
major	O
,	O
which	O
produces	O
heavily	O
infected	O
nonhealing	O
lesions	O
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
derived	O
from	O
Foxp3	B-Protein
-	O
Th1	O
cells	O
that	O
coproduce	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
and	O
the	O
immune	O
response	O
during	O
T	O
.	O
gondii	O
infection	O
was	O
found	O
also	O
to	O
be	O
regulated	O
by	O
Foxp3	B-Protein
-	O
Th1	O
cells	O
(	O
Jankovic	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

It	O
is	O
likely	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
is	O
evoked	O
under	O
conditions	O
of	O
high	O
inflammation	O
and	O
antigenic	O
stimulation	O
,	O
whereas	O
regulatory	O
CD4	B-Protein
+	O
T	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
operate	O
to	O
regulate	O
the	O
immune	O
response	O
under	O
conditions	O
in	O
which	O
the	O
pathogen	O
is	O
clinically	O
controlled	O
,	O
such	O
as	O
in	O
infection	O
with	O
L	O
.	O
major	O
(	O
Friedlin	O
strain	O
)	O
(	O
Belkaid	O
et	O
al	O
.	O
,	O
2002	O
;	O
Suffia	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

We	O
now	O
also	O
reported	O
that	O
CD4	B-Protein
+	O
T	O
cells	O
cultured	O
with	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
differentiate	O
into	O
canonical	O
Th1	O
effector	O
cells	O
,	O
which	O
,	O
in	O
addition	O
to	O
expressing	O
large	O
amounts	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
lose	O
their	O
IL	B-Protein
-	I-Protein
2	I-Protein
expression	O
as	O
described	O
before	O
in	O
certain	O
chronic	O
infection	O
models	O
(	O
Sallusto	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

Our	O
demonstration	O
that	O
loss	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
is	O
accompanied	O
by	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
offers	O
potential	O
additional	O
mechanisms	O
whereby	O
effector	O
T	O
cell	O
responses	O
may	O
be	O
dampened	O
during	O
chronic	O
disease	O
.	O

Using	O
an	O
in	O
vivo	O
transfer	O
model	O
of	O
DO11	O
.	O
10	O
TCR	O
transgenic	O
cells	O
(	O
Castro	O
et	O
al	O
.	O
,	O
2000	O
)	O
,	O
we	O
showed	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
were	O
differentiated	O
in	O
the	O
presence	O
of	O
high	O
doses	O
of	O
OVA	B-Protein
protein	O
and	O
LPS	O
.	O

We	O
showed	O
here	O
that	O
this	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
Th1	O
cells	O
in	O
vivo	O
was	O
markedly	O
,	O
but	O
not	O
totally	O
,	O
reduced	O
in	O
STAT4	B-Protein
-	O
deficient	O
T	O
cells	O
as	O
observed	O
during	O
T	O
.	O
gondii	O
infection	O
(	O
Jankovic	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

A	O
high	O
antigenic	O
activation	O
during	O
T	O
.	O
gondii	O
infection	O
or	O
high	O
antigen	O
doses	O
delivered	O
in	O
the	O
presence	O
of	O
LPS	O
,	O
as	O
seen	O
in	O
our	O
system	O
,	O
may	O
compensate	O
for	O
an	O
absolute	O
requirement	O
for	O
IL	B-Protein
-	I-Protein
12	I-Protein
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
.	O

In	O
our	O
in	O
vitro	O
system	O
,	O
repeated	O
stimulation	O
of	O
Th1	O
cells	O
with	O
high	O
antigen	O
doses	O
allowed	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
an	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
dependent	O
manner	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
induced	O
by	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
was	O
independent	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
in	O
keeping	O
with	O
previous	O
findings	O
(	O
Jankovic	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

However	O
,	O
a	O
role	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
mediating	O
IL	B-Protein
-	I-Protein
10	I-Protein
reactivation	O
by	O
Th1	O
cells	O
during	O
secondary	O
infection	O
with	O
T	O
.	O
gondii	O
has	O
been	O
suggested	O
(	O
Shaw	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

We	O
have	O
found	O
that	O
CD4	B-Protein
+	O
T	O
cells	O
exposed	O
to	O
a	O
high	O
dose	O
of	O
antigen	O
do	O
not	O
express	O
IL	B-Protein
-	I-Protein
10	I-Protein
upon	O
restimulation	O
,	O
but	O
can	O
be	O
induced	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
upon	O
re	O
-	O
exposure	O
to	O
a	O
high	O
dose	O
of	O
antigen	O
in	O
the	O
recall	O
phase	O
in	O
the	O
absence	O
of	O
added	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

However	O
,	O
this	O
is	O
dependent	O
on	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
by	O
antigen	O
-	O
presenting	O
DCs	O
.	O

The	O
combination	O
of	O
both	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
resulted	O
in	O
the	O
highest	O
levels	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
and	O
correlated	O
with	O
the	O
high	O
levels	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
.	O

The	O
increased	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
observed	O
during	O
the	O
secondary	O
phase	O
will	O
induce	O
increased	O
IL	B-Protein
-	I-Protein
12	I-Protein
production	O
by	O
DCs	O
and	O
suggests	O
that	O
repeated	O
high	O
-	O
level	O
TCR	O
activation	O
feeds	O
back	O
to	O
upregulate	O
IL	B-Protein
-	I-Protein
12	I-Protein
production	O
by	O
DC	O
.	O

It	O
is	O
thus	O
likely	O
that	O
in	O
T	O
.	O
gondii	O
infection	O
in	O
vivo	O
(	O
Shaw	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
the	O
requirement	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
to	O
induce	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
was	O
for	O
feedback	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
by	O
DCs	O
,	O
which	O
in	O
turn	O
induced	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
the	O
Th1	O
cells	O
.	O

Although	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
be	O
differentially	O
regulated	O
in	O
Th1	O
and	O
Th2	O
cells	O
as	O
has	O
been	O
reported	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Wang	O
et	O
al	O
.	O
,	O
2005	O
)	O
,	O
some	O
studies	O
suggest	O
the	O
existence	O
of	O
common	O
pathways	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
these	O
is	O
as	O
yet	O
unclear	O
.	O

Costimulatory	O
OX	B-Protein
-	I-Protein
40	I-Protein
signals	O
have	O
been	O
shown	O
to	O
negatively	O
regulate	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
(	O
Ito	O
et	O
al	O
.	O
,	O
2005	O
)	O
both	O
in	O
Th1	O
and	O
Th2	O
cells	O
,	O
whereas	O
ICOS	B-Protein
signaling	O
has	O
been	O
suggested	O
to	O
induce	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Ito	O
et	O
al	O
.	O
,	O
2007	O
;	O
Witsch	O
et	O
al	O
.	O
,	O
2002	O
)	O
in	O
both	O
Th1	O
and	O
Th2	O
cells	O
.	O

However	O
,	O
in	O
some	O
cases	O
,	O
ICOS	B-Protein
signaling	O
also	O
regulates	O
IL	B-Protein
-	I-Protein
4	I-Protein
production	O
and	O
Th2	O
responses	O
(	O
Greenwald	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

We	O
now	O
provide	O
a	O
common	O
mechanism	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
for	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
in	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
,	O
although	O
each	O
subset	O
differentiates	O
along	O
a	O
distinct	O
and	O
subset	O
-	O
specific	O
transcriptional	O
pathway	O
.	O

This	O
reinforces	O
the	O
fact	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
is	O
not	O
a	O
Th	O
cell	O
-	O
subset	O
-	O
specific	O
cytokine	O
,	O
but	O
instead	O
is	O
produced	O
in	O
a	O
tightly	O
regulated	O
fashion	O
during	O
each	O
differentiation	O
pathway	O
.	O

Of	O
note	O
,	O
a	O
role	O
for	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
has	O
already	O
been	O
described	O
for	O
macrophages	O
and	O
DC	O
(	O
Agrawal	O
et	O
al	O
.	O
,	O
2006	O
;	O
Hacker	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Differential	O
transcriptional	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
Th1	O
and	O
Th2	O
cells	O
has	O
been	O
suggested	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Wang	O
et	O
al	O
.	O
,	O
2005	O
)	O
,	O
and	O
extensive	O
histone	B-Protein
acetylation	O
of	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
gene	O
is	O
detectable	O
in	O
fully	O
polarized	O
Th2	O
cells	O
,	O
but	O
not	O
Th1	O
cells	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

We	O
provide	O
evidence	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
is	O
produced	O
in	O
canonical	O
Th1	O
cells	O
and	O
that	O
its	O
expression	O
correlates	O
with	O
the	O
expression	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
the	O
highest	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
,	O
in	O
keeping	O
with	O
our	O
observations	O
that	O
high	O
-	O
dose	O
antigen	O
stimulation	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
signaling	O
are	O
required	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
maintenance	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
is	O
conditional	O
on	O
IL	B-Protein
-	I-Protein
12	I-Protein
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
unless	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
gene	O
is	O
imprinted	O
by	O
GATA	B-Protein
-	I-Protein
3	I-Protein
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
which	O
can	O
remodel	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
locus	O
,	O
thus	O
explaining	O
the	O
highest	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
produced	O
by	O
Th2	O
cells	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

We	O
show	O
here	O
that	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
drastically	O
downregulate	O
Gata	B-Protein
-	I-Protein
3	I-Protein
expression	O
,	O
suggesting	O
that	O
additional	O
factors	O
are	O
in	O
place	O
to	O
induce	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
in	O
Th1	O
cells	O
,	O
albeit	O
transiently	O
.	O

Expression	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
was	O
greatly	O
diminished	O
by	O
high	O
antigen	O
doses	O
in	O
T	O
cells	O
and	O
yet	O
was	O
unexpectedly	O
maintained	O
by	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
present	O
in	O
Th17	O
cells	O
.	O

That	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
is	O
common	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
and	O
,	O
like	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
is	O
dependent	O
on	O
ERK	B-Protein
activation	O
in	O
Th1	O
and	O
Th17	O
cells	O
for	O
its	O
expression	O
is	O
of	O
interest	O
because	O
c	B-Protein
-	I-Protein
Maf	I-Protein
has	O
been	O
shown	O
to	O
be	O
an	O
essential	O
transcription	O
factor	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
in	O
macrophages	O
(	O
Cao	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

In	O
summary	O
,	O
we	O
show	O
that	O
although	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
CD4	B-Protein
+	O
T	O
cell	O
subsets	O
differentiate	O
along	O
distinct	O
signaling	O
and	O
transcriptional	O
pathways	O
,	O
they	O
can	O
all	O
be	O
induced	O
to	O
make	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
is	O
required	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
all	O
these	O
Th	O
cell	O
subsets	O
.	O

With	O
regard	O
to	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
,	O
our	O
data	O
provide	O
a	O
mechanism	O
for	O
how	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
is	O
induced	O
and	O
then	O
amplified	O
and	O
regulated	O
by	O
the	O
levels	O
of	O
antigen	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
encountered	O
in	O
the	O
environment	O
.	O

This	O
provides	O
a	O
mechanism	O
whereby	O
a	O
Th1	O
cell	O
responds	O
to	O
extrinsic	O
signals	O
,	O
reflecting	O
increased	O
inflammation	O
in	O
the	O
tissue	O
,	O
to	O
tightly	O
regulate	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
so	O
as	O
to	O
allow	O
a	O
protective	O
response	O
to	O
eradicate	O
a	O
pathogen	O
with	O
minimal	O
damage	O
to	O
the	O
host	O
and	O
also	O
prevent	O
chronic	O
infection	O
.	O

Moreover	O
,	O
our	O
findings	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
during	O
an	O
inflammatory	O
Th1	O
response	O
in	O
infection	O
and	O
may	O
be	O
of	O
relevance	O
for	O
the	O
design	O
of	O
vaccines	O
and	O
for	O
strategies	O
in	O
immunotherapy	O
in	O
infectious	O
diseases	O
.	O

Mice	O
,	O
Cytokines	O
,	O
Antibodies	O
,	O
and	O
Other	O
Reagents	O

BALB	O
/	O
c	O
DO11	O
.	O
10	O
mice	O
transgenic	O
for	O
OVA	B-Protein
-	O
specific	O
TCR	O
WT	O
or	O
crossed	O
back	O
with	O
Rag1	B-Protein
-	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
,	O
STAT4	B-Protein
-	O
,	O
and	O
STAT6	B-Protein
-	O
deficient	O
mice	O
were	O
used	O
as	O
a	O
source	O
of	O
antigen	O
-	O
specific	O
T	O
cells	O
(	O
Murphy	O
et	O
al	O
.	O
,	O
1990	O
;	O
Ouyang	O
et	O
al	O
.	O
,	O
1998	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
and	O
were	O
bred	O
and	O
maintained	O
under	O
SPF	O
conditions	O
at	O
the	O
NIMR	O
,	O
London	O
,	O
Home	O
Office	O
,	O
UK	O
,	O
Animals	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
1986	O
or	O
at	O
the	O
Washington	O
University	O
School	O
of	O
Medicine	O
.	O

Female	O
mice	O
were	O
used	O
at	O
8	O
-	O
12	O
weeks	O
old	O
,	O
and	O
animal	O
protocols	O
were	O
approved	O
according	O
to	O
the	O
Animals	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
1986	O
,	O
Home	O
Office	O
,	O
UK	O
.	O

Reagents	O
,	O
including	O
antibodies	O
for	O
T	O
cell	O
and	O
DC	O
preparation	O
,	O
purification	O
and	O
culture	O
,	O
media	O
,	O
cytokines	O
,	O
and	O
cytokine	O
mAbs	O
have	O
been	O
described	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2009	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

LPS	O
(	O
S	O
.	O
minnesota	O
)	O
was	O
from	O
Alexis	O
,	O
chicken	O
ovalbumin	B-Protein
protein	O
(	O
OVA	B-Protein
protein	O
)	O
was	O
from	O
from	O
Sigma	O
-	O
Aldrich	O
,	O
and	O
ovalbumin	B-Protein
peptide323	O
-	O
339	O
(	O
OVA	O
)	O
(	O
endotoxin	O
-	O
free	O
)	O
was	O
from	O
Biosynthesis	O
.	O

U0126	O
was	O
from	O
BioMol	O
International	O
.	O

PD184352	O
(	O
MEK	B-Protein
inhibitors	O
)	O
,	O
SB203580	O
(	O
p38	B-Protein
inhibitor	O
)	O
,	O
and	O
CT99021	O
(	O
GSK3beta	B-Protein
inhibitor	O
)	O
were	O
kind	O
gifts	O
from	O
P	O
.	O

Cohen	O
and	O
N	O
.	O

Shpiro	O
,	O
University	O
of	O
Dundee	O
,	O
UK	O
.	O

Isolation	O
of	O
CD4	B-Protein
+	O
T	O
Cells	O
and	O
of	O
Splenic	O
DC	O
and	O
Cell	O
Culture	O
for	O
T	O
Cell	O
Phenotype	O
Differentiation	O

T	O
cells	O
were	O
sorted	O
for	O
CD4	B-Protein
+	O
CD62Lhi	B-Protein
,	O
CD4	B-Protein
+	O
CD62LhiCD25	B-Protein
-	O
,	O
or	O
CD4	B-Protein
+	O
CD44loCD25	B-Protein
-	O
to	O
>	O
98	O
%	O
on	O
a	O
Moflo	O
cytometer	O
(	O
Cytomation	O
)	O
as	O
before	O
(	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

In	O
most	O
cases	O
,	O
experiments	O
were	O
reproduced	O
with	O
each	O
type	O
of	O
purified	O
CD4	B-Protein
+	O
T	O
cell	O
population	O
with	O
similar	O
results	O
obtained	O
.	O

Splenic	O
DCs	O
were	O
prepared	O
as	O
described	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
)	O
,	O
and	O
sort	O
purified	O
CD11c	B-Protein
+	O
cells	O
were	O
added	O
to	O
the	O
T	O
cell	O
culture	O
.	O

Purified	O
DO11	O
.	O
10	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
1	O
x	O
105	O
cells	O
/	O
ml	O
)	O
were	O
cultured	O
as	O
before	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
)	O
,	O
in	O
a	O
total	O
volume	O
of	O
1	O
ml	O
cRPMI	O
medium	O
in	O
a	O
48	O
-	O
well	O
plate	O
,	O
with	O
splenic	O
DCs	O
(	O
2	O
x	O
104	O
cells	O
/	O
ml	O
)	O
,	O
and	O
varying	O
amounts	O
of	O
OVA	B-Protein
and	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

APC	O
-	O
independent	O
differentiation	O
of	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
into	O
Th1	O
and	O
Th2	O
cells	O
used	O
stimulation	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
and	O
appropriate	O
cytokine	O
conditions	O
,	O
and	O
control	O
Th1	O
and	O
Th2	O
cells	O
were	O
cultured	O
as	O
described	O
before	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Culture	O
conditions	O
for	O
Th17	O
cells	O
were	O
as	O
described	O
before	O
(	O
Veldhoen	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Importantly	O
,	O
Th1	O
and	O
Th2	O
cells	O
could	O
be	O
differentiated	O
in	O
cRPMI	O
or	O
IMDM	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
but	O
Th17	O
cells	O
were	O
only	O
differentiated	O
optimally	O
in	O
IMDM	O
(	O
Veldhoen	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

When	O
indicated	O
,	O
U0126	O
or	O
PD184352	O
(	O
MEK	B-Protein
inhibitors	O
)	O
,	O
SB203580	O
(	O
p38	B-Protein
inhibitor	O
)	O
,	O
CT99021	O
(	O
GSK3beta	B-Protein
inhibitor	O
)	O
,	O
or	O
a	O
similar	O
amount	O
of	O
DMSO	O
were	O
present	O
in	O
the	O
culture	O
.	O

More	O
details	O
of	O
specific	O
culture	O
conditions	O
are	O
provided	O
in	O
Figures	O
S6	O
and	O
S7	O
.	O

Cytokine	O
Detection	O
by	O
ICS	O
and	O
ELISA	O

At	O
day	O
5	O
or	O
7	O
,	O
cells	O
were	O
restimulated	O
with	O
immobilized	O
anti	O
-	O
CD3	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
and	O
anti	O
-	O
CD28	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
(	O
4	O
hr	O
with	O
BrefeldinA	O
[	O
10	O
mug	O
/	O
ml	O
]	O
in	O
the	O
last	O
2	O
hr	O
)	O
or	O
with	O
PdBU	O
and	O
Ionomycin	O
(	O
5	O
hr	O
with	O
BrefeldinA	O
[	O
1	O
mug	O
/	O
ml	O
]	O
)	O
.	O

After	O
ICS	O
FACS	O
,	O
data	O
were	O
collected	O
on	O
a	O
FACSCalibur	O
(	O
Becton	O
Dickinson	O
)	O
and	O
analyzed	O
with	O
FlowJo	O
(	O
Tree	O
Star	O
)	O
.	O

For	O
ELISA	O
,	O
cells	O
were	O
similarly	O
restimulated	O
for	O
48	O
hr	O
and	O
supernatant	O
was	O
collected	O
and	O
analyzed	O
for	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
as	O
described	O
before	O
(	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

In	O
Vivo	O
Studies	O

BALB	O
/	O
c	O
mice	O
were	O
injected	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
with	O
a	O
red	O
blood	O
cell	O
-	O
depleted	O
single	O
-	O
cell	O
spleen	O
suspension	O
(	O
2	O
.	O
5	O
x	O
107	O
cells	O
)	O
(	O
Castro	O
et	O
al	O
.	O
,	O
2000	O
)	O
from	O
DO11	O
.	O
10	O
WT	O
or	O
STAT	B-Protein
-	O
deficient	O
mice	O
.	O

After	O
48	O
hr	O
,	O
they	O
were	O
injected	O
subcutaneously	O
with	O
PBS	O
or	O
with	O
OVA	B-Protein
protein	O
(	O
5	O
mg	O
)	O
plus	O
LPS	O
(	O
5	O
mug	O
)	O
.	O

The	O
inguinal	O
lymph	O
nodes	O
were	O
removed	O
48	O
hr	O
later	O
.	O

A	O
single	O
-	O
cell	O
suspension	O
(	O
1	O
x	O
106	O
cells	O
)	O
was	O
restimulated	O
for	O
24	O
or	O
48	O
hr	O
with	O
1	O
muM	O
or	O
3	O
muM	O
of	O
OVA	B-Protein
and	O
with	O
BrefeldinA	O
for	O
the	O
last	O
6	O
hr	O
.	O

Half	O
of	O
the	O
supernatant	O
was	O
removed	O
before	O
the	O
addition	O
of	O
BrefeldinA	O
for	O
use	O
in	O
an	O
ELISA	O
assay	O
.	O

The	O
cells	O
were	O
fixed	O
and	O
stained	O
as	O
before	O
.	O

Those	O
positive	O
for	O
KJ1	B-Protein
-	I-Protein
26	I-Protein
-	O
Bio	O
and	O
for	O
CD4	B-Protein
-	O
PerCP	O
were	O
gated	O
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
staining	O
was	O
examined	O
for	O
this	O
population	O
and	O
analyzed	O
as	O
before	O
.	O

Real	O
-	O
Time	O
Quantitative	O
RT	O
-	O
PCR	O

Cells	O
were	O
harvested	O
and	O
restimulated	O
in	O
the	O
presence	O
of	O
immobilized	O
anti	O
-	O
CD3	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
plus	O
anti	O
-	O
CD28	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
for	O
3	O
hr	O
or	O
immediately	O
lysed	O
.	O

RNA	O
was	O
extracted	O
and	O
reverse	O
-	O
transcribed	O
and	O
cDNA	O
was	O
analyzed	O
for	O
the	O
expression	O
of	O
cytokines	O
and	O
transcription	O
factors	O
by	O
real	O
-	O
time	O
PCR	O
assay	O
as	O
before	O
(	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Target	O
gene	O
mRNA	O
expression	O
was	O
quantified	O
either	O
with	O
SYBR	O
Green	O
(	O
Applied	O
Biosystems	O
)	O
or	O
with	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
and	O
normalized	O
to	O
ubiquitin	B-Protein
or	O
HPRT	B-Protein
mRNA	O
levels	O
,	O
respectively	O
.	O

Immunoblotting	O

Differentiated	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
rested	O
for	O
5	O
hr	O
in	O
1	O
%	O
FCS	O
-	O
containing	O
medium	O
and	O
restimulated	O
as	O
described	O
for	O
specific	O
experiments	O
.	O

Cell	O
lysates	O
were	O
prepared	O
,	O
equal	O
amounts	O
of	O
protein	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
phosphorylated	O
or	O
total	O
ERK	B-Protein
and	O
actin	B-Protein
were	O
detected	O
as	O
described	O
before	O
(	O
Beinke	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

Differential	O
cytokine	O
regulation	O
by	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
in	O
Jurkat	O
T	O
-	O
cells	O

Background	O

Activator	O
protein	O
(	O
AP	O
)	O
-	O
1	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
largely	O
control	O
T	O
-	O
cell	O
activation	O
,	O
following	O
binding	O
of	O
foreign	O
antigens	O
to	O
the	O
T	O
-	O
cell	O
receptor	O
leading	O
to	O
cytokine	O
secretion	O
.	O

Elevated	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
such	O
as	O
TNF	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
are	O
associated	O
with	O
several	O
human	O
diseases	O
including	O
cystic	O
fibrosis	O
,	O
pulmonary	O
fibrosis	O
and	O
AIDS	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
transcription	O
factors	O
,	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
,	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
regulation	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

Results	O

Phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
exposure	O
resulted	O
in	O
an	O
up	O
-	O
regulation	O
of	O
AP	O
-	O
1	O
and	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
however	O
,	O
exposure	O
to	O
heat	O
killed	O
(	O
HK	O
)	O
Escherichia	O
.	O
coli	O
MG1655	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
NF	O
-	O
kappaB	O
activity	O
without	O
affecting	O
AP	O
-	O
1	O
.	O

The	O
cytokine	O
profile	O
revealed	O
an	O
up	O
-	O
regulation	O
of	O
the	O
chemokine	O
CXCL8	B-Protein
and	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
TNF	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
following	O
treatment	O
with	O
both	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
,	O
while	O
the	O
levels	O
of	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
10	I-Protein
were	O
not	O
affected	O
by	O
PMA	O
but	O
were	O
significantly	O
down	O
-	O
regulated	O
by	O
HK	O
E	O
.	O
coli	O
.	O

AP	O
-	O
1	O
activation	O
was	O
significantly	O
increased	O
2	O
h	O
after	O
PMA	O
exposure	O
and	O
continued	O
to	O
increase	O
thereafter	O
.	O

In	O
contrast	O
,	O
NF	O
-	O
kappaB	O
responded	O
to	O
PMA	O
exposure	O
by	O
a	O
rapid	O
up	O
-	O
regulation	O
followed	O
by	O
a	O
subsequent	O
down	O
-	O
regulation	O
.	O

Increased	O
intracellular	O
Ca2	O
+	O
concentrations	O
countered	O
the	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
by	O
PMA	O
,	O
while	O
similar	O
treatment	O
with	O
calcium	O
ionophore	O
resulted	O
in	O
a	O
reduced	O
NF	O
-	O
kappaB	O
activity	O
following	O
induction	O
with	O
HK	O
E	O
.	O
coli	O
.	O

In	O
order	O
to	O
further	O
study	O
NF	O
-	O
kappaB	O
activation	O
,	O
we	O
considered	O
two	O
up	O
-	O
stream	O
signalling	O
proteins	O
,	O
PKC	O
and	O
Bcl10	B-Protein
.	O

Phosphorylated	O
-	O
PKC	O
levels	O
increased	O
in	O
response	O
to	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
,	O
while	O
Bcl10	B-Protein
levels	O
significantly	O
decreased	O
following	O
PMA	O
treatment	O
.	O

Using	O
an	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
,	O
we	O
observed	O
complete	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
while	O
CXCL8	B-Protein
levels	O
only	O
decreased	O
by	O
40	O
%	O
at	O
the	O
highest	O
concentration	O
.	O

Treatment	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
in	O
the	O
presence	O
of	O
JNK	O
-	O
inhibitor	O
suppressed	O
both	O
CXCL8	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
while	O
PKC	O
-	O
inhibitor	O
primarily	O
decreased	O
CXCL8	B-Protein
expression	O
.	O

Conclusion	O

The	O
present	O
study	O
shows	O
that	O
NF	O
-	O
kappaB	O
regulated	O
IL	B-Protein
-	I-Protein
6	I-Protein
but	O
not	O
CXCL8	B-Protein
.	O

This	O
complex	O
regulation	O
of	O
CXCL8	B-Protein
suggests	O
that	O
there	O
is	O
a	O
need	O
to	O
further	O
evaluate	O
the	O
signalling	O
pathways	O
in	O
order	O
to	O
develop	O
new	O
treatment	O
for	O
diseases	O
with	O
elevated	O
CXCL8	B-Protein
levels	O
,	O
such	O
as	O
AIDS	O
and	O
autoimmune	O
diseases	O
.	O

Cytokines	O
and	O
chemokines	O
are	O
important	O
in	O
immune	O
cell	O
recruitment	O
and	O
in	O
regulation	O
of	O
inflammatory	O
responses	O
[	O
1	O
]	O
.	O

T	O
-	O
cells	O
produce	O
a	O
broad	O
range	O
of	O
inflammatory	O
mediators	O
,	O
including	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	O
and	O
CXCL8	B-Protein
,	O
all	O
of	O
which	O
are	O
important	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
communication	O
and	O
initiation	O
of	O
inflammatory	O
responses	O
[	O
2	O
]	O
.	O

Elevated	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
such	O
as	O
TNF	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
,	O
are	O
associated	O
with	O
several	O
human	O
diseases	O
including	O
cystic	O
fibrosis	O
[	O
3	O
-	O
5	O
]	O
,	O
pulmonary	O
fibrosis	O
[	O
6	O
,	O
7	O
]	O
and	O
AIDS	O
[	O
8	O
,	O
9	O
]	O
.	O

Induction	O
of	O
CXCL8	B-Protein
has	O
been	O
suggested	O
to	O
be	O
mediated	O
through	O
NF	O
-	O
kappaB	O
in	O
cooperation	O
with	O
AP	O
-	O
1	O
[	O
10	O
,	O
11	O
]	O
,	O
however	O
the	O
precise	O
mechanism	O
is	O
not	O
fully	O
elucidated	O
,	O
and	O
treatment	O
strategies	O
aimed	O
at	O
inhibiting	O
CXCL8	B-Protein
have	O
failed	O
[	O
12	O
]	O
.	O

Persistent	O
production	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
leads	O
to	O
chronic	O
inflammation	O
and	O
enhanced	O
survival	O
of	O
lymphocytes	O
increasing	O
serum	O
cytokine	O
/	O
chemokine	O
levels	O
.	O

This	O
forms	O
the	O
basis	O
of	O
several	O
autoimmune	O
disorders	O
including	O
plasmacytosis	O
and	O
hyperplasia	O
[	O
13	O
]	O
.	O

To	O
develop	O
viable	O
CXCL8	B-Protein
based	O
treatment	O
strategies	O
,	O
it	O
is	O
necessary	O
to	O
identify	O
the	O
signalling	O
pathways	O
regulating	O
CXCL8	B-Protein
and	O
determine	O
how	O
this	O
is	O
coupled	O
to	O
NF	O
-	O
kappaB	O
,	O
AP	O
-	O
1	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

The	O
signalling	O
pathways	O
leading	O
to	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
activation	O
are	O
overlapping	O
,	O
where	O
both	O
are	O
involved	O
in	O
the	O
induction	O
and	O
regulation	O
of	O
cytokines	O
/	O
chemokines	O
.	O

NF	O
-	O
kappaB	O
is	O
activated	O
in	O
response	O
to	O
stress	O
,	O
such	O
as	O
oxidative	O
stress	O
,	O
bacterial	O
toxins	O
,	O
viruses	O
and	O
UV	O
light	O
[	O
14	O
]	O
,	O
and	O
is	O
essential	O
for	O
differentiation	O
,	O
proliferation	O
and	O
survival	O
of	O
many	O
cell	O
types	O
including	O
T	O
-	O
lymphocytes	O
[	O
15	O
]	O
.	O

AP	O
-	O
1	O
activation	O
requires	O
Fos	O
(	O
c	B-Protein
-	I-Protein
Fos	I-Protein
,	O
FosB	B-Protein
,	O
Fra	B-Protein
-	I-Protein
1	I-Protein
,	O
Fra	B-Protein
-	I-Protein
2	I-Protein
)	O
and	O
Jun	O
(	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
v	B-Protein
-	I-Protein
Jun	I-Protein
,	O
JunB	B-Protein
,	O
JunD	B-Protein
)	O
through	O
the	O
formation	O
of	O
homo	O
-	O
and	O
hetero	O
-	O
dimers	O
[	O
16	O
,	O
17	O
]	O
,	O
and	O
regulates	O
transcription	O
of	O
a	O
broad	O
range	O
of	O
genes	O
involved	O
in	O
immune	O
responses	O
[	O
18	O
-	O
21	O
]	O
.	O

Both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
binding	O
sites	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
[	O
12	O
,	O
22	O
]	O
,	O
however	O
,	O
the	O
mechanism	O
by	O
which	O
these	O
interleukins	O
are	O
regulated	O
in	O
T	O
-	O
cells	O
is	O
still	O
not	O
clear	O
.	O

CXCL8	B-Protein
is	O
a	O
C	O
-	O
X	O
-	O
C	O
chemokine	O
with	O
properties	O
enabling	O
it	O
to	O
recruit	O
T	O
-	O
cells	O
and	O
basophils	O
and	O
to	O
activate	O
neutrophils	O
and	O
monocytes	O
[	O
23	O
]	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
is	O
a	O
cytokine	O
that	O
possesses	O
both	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
characteristics	O
and	O
that	O
plays	O
a	O
key	O
role	O
in	O
haematopoiesis	O
and	O
acute	O
-	O
phase	O
responses	O
[	O
24	O
,	O
25	O
]	O
.	O

The	O
present	O
study	O
suggests	O
that	O
the	O
regulation	O
of	O
CXCL8	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
uncoupled	O
.	O

Using	O
Jurkat	O
T	O
-	O
cells	O
exposed	O
to	O
PMA	O
and	O
heat	O
killed	O
(	O
HK	O
)	O
Escherichia	O
coli	O
MG1655	O
in	O
combination	O
with	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
,	O
JNK	O
and	O
PKC	O
,	O
we	O
demonstrated	O
that	O
NF	O
-	O
kappaB	O
regulates	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
while	O
the	O
regulation	O
of	O
CXCL8	B-Protein
more	O
closely	O
correlated	O
to	O
AP	B-Protein
-	I-Protein
1	I-Protein
activity	O
.	O

These	O
results	O
indicate	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
is	O
not	O
an	O
effective	O
strategy	O
in	O
countering	O
the	O
high	O
CXCL8	B-Protein
activities	O
in	O
diseases	O
such	O
as	O
cystic	O
fibrosis	O
,	O
AIDS	O
and	O
pulmonary	O
fibrosis	O
.	O

Regulation	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
activation	O

The	O
transcription	O
factors	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
play	O
key	O
roles	O
in	O
the	O
initiation	O
of	O
an	O
inflammatory	O
response	O
by	O
inducing	O
the	O
expression	O
and	O
secretion	O
of	O
chemokines	O
and	O
cytokines	O
that	O
attract	O
and	O
activate	O
immune	O
cells	O
.	O

However	O
,	O
the	O
signal	O
transduction	O
pathways	O
and	O
subsequent	O
inflammatory	O
cytokine	O
induction	O
by	O
these	O
transcription	O
factors	O
is	O
not	O
fully	O
elucidated	O
.	O

The	O
present	O
study	O
is	O
aimed	O
at	O
determining	O
the	O
involvement	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
in	O
cytokine	O
induction	O
and	O
regulation	O
.	O

PMA	O
treatment	O
resulted	O
in	O
an	O
up	O
-	O
regulation	O
of	O
AP	O
-	O
1	O
after	O
2	O
h	O
exposure	O
and	O
continued	O
to	O
increase	O
throughout	O
the	O
analysis	O
period	O
(	O
figure	O
1a	O
)	O
.	O

HK	O
E	O
.	O
coli	O
treatment	O
did	O
not	O
affect	O
AP	O
-	O
1	O
activation	O
in	O
Jurkat	O
T	O
-	O
cells	O
(	O
figure	O
1b	O
)	O
.	O

To	O
determine	O
the	O
involvement	O
of	O
associated	O
pathways	O
,	O
we	O
exposed	O
cells	O
to	O
Ca2	O
+	O
ionophore	O
with	O
or	O
without	O
PMA	O
and	O
observed	O
a	O
modest	O
involvement	O
of	O
Ca2	O
+	O
in	O
PMA	O
-	O
dependent	O
AP	O
-	O
1	O
activation	O
(	O
figure	O
1c	O
)	O
while	O
Ca2	O
+	O
alone	O
did	O
not	O
alter	O
AP	O
-	O
1	O
activity	O
(	O
data	O
not	O
shown	O
)	O
.	O

Furthermore	O
,	O
AP	O
-	O
1	O
activity	O
decreased	O
in	O
a	O
TCR	O
-	O
deficient	O
Jurkat	O
cell	O
line	O
when	O
exposed	O
to	O
PMA	O
compared	O
to	O
the	O
parent	O
cell	O
line	O
indicating	O
that	O
regulation	O
of	O
AP	O
-	O
1	O
was	O
only	O
partially	O
T	O
-	O
cell	O
receptor	O
dependent	O
(	O
figure	O
1d	O
)	O
.	O

NF	O
-	O
kappaB	O
levels	O
showed	O
a	O
transient	O
increase	O
at	O
1	O
min	O
after	O
exposure	O
to	O
PMA	O
(	O
figure	O
2a	O
)	O
.	O

However	O
,	O
1	O
h	O
after	O
exposure	O
the	O
NF	O
-	O
kappaB	O
levels	O
began	O
to	O
drop	O
reaching	O
the	O
lowest	O
levels	O
by	O
6	O
h	O
,	O
after	O
which	O
they	O
increased	O
again	O
by	O
24	O
h	O
.	O

Exposure	O
of	O
Jurkat	O
T	O
-	O
cells	O
to	O
HK	O
E	O
.	O
coli	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
,	O
with	O
the	O
highest	O
activity	O
observed	O
at	O
a	O
relative	O
concentration	O
of	O
5	O
x	O
107	O
CFU	O
/	O
ml	O
(	O
figure	O
2b	O
)	O
.	O

The	O
time	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
HK	O
E	O
.	O
coli	O
was	O
assessed	O
further	O
using	O
the	O
optimal	O
concentration	O
obtained	O
from	O
figure	O
2b	O
and	O
showed	O
that	O
the	O
NF	O
-	O
kappaB	O
activity	O
increased	O
after	O
3	O
h	O
of	O
exposure	O
(	O
figure	O
2c	O
)	O
.	O

Furthermore	O
,	O
increased	O
intracellular	O
Ca2	O
+	O
reversed	O
the	O
PMA	O
dependent	O
NF	O
-	O
kappaB	O
inhibition	O
(	O
figure	O
2d	O
)	O
and	O
reduced	O
the	O
HK	O
E	O
.	O
coli	O
-	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
(	O
figure	O
2e	O
)	O
.	O

Induction	O
of	O
inflammatory	O
responses	O

The	O
ability	O
of	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
to	O
induce	O
an	O
inflammatory	O
response	O
in	O
Jurkat	O
T	O
-	O
cells	O
was	O
evaluated	O
using	O
a	O
multiplex	O
cytokine	O
assay	O
following	O
24	O
h	O
stimulation	O
.	O

The	O
cytokine	O
profile	O
revealed	O
an	O
enhanced	O
induction	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	O
and	O
the	O
chemokine	O
CXCL8	B-Protein
.	O

The	O
levels	O
of	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
10	I-Protein
were	O
unaffected	O
by	O
PMA	O
but	O
were	O
significantly	O
decreased	O
by	O
HK	O
E	O
.	O
coli	O
(	O
Table	O
1	O
)	O
.	O

These	O
results	O
confirmed	O
that	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
induced	O
an	O
inflammatory	O
response	O
in	O
the	O
Jurkat	O
T	O
-	O
cells	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
PMA	O
was	O
120	O
-	O
fold	O
more	O
effective	O
at	O
inducing	O
CXCL8	B-Protein
than	O
HK	O
E	O
.	O
coli	O
.	O

PMA	O
-	O
dependent	O
induction	O
of	O
AP	O
-	O
1	O
and	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
suggests	O
an	O
involvement	O
of	O
AP	O
-	O
1	O
in	O
CXCL8	B-Protein
regulation	O
.	O

Determination	O
of	O
the	O
time	O
course	O
of	O
cytokine	O
induction	O
in	O
response	O
to	O
PMA	O
showed	O
that	O
CXCL8	B-Protein
was	O
already	O
released	O
between	O
2	O
-	O
6	O
h	O
,	O
while	O
TNF	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
were	O
released	O
between	O
6	O
-	O
24	O
h	O
(	O
figure	O
3	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
cytokines	O
were	O
differentially	O
regulated	O
and	O
that	O
the	O
release	O
was	O
not	O
associated	O
with	O
the	O
early	O
transient	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
temporal	O
induction	O
of	O
AP	O
-	O
1	O
correlated	O
to	O
the	O
CXCL8	B-Protein
levels	O
and	O
preceded	O
the	O
TNF	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
release	O
.	O

This	O
suggests	O
an	O
association	O
between	O
CXCL8	B-Protein
release	O
and	O
AP	O
-	O
1	O
signalling	O
.	O

Cooperative	O
induction	O
of	O
cytokines	O
by	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O

To	O
further	O
characterize	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
cytokine	O
regulation	O
,	O
we	O
treated	O
cells	O
with	O
an	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
(	O
NAI	O
)	O
.	O

The	O
results	O
showed	O
that	O
NAI	O
selectively	O
down	O
-	O
regulated	O
NF	O
-	O
kappaB	O
activation	O
(	O
figures	O
4a	O
and	O
4b	O
)	O
and	O
did	O
not	O
alter	O
AP	O
-	O
1	O
activity	O
(	O
figures	O
4c	O
and	O
4d	O
)	O
.	O

Exposure	O
of	O
Jurkat	O
T	O
-	O
cells	O
to	O
NAI	O
resulted	O
in	O
a	O
modest	O
reduction	O
of	O
CXCL8	B-Protein
following	O
PMA	O
exposure	O
,	O
while	O
it	O
did	O
not	O
alter	O
the	O
CXCL8	B-Protein
release	O
following	O
HK	O
E	O
.	O
coli	O
exposure	O
(	O
figure	O
5a	O
)	O
.	O

NAI	O
did	O
not	O
affect	O
TNF	O
expression	O
(	O
figure	O
5b	O
)	O
indicating	O
that	O
NF	O
-	O
kappaB	O
is	O
not	O
the	O
main	O
regulator	O
of	O
CXCL8	B-Protein
or	O
TNF	O
following	O
either	O
PMA	O
or	O
HK	O
E	O
.	O
coli	O
exposure	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

In	O
contrast	O
,	O
NAI	O
resulted	O
in	O
a	O
complete	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
following	O
PMA	O
exposure	O
and	O
a	O
45	O
%	O
inhibition	O
following	O
HK	O
E	O
.	O
coli	O
exposure	O
(	O
figure	O
5c	O
)	O
,	O
suggesting	O
an	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
regulation	O
.	O

Ca2	O
+	O
was	O
observed	O
to	O
increase	O
AP	O
-	O
1	O
activity	O
(	O
figure	O
1c	O
)	O
and	O
reduce	O
NF	O
-	O
kappaB	O
activity	O
(	O
figure	O
2e	O
)	O
;	O
therefore	O
,	O
we	O
exposed	O
T	O
-	O
cells	O
to	O
a	O
PKC	O
inhibitor	O
together	O
with	O
PMA	O
to	O
determine	O
its	O
effect	O
on	O
cytokine	O
expression	O
.	O

Inhibition	O
of	O
PKC	O
reduced	O
CXCL8	B-Protein
release	O
from	O
7	O
ng	O
/	O
ml	O
to	O
3	O
ng	O
/	O
ml	O
while	O
it	O
had	O
a	O
modest	O
effect	O
on	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	O
(	O
figure	O
6a	O
-	O
c	O
)	O
.	O

This	O
prompted	O
us	O
to	O
test	O
the	O
effect	O
of	O
JNK	O
inhibition	O
on	O
PMA	O
-	O
induced	O
cytokine	O
expression	O
.	O

JNK	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
multitude	O
of	O
different	O
transcription	O
factors	O
,	O
including	O
the	O
phosphorylation	O
and	O
activation	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
c	B-Protein
-	I-Protein
Fos	I-Protein
and	O
p53	B-Protein
,	O
leading	O
to	O
cellular	O
apoptosis	O
[	O
26	O
]	O
.	O

Inhibition	O
of	O
the	O
JNK	O
pathways	O
resulted	O
in	O
a	O
down	O
-	O
regulation	O
of	O
both	O
CXCL8	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
while	O
no	O
clear	O
effect	O
was	O
observed	O
on	O
TNF	O
expression	O
(	O
figure	O
6a	O
-	O
c	O
)	O
.	O

Analysis	O
of	O
mRNA	O
levels	O
using	O
RT	O
-	O
qPCR	O
(	O
table	O
2	O
)	O
showed	O
that	O
PMA	O
induced	O
both	O
il	B-Protein
-	I-Protein
6	I-Protein
and	O
cxcl8	B-Protein
mRNA	O
(	O
5	O
.	O
1	O
-	O
fold	O
and	O
111	O
.	O
8	O
fold	O
respectively	O
)	O
.	O

Addition	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
NAI	O
and	O
the	O
JNK	O
inhibitor	O
reduced	O
the	O
il	B-Protein
-	I-Protein
6	I-Protein
expression	O
below	O
basal	O
levels	O
.	O

In	O
contrast	O
,	O
while	O
the	O
cxcl8	B-Protein
levels	O
were	O
suppressed	O
by	O
the	O
same	O
treatments	O
the	O
levels	O
remained	O
elevated	O
above	O
basal	O
level	O
.	O

NF	O
-	O
kappaB	O
inhibition	O
due	O
to	O
PKC	O
-	O
dependent	O
Bcl10	B-Protein
degradation	O

Western	O
blot	O
analysis	O
revealed	O
an	O
up	O
-	O
regulation	O
of	O
phosphorylated	O
-	O
PKC	O
after	O
24	O
h	O
treatment	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
or	O
HK	O
E	O
.	O
coli	O
(	O
figure	O
7a	O
)	O
,	O
while	O
IkappaBbeta	B-Protein
levels	O
remained	O
unaffected	O
(	O
figure	O
7b	O
)	O
.	O

Bcl10	B-Protein
is	O
a	O
signalling	O
protein	O
that	O
acts	O
upstream	O
of	O
NF	O
-	O
kappaB	O
in	O
concert	O
with	O
CARMA1	B-Protein
and	O
MALT1	B-Protein
and	O
has	O
been	O
suggested	O
to	O
directly	O
regulate	O
NF	O
-	O
kappaB	O
activity	O
in	O
T	O
-	O
cells	O
[	O
27	O
]	O
.	O

Therefore	O
,	O
Bcl10	B-Protein
activation	O
was	O
evaluated	O
in	O
both	O
control	O
and	O
PMA	O
stimulated	O
cells	O
after	O
10	O
min	O
,	O
1	O
h	O
,	O
6	O
h	O
,	O
and	O
24	O
h	O
using	O
western	O
blot	O
analysis	O
.	O

The	O
Bcl10	B-Protein
levels	O
decreased	O
following	O
treatment	O
with	O
PMA	O
,	O
while	O
in	O
control	O
cells	O
,	O
Bcl10	B-Protein
returned	O
to	O
higher	O
levels	O
by	O
24	O
h	O
(	O
figure	O
7c	O
)	O
.	O

This	O
suggests	O
that	O
Bcl10	B-Protein
is	O
involved	O
in	O
the	O
PMA	O
dependent	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
are	O
critical	O
regulators	O
of	O
inflammatory	O
responses	O
,	O
proliferation	O
and	O
differentiation	O
of	O
T	O
-	O
cells	O
[	O
28	O
-	O
30	O
]	O
,	O
however	O
,	O
the	O
signal	O
transduction	O
and	O
subsequent	O
cytokine	O
/	O
chemokine	O
expression	O
is	O
not	O
fully	O
understood	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
regulation	O
by	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
PMA	O
induced	O
AP	O
-	O
1	O
activation	O
,	O
indicating	O
a	O
specific	O
activation	O
of	O
the	O
MAPK	O
pathway	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
PMA	O
dependent	O
AP	O
-	O
1	O
activation	O
in	O
T	O
-	O
cells	O
was	O
delayed	O
(	O
>	O
2	O
h	O
)	O
and	O
increased	O
following	O
long	O
-	O
term	O
treatment	O
.	O

MAPK	O
is	O
one	O
of	O
the	O
main	O
signalling	O
pathways	O
in	O
T	O
-	O
cells	O
that	O
regulate	O
cell	O
-	O
and	O
transcriptional	O
activation	O
[	O
31	O
,	O
32	O
]	O
.	O

Several	O
studies	O
[	O
20	O
,	O
33	O
,	O
34	O
]	O
have	O
indicated	O
the	O
importance	O
of	O
AP	O
-	O
1	O
in	O
T	O
-	O
cell	O
activation	O
and	O
the	O
induction	O
of	O
inflammatory	O
responses	O
[	O
35	O
]	O
,	O
including	O
pro	O
-	O
inflammatory	O
cytokine	O
release	O
.	O

In	O
contrast	O
to	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappaB	O
activity	O
rapidly	O
increased	O
(	O
1	O
min	O
)	O
during	O
PMA	O
exposure	O
followed	O
by	O
a	O
down	O
-	O
regulation	O
to	O
the	O
lowest	O
levels	O
at	O
6	O
h	O
.	O

This	O
is	O
in	O
line	O
with	O
Park	O
and	O
colleagues	O
[	O
36	O
]	O
who	O
demonstrated	O
a	O
rapid	O
increase	O
in	O
NF	O
-	O
kappaB	O
activity	O
following	O
short	O
-	O
term	O
stimulation	O
with	O
PMA	O
,	O
but	O
prolonged	O
challenge	O
resulted	O
in	O
a	O
persistent	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
.	O

They	O
showed	O
that	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
was	O
due	O
to	O
PKC	O
-	O
dependent	O
degradation	O
of	O
IkappaB	B-Protein
kinase	I-Protein
beta	I-Protein
and	O
gamma	B-Protein
in	O
response	O
to	O
PMA	O
.	O

Interestingly	O
,	O
the	O
HK	O
E	O
.	O
coli	O
exposure	O
induced	O
NF	O
-	O
kappaB	O
activation	O
without	O
affecting	O
AP	O
-	O
1	O
activity	O
.	O

Wang	O
and	O
colleagues	O
[	O
37	O
]	O
reported	O
an	O
elevated	O
inflammatory	O
response	O
by	O
obtaining	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
following	O
the	O
exposure	O
of	O
T	O
-	O
cells	O
to	O
peptidoglycan	O
.	O

Reduction	O
in	O
NF	O
-	O
kappaB	O
by	O
calcium	O
ionophore	O
following	O
HK	O
E	O
.	O
coli	O
stimulation	O
may	O
be	O
due	O
to	O
the	O
Ca2	O
+	O
binding	O
protein	O
calmodulin	O
(	O
CaM	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
negatively	O
regulate	O
c	B-Protein
-	I-Protein
Rel	I-Protein
when	O
activated	O
[	O
38	O
]	O
.	O

The	O
regulation	O
of	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
observed	O
in	O
the	O
present	O
study	O
was	O
in	O
agreement	O
with	O
earlier	O
studies	O
.	O

T	O
-	O
cells	O
produce	O
a	O
broad	O
range	O
of	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
CXCL8	B-Protein
,	O
TNF	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
in	O
response	O
to	O
infections	O
or	O
other	O
stress	O
factors	O
[	O
39	O
]	O
.	O

The	O
assessment	O
of	O
Jurkat	O
T	O
-	O
cell	O
inflammatory	O
responses	O
(	O
Table	O
1	O
)	O
revealed	O
an	O
enhanced	O
IL	B-Protein
-	I-Protein
2	I-Protein
expression	O
upon	O
exposure	O
to	O
PMA	O
or	O
HK	O
E	O
.	O
coli	O
due	O
to	O
PKC	O
activation	O
[	O
40	O
]	O
.	O

In	O
addition	O
to	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
AP	O
-	O
1	O
binding	O
sites	O
have	O
been	O
identified	O
in	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
region	O
,	O
indicating	O
multiple	O
regulation	O
[	O
22	O
]	O
.	O

AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
have	O
also	O
been	O
demonstrated	O
to	O
regulate	O
CXCL8	B-Protein
expression	O
during	O
induction	O
of	O
inflammatory	O
responses	O
in	O
T	O
-	O
cells	O
[	O
12	O
]	O
.	O

Furthermore	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
gene	O
-	O
expression	O
is	O
associated	O
with	O
an	O
early	O
immune	O
response	O
in	O
Jurkat	O
T	O
-	O
cells	O
[	O
41	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
both	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
resulted	O
in	O
comparable	O
increases	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
while	O
PMA	O
was	O
more	O
potent	O
at	O
activating	O
CXCL8	B-Protein
release	O
.	O

PMA	O
and	O
HK	O
E	O
.	O
coli	O
treatment	O
also	O
induced	O
TNF	O
expression	O
.	O

TNF	O
is	O
one	O
of	O
the	O
first	O
cytokines	O
induced	O
by	O
T	O
-	O
cells	O
[	O
42	O
]	O
and	O
its	O
expression	O
is	O
regulated	O
by	O
calcineurin	O
,	O
NFAT	O
and	O
ATF	B-Protein
-	I-Protein
2	I-Protein
/	O
Jun	O
[	O
20	O
]	O
.	O

However	O
,	O
PMA	O
-	O
stimulated	O
Jurkat	O
T	O
-	O
cells	O
showed	O
no	O
difference	O
in	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
indicating	O
an	O
induced	O
inflammatory	O
response	O
.	O

HK	O
E	O
.	O
coli	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
.	O

The	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
10	I-Protein
is	O
known	O
to	O
inhibit	O
T	O
-	O
cell	O
activation	O
,	O
proliferation	O
and	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
such	O
as	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
and	O
INF	B-Protein
-	I-Protein
gamma	I-Protein
[	O
39	O
,	O
43	O
]	O
and	O
regulate	O
inflammatory	O
responses	O
by	O
inducing	O
T	O
-	O
cell	O
anergy	O
[	O
44	O
]	O
.	O

The	O
time	O
course	O
analysis	O
of	O
cytokine	O
expression	O
showed	O
a	O
correlation	O
between	O
AP	O
-	O
1	O
and	O
the	O
chemokine	O
CXCL8	B-Protein
where	O
CXCL8	O
expression	O
was	O
significantly	O
elevated	O
already	O
at	O
2	O
-	O
6	O
h	O
after	O
PMA	O
exposure	O
.	O

The	O
CXCL8	O
expression	O
did	O
not	O
correlate	O
with	O
the	O
early	O
NF	O
-	O
kappaB	O
activation	O
(	O
1	O
min	O
)	O
or	O
with	O
the	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
at	O
2	O
h	O
post	O
exposure	O
.	O

Both	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	O
expression	O
were	O
up	O
regulated	O
between	O
6	O
-	O
24	O
h	O
.	O

During	O
this	O
period	O
,	O
NF	O
-	O
kappaB	O
increased	O
from	O
its	O
minimum	O
level	O
at	O
6	O
h	O
.	O

PKC	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
the	O
activation	O
of	O
AP	O
-	O
1	O
,	O
but	O
not	O
with	O
NF	O
-	O
kappaB	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
[	O
45	O
]	O
.	O

Mutation	O
of	O
the	O
NF	O
-	O
kappaB	O
site	O
did	O
not	O
affect	O
IL	B-Protein
-	I-Protein
2	I-Protein
expression	O
,	O
whereas	O
mutation	O
of	O
the	O
AP	O
-	O
1	O
site	O
or	O
PKC	O
depletion	O
almost	O
revoked	O
IL	B-Protein
-	I-Protein
2	I-Protein
release	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
MAPK	O
pathway	O
and	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
play	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
inflammatory	O
responses	O
in	O
Jurkat	O
T	O
-	O
cells	O
[	O
12	O
,	O
20	O
,	O
22	O
]	O
.	O

The	O
obtained	O
results	O
signify	O
that	O
CXCL8	O
was	O
primarily	O
regulated	O
through	O
the	O
MAPK	O
pathway	O
.	O

The	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
(	O
NAI	O
)	O
showed	O
specificity	O
against	O
NF	O
-	O
kappaB	O
and	O
resulted	O
in	O
a	O
complete	O
IL	B-Protein
-	I-Protein
6	I-Protein
inhibition	O
following	O
induction	O
with	O
PMA	O
and	O
significant	O
IL	B-Protein
-	I-Protein
6	I-Protein
reduction	O
after	O
HK	O
E	O
.	O
coli	O
treatment	O
.	O

CXCL8	O
was	O
highly	O
up	O
regulated	O
by	O
PMA	O
and	O
the	O
addition	O
of	O
NAI	O
resulted	O
in	O
a	O
minor	O
reduction	O
in	O
CXCL8	B-Protein
expression	O
.	O

Furthermore	O
,	O
CXCL8	B-Protein
expression	O
was	O
not	O
affected	O
by	O
NAI	O
following	O
HK	O
E	O
.	O
coli	O
treatment	O
,	O
indicating	O
a	O
lack	O
of	O
correlation	O
between	O
CXCL8	B-Protein
and	O
NF	O
-	O
kappaB	O
.	O

Further	O
analysis	O
of	O
CXCL8	B-Protein
expression	O
revealed	O
a	O
down	O
-	O
regulation	O
by	O
PKC	O
-	O
and	O
JNK	O
-	O
inhibitors	O
,	O
suggesting	O
an	O
involvement	O
of	O
AP	O
-	O
1	O
via	O
PKC	O
and	O
JNK	O
,	O
respectively	O
.	O

Analysis	O
of	O
gene	O
expression	O
further	O
confirmed	O
that	O
il	B-Protein
-	I-Protein
6	I-Protein
and	O
cxcl8	B-Protein
were	O
upregulated	O
by	O
PMA	O
.	O

Expression	O
of	O
il	B-Protein
-	I-Protein
6	I-Protein
dropped	O
below	O
basal	O
levels	O
following	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
and	O
JNK	O
whereas	O
cxcl8	B-Protein
remained	O
elevated	O
above	O
basal	O
levels	O
(	O
16	O
.	O
5	O
-	O
fold	O
and	O
7	O
.	O
1	O
-	O
fold	O
respectively	O
)	O
following	O
the	O
same	O
treatment	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
PKC	O
did	O
not	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
il	B-Protein
-	I-Protein
6	I-Protein
or	O
cxcl8	B-Protein
,	O
which	O
is	O
in	O
accordance	O
with	O
protein	O
data	O
(	O
figure	O
6	O
)	O
.	O

These	O
results	O
suggest	O
that	O
NF	O
-	O
kappaB	O
is	O
involved	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
regulation	O
and	O
release	O
while	O
it	O
is	O
not	O
required	O
for	O
the	O
expression	O
of	O
CXCL8	B-Protein
in	O
Jurkat	O
T	O
cells	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
responsible	O
for	O
a	O
rapid	O
immune	O
response	O
which	O
is	O
followed	O
by	O
an	O
increase	O
in	O
transcription	O
of	O
IkappaB	O
thus	O
inhibiting	O
NF	O
-	O
kappaB	O
[	O
46	O
]	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
in	O
Jurkat	O
T	O
-	O
cells	O
is	O
dependent	O
on	O
Bcl10	B-Protein
activation	O
,	O
which	O
in	O
turn	O
is	O
regulated	O
by	O
PKC	O
.	O

Recent	O
studies	O
have	O
established	O
the	O
importance	O
of	O
a	O
protein	O
complex	O
consisting	O
of	O
CARMA1	B-Protein
,	O
Bcl10	B-Protein
and	O
MALT1	B-Protein
(	O
CBM	O
)	O
,	O
in	O
the	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

Investigating	O
Bcl10	B-Protein
,	O
Scharschmidt	O
and	O
colleagues	O
[	O
47	O
]	O
demonstrated	O
that	O
it	O
is	O
a	O
critical	O
regulator	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

Down	O
-	O
regulation	O
of	O
Bcl10	B-Protein
from	O
signals	O
transduced	O
via	O
the	O
TCR	O
/	O
CD28	B-Protein
and	O
PKC	O
resulted	O
in	O
a	O
concomitant	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
.	O

They	O
suggested	O
that	O
Bcl10	B-Protein
is	O
initially	O
activated	O
by	O
TCR	O
/	O
PKC	O
but	O
that	O
continued	O
activation	O
(	O
>	O
1	O
h	O
)	O
promotes	O
its	O
degradation	O
.	O

Narayan	O
and	O
colleagues	O
[	O
27	O
]	O
suggested	O
that	O
deletion	O
in	O
any	O
of	O
the	O
three	O
CBM	O
complex	O
proteins	O
impairs	O
antigen	O
-	O
receptor	O
dependent	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

They	O
showed	O
that	O
NF	O
-	O
kappaB	O
activation	O
via	O
Akt	O
requires	O
CARMA1	B-Protein
and	O
acts	O
in	O
cooperation	O
with	O
PKC	O
following	O
short	O
-	O
term	O
exposure	O
(	O
30	O
min	O
)	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
.	O

Akt	O
phosphorylates	O
and	O
thus	O
activates	O
Bcl10	B-Protein
.	O

These	O
studies	O
indicate	O
that	O
PKC	O
is	O
crucial	O
for	O
NF	O
-	O
kappaB	O
activation	O
following	O
short	O
-	O
term	O
treatment	O
through	O
signals	O
via	O
membrane	O
bound	O
receptors	O
such	O
as	O
the	O
TCR	O
and	O
the	O
co	O
-	O
stimulatory	O
receptor	O
CD28	B-Protein
.	O

Thus	O
,	O
the	O
CBM	O
complex	O
proteins	O
play	O
a	O
key	O
role	O
in	O
this	O
signalling	O
process	O
.	O

PMA	O
diffuses	O
into	O
the	O
cytosol	O
and	O
directly	O
activates	O
PKC	O
since	O
it	O
is	O
an	O
analogue	O
to	O
diacylglycerol	O
[	O
48	O
]	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
inhibition	O
of	O
PKC	O
blocks	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
activity	O
,	O
suggesting	O
a	O
direct	O
regulation	O
of	O
these	O
transcription	O
factors	O
by	O
PKC	O
[	O
49	O
,	O
50	O
]	O
.	O

PKC	O
is	O
activated	O
at	O
an	O
early	O
stage	O
following	O
T	O
-	O
cell	O
stimulation	O
and	O
is	O
therefore	O
an	O
important	O
regulator	O
of	O
downstream	O
inflammatory	O
signalling	O
pathways	O
leading	O
to	O
cytokine	O
expression	O
[	O
50	O
]	O
.	O

We	O
have	O
shown	O
that	O
phosphorylated	O
-	O
PKC	O
is	O
up	O
regulated	O
in	O
response	O
to	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
,	O
indicating	O
an	O
association	O
between	O
PKC	O
and	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
.	O

Bcl10	B-Protein
levels	O
were	O
down	O
-	O
regulated	O
following	O
extended	O
treatment	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
.	O

In	O
the	O
control	O
groups	O
,	O
a	O
loss	O
of	O
Bcl10	B-Protein
occurred	O
after	O
6	O
h	O
,	O
followed	O
by	O
an	O
increase	O
after	O
24	O
h	O
,	O
which	O
is	O
in	O
accordance	O
with	O
the	O
observed	O
NF	O
-	O
kappaB	O
activity	O
(	O
figure	O
7	O
)	O
.	O

These	O
results	O
are	O
supported	O
by	O
an	O
earlier	O
study	O
[	O
47	O
]	O
,	O
demonstrating	O
that	O
prolonged	O
PKC	O
activation	O
by	O
PMA	O
leads	O
to	O
an	O
inhibition	O
of	O
Bcl10	B-Protein
and	O
NF	O
-	O
kappaB	O
.	O

It	O
has	O
been	O
shown	O
that	O
NF	O
-	O
kappaB	O
is	O
an	O
important	O
transcription	O
factor	O
complex	O
involved	O
in	O
almost	O
every	O
aspect	O
of	O
cell	O
regulation	O
including	O
apoptosis	O
,	O
differentiation	O
,	O
proliferation	O
and	O
initiation	O
of	O
immune	O
responses	O
[	O
51	O
-	O
53	O
]	O
.	O

NF	O
-	O
kappaB	O
is	O
constitutively	O
active	O
in	O
many	O
human	O
malignancies	O
,	O
which	O
makes	O
it	O
an	O
attractive	O
therapeutic	O
target	O
[	O
54	O
]	O
.	O

Elevated	O
CXCL8	B-Protein
levels	O
during	O
chronic	O
inflammation	O
result	O
in	O
an	O
enhanced	O
recruitment	O
of	O
immune	O
cells	O
to	O
the	O
site	O
of	O
infection	O
,	O
which	O
may	O
lead	O
to	O
the	O
development	O
of	O
autoimmune	O
diseases	O
following	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

In	O
HIV	O
infected	O
persons	O
,	O
serum	O
CXCL8	B-Protein
levels	O
are	O
elevated	O
and	O
this	O
could	O
recruit	O
more	O
T	O
-	O
cells	O
potentially	O
leading	O
to	O
a	O
more	O
rapid	O
progression	O
of	O
the	O
disease	O
since	O
there	O
will	O
be	O
more	O
T	O
-	O
cells	O
available	O
to	O
infect	O
.	O

In	O
the	O
present	O
study	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
release	O
was	O
found	O
to	O
be	O
associated	O
with	O
NF	O
-	O
kappaB	O
activity	O
while	O
CXCL8	B-Protein
release	O
more	O
closely	O
correlated	O
with	O
AP	O
-	O
1	O
activity	O
.	O

Treatment	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
was	O
more	O
potent	O
than	O
HK	O
E	O
.	O
coli	O
at	O
elevating	O
the	O
CXCL8	B-Protein
levels	O
.	O

PMA	O
induced	O
AP	O
-	O
1	O
activation	O
and	O
down	O
-	O
regulated	O
NF	O
-	O
kappaB	O
while	O
HK	O
E	O
.	O
coli	O
up	O
-	O
regulated	O
NF	O
-	O
kappaB	O
without	O
affecting	O
AP	O
-	O
1	O
activity	O
.	O

In	O
addition	O
,	O
the	O
temporal	O
induction	O
pattern	O
of	O
AP	O
-	O
1	O
correlated	O
to	O
the	O
release	O
of	O
CXCL8	B-Protein
while	O
IL	B-Protein
-	I-Protein
6	I-Protein
followed	O
the	O
NF	O
-	O
kappaB	O
activity	O
.	O

Likewise	O
,	O
blocking	O
NF	O
-	O
kappaB	O
activation	O
resulted	O
in	O
a	O
complete	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
while	O
the	O
CXCL8	B-Protein
levels	O
remained	O
elevated	O
as	O
shown	O
both	O
at	O
the	O
protein	O
and	O
mRNA	O
level	O
.	O

Furthermore	O
,	O
the	O
CXCL8	B-Protein
release	O
was	O
down	O
-	O
regulated	O
by	O
inhibition	O
of	O
JNK	O
activity	O
.	O

The	O
present	O
study	O
indicates	O
that	O
in	O
Jurkat	O
T	O
-	O
cells	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
regulated	O
through	O
NF	O
-	O
kappaB	O
while	O
CXCL8	B-Protein
regulation	O
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
and	O
closely	O
associated	O
with	O
AP	O
-	O
1	O
activation	O
.	O

Chemicals	O

The	O
following	O
chemicals	O
were	O
used	O
in	O
the	O
present	O
study	O
:	O
PMA	O
(	O
Phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
,	O
(	O
Sigma	O
#	O
P1585	O
,	O
USA	O
)	O
)	O
;	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
(	O
NAI	O
)	O
,	O
(	O
InSolution	O
(	O
TM	O
)	O
NF	O
-	O
kappaB	O
Activation	O
Inhibitor	O
,	O
Calbiochem	O
#	O
481407	O
,	O
USA	O
)	O
;	O
JNK	O
inhibitor	O
,	O
(	O
InSolution	O
(	O
TM	O
)	O
JNK	O
Inhibitor	O
II	O
,	O
Calbiochem	O
#	O
420128	O
,	O
USA	O
)	O
;	O
PKC	O
Inhibitor	O
,	O
(	O
InSolution	O
(	O
TM	O
)	O
Bisindolylmaleimide	O
I	O
,	O
Calbiochem	O
#	O
203293	O
,	O
USA	O
)	O
;	O
Calcium	O
Ionophore	O
,	O
(	O
Calcium	O
Ionophore	O
A23187	O
mixed	O
calcium	O
magnesium	O
salt	O
,	O
Sigma	O
#	O
C5149	O
,	O
USA	O
)	O
.	O

Heat	O
killed	O
(	O
HK	O
)	O
Escherichia	O
coli	O

E	O
.	O
coli	O
MG1655	O
were	O
grown	O
on	O
Luria	O
-	O
Bertani	O
(	O
LB	O
)	O
agar	O
and	O
incubated	O
at	O
37degreesC	O
overnight	O
.	O

One	O
colony	O
was	O
inoculated	O
into	O
10	O
ml	O
LB	O
broth	O
and	O
incubated	O
on	O
a	O
shaker	O
(	O
200	O
rpm	O
)	O
at	O
37degreesC	O
overnight	O
.	O

The	O
bacteria	O
were	O
centrifuged	O
for	O
10	O
min	O
at	O
3000	O
x	O
g	O
,	O
washed	O
with	O
3	O
ml	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
;	O
8	O
g	O
NaCl	O
,	O
1	O
.	O
16	O
g	O
Na2HPO4	O
,	O
0	O
.	O
2	O
g	O
KH2PO4	O
,	O
0	O
.	O
2	O
g	O
KCl	O
,	O
pH7	O
)	O
and	O
resuspended	O
in	O
50	O
mul	O
PBS	O
.	O

The	O
bacteria	O
were	O
killed	O
by	O
heating	O
to	O
70degreesC	O
for	O
1	O
h	O
.	O

To	O
ensure	O
that	O
the	O
bacteria	O
were	O
killed	O
;	O
10	O
mul	O
of	O
the	O
heat	O
-	O
killed	O
suspension	O
was	O
spread	O
on	O
a	O
LB	O
plate	O
and	O
incubated	O
overnight	O
at	O
37degreesC	O
.	O

Cell	O
culturing	O
,	O
transfection	O
and	O
stimulation	O

Jurkat	O
T	O
-	O
cells	O
(	O
wild	O
type	O
and	O
TCR	O
deficient	O
-	O
TCR	O
-	O
/	O
-	O
)	O
were	O
maintained	O
in	O
90	O
%	O
RPMI	O
1640	O
medium	O
(	O
PAA	O
laboratories	O
,	O
Austria	O
)	O
with	O
1	O
.	O
5	O
mM	O
L	O
-	O
glutamine	O
(	O
Invitrogen	O
,	O
USA	O
)	O
,	O
10	O
%	O
foetal	O
bovine	O
serum	O
(	O
Invitrogen	O
,	O
USA	O
)	O
and	O
1	O
%	O
antibiotic	O
-	O
antimycotic	O
(	O
Invitrogen	O
,	O
USA	O
)	O
and	O
incubated	O
in	O
a	O
stable	O
environment	O
of	O
5	O
%	O
CO2	O
at	O
37degreesC	O
.	O

The	O
cells	O
were	O
centrifuged	O
at	O
1000	O
x	O
g	O
for	O
8	O
min	O
and	O
resuspended	O
in	O
fresh	O
media	O
to	O
a	O
final	O
cell	O
density	O
of	O
1	O
.	O
6	O
x	O
107	O
cells	O
/	O
ml	O
in	O
a	O
24	O
-	O
well	O
plate	O
.	O

Reporter	O
plasmid	O
(	O
pNFkappaB	O
-	O
Luc	O
,	O
pAP1	O
(	O
PMA	O
)	O
-	O
TA	O
-	O
Luc	O
,	O
pNFkappaB	O
-	O
SEAP	O
)	O
,	O
internal	O
control	O
plasmid	O
(	O
pRL	O
)	O
(	O
Promega	O
,	O
USA	O
)	O
and	O
lipofectamine	O
2000	O
(	O
Invitrogen	O
,	O
USA	O
)	O
were	O
added	O
to	O
each	O
well	O
at	O
0	O
.	O
54	O
mug	O
/	O
well	O
,	O
0	O
.	O
06	O
mug	O
/	O
well	O
and	O
1	O
.	O
5	O
mul	O
/	O
well	O
,	O
respectively	O
.	O

Initially	O
,	O
the	O
reporter	O
plasmid	O
and	O
pRL	O
were	O
mixed	O
separately	O
with	O
OptiMEM	O
(	O
Gibco	O
,	O
USA	O
)	O
.	O

After	O
5	O
min	O
of	O
incubation	O
at	O
room	O
temperature	O
,	O
lipofectamine	O
2000	O
was	O
added	O
and	O
the	O
mixture	O
was	O
incubated	O
further	O
for	O
20	O
min	O
at	O
room	O
temperature	O
.	O

The	O
transfection	O
was	O
allowed	O
to	O
proceed	O
overnight	O
at	O
37degreesC	O
,	O
after	O
which	O
,	O
the	O
cells	O
were	O
centrifuged	O
,	O
the	O
media	O
removed	O
and	O
fresh	O
pre	O
-	O
warmed	O
media	O
added	O
.	O

The	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
NF	O
-	O
kappaB	O
,	O
JNK	O
and	O
PKC	O
inhibitors	O
and	O
stimulated	O
in	O
24	O
-	O
well	O
plates	O
with	O
different	O
concentrations	O
of	O
PMA	O
,	O
HK	O
E	O
.	O
coli	O
MG1655	O
and	O
Calcium	O
Ionophore	O
A23187	O
.	O

The	O
cells	O
were	O
lysed	O
and	O
luciferase	B-Protein
activity	O
(	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
)	O
was	O
measured	O
using	O
the	O
Dual	O
-	O
Luciferase	O
(	O
R	O
)	O
reporter	O
assay	O
system	O
(	O
Promega	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
on	O
a	O
TD	O
20	O
/	O
20	O
luminometer	O
(	O
Turner	O
Designs	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
.	O

Secreted	O
alkaline	O
phosphatase	O
(	O
NFkappaB	O
-	O
SEAP	O
,	O
figure	O
4a	O
,	O
b	O
)	O
levels	O
were	O
measured	O
using	O
Great	O
EscAPe	O
(	O
TM	O
)	O
SEAP	O
Detection	O
Kit	O
(	O
Clontech	O
,	O
USA	O
)	O
.	O

Multiplex	O
cytokine	O
assay	O

Quantification	O
of	O
the	O
levels	O
of	O
cytokines	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
TNF	O
and	O
the	O
chemokine	O
CXCL8	B-Protein
was	O
performed	O
on	O
culture	O
supernatants	O
using	O
multiplexed	O
biomarker	O
immunoassay	O
kits	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

A	O
Bio	O
-	O
Plex	O
(	O
TM	O
)	O
200	O
readout	O
System	O
was	O
used	O
(	O
Bio	O
-	O
Rad	O
)	O
,	O
which	O
utilizes	O
Luminex	O
(	O
R	O
)	O
xMAP	O
(	O
TM	O
)	O
fluorescent	O
bead	O
-	O
based	O
technology	O
(	O
Luminex	O
Corp	O
.	O
,	O
Austin	O
)	O
.	O

Levels	O
were	O
automatically	O
calculated	O
from	O
standard	O
curves	O
using	O
Bio	O
-	O
Plex	O
Manager	O
software	O
(	O
v	O
.	O
4	O
.	O
1	O
.	O
1	O
,	O
Bio	O
-	O
Rad	O
)	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O

ELISA	O
was	O
performed	O
on	O
supernatants	O
from	O
challenged	O
Jurkat	O
T	O
-	O
cells	O
to	O
quantify	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
CXCL8	B-Protein
and	O
TNF	O
(	O
BD	O
OptEIA	O
Human	O
IL	B-Protein
-	I-Protein
6	I-Protein
Elisa	O
Set	O
,	O
BD	O
OptEIA	O
Human	O
CXCL8	B-Protein
Elisa	O
Set	O
and	O
BD	O
OptEIA	O
Human	O
TNF	B-Protein
Elisa	O
Set	O
,	O
Biosciences	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Briefly	O
,	O
Jurkat	O
T	O
-	O
cells	O
were	O
stimulated	O
with	O
PMA	O
(	O
162	O
nM	O
)	O
for	O
1	O
h	O
,	O
centrifuged	O
(	O
1000	O
x	O
g	O
,	O
8	O
min	O
)	O
and	O
the	O
supernatants	O
were	O
collected	O
and	O
stored	O
at	O
-	O
80degreesC	O
until	O
use	O
.	O

Following	O
centrifugation	O
,	O
the	O
cells	O
were	O
resuspended	O
in	O
1	O
h	O
aged	O
media	O
,	O
where	O
cells	O
have	O
been	O
grown	O
in	O
,	O
containing	O
PMA	O
.	O

The	O
same	O
procedure	O
was	O
performed	O
to	O
collect	O
media	O
after	O
2	O
h	O
and	O
6	O
h	O
.	O

The	O
final	O
collection	O
of	O
media	O
was	O
performed	O
after	O
24	O
h	O
.	O

Western	O
blot	O
analysis	O

Following	O
stimulation	O
,	O
Jurkat	O
T	O
-	O
cells	O
were	O
centrifuged	O
at	O
1000	O
x	O
g	O
for	O
8	O
min	O
and	O
lysed	O
on	O
ice	O
for	O
2	O
h	O
using	O
sodium	O
hydroxide	O
with	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
,	O
Mannheim	O
)	O
.	O

The	O
cells	O
were	O
further	O
centrifuged	O
at	O
8000	O
x	O
g	O
,	O
4degreesC	O
for	O
10	O
min	O
and	O
the	O
supernatants	O
were	O
transferred	O
to	O
new	O
tubes	O
.	O

Cytoplasmic	O
proteins	O
(	O
~	O
8	O
mug	O
)	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
(	O
10	O
%	O
)	O
followed	O
by	O
western	O
blotting	O
using	O
anti	O
-	O
IkappaBbeta	O
,	O
phospho	O
-	O
PKC	O
(	O
pan	O
)	O
(	O
zeta	O
Thr410	O
)	O
(	O
190D10	O
)	O
,	O
anti	O
-	O
Bcl10	O
(	O
Cell	O
Signalling	O
Technology	O
,	O
Boston	O
)	O
and	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
Abcam	O
,	O
Cambridge	O
)	O
.	O

Detection	O
was	O
performed	O
following	O
incubation	O
with	O
ECL	O
(	O
TM	O
)	O
Anti	O
-	O
rabbit	O
IgG	O
,	O
horseradish	O
peroxidase	O
linked	O
whole	O
antibodies	O
(	O
Amersham	O
Biosciences	O
,	O
Buckinghamshire	O
)	O
and	O
developed	O
using	O
ECL	O
(	O
TM	O
)	O
Western	O
Blotting	O
Detection	O
Reagents	O
(	O
GE	O
Healthcare	O
,	O
UK	O
)	O
.	O

RNA	O
extraction	O

Jurkat	O
T	O
-	O
cells	O
were	O
treated	O
with	O
NF	O
-	O
kappaB	O
,	O
JNK	O
and	O
PKC	O
inhibitors	O
for	O
2	O
h	O
in	O
6	O
-	O
well	O
plates	O
followed	O
by	O
stimulation	O
with	O
162	O
nM	O
PMA	O
for	O
24	O
h	O
.	O

At	O
sampling	O
the	O
cells	O
were	O
pelleted	O
followed	O
by	O
RNA	O
extraction	O
using	O
100	O
mul	O
TRI	O
-	O
reagent	O
(	O
Sigma	O
,	O
USA	O
)	O
.	O

This	O
was	O
followed	O
by	O
addition	O
of	O
100	O
mul	O
chloroform	O
/	O
isoamylalcohol	O
(	O
24	O
/	O
1	O
)	O
.	O

The	O
solutions	O
were	O
mixed	O
by	O
vortexing	O
followed	O
by	O
centrifugation	O
at	O
12	O
,	O
000	O
rpm	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

The	O
upper	O
phase	O
was	O
transferred	O
to	O
a	O
new	O
tube	O
followed	O
by	O
addition	O
of	O
100	O
mul	O
iso	O
-	O
propanol	O
and	O
incubated	O
at	O
room	O
temperature	O
for	O
10	O
min	O
.	O

RNA	O
was	O
then	O
pelleted	O
by	O
centrifugation	O
at	O
12	O
,	O
000	O
rpm	O
for	O
15	O
min	O
at	O
4degreesC	O
and	O
washed	O
with	O
70	O
%	O
ethanol	O
.	O

The	O
RNA	O
pellet	O
was	O
dissolved	O
in	O
25	O
mul	O
RNase	O
free	O
water	O
and	O
the	O
yield	O
and	O
ratio	O
(	O
A260	O
/	O
A280	O
)	O
was	O
determined	O
using	O
NanoVue	O
(	O
GE	O
Healthcare	O
,	O
UK	O
)	O
.	O

The	O
samples	O
were	O
stored	O
at	O
-	O
80degreesC	O
until	O
further	O
use	O
.	O

Reverse	O
transcription	O
quantitative	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O

RT	O
-	O
qPCR	O
was	O
used	O
to	O
determine	O
gene	O
expression	O
levels	O
of	O
il	B-Protein
-	I-Protein
6	I-Protein
and	O
cxcl8	B-Protein
in	O
response	O
to	O
PMA	O
following	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
,	O
JNK	O
and	O
PKC	O
.	O

The	O
following	O
primer	O
sequences	O
were	O
used	O
,	O
il	B-Protein
-	I-Protein
6	I-Protein
:	O
forward	O
-	O
TGTGAAAGCAGCAAAGAGGCACTG	O
,	O
reverse	O
-	O
ACAGCTCTGGCTTGTTCCTCACTA	O
;	O
cxcl8	B-Protein
:	O
forward	O
-	O
ACCACACTGCGCCAACACAGAAAT	O
,	O
reverse	O
-	O
AAACTTCTCCACAACCCTCTGCAC	O
.	O

Thermocycling	O
conditions	O
for	O
CYBR	O
Green	O
(	O
Quanta	O
,	O
USA	O
)	O
consisted	O
of	O
a	O
denaturation	O
step	O
for	O
10	O
min	O
at	O
95	O
degreesC	O
followed	O
by	O
60	O
cycles	O
of	O
95degreesC	O
for	O
1s	O
and	O
60degreesC	O
for	O
30s	O
.	O

Gene	O
expression	O
was	O
analysed	O
using	O
Stratagene	O
(	O
Mx3000p	O
(	O
TM	O
)	O
)	O
(	O
AH	O
diagnostics	O
)	O
.	O

The	O
obtained	O
Ct	O
values	O
were	O
normalized	O
against	O
18S	O
.	O

Initially	O
,	O
all	O
measured	O
18S	O
Ct	O
values	O
were	O
used	O
to	O
calculate	O
a	O
mean	O
Ct	O
value	O
that	O
was	O
used	O
to	O
determine	O
the	O
deltaCt	O
values	O
for	O
each	O
sample	O
.	O

Gene	O
expression	O
patterns	O
for	O
il	B-Protein
-	I-Protein
6	I-Protein
and	O
cxcl8	B-Protein
were	O
then	O
normalized	O
with	O
regard	O
to	O
the	O
samples	O
18S	O
deltaCt	O
.	O

Statistical	O
analysis	O

Statistical	O
significant	O
differences	O
were	O
determined	O
using	O
two	O
-	O
tailed	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

AP	O
-	O
1	O
activation	O
following	O
long	O
-	O
term	O
exposure	O
of	O
Jurkat	O
T	O
-	O
cells	O
to	O
PMA	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
transfected	O
with	O
luciferase	B-Protein
reporter	O
plasmids	O
containing	O
the	O
AP	O
-	O
1	O
cis	O
-	O
elements	O
.	O

(	O
A	O
)	O
Time	O
-	O
dependent	O
AP	O
-	O
1	O
activation	O
in	O
response	O
to	O
PMA	O
.	O

(	O
B	O
)	O
HK	O
E	O
.	O
coli	O
does	O
not	O
activate	O
AP	O
-	O
1	O
.	O

(	O
C	O
)	O
Dose	O
-	O
dependent	O
activation	O
of	O
AP	O
-	O
1	O
were	O
performed	O
using	O
PMA	O
alone	O
(	O
grey	O
bars	O
)	O
and	O
in	O
combination	O
with	O
calcium	O
ionophore	O
(	O
CaI	O
955	O
muM	O
,	O
black	O
bars	O
)	O
.	O

(	O
D	O
)	O
TCR	O
-	O
/	O
-	O
deficient	O
cells	O
responded	O
to	O
PMA	O
(	O
162	O
nM	O
)	O
by	O
up	O
-	O
regulating	O
AP	O
-	O
1	O
activity	O
.	O

Statistical	O
significance	O
from	O
the	O
control	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
4	O
)	O
.	O

Controls	O
were	O
arbitrarily	O
set	O
to	O
1	O
.	O

NF	O
-	O
kappaB	O
down	O
-	O
regulation	O
by	O
PMA	O
and	O
up	O
-	O
regulation	O
by	O
heat	O
killed	O
E	O
.	O
coli	O
MG1655	O
following	O
long	O
-	O
term	O
stimulation	O
.	O

Transfection	O
of	O
Jurkat	O
T	O
-	O
cells	O
was	O
performed	O
using	O
luciferase	B-Protein
reporter	O
plasmids	O
containing	O
NF	O
-	O
kappaB	O
cis	O
-	O
elements	O
.	O

(	O
A	O
)	O
Time	O
-	O
dependent	O
stimulation	O
of	O
Jurkat	O
T	O
-	O
cells	O
using	O
PMA	O
.	O

NF	O
-	O
kappaB	O
activation	O
was	O
evaluated	O
using	O
HK	O
E	O
.	O
coli	O
in	O
a	O
(	O
B	O
)	O
dose	O
-	O
and	O
(	O
C	O
)	O
time	O
-	O
dependant	O
manner	O
.	O

Calcium	O
ionophore	O
increased	O
NF	O
-	O
kappaB	O
activity	O
following	O
PMA	O
exposure	O
(	O
E	O
)	O
and	O
resulted	O
in	O
a	O
negative	O
regulation	O
in	O
response	O
to	O
HK	O
E	O
.	O
coli	O
stimulation	O
(	O
D	O
)	O
.	O

Statistical	O
significance	O
from	O
the	O
control	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
4	O
)	O
.	O

Controls	O
were	O
arbitrarily	O
set	O
to	O
1	O
.	O

CXCL8	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	O
expression	O
following	O
long	O
-	O
term	O
stimulation	O
with	O
PMA	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
either	O
treated	O
with	O
media	O
(	O
white	O
bars	O
)	O
or	O
stimulated	O
with	O
PMA	O
(	O
black	O
bars	O
)	O
and	O
incubated	O
for	O
1	O
h	O
,	O
2	O
h	O
,	O
6	O
h	O
and	O
24	O
h	O
.	O

Aged	O
media	O
was	O
added	O
following	O
each	O
centrifugation	O
step	O
representative	O
to	O
the	O
stimulation	O
time	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
.	O

Cytokine	O
levels	O
(	O
A	O
)	O
CXCL8	B-Protein
,	O
(	O
B	O
)	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
(	O
C	O
)	O
TNF	O
were	O
detected	O
by	O
ELISA	O
.	O

Statistical	O
significance	O
from	O
the	O
control	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
3	O
)	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
NAI	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
transfected	O
with	O
luciferase	B-Protein
reporter	O
plasmids	O
containing	O
either	O
NF	O
-	O
kappaB	O
or	O
AP	O
-	O
1	O
cis	O
-	O
acting	O
elements	O
.	O

The	O
cells	O
were	O
incubated	O
with	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
(	O
NAI	O
)	O
for	O
1	O
h	O
followed	O
by	O
stimulation	O
with	O
PMA	O
(	O
162	O
nM	O
,	O
A	O
and	O
C	O
)	O
or	O
HK	O
E	O
.	O
coli	O
(	O
5	O
x	O
107	O
CFU	O
/	O
ml	O
,	O
B	O
and	O
D	O
)	O
for	O
24	O
h	O
.	O

(	O
A	O
,	O
B	O
)	O
NF	O
-	O
kappaB	O
,	O
but	O
not	O
(	O
C	O
,	O
D	O
)	O
AP	O
-	O
1	O
was	O
inhibited	O
.	O

Statistical	O
significance	O
from	O
the	O
positive	O
control	O
(	O
PMA	O
/	O
HK	O
E	O
.	O
coli	O
)	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
4	O
)	O
.	O

Controls	O
were	O
set	O
to	O
1	O
.	O

Involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
cytokine	O
regulation	O
.	O

Cytokine	O
/	O
chemokine	O
levels	O
were	O
determined	O
using	O
ELISA	O
following	O
incubation	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
NAI	O
(	O
1	O
h	O
)	O
and	O
stimulation	O
(	O
24	O
h	O
)	O
.	O

(	O
A	O
)	O
CXCL8	B-Protein
expression	O
was	O
partially	O
inhibited	O
following	O
PMA	O
stimulation	O
(	O
grey	O
bars	O
)	O
,	O
whereas	O
the	O
levels	O
were	O
not	O
altered	O
following	O
stimulation	O
with	O
HK	O
E	O
.	O
coli	O
(	O
black	O
bars	O
)	O
,	O
this	O
indicates	O
an	O
induction	O
mainly	O
regulated	O
by	O
AP	O
-	O
1	O
.	O

(	O
B	O
)	O
TNF	O
expression	O
was	O
not	O
affected	O
by	O
NAI	O
.	O

(	O
C	O
)	O
IL	B-Protein
-	I-Protein
6	I-Protein
release	O
was	O
completely	O
inhibited	O
by	O
NAI	O
following	O
PMA	O
exposure	O
,	O
indicating	O
regulation	O
through	O
NF	O
-	O
kappaB	O
since	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
was	O
significantly	O
increased	O
in	O
response	O
to	O
HK	O
E	O
.	O
coli	O
than	O
PMA	O
.	O

Statistical	O
significance	O
from	O
the	O
positive	O
control	O
(	O
PMA	O
/	O
HK	O
E	O
.	O
coli	O
)	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
3	O
)	O
.	O

Involvement	O
of	O
PKC	O
and	O
JNK	O
in	O
cytokine	O
expression	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
incubated	O
with	O
PKC	O
-	O
and	O
JNK	O
inhibitors	O
for	O
1	O
h	O
followed	O
by	O
stimulation	O
with	O
PMA	O
(	O
162	O
nM	O
)	O
for	O
24	O
h	O
.	O

(	O
A	O
)	O
CXCL8	B-Protein
expression	O
was	O
inhibited	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
both	O
inhibitors	O
.	O

(	O
B	O
)	O
JNK	O
-	O
I	O
revealed	O
a	O
stronger	O
inhibitory	O
effect	O
on	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
than	O
the	O
PKC	O
-	O
I	O
.	O

(	O
C	O
)	O
TNF	O
expression	O
was	O
not	O
affected	O
by	O
either	O
inhibitor	O
.	O

Statistical	O
significance	O
from	O
the	O
positive	O
control	O
(	O
PMA	O
)	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
3	O
)	O
.	O

NF	O
-	O
kappaB	O
inhibition	O
by	O
PMA	O
correlated	O
to	O
PKC	O
-	O
dependent	O
Bcl10	B-Protein
degradation	O
.	O

Levels	O
of	O
intracellular	O
protein	O
were	O
assessed	O
following	O
24	O
h	O
stimulation	O
with	O
PMA	O
(	O
162	O
nM	O
)	O
or	O
HK	O
E	O
.	O
coli	O
(	O
5	O
x	O
107	O
CFU	O
/	O
ml	O
)	O
.	O

(	O
A	O
)	O
Phospho	O
-	O
PKC	O
increased	O
in	O
response	O
to	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
stimulation	O
.	O

(	O
B	O
)	O
IkappaB	O
decreased	O
following	O
stimulation	O
with	O
HK	O
E	O
.	O
coli	O
indicating	O
NF	O
-	O
kappaB	O
activation	O
.	O

(	O
C	O
)	O
Bcl10	B-Protein
activation	O
was	O
inhibited	O
following	O
long	O
-	O
term	O
stimulation	O
with	O
PMA	O
,	O
which	O
explains	O
the	O
inhibitory	O
effect	O
of	O
PMA	O
on	O
NF	O
-	O
kappaB	O
activation	O
.	O
beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
n	O
=	O
3	O
)	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
stimulated	O
with	O
162	O
nM	O
PMA	O
and	O
5	O
x	O
107	O
CFU	O
/	O
ml	O
HK	O
E	O
.	O
coli	O
for	O
24	O
h	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
treated	O
with	O
10	O
nM	O
NAI	O
,	O
10	O
muM	O
JNK	O
-	O
I	O
or10	O
nM	O
PKC	O
-	O
I	O
for	O
2	O
h	O
followed	O
by	O
induction	O
with	O
162	O
nM	O
PMA	O
for	O
24	O
h	O
.	O

HOIL	B-Protein
-	I-Protein
1L	I-Protein
Interacting	I-Protein
Protein	I-Protein
(	O
HOIP	B-Protein
)	O
Is	O
Essential	O
for	O
CD40	B-Protein
Signaling	O

CD40	B-Protein
is	O
a	O
cell	O
surface	O
receptor	O
important	O
in	O
the	O
activation	O
of	O
antigen	O
-	O
presenting	O
cells	O
during	O
immune	O
responses	O
.	O

In	O
macrophages	O
and	O
dendritic	O
cells	O
,	O
engagement	O
of	O
CD40	B-Protein
by	O
its	O
ligand	B-Protein
CD154	B-Protein
provides	O
signals	O
critical	O
for	O
anti	O
-	O
microbial	O
and	O
T	O
cell	O
-	O
mediated	O
immune	O
responses	O
,	O
respectively	O
.	O

In	O
B	O
cells	O
,	O
CD40	B-Protein
signaling	O
has	O
a	O
major	O
role	O
in	O
regulating	O
cell	O
proliferation	O
,	O
antibody	O
production	O
,	O
and	O
memory	O
B	O
cell	O
development	O
.	O

CD40	B-Protein
engagement	O
results	O
in	O
the	O
formation	O
of	O
a	O
receptor	O
-	O
associated	O
complex	O
that	O
mediates	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
stress	O
-	O
activated	O
protein	O
kinases	O
,	O
and	O
other	O
signaling	O
molecules	O
.	O

However	O
,	O
the	O
mechanisms	O
that	O
link	O
CD40	B-Protein
to	O
these	O
signaling	O
events	O
have	O
been	O
only	O
partially	O
characterized	O
.	O

Known	O
components	O
of	O
the	O
CD40	O
signaling	O
complex	O
include	O
members	O
of	O
the	O
TNF	O
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
family	O
of	O
proteins	O
.	O

We	O
previously	O
showed	O
that	O
the	O
TRAF	O
family	O
member	O
TRAF2	B-Protein
mediates	O
recruitment	O
of	O
HOIL	B-Protein
-	I-Protein
1L	I-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
(	O
HOIP	B-Protein
)	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
CD40	B-Protein
,	O
suggesting	O
that	O
HOIP	B-Protein
has	O
a	O
role	O
in	O
the	O
CD40	B-Protein
signaling	O
pathway	O
.	O

To	O
determine	O
the	O
role	O
of	O
HOIP	B-Protein
in	O
CD40	B-Protein
signaling	O
,	O
we	O
used	O
somatic	O
cell	O
gene	O
targeting	O
to	O
generate	O
mouse	O
B	O
cell	O
lines	O
deficient	O
in	O
HOIP	B-Protein
.	O

We	O
found	O
that	O
the	O
CD40	B-Protein
-	O
induced	O
upregulation	O
of	O
CD80	B-Protein
and	O
activation	O
of	O
germline	O
immunoglobulin	O
epsilon	O
transcription	O
were	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

We	O
also	O
found	O
that	O
the	O
CD40	B-Protein
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
kinase	O
was	O
impaired	O
.	O

Recruitment	O
of	O
IkappaB	O
kinase	O
proteins	O
to	O
the	O
CD40	O
signaling	O
complex	O
was	O
undetectable	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
,	O
potentially	O
explaining	O
the	O
defect	O
in	O
NF	O
-	O
kappaB	O
activation	O
.	O

Restoration	O
of	O
HOIP	B-Protein
expression	O
reversed	O
the	O
defects	O
in	O
cellular	O
activation	O
and	O
signaling	O
.	O

These	O
results	O
reveal	O
HOIP	B-Protein
as	O
a	O
key	O
component	O
of	O
the	O
CD40	B-Protein
signaling	O
pathway	O
.	O

CD40	B-Protein
signaling	O
in	O
professional	O
antigen	O
-	O
presenting	O
cells	O
,	O
including	O
B	O
cells	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
,	O
is	O
critical	O
for	O
the	O
efficient	O
activation	O
of	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
responses	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

CD40	B-Protein
signaling	O
is	O
activated	O
in	O
a	O
T	O
cell	O
-	O
dependent	O
manner	O
,	O
as	O
the	O
ligand	O
for	O
CD40	B-Protein
,	O
CD154	B-Protein
,	O
is	O
expressed	O
primarily	O
by	O
activated	O
T	O
cells	O
.	O

CD40	B-Protein
engagement	O
leads	O
to	O
the	O
activation	O
of	O
various	O
signaling	O
molecules	O
,	O
including	O
stress	O
-	O
activated	O
protein	O
kinases	O
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
which	O
upregulate	O
the	O
expression	O
of	O
cytokines	O
and	O
other	O
factors	O
that	O
promote	O
immune	O
responses	O
.	O

The	O
mechanism	O
by	O
which	O
CD40	B-Protein
induces	O
these	O
signaling	O
pathways	O
has	O
not	O
been	O
completely	O
defined	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
CD40	B-Protein
does	O
not	O
appear	O
to	O
have	O
intrinsic	O
enzymatic	O
activity	O
,	O
but	O
is	O
able	O
to	O
mediate	O
signaling	O
through	O
the	O
recruitment	O
of	O
several	O
intracellular	O
proteins	O
.	O

Members	O
of	O
the	O
TNF	O
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
family	O
,	O
including	O
TRAF1	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
and	O
TRAF6	B-Protein
,	O
appear	O
to	O
be	O
particularly	O
important	O
for	O
the	O
initiation	O
and	O
regulation	O
of	O
CD40	B-Protein
signaling	O
[	O
4	O
]	O
.	O

These	O
proteins	O
function	O
in	O
part	O
as	O
adaptor	O
molecules	O
,	O
binding	O
to	O
the	O
cytoplasmic	O
tail	O
of	O
CD40	B-Protein
and	O
recruiting	O
other	O
proteins	O
to	O
the	O
receptor	O
-	O
associated	O
complex	O
.	O

Some	O
of	O
the	O
TRAFs	O
also	O
function	O
as	O
E3	O
ubiquitin	O
ligases	O
,	O
and	O
this	O
enzymatic	O
activity	O
may	O
contribute	O
to	O
signal	O
propagation	O
and	O
regulation	O
.	O

Among	O
the	O
multiple	O
TRAFs	O
that	O
associate	O
with	O
CD40	B-Protein
,	O
TRAF3	B-Protein
can	O
function	O
as	O
a	O
negative	O
regulator	O
of	O
signaling	O
,	O
while	O
TRAF2	B-Protein
and	O
TRAF6	B-Protein
promote	O
the	O
activation	O
of	O
downstream	O
signaling	O
pathways	O
[	O
4	O
]	O
.	O

We	O
recently	O
demonstrated	O
that	O
HOIL	B-Protein
-	I-Protein
1L	I-Protein
interacting	I-Protein
protein	I-Protein
(	O
HOIP	B-Protein
)	O
,	O
a	O
ubiquitin	O
ligase	O
that	O
can	O
catalyze	O
the	O
assembly	O
of	O
linear	O
polyubiquitin	O
chains	O
[	O
5	O
]	O
,	O
is	O
recruited	O
to	O
CD40	B-Protein
in	O
a	O
TRAF2	B-Protein
-	O
dependent	O
manner	O
following	O
engagement	O
of	O
CD40	B-Protein
by	O
agonistic	O
antibody	O
[	O
6	O
]	O
.	O

These	O
and	O
other	O
findings	O
led	O
us	O
to	O
hypothesize	O
that	O
HOIP	B-Protein
functions	O
downstream	O
of	O
TRAF2	B-Protein
in	O
the	O
CD40	B-Protein
signaling	O
pathway	O
and	O
that	O
HOIP	B-Protein
is	O
necessary	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
possibly	O
other	O
signaling	O
molecules	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
employed	O
somatic	O
cell	O
gene	O
targeting	O
to	O
ablate	O
expression	O
of	O
HOIP	B-Protein
in	O
a	O
mouse	O
B	O
cell	O
line	O
that	O
has	O
proven	O
to	O
be	O
a	O
useful	O
model	O
for	O
B	O
cell	O
CD40	B-Protein
signaling	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

We	O
found	O
that	O
the	O
CD40	B-Protein
-	O
induced	O
upregulation	O
of	O
CD80	B-Protein
(	O
a	O
costimulatory	O
molecule	O
for	O
T	O
cells	O
)	O
was	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

Similarly	O
,	O
the	O
CD40	B-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
driven	O
production	O
of	O
germline	O
transcripts	O
from	O
the	O
immunoglobulin	O
epsilon	O
heavy	O
chain	O
locus	O
,	O
an	O
event	O
that	O
precedes	O
immunoglobulin	O
gene	O
rearrangement	O
and	O
isotype	O
switching	O
,	O
was	O
defective	O
in	O
the	O
absence	O
of	O
HOIP	B-Protein
.	O

We	O
also	O
found	O
that	O
the	O
CD40	B-Protein
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
stress	O
-	O
activated	O
protein	O
kinase	O
c	O
-	O
Jun	O
kinase	O
(	O
JNK	O
)	O
was	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

Consistent	O
with	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
,	O
association	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
with	O
CD40	B-Protein
was	O
undetectable	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
HOIP	B-Protein
plays	O
a	O
critical	O
role	O
in	O
the	O
activation	O
of	O
signaling	O
pathways	O
that	O
regulate	O
cellular	O
responses	O
to	O
CD40	B-Protein
engagement	O
.	O

Generation	O
of	O
HOIP	B-Protein
-	O
deficient	O
B	O
cells	O
via	O
targeted	O
disruption	O
of	O
Rnf31	B-Protein
,	O
the	O
gene	O
encoding	O
HOIP	B-Protein

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
HOIP	B-Protein
is	O
recruited	O
to	O
the	O
CD40	O
signaling	O
complex	O
in	O
two	O
mouse	O
B	O
cell	O
lines	O
[	O
6	O
]	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
mouse	O
splenocytes	O
,	O
indicating	O
that	O
the	O
interaction	O
of	O
CD40	B-Protein
with	O
HOIP	B-Protein
is	O
not	O
limited	O
to	O
transformed	O
B	O
cell	O
lines	O
(	O
unpublished	O
observations	O
)	O
.	O

We	O
also	O
found	O
that	O
the	O
recruitment	O
of	O
HOIP	B-Protein
to	O
CD40	B-Protein
was	O
TRAF2	B-Protein
-	O
dependent	O
and	O
that	O
overexpression	O
of	O
a	O
truncated	O
HOIP	B-Protein
mutant	O
partially	O
inhibited	O
CD40	B-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
HOIP	B-Protein
plays	O
a	O
role	O
in	O
CD40	B-Protein
signal	O
transduction	O
.	O

To	O
further	O
define	O
the	O
role	O
and	O
evaluate	O
the	O
importance	O
of	O
HOIP	B-Protein
in	O
CD40	B-Protein
signaling	O
,	O
we	O
used	O
somatic	O
cell	O
gene	O
targeting	O
to	O
disrupt	O
the	O
gene	O
encoding	O
HOIP	B-Protein
in	O
the	O
mouse	O
B	O
cell	O
line	O
A20	O
.	O
2J	O
.	O

This	O
cell	O
line	O
has	O
been	O
particularly	O
useful	O
in	O
the	O
characterization	O
of	O
CD40	B-Protein
signaling	O
mechanisms	O
due	O
to	O
the	O
relative	O
ease	O
with	O
which	O
its	O
genome	O
can	O
be	O
modified	O
by	O
homologous	O
recombination	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

We	O
used	O
a	O
targeting	O
vector	O
capable	O
of	O
undergoing	O
homologous	O
recombination	O
with	O
Rnf31	B-Protein
(	O
the	O
gene	O
encoding	O
HOIP	B-Protein
)	O
to	O
disrupt	O
the	O
coding	O
sequence	O
of	O
the	O
gene	O
in	O
exon	O
5	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Following	O
introduction	O
of	O
the	O
vector	O
,	O
the	O
neomycin	O
-	O
resistant	O
clones	O
that	O
arose	O
were	O
screened	O
by	O
PCR	O
amplification	O
of	O
genomic	O
DNA	O
to	O
identify	O
cells	O
containing	O
a	O
disrupted	O
Rnf31	B-Protein
allele	O
.	O

To	O
remove	O
the	O
selectable	O
marker	O
gene	O
cassette	O
from	O
the	O
disrupted	O
Rnf31	B-Protein
allele	O
,	O
recombinant	O
cell	O
lines	O
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
that	O
encodes	O
Cre	B-Protein
recombinase	I-Protein
.	O

This	O
step	O
allowed	O
us	O
to	O
perform	O
a	O
second	O
round	O
of	O
targeting	O
and	O
drug	O
selection	O
,	O
generating	O
cells	O
in	O
which	O
both	O
copies	O
of	O
Rnf31	B-Protein
were	O
disrupted	O
.	O

Two	O
independent	O
clonal	O
cell	O
lines	O
were	O
chosen	O
for	O
further	O
analysis	O
.	O

HOIP	B-Protein
protein	O
expression	O
was	O
undetectable	O
in	O
both	O
cell	O
lines	O
,	O
as	O
determined	O
by	O
Western	O
blot	O
analysis	O
of	O
cell	O
lysates	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
demonstrating	O
that	O
the	O
targeting	O
process	O
was	O
successful	O
.	O

In	O
the	O
text	O
that	O
follows	O
,	O
the	O
two	O
gene	O
-	O
targeted	O
cell	O
lines	O
are	O
referred	O
to	O
as	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

To	O
enable	O
us	O
to	O
confirm	O
that	O
any	O
signaling	O
or	O
functional	O
defects	O
observed	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
were	O
due	O
to	O
disruption	O
of	O
the	O
Rnf31	B-Protein
gene	O
,	O
both	O
HOIP	B-Protein
-	O
deficient	O
cell	O
lines	O
were	O
transduced	O
with	O
a	O
retrovirus	O
encoding	O
FLAG	O
-	O
tagged	O
wild	O
-	O
type	O
HOIP	B-Protein
,	O
thus	O
restoring	O
HOIP	B-Protein
protein	O
expression	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

These	O
cells	O
are	O
referred	O
to	O
as	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
.	O

In	O
the	O
experiments	O
that	O
follow	O
,	O
responses	O
by	O
these	O
cells	O
were	O
compared	O
to	O
those	O
of	O
A20	O
.	O
2J	O
cells	O
and	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
a	O
retroviral	O
vector	O
(	O
pMIP	O
)	O
lacking	O
a	O
cDNA	O
insert	O
(	O
empty	O
vector	O
)	O
.	O

HOIP	B-Protein
is	O
required	O
for	O
CD40	B-Protein
-	O
mediated	O
CD80	B-Protein
upregulation	O
and	O
activation	O
of	O
germline	B-Protein
epsilon	I-Protein
transcription	O

Engagement	O
of	O
CD40	B-Protein
on	O
B	O
cells	O
upregulates	O
expression	O
of	O
CD80	B-Protein
[	O
10	O
]	O
,	O
a	O
cell	O
surface	O
protein	O
that	O
promotes	O
activation	O
of	O
T	O
cells	O
interacting	O
with	O
B	O
cells	O
and	O
other	O
APC	O
.	O

To	O
begin	O
evaluating	O
potential	O
contributions	O
of	O
HOIP	B-Protein
to	O
CD40	B-Protein
signaling	O
,	O
we	O
assayed	O
the	O
upregulation	O
of	O
CD80	B-Protein
induced	O
by	O
engagement	O
of	O
CD40	B-Protein
on	O
parental	O
A20	O
.	O
2J	O
,	O
HOIP	B-Protein
-	O
deficient	O
,	O
and	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Compared	O
to	O
the	O
parental	O
cell	O
line	O
,	O
the	O
CD40	B-Protein
-	O
stimulated	O
upregulation	O
of	O
CD80	B-Protein
was	O
dramatically	O
reduced	O
in	O
all	O
HOIP	B-Protein
-	O
deficient	O
cells	O
tested	O
.	O

In	O
contrast	O
,	O
upregulation	O
of	O
CD80	B-Protein
was	O
restored	O
in	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
,	O
confirming	O
that	O
the	O
defect	O
in	O
CD80	B-Protein
upregulation	O
in	O
the	O
HOIP	B-Protein
-	O
deficient	O
cells	O
was	O
due	O
to	O
the	O
disruption	O
of	O
Rnf31	B-Protein
.	O

CD40	B-Protein
signals	O
in	O
B	O
cells	O
can	O
also	O
contribute	O
to	O
the	O
activation	O
of	O
DNA	O
recombination	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
locus	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O

This	O
process	O
,	O
known	O
as	O
immunoglobulin	O
class	O
switching	O
(	O
or	O
isotype	O
switching	O
)	O
,	O
allows	O
B	O
cells	O
,	O
initially	O
expressing	O
IgM	O
,	O
to	O
switch	O
to	O
IgA	O
,	O
IgG	O
,	O
or	O
IgE	O
depending	O
on	O
the	O
class	O
of	O
antibody	O
most	O
appropriate	O
for	O
a	O
particular	O
immune	O
response	O
.	O

Switching	O
to	O
IgE	O
can	O
be	O
induced	O
by	O
the	O
combination	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
CD40	B-Protein
signals	O
.	O

The	O
gene	O
rearrangement	O
necessary	O
for	O
IgE	O
production	O
is	O
preceded	O
by	O
the	O
production	O
of	O
non	O
-	O
coding	O
RNA	O
transcripts	O
from	O
germline	O
sequences	O
in	O
the	O
IgE	O
heavy	O
chain	O
locus	O
[	O
13	O
]	O
.	O

To	O
determine	O
whether	O
HOIP	B-Protein
is	O
required	O
in	O
the	O
initiation	O
of	O
the	O
class	O
switching	O
process	O
,	O
the	O
relevant	O
B	O
cell	O
lines	O
were	O
stimulated	O
through	O
CD40	B-Protein
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
tested	O
for	O
production	O
of	O
germline	B-Protein
epsilon	I-Protein
(	O
GLepsilon	B-Protein
)	O
transcripts	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Anti	O
-	O
CD40	O
antibody	O
stimulation	O
alone	O
or	O
together	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
induced	O
GLepsilon	B-Protein
transcription	O
in	O
parental	O
A20	O
.	O
2J	O
cells	O
as	O
expected	O
.	O

In	O
contrast	O
,	O
only	O
low	O
levels	O
of	O
GLepsilon	B-Protein
expression	O
were	O
detected	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
stimulated	O
with	O
either	O
anti	O
-	O
CD40	O
antibody	O
alone	O
or	O
anti	O
-	O
CD40	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

Normal	O
levels	O
of	O
GLepsilon	B-Protein
expression	O
were	O
induced	O
in	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD40	O
antibody	O
alone	O
or	O
together	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

Collectively	O
,	O
these	O
data	O
demonstrate	O
that	O
HOIP	B-Protein
has	O
a	O
critical	O
role	O
in	O
cellular	O
responses	O
to	O
CD40	B-Protein
signaling	O
.	O

HOIP	B-Protein
mediates	O
CD40	B-Protein
-	O
stimulated	O
NF	O
-	O
kappaB	O
and	O
JNK	O
activation	O

The	O
results	O
described	O
above	O
show	O
that	O
HOIP	B-Protein
plays	O
an	O
important	O
role	O
in	O
CD40	B-Protein
-	O
mediated	O
effector	O
functions	O
of	O
B	O
cells	O
.	O

It	O
follows	O
that	O
HOIP	B-Protein
is	O
likely	O
a	O
key	O
mediator	O
of	O
CD40	B-Protein
signaling	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
stimulated	O
A20	O
.	O
2J	O
and	O
HOIP	O
-	O
deficient	O
cells	O
with	O
CD154	B-Protein
(	O
CD40	B-Protein
ligand	I-Protein
)	O
expressed	O
by	O
HI5	O
insect	O
cells	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
and	O
measured	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
and	O
JNK	O
pathways	O
,	O
two	O
of	O
the	O
major	O
transcriptional	O
regulators	O
activated	O
by	O
CD40	B-Protein
[	O
4	O
]	O
.	O

Cell	O
-	O
associated	O
CD154	B-Protein
was	O
used	O
as	O
the	O
stimulus	O
in	O
these	O
experiments	O
as	O
it	O
typically	O
provides	O
more	O
robust	O
,	O
and	O
therefore	O
more	O
readily	O
detected	O
,	O
activation	O
signals	O
than	O
does	O
anti	O
-	O
CD40	O
antibody	O
.	O

Activation	O
of	O
the	O
canonical	O
NF	O
-	O
kappaB	O
pathway	O
is	O
initiated	O
with	O
the	O
phosphorylation	O
of	O
IkappaB	O
proteins	O
by	O
the	O
IkappaB	O
kinase	O
complex	O
(	O
IKK	O
)	O
.	O

In	O
resting	O
cells	O
,	O
IkappaB	O
proteins	O
are	O
responsible	O
for	O
sequestering	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
subunits	I-Protein
in	O
the	O
cytoplasm	O
.	O

Phosphorylation	O
by	O
the	O
IKK	O
complex	O
targets	O
IkappaB	O
proteins	O
for	O
ubiquitination	O
and	O
degradation	O
,	O
allowing	O
NF	O
-	O
kappaB	O
to	O
enter	O
the	O
nucleus	O
and	O
activate	O
gene	O
expression	O
.	O

CD40	B-Protein
-	O
mediated	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-Protein
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
was	O
dramatically	O
impaired	O
relative	O
to	O
that	O
observed	O
in	O
parental	O
A20	O
.	O
2J	O
cells	O
(	O
Fig	O
.	O
4	O
)	O
.	O

We	O
also	O
assayed	O
activation	O
of	O
the	O
stress	O
-	O
activated	O
protein	O
kinase	O
JNK	O
in	O
response	O
to	O
CD40	B-Protein
engagement	O
(	O
Fig	O
.	O
4	O
)	O
.	O

CD40	B-Protein
-	O
mediated	O
JNK	O
activation	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
was	O
impaired	O
as	O
measured	O
by	O
phosphorylation	O
of	O
Thr183	O
and	O
Tyr185	O
in	O
JNK	O
.	O

CD40	B-Protein
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
JNK	O
in	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
was	O
normal	O
,	O
demonstrating	O
that	O
the	O
defects	O
observed	O
in	O
gene	O
-	O
deficient	O
cells	O
were	O
due	O
to	O
the	O
absence	O
of	O
HOIP	B-Protein
expression	O
.	O

HOIP	B-Protein
is	O
necessary	O
for	O
association	O
of	O
the	O
IKK	O
complex	O
with	O
CD40	B-Protein

The	O
marked	O
defects	O
in	O
CD40	B-Protein
-	O
mediated	O
cell	O
activation	O
and	O
signaling	O
displayed	O
by	O
HOIP	B-Protein
-	O
deficient	O
cells	O
suggested	O
that	O
HOIP	B-Protein
mediates	O
recruitment	O
of	O
critical	O
components	O
of	O
the	O
CD40	O
signaling	O
apparatus	O
to	O
the	O
receptor	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
HOIP	B-Protein
is	O
recruited	O
to	O
the	O
CD40	O
signaling	O
complex	O
in	O
a	O
TRAF2	B-Protein
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
HOIP	B-Protein
functions	O
downstream	O
of	O
TRAF2	B-Protein
[	O
6	O
]	O
.	O

Studies	O
by	O
others	O
suggest	O
that	O
the	O
TRAF2	B-Protein
-	O
associated	O
proteins	O
cIAP1	B-Protein
and	O
cIAP2	B-Protein
play	O
a	O
role	O
in	O
the	O
recruitment	O
of	O
HOIP	B-Protein
to	O
TNFR1	B-Protein
and	O
CD40	B-Protein
[	O
14	O
]	O
.	O

Therefore	O
,	O
we	O
determined	O
whether	O
the	O
association	O
of	O
HOIP	B-Protein
with	O
CD40	B-Protein
in	O
A20	O
.	O
2J	O
cells	O
was	O
altered	O
by	O
treatment	O
of	O
cells	O
with	O
an	O
inhibitor	O
of	O
cIAP	O
activity	O
,	O
a	O
membrane	O
-	O
permeable	O
peptide	O
derived	O
from	O
the	O
apoptosis	O
regulator	O
SMAC	O
[	O
15	O
]	O
.	O

We	O
found	O
that	O
pretreatment	O
of	O
cells	O
with	O
the	O
SMAC	O
peptide	O
dramatically	O
reduced	O
the	O
amount	O
of	O
cIAP1	B-Protein
associated	O
with	O
the	O
CD40	O
signaling	O
complex	O
in	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD40	O
antibody	O
-	O
coated	O
beads	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

SMAC	O
peptide	O
treatment	O
also	O
resulted	O
in	O
a	O
slight	O
but	O
reproducible	O
decrease	O
in	O
the	O
amount	O
of	O
the	O
major	O
HOIP	B-Protein
form	O
recovered	O
by	O
CD40	B-Protein
immunoprecipitation	O
,	O
along	O
with	O
an	O
apparent	O
increase	O
in	O
higher	O
molecular	O
weight	O
species	O
recognized	O
by	O
anti	O
-	O
HOIP	O
antibody	O
.	O

In	O
contrast	O
,	O
treatment	O
with	O
the	O
SMAC	O
peptide	O
did	O
not	O
alter	O
the	O
amount	O
or	O
molecular	O
weight	O
of	O
HOIP	B-Protein
present	O
in	O
cell	O
lysates	O
.	O

These	O
data	O
suggest	O
that	O
SMAC	O
peptide	O
treatment	O
specifically	O
alters	O
the	O
characteristics	O
of	O
CD40	B-Protein
-	O
associated	O
HOIP	B-Protein
rather	O
than	O
the	O
entire	O
cellular	O
pool	O
of	O
this	O
protein	O
.	O

Together	O
,	O
these	O
results	O
support	O
the	O
idea	O
that	O
the	O
cIAP	B-Protein
proteins	O
influence	O
the	O
recruitment	O
and	O
post	O
-	O
translational	O
modification	O
state	O
of	O
CD40	B-Protein
-	O
associated	O
HOIP	B-Protein
.	O

To	O
test	O
the	O
possibility	O
that	O
HOIP	B-Protein
is	O
responsible	O
for	O
the	O
recruitment	O
of	O
other	O
critical	O
signaling	O
proteins	O
to	O
CD40	B-Protein
,	O
we	O
immunoprecipitated	O
CD40	O
signaling	O
complexes	O
from	O
HOIP	B-Protein
-	O
deficient	O
and	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
(	O
Fig	O
.	O
5B	O
)	O
.	O

As	O
described	O
previously	O
,	O
CD40	O
signaling	O
complexes	O
immunoprecipitated	O
from	O
A20	O
.	O
2J	O
cells	O
contained	O
HOIP	B-Protein
as	O
well	O
as	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
IKKalpha	B-Protein
/	O
beta	B-Protein
,	O
and	O
IKKgamma	B-Protein
[	O
6	O
]	O
.	O

The	O
amounts	O
of	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
and	O
cIAP1	B-Protein
in	O
CD40	B-Protein
immunoprecipitates	O
from	O
HOIP	B-Protein
-	O
deficient	O
cells	O
were	O
similar	O
to	O
those	O
from	O
parental	O
A20	O
.	O
2J	O
cells	O
,	O
indicating	O
that	O
HOIP	B-Protein
is	O
not	O
required	O
for	O
the	O
association	O
of	O
these	O
proteins	O
with	O
CD40	B-Protein
.	O

In	O
contrast	O
,	O
IKKalpha	B-Protein
/	O
beta	B-Protein
and	O
IKKgamma	B-Protein
were	O
not	O
detectable	O
in	O
CD40	B-Protein
immunoprecipitates	O
recovered	O
from	O
HOIP	B-Protein
-	O
deficient	O
cells	O
(	O
Fig	O
.	O
5B	O
,	O
C	O
)	O
.	O

The	O
amounts	O
of	O
IKKalpha	B-Protein
/	O
beta	B-Protein
and	O
IKKgamma	B-Protein
in	O
CD40	B-Protein
immunoprecipitates	O
from	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
were	O
similar	O
to	O
those	O
detected	O
in	O
samples	O
prepared	O
from	O
parental	O
cells	O
,	O
demonstrating	O
that	O
the	O
defects	O
in	O
IKK	O
recruitment	O
we	O
observed	O
were	O
due	O
specifically	O
to	O
the	O
absence	O
of	O
HOIP	B-Protein
expression	O
.	O

These	O
data	O
indicate	O
that	O
HOIP	B-Protein
is	O
required	O
for	O
recruitment	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
activating	O
complex	O
to	O
the	O
CD40	O
signaling	O
complex	O
.	O

As	O
shown	O
here	O
and	O
in	O
our	O
previous	O
study	O
[	O
6	O
]	O
,	O
IKKgamma	B-Protein
present	O
in	O
CD40	B-Protein
immunoprecipitates	O
appears	O
to	O
have	O
a	O
higher	O
molecular	O
weight	O
than	O
that	O
found	O
in	O
cell	O
lysates	O
.	O

To	O
confirm	O
that	O
this	O
higher	O
molecular	O
weight	O
species	O
was	O
indeed	O
IKKgamma	B-Protein
,	O
we	O
generated	O
A20	O
.	O
2J	O
cell	O
lines	O
containing	O
a	O
stably	O
integrated	O
retroviral	O
vector	O
that	O
encoded	O
an	O
epitope	O
-	O
tagged	O
version	O
of	O
mouse	O
IKKgamma	B-Protein
.	O

Cell	O
lysates	O
and	O
CD40	B-Protein
immunoprecipitates	O
prepared	O
from	O
these	O
cells	O
were	O
analyzed	O
by	O
Western	O
blotting	O
for	O
the	O
epitope	O
tag	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

This	O
analysis	O
produced	O
a	O
pattern	O
of	O
bands	O
that	O
was	O
essentially	O
the	O
same	O
as	O
that	O
obtained	O
using	O
an	O
antibody	O
specific	O
for	O
native	O
IKKgamma	B-Protein
(	O
compare	O
panels	O
B	O
and	O
C	O
in	O
Fig	O
.	O
5	O
)	O
.	O

Moreover	O
,	O
analysis	O
of	O
cells	O
expressing	O
epitope	O
tagged	O
-	O
IKKgamma	B-Protein
confirmed	O
that	O
recruitment	O
of	O
IKKgamma	B-Protein
to	O
CD40	B-Protein
requires	O
HOIP	B-Protein
.	O

To	O
determine	O
what	O
was	O
responsible	O
for	O
the	O
increased	O
molecular	O
weight	O
of	O
IKKgamma	B-Protein
in	O
CD40	B-Protein
immunoprecipitates	O
,	O
the	O
protein	O
samples	O
were	O
incubated	O
with	O
lambda	O
phosphatase	O
,	O
which	O
removes	O
phosphates	O
attached	O
to	O
tyrosine	O
,	O
threonine	O
,	O
or	O
serine	O
residues	O
in	O
proteins	O
.	O

This	O
treatment	O
reduced	O
much	O
of	O
CD40	B-Protein
-	O
associated	O
IKKgamma	B-Protein
to	O
an	O
apparent	O
molecular	O
weight	O
similar	O
to	O
that	O
of	O
the	O
protein	O
in	O
cell	O
lysates	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

However	O
,	O
at	O
least	O
one	O
band	O
of	O
significantly	O
higher	O
molecular	O
weight	O
remained	O
after	O
phosphatase	O
treatment	O
,	O
suggesting	O
that	O
CD40	B-Protein
-	O
associated	O
IKKgamma	B-Protein
is	O
subject	O
to	O
at	O
least	O
one	O
other	O
modification	O
in	O
addition	O
to	O
phosphorylation	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
HOIP	B-Protein
is	O
required	O
for	O
the	O
association	O
of	O
IKKgamma	B-Protein
with	O
CD40	B-Protein
,	O
and	O
suggest	O
that	O
this	O
event	O
is	O
coupled	O
to	O
post	O
-	O
translational	O
modifications	O
of	O
IKKgamma	B-Protein
.	O

Our	O
results	O
indicate	O
that	O
the	O
protein	O
HOIP	B-Protein
is	O
critical	O
for	O
CD40	B-Protein
-	O
induced	O
signals	O
that	O
regulate	O
B	O
cell	O
function	O
.	O

Our	O
data	O
show	O
that	O
HOIP	B-Protein
-	O
dependent	O
cellular	O
responses	O
include	O
CD40	B-Protein
-	O
mediated	O
upregulation	O
of	O
CD80	B-Protein
expression	O
and	O
synthesis	O
of	O
germline	O
RNA	O
transcripts	O
from	O
the	O
immunoglobulin	O
heavy	O
chain	O
locus	O
,	O
two	O
events	O
that	O
are	O
important	O
for	O
T	O
-	O
cell	O
-	O
dependent	O
antibody	O
-	O
mediated	O
immune	O
responses	O
.	O

At	O
the	O
molecular	O
level	O
,	O
our	O
data	O
indicate	O
that	O
HOIP	B-Protein
functions	O
downstream	O
of	O
TRAF2	B-Protein
in	O
the	O
CD40	B-Protein
signaling	O
pathway	O
and	O
that	O
HOIP	B-Protein
has	O
a	O
key	O
role	O
in	O
promoting	O
the	O
recruitment	O
of	O
the	O
IKK	O
complex	O
to	O
CD40	B-Protein
.	O

Consistent	O
with	O
this	O
,	O
CD40	B-Protein
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
HOIP	O
.	O

In	O
addition	O
,	O
our	O
data	O
show	O
that	O
HOIP	B-Protein
facilitates	O
the	O
activation	O
of	O
JNK	O
in	O
response	O
to	O
CD40	B-Protein
engagement	O
.	O

Together	O
,	O
our	O
findings	O
provide	O
support	O
for	O
the	O
conclusion	O
that	O
HOIP	B-Protein
is	O
a	O
key	O
component	O
of	O
the	O
CD40	B-Protein
signaling	O
pathway	O
.	O

Given	O
the	O
importance	O
of	O
CD40	B-Protein
signaling	O
in	O
both	O
cellular	O
and	O
humoral	O
immune	O
responses	O
,	O
our	O
results	O
indicate	O
that	O
HOIP	B-Protein
has	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
system	O
.	O

The	O
functional	O
properties	O
of	O
HOIP	B-Protein
have	O
only	O
been	O
partially	O
characterized	O
.	O

Initial	O
studies	O
showed	O
that	O
HOIP	B-Protein
and	O
the	O
related	O
protein	O
HOIL	B-Protein
-	I-Protein
1	I-Protein
are	O
components	O
of	O
a	O
large	O
(	O
~	O
600	O
kDa	O
)	O
protein	O
complex	O
capable	O
of	O
synthesizing	O
linear	O
polyubiquitin	O
chains	O
[	O
5	O
]	O
.	O

Subsequent	O
studies	O
showed	O
that	O
a	O
HOIP	O
-	O
containing	O
complex	O
can	O
interact	O
with	O
IKKgamma	B-Protein
and	O
facilitate	O
activation	O
of	O
NF	O
-	O
kappaB	O
via	O
the	O
canonical	O
pathway	O
[	O
16	O
]	O
.	O

These	O
data	O
,	O
considered	O
together	O
with	O
ours	O
,	O
suggest	O
that	O
a	O
HOIP	O
-	O
containing	O
complex	O
mediates	O
recruitment	O
of	O
IKKgamma	B-Protein
to	O
the	O
CD40	O
signaling	O
complex	O
.	O

In	O
addition	O
,	O
CD40	B-Protein
-	O
associated	O
HOIP	B-Protein
could	O
play	O
a	O
role	O
in	O
activating	O
IKKgamma	B-Protein
after	O
its	O
recruitment	O
to	O
the	O
signaling	O
complex	O
[	O
16	O
]	O
.	O

The	O
higher	O
molecular	O
weight	O
forms	O
of	O
IKKgamma	B-Protein
we	O
observed	O
in	O
CD40	B-Protein
immunoprecipitates	O
would	O
be	O
consistent	O
with	O
the	O
presence	O
of	O
post	O
-	O
transcriptional	O
modifications	O
including	O
phosphorylation	O
and	O
ubiquitination	O
,	O
which	O
have	O
been	O
suggested	O
to	O
reduce	O
or	O
enhance	O
IKKgamma	B-Protein
activity	O
,	O
respectively	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

The	O
mechanisms	O
by	O
which	O
HOIP	B-Protein
mediates	O
recruitment	O
of	O
the	O
IKK	O
complex	O
to	O
CD40	B-Protein
and	O
by	O
which	O
HOIP	B-Protein
is	O
recruited	O
to	O
CD40	B-Protein
remain	O
unclear	O
.	O

A	O
previous	O
study	O
indicates	O
that	O
HOIP	B-Protein
may	O
mediate	O
direct	O
contacts	O
with	O
the	O
IKK	O
complex	O
[	O
16	O
]	O
,	O
suggesting	O
that	O
it	O
functions	O
as	O
an	O
adaptor	O
for	O
the	O
recruitment	O
of	O
the	O
IKK	O
complex	O
to	O
CD40	B-Protein
.	O

However	O
,	O
the	O
ubiquitin	O
ligase	O
activity	O
of	O
HOIP	B-Protein
suggests	O
that	O
it	O
is	O
more	O
than	O
a	O
simple	O
adapter	O
molecule	O
.	O

As	O
IKKgamma	B-Protein
appears	O
capable	O
of	O
binding	O
linear	O
polyubiquitin	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
it	O
is	O
possible	O
that	O
HOIP	B-Protein
directs	O
formation	O
of	O
linear	O
polyubiquitin	O
chains	O
on	O
a	O
CD40	O
-	O
associated	O
factor	O
,	O
and	O
it	O
is	O
these	O
chains	O
that	O
serve	O
to	O
recruit	O
IKKgamma	B-Protein
to	O
the	O
CD40	O
signaling	O
complex	O
.	O

The	O
molecular	O
interactions	O
necessary	O
for	O
recruitment	O
of	O
HOIP	B-Protein
itself	O
to	O
the	O
CD40	O
signaling	O
complex	O
also	O
remain	O
to	O
be	O
fully	O
characterized	O
.	O

We	O
previously	O
showed	O
that	O
the	O
recruitment	O
of	O
HOIP	B-Protein
to	O
the	O
signaling	O
complex	O
is	O
TRAF2	B-Protein
-	O
dependent	O
[	O
8	O
]	O
.	O

Potentially	O
,	O
TRAF2	B-Protein
and	O
HOIP	B-Protein
directly	O
interact	O
,	O
but	O
it	O
is	O
possible	O
that	O
the	O
ubiquitin	O
ligase	O
activity	O
of	O
TRAF2	B-Protein
[	O
20	O
]	O
(	O
or	O
TRAF2	O
-	O
associated	O
proteins	O
,	O
such	O
as	O
the	O
cIAPs	O
[	O
21	O
]	O
)	O
generates	O
K63	O
-	O
linked	O
polyubiquitin	O
chains	O
to	O
which	O
HOIP	B-Protein
can	O
bind	O
and	O
thus	O
associate	O
with	O
the	O
CD40	O
signaling	O
complex	O
[	O
22	O
]	O
.	O

While	O
our	O
previous	O
work	O
indicated	O
a	O
potentially	O
important	O
link	O
between	O
TRAF2	B-Protein
and	O
HOIP	B-Protein
in	O
CD40	B-Protein
signaling	O
,	O
the	O
signals	O
and	O
functions	O
tested	O
here	O
are	O
dependent	O
upon	O
TRAF6	B-Protein
as	O
well	O
as	O
TRAF2	B-Protein
.	O

In	O
previous	O
experiments	O
with	O
TRAF	O
-	O
deficient	O
A20	O
.	O
2J	O
cells	O
,	O
we	O
found	O
that	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
CD40	B-Protein
could	O
be	O
mediated	O
by	O
either	O
TRAF2	B-Protein
or	O
TRAF6	B-Protein
,	O
while	O
activation	O
of	O
JNK	O
by	O
CD40	B-Protein
was	O
largely	O
dependent	O
on	O
TRAF6	B-Protein
alone	O
[	O
8	O
]	O
.	O

HOIP	B-Protein
deficiency	O
compromises	O
the	O
CD40	B-Protein
-	O
mediated	O
activation	O
of	O
both	O
NF	O
-	O
kappaB	O
and	O
JNK	O
,	O
indicating	O
that	O
signals	O
mediated	O
by	O
both	O
TRAF2	B-Protein
and	O
TRAF6	B-Protein
likely	O
pass	O
through	O
HOIP	B-Protein
.	O

Our	O
previous	O
work	O
also	O
demonstrated	O
that	O
the	O
CD40	B-Protein
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
JNK	O
,	O
while	O
TRAF6	B-Protein
-	O
dependent	O
,	O
was	O
not	O
compromised	O
by	O
the	O
disruption	O
of	O
the	O
binding	O
site	O
for	O
TRAF6	B-Protein
in	O
the	O
cytoplasmic	O
domain	O
of	O
CD40	B-Protein
or	O
deletion	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
the	O
TRAF	O
-	O
C	O
domain	O
)	O
in	O
TRAF6	B-Protein
[	O
8	O
]	O
.	O

These	O
observations	O
indicate	O
that	O
TRAF6	B-Protein
need	O
not	O
directly	O
bind	O
CD40	B-Protein
in	O
order	O
to	O
mediate	O
certain	O
signals	O
,	O
suggesting	O
the	O
assembly	O
of	O
a	O
signaling	O
complex	O
not	O
directly	O
associated	O
with	O
the	O
receptor	O
.	O

If	O
such	O
a	O
complex	O
exists	O
,	O
our	O
results	O
indicate	O
that	O
the	O
absence	O
of	O
HOIP	B-Protein
compromises	O
its	O
function	O
as	O
well	O
.	O

Although	O
the	O
experiments	O
presented	O
here	O
focus	O
on	O
CD40	B-Protein
,	O
our	O
results	O
and	O
those	O
of	O
other	O
groups	O
[	O
16	O
]	O
,	O
[	O
22	O
]	O
support	O
the	O
possibility	O
that	O
HOIP	B-Protein
is	O
important	O
in	O
many	O
signaling	O
pathways	O
in	O
which	O
TRAF2	B-Protein
or	O
TRAF6	B-Protein
are	O
involved	O
,	O
including	O
those	O
associated	O
with	O
various	O
members	O
of	O
the	O
TNF	O
receptor	O
superfamily	O
and	O
the	O
Toll	O
-	O
like	O
receptors	O
.	O

The	O
potential	O
importance	O
of	O
HOIP	B-Protein
in	O
immune	O
function	O
and	O
TNFR	O
family	O
signaling	O
is	O
further	O
supported	O
by	O
the	O
recent	O
discovery	O
that	O
HOIP	B-Protein
interacts	O
with	O
a	O
protein	O
known	O
as	O
SHARPIN	B-Protein
(	O
SHANK	B-Protein
-	I-Protein
associated	I-Protein
RH	I-Protein
domain	I-Protein
interacting	I-Protein
protein	I-Protein
in	I-Protein
postsynaptic	I-Protein
density	I-Protein
)	O
,	O
which	O
appears	O
capable	O
of	O
working	O
together	O
with	O
HOIP	B-Protein
and	O
HOIL	B-Protein
to	O
mediate	O
the	O
assembly	O
of	O
linear	O
polyubiquitin	O
[	O
14	O
]	O
,	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

Interestingly	O
,	O
mice	O
with	O
a	O
spontaneous	O
mutation	O
in	O
the	O
gene	O
encoding	O
SHARPIN	B-Protein
(	O
chronic	O
proliferative	O
dermatitis	O
(	O
cpdm	O
)	O
mice	O
)	O
exhibit	O
chronic	O
inflammation	O
of	O
the	O
skin	O
and	O
internal	O
organs	O
,	O
defective	O
development	O
of	O
secondary	O
lymphoid	O
tissue	O
,	O
and	O
defects	O
in	O
the	O
production	O
of	O
switched	O
immunoglobulin	O
isotypes	O
[	O
17	O
]	O
,	O
[	O
25	O
]	O
.	O

The	O
apparently	O
intimate	O
functional	O
link	O
between	O
SHARPIN	B-Protein
and	O
HOIP	B-Protein
strongly	O
suggests	O
that	O
at	O
least	O
part	O
of	O
the	O
cpdm	O
phenotype	O
stems	O
from	O
defects	O
in	O
the	O
regulation	O
or	O
function	O
of	O
HOIP	B-Protein
.	O

Cell	O
lines	O

The	O
mouse	O
B	O
cell	O
line	O
A20	O
.	O
2J	O
has	O
been	O
previously	O
described	O
[	O
26	O
]	O
,	O
[	O
27	O
]	O
.	O

Cells	O
were	O
grown	O
in	O
RPMI	O
1640	O
,	O
10	O
%	O
FCS	O
,	O
10	O
microM	O
2	O
-	O
ME	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
and	O
antibiotics	O
.	O

HI	O
-	O
5	O
insect	O
cells	O
(	O
Invitrogen	O
)	O
expressing	O
CD154	B-Protein
have	O
been	O
described	O
[	O
28	O
]	O
.	O

Antibodies	O

Mouse	O
anti	O
-	O
birch	O
profilin	O
antibody	O
(	O
4A6	O
[	O
29	O
]	O
)	O
,	O
rat	O
anti	O
-	O
mouse	O
CD40	O
(	O
1C10	O
[	O
30	O
]	O
)	O
and	O
a	O
rat	O
isotype	O
control	O
antibody	O
(	O
mAb72	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
,	O
IA	O
)	O
were	O
isolated	O
from	O
hybridoma	O
supernatants	O
.	O

FITC	O
-	O
labeled	O
anti	O
-	O
mouse	O
CD80	O
and	O
an	O
isotype	O
control	O
Ab	O
were	O
from	O
eBiosciences	O
.	O

Rabbit	O
anti	O
-	O
HOIP	O
Ab	O
[	O
6	O
]	O
was	O
the	O
kind	O
gift	O
of	O
Dr	O
.	O
Betty	O
Eipper	O
(	O
University	O
of	O
Connecticut	O
Health	O
Center	O
,	O
Farmington	O
,	O
Connecticut	O
)	O
.	O

Goat	O
anti	O
-	O
rat	O
IgG	O
,	O
and	O
HRP	O
-	O
labeled	O
secondary	O
Abs	O
were	O
from	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
Inc	O
.	O

All	O
other	O
antibodies	O
used	O
were	O
described	O
previously	O
[	O
6	O
]	O
.	O

Somatic	O
cell	O
gene	O
targeting	O

The	O
generation	O
of	O
HOIP	B-Protein
-	O
deficient	O
cells	O
was	O
accomplished	O
using	O
a	O
homologous	O
recombination	O
approach	O
described	O
previously	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
.	O

Segments	O
of	O
Rnf31	B-Protein
gene	O
sequence	O
used	O
in	O
the	O
targeting	O
construct	O
(	O
Fig	O
.	O
1A	O
)	O
were	O
amplified	O
by	O
PCR	O
from	O
A20	O
.	O
2J	O
genomic	O
DNA	O
.	O

The	O
oligonucleotide	O
primers	O
used	O
to	O
generate	O
the	O
5	O
'	O
flank	O
(	O
1224	O
bp	O
)	O
were	O
5	O
'	O
-	O
ttttctagagcggtggcttaagtgaccc	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
tattctagatgcagcatctgagaaagcaagc	O
-	O
3	O
'	O
.	O

The	O
3	O
'	O
flank	O
(	O
6032	O
bp	O
)	O
primers	O
were	O
5	O
'	O
-	O
aaaaccggtgtatgcttctttacgggagaaaaatattag	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
tataccggtatgaagccaaaggaacactgagag	O
-	O
3	O
'	O
.	O

Restriction	O
endonuclease	O
sites	O
in	O
the	O
oligonucleotide	O
primers	O
allowed	O
insertion	O
of	O
the	O
PCR	O
products	O
into	O
the	O
targeting	O
vector	O
.	O

A20	O
.	O
2J	O
cells	O
were	O
transfected	O
(	O
by	O
electroporation	O
[	O
7	O
]	O
)	O
with	O
the	O
targeting	O
construct	O
and	O
subcloned	O
in	O
medium	O
containing	O
600	O
microg	O
/	O
ml	O
G418	O
sulfate	O
.	O

Homologous	O
recombination	O
in	O
G418	O
-	O
resistant	O
clones	O
was	O
detected	O
by	O
PCR	O
of	O
genomic	O
DNA	O
,	O
as	O
described	O
[	O
7	O
]	O
.	O

Oligonucleotide	O
primers	O
used	O
for	O
screening	O
were	O
5	O
'	O
-	O
cttcctgatctcagctttaccgtcac	O
-	O
3	O
'	O
(	O
homologous	O
to	O
genomic	O
sequence	O
;	O
approximate	O
position	O
noted	O
in	O
Fig	O
.	O
1	O
)	O
and	O
5	O
'	O
-	O
caatccatcttgttcagccat	O
-	O
3	O
'	O
(	O
homologous	O
to	O
sequence	O
in	O
NeoR	O
)	O
.	O

Clones	O
in	O
which	O
one	O
copy	O
of	O
Rnf31	B-Protein
had	O
been	O
disrupted	O
were	O
transiently	O
transfected	O
with	O
an	O
expression	O
plasmid	O
encoding	O
Cre	O
,	O
in	O
order	O
to	O
remove	O
NeoR	O
.	O

G418	O
-	O
sensitive	O
subclones	O
were	O
subjected	O
to	O
a	O
second	O
round	O
of	O
targeting	O
to	O
disrupt	O
the	O
remaining	O
copy	O
of	O
Rnf31	B-Protein
.	O

G418	O
-	O
resistant	O
clones	O
were	O
tested	O
for	O
homologous	O
recombination	O
by	O
PCR	O
and	O
HOIP	B-Protein
protein	O
expression	O
by	O
Western	O
blot	O
.	O

Retroviral	O
transduction	O

A	O
retroviral	O
vector	O
(	O
pMIP	O
)	O
was	O
used	O
for	O
the	O
stable	O
transduction	O
of	O
cells	O
with	O
HOIP	B-Protein
and	O
IKKgamma	B-Protein
cDNA	O
constructs	O
.	O

pMIP	O
was	O
constructed	O
by	O
replacing	O
the	O
IRES	O
and	O
GFP	O
encoding	O
sequences	O
in	O
pMIG	O
[	O
31	O
]	O
with	O
the	O
IRES	O
and	O
puromycin	O
resistance	O
gene	O
from	O
pIRESpuro2	O
(	O
Clontech	O
)	O
.	O

FLAG	O
-	O
tagged	O
mouse	O
HOIP	B-Protein
cDNA	O
was	O
inserted	O
into	O
the	O
multiple	O
cloning	O
site	O
of	O
pMIP	O
.	O

A	O
pMIP	O
construct	O
encoding	O
mouse	O
IKKgamma	B-Protein
with	O
an	O
amino	O
terminal	O
birch	O
profilin	O
peptide	O
(	O
BP	O
)	O
-	O
tag	O
was	O
also	O
prepared	O
.	O

Retroviral	O
particles	O
were	O
generated	O
by	O
transient	O
transfection	O
of	O
293T	O
cells	O
with	O
pMIP	O
,	O
pMIP	O
-	O
HOIP	B-Protein
,	O
or	O
pMIP	O
-	O
IKKgamma	B-Protein
and	O
the	O
packaging	O
vector	O
pCL	O
-	O
Eco	O
[	O
32	O
]	O
.	O

Two	O
days	O
after	O
transfection	O
,	O
culture	O
supernatants	O
were	O
harvested	O
and	O
filtered	O
.	O

A20	O
.	O
2J	O
or	O
HOIP	B-Protein
-	O
deficient	O
cells	O
were	O
added	O
to	O
24	O
-	O
well	O
plates	O
(	O
2	O
.	O
5x105	O
cells	O
/	O
well	O
)	O
with	O
1	O
ml	O
virus	O
-	O
containing	O
supernatant	O
and	O
8	O
microg	O
/	O
ml	O
polybrene	O
.	O

Plates	O
were	O
centrifuged	O
at	O
500	O
x	O
g	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
.	O

Cells	O
were	O
cultured	O
in	O
B	O
cell	O
culture	O
medium	O
for	O
48	O
hrs	O
,	O
after	O
which	O
the	O
transduced	O
cells	O
were	O
selected	O
in	O
3	O
microg	O
/	O
ml	O
puromycin	O
.	O

CD80	B-Protein
upregulation	O
and	O
flow	O
cytometry	O

Cells	O
(	O
5x104	O
in	O
2	O
ml	O
)	O
were	O
cultured	O
in	O
24	O
-	O
well	O
plates	O
for	O
3	O
days	O
with	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
CD40	O
or	O
an	O
isotype	O
control	O
antibody	O
.	O

Cells	O
were	O
stained	O
for	O
flow	O
cytometry	O
with	O
FITC	O
-	O
anti	O
-	O
CD80	O
or	O
an	O
appropriate	O
control	O
antibody	O
as	O
described	O
[	O
28	O
]	O
.	O

Data	O
acquired	O
with	O
a	O
FACScan	O
flow	O
cytometer	O
(	O
BD	O
Biosciences	O
)	O
were	O
analyzed	O
with	O
WinMDI	O
2	O
.	O
8	O
(	O
Scripps	O
Research	O
Institute	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

GLepsilon	B-Protein
transcript	O
assay	O

The	O
CD40	B-Protein
-	O
simulated	O
activation	O
of	O
GLepsilon	B-Protein
transcription	O
was	O
evaluated	O
as	O
previously	O
reported	O
[	O
33	O
]	O
.	O

Briefly	O
,	O
1x106	O
cells	O
were	O
stimulated	O
overnight	O
with	O
anti	O
-	O
CD40	O
antibody	O
(	O
10	O
microg	O
/	O
ml	O
)	O
or	O
an	O
isotype	O
control	O
antibody	O
,	O
with	O
or	O
without	O
500	O
U	O
/	O
ml	O
mouse	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
BD	O
Biosciences	O
)	O
.	O

RNA	O
was	O
isolated	O
using	O
Trizol	O
(	O
Invitrogen	O
)	O
,	O
and	O
reverse	O
-	O
transcribed	O
(	O
Superscript	O
III	O
kit	O
,	O
Invitrogen	O
)	O
.	O

Quantitative	O
PCR	O
for	O
GLepsilon	B-Protein
and	O
Hprt1	B-Protein
was	O
performed	O
using	O
SYBR	O
GREEN	O
master	O
mix	O
(	O
Applied	O
Biosystems	O
)	O
,	O
and	O
an	O
Applied	O
Biosystems	O
7900HT	O
Fast	O
Real	O
-	O
Time	O
PCR	O
instrument	O
.	O

Expression	O
of	O
GLepsilon	B-Protein
in	O
each	O
sample	O
was	O
normalized	O
to	O
the	O
expression	O
of	O
Hprt1	B-Protein
.	O

NF	O
-	O
kappaB	O
and	O
JNK	O
activation	O
assays	O

For	O
activation	O
of	O
CD40	B-Protein
signaling	O
,	O
5x104	O
HI5	O
insect	O
cells	O
or	O
HI5	O
insect	O
cells	O
expressing	O
mouse	O
CD154	B-Protein
(	O
CD40	B-Protein
ligand	I-Protein
)	O
were	O
added	O
to	O
1x106	O
B	O
cells	O
.	O

Cells	O
were	O
centrifuged	O
for	O
1	O
minute	O
at	O
400	O
x	O
g	O
(	O
to	O
promote	O
contact	O
between	O
ligand	O
cells	O
and	O
B	O
cells	O
)	O
then	O
incubated	O
at	O
37degreesC	O
for	O
times	O
indicated	O
in	O
Fig	O
.	O

4	O
.	O

Following	O
stimulation	O
,	O
cells	O
were	O
chilled	O
on	O
ice	O
for	O
2	O
minutes	O
.	O

Cell	O
pellets	O
were	O
dissolved	O
in	O
2X	O
SDS	O
-	O
PAGE	O
loading	O
buffer	O
,	O
sonicated	O
,	O
and	O
heated	O
for	O
5	O
minutes	O
at	O
95degreesC	O
.	O

Total	O
cell	O
lysates	O
(	O
1x105	O
cell	O
equivalents	O
per	O
lane	O
)	O
were	O
fractionated	O
by	O
SDS	O
-	O
PAGE	O
and	O
blotted	O
to	O
polyvinylidine	O
fluoride	O
(	O
PVDF	O
)	O
membranes	O
.	O

Membranes	O
were	O
probed	O
with	O
antibodies	O
as	O
indicated	O
in	O
Fig	O
.	O

4	O
.	O

Chemiluminescent	O
detection	O
(	O
Pierce	O
Biotechnology	O
)	O
was	O
used	O
for	O
the	O
visualization	O
of	O
bands	O
on	O
Western	O
blots	O
.	O

Images	O
of	O
blots	O
were	O
recorded	O
with	O
a	O
low	O
-	O
light	O
imaging	O
system	O
(	O
LAS4000	O
,	O
Fuji	O
Medical	O
Systems	O
)	O
and	O
on	O
X	O
-	O
ray	O
film	O
.	O

Immunoprecipitations	O

Immunoprecipitation	O
of	O
CD40	B-Protein
was	O
performed	O
by	O
activated	O
receptor	O
capture	O
,	O
as	O
previously	O
described	O
[	O
6	O
]	O
.	O

Briefly	O
,	O
3x107	O
cells	O
(	O
A20	O
.	O
2J	O
and	O
derivatives	O
)	O
were	O
incubated	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
with	O
10	O
microl	O
magnetic	O
protein	O
G	O
beads	O
(	O
Dynal	O
)	O
pre	O
-	O
coated	O
with	O
10	O
microg	O
goat	O
anti	O
-	O
rat	O
IgG	O
(	O
Jackson	O
)	O
,	O
and	O
10	O
microg	O
anti	O
-	O
CD40	O
(	O
1C10	O
)	O
or	O
an	O
isotype	O
control	O
antibody	O
(	O
mAb72	O
)	O
.	O

Cells	O
/	O
beads	O
were	O
then	O
pelleted	O
by	O
centrifugation	O
and	O
lysed	O
in	O
buffer	O
containing	O
1	O
%	O
Triton	O
X100	O
.	O

Beads	O
were	O
washed	O
with	O
lysis	O
buffer	O
to	O
remove	O
unbound	O
material	O
.	O

In	O
some	O
experiments	O
,	O
material	O
associated	O
with	O
the	O
beads	O
was	O
dephosphorylated	O
with	O
lambda	O
phosphatase	O
(	O
New	O
England	O
BioLabs	O
)	O
as	O
per	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Beads	O
were	O
resuspended	O
in	O
2X	O
SDS	O
-	O
PAGE	O
sample	O
buffer	O
and	O
heated	O
for	O
5	O
minutes	O
at	O
95degreesC	O
.	O

Material	O
eluted	O
from	O
the	O
beads	O
was	O
fractionated	O
by	O
SDS	O
-	O
PAGE	O
and	O
transferred	O
to	O
PVDF	O
membranes	O
for	O
Western	O
blotting	O
.	O

In	O
some	O
experiments	O
,	O
cells	O
were	O
cultured	O
for	O
6	O
hrs	O
with	O
25	O
microM	O
antennapedia	O
-	O
linked	O
SMAC	O
-	O
N7	O
peptide	O
(	O
Calbiochem	O
)	O
or	O
an	O
appropriate	O
volume	O
of	O
the	O
solvent	O
used	O
for	O
the	O
peptide	O
(	O
DMSO	O
)	O
.	O

After	O
incubation	O
,	O
cells	O
(	O
in	O
peptide	O
-	O
or	O
DMSO	O
-	O
containing	O
medium	O
)	O
were	O
stimulated	O
with	O
antibody	O
-	O
coated	O
beads	O
as	O
outlined	O
above	O
.	O

HOIP	B-Protein
gene	O
targeting	O
.	O

(	O
A	O
)	O
Regions	O
of	O
Rnf31	B-Protein
gene	O
sequence	O
(	O
bottom	O
)	O
used	O
in	O
the	O
HOIP	B-Protein
gene	O
targeting	O
vector	O
(	O
top	O
)	O
are	O
shown	O
.	O

Arrows	O
(	O
F	O
and	O
R	O
)	O
indicate	O
approximate	O
positions	O
of	O
sequences	O
homologous	O
to	O
oligonucleotides	O
used	O
for	O
PCR	O
-	O
mediated	O
detection	O
of	O
homologous	O
recombination	O
.	O

Homologous	O
recombination	O
of	O
the	O
vector	O
with	O
Rnf31	B-Protein
resulted	O
in	O
a	O
small	O
chromosomal	O
deletion	O
and	O
the	O
in	O
-	O
frame	O
insertion	O
of	O
neomycin	O
phosphotransferase	O
(	O
NeoR	O
)	O
into	O
the	O
amino	O
-	O
terminal	O
HOIP	B-Protein
coding	O
sequence	O
.	O

A	O
diphtheria	O
toxin	O
(	O
DT	O
)	O
cassette	O
in	O
the	O
vector	O
facilitates	O
the	O
negative	O
selection	O
of	O
cells	O
in	O
which	O
random	O
chromosomal	O
insertion	O
of	O
the	O
vector	O
takes	O
place	O
.	O

LoxP	O
sequences	O
allow	O
the	O
Cre	O
-	O
mediated	O
deletion	O
of	O
the	O
NeoR	O
coding	O
sequence	O
.	O

The	O
SV40pA	O
sequence	O
helps	O
to	O
ensure	O
disruption	O
of	O
gene	O
expression	O
after	O
deletion	O
of	O
the	O
NeoR	O
sequence	O
.	O

(	O
B	O
)	O
Anti	O
-	O
HOIP	O
and	O
anti	O
-	O
FLAG	O
Western	O
blots	O
of	O
cell	O
lysates	O
from	O
A20	O
.	O
2J	O
cells	O
and	O
HOIP	B-Protein
-	O
deficient	O
(	O
HOIP	B-Protein
-	O
/	O
-	O
)	O
clones	O
.	O

A	O
partial	O
decrease	O
in	O
HOIP	B-Protein
protein	O
expression	O
is	O
evident	O
in	O
cells	O
following	O
disruption	O
of	O
one	O
copy	O
of	O
Rnf31	B-Protein
(	O
HOIP	B-Protein
-	O
/	O
+	O
)	O
.	O

HOIP	B-Protein
expression	O
in	O
clones	O
reconstituted	O
with	O
an	O
empty	O
retroviral	O
vector	O
(	O
pMIP	O
)	O
or	O
a	O
retroviral	O
vector	O
encoding	O
FLAG	O
-	O
tagged	O
HOIP	B-Protein
is	O
also	O
shown	O
.	O

Approximate	O
molecular	O
weight	O
of	O
HOIP	B-Protein
is	O
120	O
kD	O
.	O

CD40	B-Protein
-	O
mediated	O
CD80	B-Protein
upregulation	O
is	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

Cells	O
were	O
incubated	O
for	O
72	O
hrs	O
with	O
an	O
isotype	O
control	O
antibody	O
(	O
left	O
)	O
or	O
anti	O
-	O
CD40	O
antibody	O
(	O
right	O
)	O
and	O
then	O
stained	O
for	O
expression	O
of	O
CD80	B-Protein
(	O
filled	O
profiles	O
indicate	O
staining	O
with	O
anti	O
-	O
CD80	O
antibody	O
;	O
open	O
profiles	O
are	O
staining	O
with	O
an	O
isotype	O
control	O
antibody	O
)	O
.	O

Transduction	O
of	O
both	O
HOIP	B-Protein
-	O
deficient	O
(	O
HOIP	B-Protein
-	O
/	O
-	O
)	O
clones	O
with	O
a	O
retrovirus	O
encoding	O
FLAG	O
-	O
HOIP	B-Protein
reversed	O
defective	O
CD80	B-Protein
upregulation	O
,	O
while	O
transduction	O
with	O
an	O
empty	O
vector	O
(	O
pMIP	O
)	O
did	O
not	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
a	O
second	O
experiment	O
.	O

GLepsilon	B-Protein
transcription	O
is	O
defective	O
in	O
CD40	B-Protein
-	O
stimulated	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

A20	O
.	O
2J	O
and	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
an	O
empty	O
retroviral	O
vector	O
(	O
A20	O
.	O
2J	O
+	O
pMIP	O
and	O
HOIP	B-Protein
-	O
/	O
-	O
+	O
pMIP	O
,	O
respectively	O
)	O
,	O
or	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
a	O
HOIP	B-Protein
-	O
encoding	O
retrovirus	O
(	O
HOIP	B-Protein
-	O
/	O
-	O
+	O
HOIP	B-Protein
)	O
were	O
cultured	O
overnight	O
with	O
agonistic	O
anti	O
-	O
CD40	O
or	O
an	O
isotype	O
control	O
antibody	O
(	O
iso	O
)	O
,	O
with	O
or	O
without	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

RNA	O
was	O
isolated	O
from	O
the	O
cells	O
,	O
reverse	O
-	O
transcribed	O
,	O
and	O
then	O
subjected	O
to	O
quantitative	O
PCR	O
to	O
determine	O
levels	O
of	O
GLepsilon	B-Protein
transcripts	O
.	O

Results	O
were	O
normalized	O
to	O
the	O
levels	O
of	O
Hprt1	B-Protein
transcripts	O
in	O
each	O
sample	O
.	O

Symbols	O
indicate	O
the	O
values	O
from	O
duplicate	O
cultures	O
(	O
a	O
line	O
indicates	O
the	O
mean	O
of	O
the	O
two	O
values	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
a	O
second	O
experiment	O
and	O
in	O
an	O
additional	O
experiment	O
with	O
a	O
second	O
HOIP	B-Protein
-	O
deficient	O
clone	O
.	O

CD40	B-Protein
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
JNK	O
is	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

CD40	B-Protein
-	O
mediated	O
signaling	O
was	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
(	O
HOIP	O
-	O
/	O
-	O
+	O
pMIP	O
)	O
,	O
but	O
intact	O
in	O
parental	O
cells	O
transduced	O
with	O
an	O
empty	O
retroviral	O
vector	O
(	O
A20	O
.	O
2J	O
+	O
pMIP	O
)	O
and	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
a	O
retroviral	O
vector	O
encoding	O
HOIP	B-Protein
(	O
HOIP	B-Protein
-	O
/	O
-	O
+	O
HOIP	B-Protein
)	O
.	O

Cells	O
were	O
activated	O
with	O
CD154	B-Protein
-	O
expressing	O
insect	O
cells	O
for	O
the	O
times	O
indicated	O
.	O

As	O
a	O
negative	O
control	O
,	O
cells	O
were	O
stimulated	O
with	O
insect	O
cells	O
lacking	O
CD154	B-Protein
(	O
5	O
minute	O
time	O
point	O
only	O
)	O
.	O

Western	O
blots	O
of	O
whole	O
-	O
cell	O
lysates	O
were	O
probed	O
with	O
the	O
indicated	O
antibodies	O
.	O

Phospho	B-Protein
-	I-Protein
IkappaBalpha	I-Protein
(	O
pIkappaBalpha	B-Protein
)	O
and	O
phospho	O
-	O
JNK	O
(	O
pJNK	O
)	O
blots	O
were	O
stripped	O
and	O
reprobed	O
for	O
total	O
IkappaBalpha	B-Protein
and	O
total	O
JNK	O
,	O
respectively	O
(	O
anti	O
-	O
JNK	O
antibodies	O
recognize	O
p46	O
and	O
p54	O
isoforms	O
)	O
.	O

IkappaBalpha	B-Protein
blots	O
were	O
also	O
reprobed	O
for	O
actin	O
to	O
demonstrate	O
equal	O
lane	O
loading	O
.	O

Molecular	O
weights	O
are	O
indicated	O
at	O
right	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
a	O
second	O
experiment	O
and	O
in	O
two	O
additional	O
experiments	O
with	O
a	O
second	O
HOIP	B-Protein
-	O
deficient	O
clone	O
.	O

IKK	O
recruitment	O
to	O
the	O
CD40	O
signaling	O
complex	O
is	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

(	O
A	O
)	O
SMAC	O
peptide	O
treatment	O
reduces	O
recruitment	O
of	O
cIAP1	B-Protein
to	O
CD40	B-Protein
and	O
may	O
modify	O
HOIP	B-Protein
recruitment	O
.	O

A20	O
.	O
2J	O
cells	O
were	O
incubated	O
for	O
six	O
hours	O
with	O
membrane	O
-	O
permeable	O
SMAC	O
-	O
N7	O
peptide	O
or	O
1	O
.	O
5	O
%	O
DMSO	O
(	O
solvent	O
used	O
for	O
the	O
peptide	O
)	O
.	O

Following	O
the	O
incubation	O
,	O
cell	O
lysates	O
were	O
prepared	O
,	O
fractionated	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
evaluated	O
by	O
Western	O
blot	O
(	O
lanes	O
1	O
and	O
2	O
)	O
.	O

Cells	O
incubated	O
with	O
DMSO	O
or	O
SMAC	O
-	O
N7	O
were	O
also	O
stimulated	O
with	O
magnetic	O
beads	O
coated	O
with	O
anti	O
-	O
CD40	O
or	O
an	O
isotype	O
control	O
antibody	O
.	O

Immunoprecipitated	O
(	O
IP	O
)	O
material	O
bound	O
to	O
the	O
beads	O
was	O
loaded	O
in	O
lanes	O
3	O
-	O
5	O
.	O

Samples	O
of	O
the	O
cell	O
lysates	O
after	O
immunoprecipitation	O
appear	O
in	O
lanes	O
6	O
-	O
8	O
.	O

Western	O
blots	O
were	O
probed	O
with	O
antibodies	O
specific	O
for	O
cIAP1	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
and	O
HOIP	B-Protein
(	O
approximate	O
molecular	O
weights	O
indicated	O
on	O
left	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
two	O
additional	O
experiments	O
.	O

(	O
B	O
)	O
CD40	B-Protein
was	O
isolated	O
by	O
immunoprecipitation	O
(	O
as	O
in	O
(	O
A	O
)	O
)	O
from	O
A20	O
.	O
2J	O
cells	O
and	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
an	O
empty	O
retroviral	O
vector	O
(	O
pMIP	O
)	O
or	O
a	O
retroviral	O
vector	O
encoding	O
HOIP	B-Protein
.	O

Material	O
immunoprecipitated	O
with	O
an	O
isotype	O
control	O
antibody	O
(	O
isotype	O
)	O
or	O
anti	O
-	O
CD40	O
antibody	O
was	O
examined	O
by	O
Western	O
blotting	O
for	O
CD40	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
cIAP1	B-Protein
,	O
HOIP	B-Protein
,	O
IKKalpha	B-Protein
/	O
beta	B-Protein
,	O
and	O
IKKgamma	B-Protein
(	O
right	O
panels	O
)	O
.	O

HOIP	B-Protein
expression	O
was	O
required	O
for	O
coprecipitation	O
of	O
IKK	O
proteins	O
with	O
CD40	B-Protein
.	O

Cell	O
lysates	O
from	O
unstimulated	O
cells	O
are	O
shown	O
in	O
the	O
left	O
panels	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
a	O
second	O
experiment	O
and	O
in	O
two	O
experiments	O
with	O
a	O
second	O
HOIP	B-Protein
-	O
deficient	O
clone	O
.	O

(	O
C	O
)	O
To	O
further	O
evaluate	O
HOIP	B-Protein
-	O
dependent	O
recruitment	O
of	O
IKKgamma	B-Protein
to	O
CD40	B-Protein
,	O
A20	O
.	O
2J	O
cells	O
or	O
HOIP	B-Protein
-	O
deficient	O
(	O
HOIP	B-Protein
-	O
/	O
-	O
)	O
A20	O
.	O
2J	O
cells	O
were	O
transduced	O
with	O
an	O
empty	O
retroviral	O
vector	O
or	O
a	O
retroviral	O
construct	O
encoding	O
BP	O
epitope	O
-	O
tagged	O
IKKgamma	B-Protein
(	O
noted	O
in	O
the	O
figure	O
as	O
pMIP	B-Protein
and	O
IKKgamma	B-Protein
,	O
respectively	O
)	O
.	O

Lysates	O
(	O
lanes	O
1	O
-	O
3	O
)	O
and	O
immunoprecipitation	O
(	O
IP	O
)	O
samples	O
(	O
lanes	O
4	O
-	O
11	O
)	O
from	O
the	O
cell	O
lines	O
were	O
fractionated	O
by	O
SDS	O
-	O
PAGE	O
and	O
evaluated	O
by	O
Western	O
blotting	O
with	O
antibodies	O
to	O
the	O
BP	O
tag	O
(	O
IKKgamma	B-Protein
,	O
upper	O
panel	O
)	O
and	O
TRAF2	B-Protein
.	O

The	O
anti	O
-	O
CD40	O
IP	O
sample	O
in	O
lane	O
11	O
was	O
treated	O
with	O
lambda	O
phosphatase	O
;	O
the	O
sample	O
in	O
lane	O
10	O
was	O
mock	O
-	O
treated	O
.	O

Protein	O
samples	O
(	O
minus	O
those	O
treated	O
with	O
phosphatase	O
)	O
were	O
also	O
fractionated	O
on	O
a	O
separate	O
gel	O
(	O
lower	O
acrylamide	O
concentration	O
)	O
for	O
the	O
evaluation	O
of	O
TRAF3	B-Protein
and	O
HOIP	B-Protein
(	O
bottom	O
two	O
panels	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
two	O
additional	O
experiments	O
.	O

M	O
-	O
CSF	O
Induces	O
Monocyte	O
Survival	O
by	O
Activating	O
NF	O
-	O
kappaB	O
p65	B-Protein
Phosphorylation	O
at	O
Ser276	O
via	O
Protein	O
Kinase	O
C	O

Macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
promotes	O
mononuclear	O
phagocyte	O
survival	O
and	O
proliferation	O
.	O

The	O
transcription	O
factor	O
Nuclear	O
Factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
key	O
regulator	O
of	O
genes	O
involved	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
mononuclear	O
phagocyte	O
survival	O
and	O
this	O
study	O
focused	O
at	O
identifying	O
the	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
M	O
-	O
CSF	O
stimulated	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
and	O
the	O
murine	O
macrophage	O
cell	O
line	O
RAW	O
264	O
.	O
7	O
.	O

The	O
general	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
,	O
the	O
conventional	O
PKCalpha	B-Protein
/	O
beta	B-Protein
inhibitor	O
Go	O
-	O
6976	O
,	O
overexpression	O
of	O
dominant	B-Protein
negative	I-Protein
PKCalpha	I-Protein
constructs	O
and	O
PKCalpha	B-Protein
siRNA	I-Protein
reduced	O
NF	O
-	O
kappaB	O
activity	O
in	O
response	O
to	O
M	O
-	O
CSF	O
.	O

Interestingly	O
,	O
Ro	O
-	O
31	O
-	O
8220	O
reduced	O
Ser276	O
phosphorylation	O
of	O
NF	O
-	O
kappaBp65	B-Protein
leading	O
to	O
decreased	O
M	O
-	O
CSF	O
-	O
induced	O
monocyte	O
survival	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
conventional	O
PKCs	O
,	O
including	O
PKCalpha	B-Protein
as	O
important	O
upstream	O
kinases	O
for	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
,	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
Ser276	O
phosphorylation	O
,	O
and	O
macrophage	O
survival	O
.	O

Lastly	O
,	O
we	O
find	O
that	O
NF	O
-	O
kappaB	O
p65	B-Protein
Ser276	O
plays	O
an	O
important	O
role	O
in	O
basal	O
and	O
M	O
-	O
CSF	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
in	O
human	O
mononuclear	O
phagocytes	O
.	O

Monocytes	O
are	O
produced	O
in	O
the	O
bone	O
marrow	O
and	O
circulate	O
in	O
blood	O
for	O
24	O
-	O
48	O
hours	O
[	O
1	O
]	O
.	O

In	O
the	O
absence	O
of	O
serum	O
,	O
monocytes	O
die	O
via	O
apoptosis	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
stimulates	O
mononuclear	O
phagocyte	O
survival	O
and	O
differentiation	O
[	O
3	O
]	O
.	O

Importantly	O
,	O
M	O
-	O
CSF	O
-	O
mediated	O
cell	O
survival	O
and	O
activation	O
is	O
associated	O
with	O
a	O
variety	O
of	O
human	O
diseases	O
,	O
including	O
atherosclerosis	O
,	O
transplant	O
vascular	O
sclerosis	O
and	O
breast	O
cancer	O
metastasis	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
.	O

We	O
previously	O
identified	O
that	O
NF	O
-	O
kappaB	O
activation	O
is	O
important	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
monocyte	O
survival	O
[	O
7	O
]	O
.	O

In	O
addition	O
to	O
its	O
role	O
in	O
mononuclear	O
phagocyte	O
survival	O
,	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
regulates	O
numerous	O
genes	O
that	O
play	O
important	O
roles	O
in	O
cellular	O
signaling	O
,	O
stress	O
response	O
,	O
cell	O
growth	O
,	O
survival	O
,	O
differentiation	O
and	O
inflammation	O
[	O
8	O
]	O
.	O

There	O
are	O
five	O
members	O
in	O
the	O
NF	O
-	O
kappaB	O
family	O
:	O
RelA	B-Protein
/	O
p65	B-Protein
,	O
p50	B-Protein
,	O
p52	B-Protein
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
and	O
RelB	B-Protein
.	O

The	O
most	O
common	O
activating	O
complex	O
is	O
the	O
p50	B-Protein
/	O
p65	B-Protein
heterodimer	O
,	O
driven	O
by	O
the	O
activation	O
domain	O
in	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
.	O

NF	O
-	O
kappaB	O
p65	B-Protein
regulates	O
important	O
developmental	O
processes	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O

Mice	O
lacking	O
NF	O
-	O
kappaB	O
p65	B-Protein
die	O
in	O
utero	O
and	O
have	O
extensive	O
liver	O
damage	O
via	O
enhanced	O
apoptosis	O
[	O
9	O
]	O
.	O

Embryonic	O
macrophages	O
from	O
NF	O
-	O
kappaB	O
p65	B-Protein
null	O
mice	O
are	O
susceptible	O
to	O
TNFalpha	B-Protein
-	O
induced	O
apoptosis	O
which	O
is	O
rescued	O
by	O
overexpressing	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
[	O
10	O
]	O
.	O

Moreover	O
,	O
inhibiting	O
NF	O
-	O
kappaB	O
induces	O
cell	O
death	O
in	O
many	O
cell	O
types	O
and	O
cytokine	O
-	O
independent	O
survival	O
is	O
mediated	O
by	O
constitutively	O
active	O
NF	O
-	O
kappaB	O
in	O
murine	O
macrophages	O
[	O
11	O
]	O
.	O

In	O
monocytes	O
and	O
macrophages	O
,	O
NF	O
-	O
kappaB	O
is	O
an	O
important	O
transcriptional	O
factor	O
for	O
expression	O
of	O
cytokines	O
and	O
cell	O
surface	O
receptors	O
[	O
12	O
]	O
.	O

However	O
,	O
unlike	O
resting	O
T	O
-	O
cells	O
,	O
NF	O
-	O
kappaB	O
is	O
constitutively	O
present	O
in	O
the	O
nuclei	O
of	O
primary	O
monocytes	O
and	O
monocytic	O
cell	O
lines	O
in	O
the	O
absence	O
of	O
exogenous	O
stimuli	O
as	O
demonstrated	O
by	O
mobility	O
shift	O
analysis	O
[	O
13	O
]	O
.	O

Similarly	O
,	O
constitutively	O
active	O
NF	O
-	O
kappaB	O
was	O
observed	O
in	O
human	O
alveolar	O
macrophages	O
[	O
14	O
]	O
.	O

In	O
the	O
classic	O
/	O
canonical	O
pathway	O
,	O
the	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
complex	O
is	O
sequestered	O
in	O
the	O
cytosol	O
by	O
IkappaBalpha	B-Protein
[	O
15	O
]	O
.	O

Upon	O
stimulation	O
by	O
cytokines	O
or	O
UV	O
radiation	O
,	O
IkappaBalpha	B-Protein
is	O
phosphorylated	O
,	O
ubiquitinated	O
,	O
and	O
degraded	O
,	O
releasing	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
transactivate	O
target	O
genes	O
.	O

After	O
its	O
release	O
from	O
IkappaBalpha	B-Protein
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
can	O
undergo	O
post	O
-	O
translational	O
modification	O
to	O
activate	O
gene	O
transcription	O
.	O

The	O
role	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
on	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
varies	O
by	O
stimulus	O
,	O
time	O
of	O
stimulation	O
and	O
cell	O
type	O
[	O
16	O
]	O
.	O

Previous	O
research	O
shows	O
that	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
,	O
Ser529	O
or	O
Ser536	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappaB	O
[	O
17	O
]	O
.	O

In	O
TNFalpha	O
-	O
treated	O
murine	O
fibroblasts	O
,	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
phosphorylated	O
by	O
MSK1	B-Protein
to	O
enhance	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
[	O
18	O
]	O
.	O

In	O
macrophages	O
treated	O
with	O
endotoxin	O
,	O
NF	O
-	O
kappaB	O
transcription	O
activity	O
is	O
associated	O
with	O
phosphorylation	O
on	O
Ser276	O
and	O
Ser536	O
that	O
is	O
regulated	O
through	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
and	O
IKKbeta	B-Protein
respectively	O
[	O
16	O
]	O
,	O
[	O
19	O
]	O
.	O

In	O
human	O
T	O
cells	O
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
constitutively	O
phosphorylated	O
on	O
Ser536	O
to	O
facilitate	O
NF	O
-	O
kappaB	O
p65	B-Protein
nuclear	O
translocation	O
following	O
cellular	O
stimulation	O
[	O
20	O
]	O
.	O

Accumulating	O
evidence	O
reveals	O
that	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
is	O
crucial	O
for	O
its	O
transcriptional	O
activity	O
.	O

Upon	O
nuclear	O
translocation	O
,	O
phosphorylation	O
of	O
Ser276	O
on	O
NF	O
-	O
kappaB	O
p65	B-Protein
by	O
PKA	O
recruits	O
the	O
transcription	O
co	O
-	O
activator	O
,	O
p300	B-Protein
to	O
potentiate	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
transcription	O
[	O
21	O
]	O
.	O

However	O
,	O
other	O
studies	O
show	O
that	O
PKA	O
inhibits	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
by	O
stabilizing	O
IkappaBalpha	B-Protein
[	O
22	O
]	O
,	O
[	O
23	O
]	O
.	O

Interestingly	O
,	O
the	O
serine	O
/	O
threonine	O
kinase	O
Pim	B-Protein
-	I-Protein
1	I-Protein
directly	O
phosphorylates	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
by	O
stabilizing	O
to	O
prevent	O
ubiquitin	O
-	O
proteasome	O
degradation	O
[	O
24	O
]	O
.	O

Several	O
other	O
phosphorylation	O
sites	O
are	O
also	O
described	O
to	O
enhance	O
NF	O
-	O
kappaB	O
gene	O
transactivation	O
[	O
25	O
]	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
.	O

PKC	O
proteins	O
are	O
multifunctional	O
kinases	O
that	O
differ	O
in	O
structure	O
,	O
function	O
and	O
co	O
-	O
factor	O
requirement	O
[	O
26	O
]	O
.	O

PKCs	O
are	O
involved	O
in	O
diverse	O
cell	O
responses	O
,	O
including	O
cell	O
growth	O
,	O
survival	O
,	O
differentiation	O
and	O
development	O
[	O
27	O
]	O
.	O

The	O
12	O
closely	O
related	O
enzymes	O
of	O
the	O
PKC	O
family	O
are	O
divided	O
into	O
three	O
classes	O
:	O
conventional	O
(	O
cPKCs	O
:	O
alpha	B-Protein
betaI	B-Protein
betaII	B-Protein
and	O
gamma	B-Protein
require	O
Ca2	O
+	O
and	O
diacylglycerol	O
(	O
DAG	O
)	O
;	O
novel	O
(	O
nPKCs	O
:	O
delta	B-Protein
,	O
epsilon	B-Protein
,	O
eta	B-Protein
,	O
theta	B-Protein
and	O
mu	B-Protein
)	O
require	O
DAG	O
;	O
and	O
atypical	O
(	O
aPKCs	O
:	O
xi	B-Protein
,	O
iota	B-Protein
and	O
lambda	B-Protein
)	O
require	O
neither	O
Ca2	O
+	O
nor	O
DAG	O
.	O

Monocytes	O
and	O
macrophages	O
predominantly	O
express	O
conventional	O
PKC	O
isoforms	O
(	O
PKCalpha	B-Protein
PKCbetaI	B-Protein
and	O
PKCbetaII	B-Protein
)	O
and	O
novel	O
PKCs	O
(	O
PKCdelta	B-Protein
and	O
PKCepsilon	B-Protein
)	O
.	O

Conventional	O
PKCs	O
regulate	O
differentiation	O
of	O
the	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
HL60	O
to	O
macrophages	O
[	O
28	O
]	O
.	O

PKCalpha	B-Protein
induces	O
IL	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
iNOS	B-Protein
and	O
TNFalpha	B-Protein
mRNA	O
production	O
after	O
lipopolysaccharide	O
(	O
LPS	O
)	O
exposure	O
[	O
29	O
]	O
.	O

In	O
addition	O
,	O
accumulating	O
evidence	O
suggests	O
that	O
conventional	O
PKCs	O
like	O
PKCalpha	B-Protein
have	O
anti	O
-	O
apoptotic	O
functions	O
.	O

For	O
example	O
,	O
PKCalpha	B-Protein
is	O
overexpressed	O
in	O
a	O
variety	O
of	O
tumor	O
cells	O
including	O
gliomas	O
,	O
liver	O
,	O
and	O
lung	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

In	O
epithelial	O
cells	O
,	O
inhibition	O
of	O
PKCalpha	B-Protein
induces	O
PKCdelta	B-Protein
-	O
dependent	O
apoptosis	O
[	O
31	O
]	O
.	O

Interestingly	O
,	O
in	O
human	O
monocytes	O
and	O
premonocytic	O
THP	O
-	O
1	O
leukemia	O
cells	O
,	O
novel	O
PKCs	O
like	O
PKCdelta	B-Protein
have	O
the	O
opposite	O
effect	O
on	O
cell	O
survival	O
,	O
Voss	O
et	O
al	O
showed	O
that	O
PKCdelta	B-Protein
directly	O
phosphorylates	O
caspase	B-Protein
-	I-Protein
3	I-Protein
and	O
promotes	O
etoposide	O
-	O
induced	O
apoptosis	O
[	O
32	O
]	O
.	O

Moreover	O
,	O
knockout	O
mouse	O
studies	O
suggest	O
that	O
another	O
novel	O
PKC	O
,	O
PKCepsilon	B-Protein
is	O
critically	O
involved	O
in	O
early	O
LPS	O
-	O
mediated	O
signaling	O
in	O
activated	O
macrophages	O
[	O
33	O
]	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
M	O
-	O
CSF	O
promotes	O
monocyte	O
survival	O
through	O
the	O
activation	O
of	O
the	O
PI3	O
-	O
K	O
/	O
AKT	O
pathway	O
[	O
3	O
]	O
.	O

In	O
addition	O
to	O
AKT	O
activation	O
,	O
M	O
-	O
CSF	O
stimulates	O
PKC	O
in	O
human	O
monocytes	O
and	O
increases	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
[	O
34	O
]	O
.	O

However	O
,	O
whether	O
PKC	O
and	O
/	O
or	O
NF	O
-	O
kappaB	O
activation	O
is	O
critical	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
mononuclear	O
phagocyte	O
survival	O
and	O
/	O
or	O
differentiation	O
is	O
unclear	O
.	O

In	O
other	O
cells	O
,	O
PKC	O
plays	O
an	O
important	O
role	O
in	O
NF	O
-	O
kappaB	O
activation	O
and	O
cell	O
survival	O
[	O
35	O
]	O
,	O
however	O
the	O
specific	O
mechanisms	O
of	O
this	O
activation	O
and	O
the	O
biological	O
effects	O
on	O
cellular	O
phenotype	O
are	O
not	O
known	O
.	O

Therefore	O
,	O
we	O
focused	O
at	O
understanding	O
the	O
role	O
of	O
PKC	O
in	O
the	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
M	O
-	O
CSF	O
-	O
induced	O
monocyte	O
survival	O
.	O

Here	O
we	O
demonstrates	O
that	O
M	O
-	O
CSF	O
upregulated	O
the	O
NF	O
-	O
kappaB	O
transcription	O
and	O
cell	O
survival	O
in	O
human	O
and	O
mouse	O
macrophages	O
.	O

This	O
activity	O
was	O
reduced	O
by	O
the	O
conventional	O
,	O
but	O
not	O
novel	O
,	O
PKC	O
inhibitors	O
,	O
dominant	B-Protein
negative	I-Protein
PKCalpha	I-Protein
constructs	O
or	O
PKCalpha	B-Protein
siRNA	I-Protein
.	O

Conventional	O
PKC	O
regulated	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
and	O
phosphorylation	O
of	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
occurred	O
in	O
an	O
M	O
-	O
CSF	O
-	O
dependent	O
fashion	O
correlating	O
with	O
its	O
maximal	O
transcriptional	O
activity	O
.	O

Furthermore	O
,	O
PKCalpha	O
-	O
regulated	O
phosphorylation	O
of	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
plays	O
an	O
important	O
role	O
in	O
regulating	O
its	O
activity	O
in	O
mononuclear	O
phagocytes	O
and	O
murine	O
embryonic	O
fibroblasts	O
.	O

M	O
-	O
CSF	O
Induces	O
NF	O
-	O
kappaB	O
Transcriptional	O
Activity	O
in	O
Human	O
Monocyte	O
-	O
Derived	O
Macrophages	O
(	O
MDMs	O
)	O
and	O
Mouse	O
Macrophage	O
Cell	O
Line	O
,	O
RAW	O
264	O
.	O
7	O

To	O
determine	O
if	O
M	O
-	O
CSF	O
induced	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
in	O
human	O
macrophages	O
,	O
we	O
performed	O
EMSA	O
analysis	O
on	O
nuclear	O
lysates	O
from	O
M	O
-	O
CSF	O
-	O
treated	O
MDMs	O
.	O

Similar	O
to	O
previous	O
reports	O
[	O
11	O
]	O
,	O
nuclear	O
NF	O
-	O
kappaB	O
constitutively	O
bound	O
DNA	O
in	O
non	O
-	O
stimulated	O
monocytes	O
(	O
Figure	O
1A	O
)	O
.	O

Interestingly	O
,	O
adding	O
M	O
-	O
CSF	O
did	O
not	O
alter	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
by	O
EMSA	O
.	O

In	O
contrast	O
,	O
after	O
transiently	O
transfecting	O
human	O
MDMs	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
constructs	O
containing	O
four	O
NF	O
-	O
kappaB	O
consensus	O
binding	O
sequences	O
,	O
M	O
-	O
CSF	O
treatment	O
of	O
the	O
transfected	O
cells	O
resulted	O
in	O
a	O
2	O
.	O
3	O
-	O
fold	O
increase	O
in	O
SEAP	O
release	O
in	O
the	O
culture	O
media	O
compared	O
to	O
PBS	O
(	O
vehicle	O
)	O
-	O
treated	O
transfected	O
MDMs	O
(	O
Figure	O
1B	O
)	O
.	O

As	O
a	O
control	O
,	O
the	O
pTAL	O
-	O
SEAP	O
construct	O
lacking	O
NF	O
-	O
kappaB	O
binding	O
sites	O
was	O
used	O
.	O

Cells	O
transfected	O
with	O
the	O
pTAL	O
-	O
SEAP	O
construct	O
did	O
not	O
produce	O
SEAP	O
in	O
the	O
absence	O
or	O
presence	O
of	O
M	O
-	O
CSF	O
(	O
Figure	O
1B	O
)	O
.	O

We	O
next	O
investigated	O
whether	O
M	O
-	O
CSF	O
induced	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
mouse	O
macrophage	O
cell	O
line	O
,	O
RAW	O
264	O
.	O
7	O
.	O

RAW	O
264	O
.	O
7	O
cells	O
were	O
transfected	O
with	O
either	O
the	O
NF	O
-	O
kappaB	O
-	O
SEAP	O
reporter	O
or	O
control	O
pTAL	O
-	O
SEAP	O
construct	O
.	O

As	O
shown	O
in	O
Figure	O
1C	O
,	O
M	O
-	O
CSF	O
treatment	O
of	O
RAW	O
264	O
.	O
7	O
cells	O
increased	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
reporter	O
activity	O
by	O
2	O
.	O
5	O
-	O
fold	O
over	O
that	O
of	O
non	O
-	O
treated	O
cells	O
.	O

Together	O
,	O
our	O
data	O
demonstrate	O
that	O
M	O
-	O
CSF	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
macrophages	O
.	O

PKC	O
Inhibition	O
Reduces	O
NF	O
-	O
kappaB	O
Activity	O
in	O
Human	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
Cells	O

Since	O
NF	O
-	O
kappaB	O
is	O
activated	O
by	O
PKC	O
in	O
several	O
cell	O
types	O
[	O
36	O
]	O
,	O
we	O
next	O
determined	O
if	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
was	O
dependent	O
on	O
PKC	O
activation	O
and	O
if	O
calcium	O
,	O
a	O
co	O
-	O
factor	O
for	O
conventional	O
PKC	O
isoform	O
activation	O
,	O
was	O
important	O
.	O

In	O
addition	O
,	O
because	O
of	O
the	O
number	O
of	O
conventional	O
PKCs	O
existing	O
within	O
mononuclear	O
cells	O
,	O
pharmacological	O
inhibitors	O
of	O
PKC	O
family	O
activation	O
was	O
used	O
to	O
determine	O
the	O
relationship	O
of	O
PKC	O
activation	O
to	O
M	O
-	O
CSF	O
-	O
induced	O
cellular	O
survival	O
.	O

MDMs	O
were	O
transfected	O
with	O
the	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
reporter	O
and	O
then	O
treated	O
with	O
the	O
general	O
PKC	O
inhibitor	O
,	O
Ro	O
-	O
31	O
-	O
8220	O
;	O
the	O
conventional	O
PKCalpha	B-Protein
/	O
beta	B-Protein
inhibitor	O
Go	O
-	O
6976	O
;	O
or	O
the	O
intracellular	O
calcium	O
blocker	O
BAPTA	O
/	O
AM	O
.	O

Ro	O
-	O
31	O
-	O
8220	O
significantly	O
suppressed	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
compared	O
to	O
cells	O
treated	O
with	O
M	O
-	O
CSF	O
alone	O
(	O
Figure	O
2A	O
)	O
.	O

In	O
addition	O
,	O
Go	O
-	O
6976	O
and	O
BAPTA	O
/	O
AM	O
also	O
blocked	O
NF	O
-	O
kappaB	O
activity	O
in	O
M	O
-	O
CSF	O
-	O
treated	O
MDMs	O
.	O

Trypan	O
blue	O
exclusion	O
analysis	O
did	O
not	O
indicate	O
cell	O
death	O
suggesting	O
that	O
this	O
suppression	O
was	O
not	O
due	O
to	O
non	O
-	O
specific	O
toxicity	O
.	O

These	O
data	O
indicate	O
that	O
M	O
-	O
CSF	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
through	O
calcium	O
-	O
dependent	O
conventional	O
PKC	O
activation	O
.	O

We	O
next	O
investigated	O
whether	O
PKC	O
inhibition	O
affected	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
mouse	O
macrophage	O
cell	O
line	O
,	O
RAW	O
264	O
.	O
7	O
.	O

Similar	O
to	O
MDMs	O
,	O
PKC	O
inhibitors	O
Ro	O
-	O
31	O
-	O
8220	O
,	O
Go	O
-	O
6976	O
and	O
BAPTA	O
/	O
AM	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
(	O
Figure	O
2B	O
)	O
.	O

To	O
ensure	O
that	O
PKC	O
specifically	O
regulated	O
NF	O
-	O
kappaB	O
p65	B-Protein
and	O
not	O
the	O
closely	O
related	O
family	O
member	O
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
we	O
co	O
-	O
transfected	O
c	O
-	O
Rel	O
and	O
NF	O
-	O
kappaB	O
-	O
SEAP	O
constructs	O
into	O
the	O
Raw	O
264	O
.	O
7	O
cell	O
line	O
and	O
measured	O
NF	O
-	O
kappaB	O
activity	O
in	O
response	O
to	O
M	O
-	O
CSF	O
.	O

There	O
was	O
no	O
increased	O
NF	O
-	O
kappaB	O
activity	O
in	O
cells	O
expressing	O
c	B-Protein
-	I-Protein
Rel	I-Protein
(	O
Figure	O
S1	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
PKC	O
functioned	O
upstream	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

NF	O
-	O
kappaB	O
and	O
PKC	O
(	O
s	O
)	O
Mediate	O
Human	O
MDM	O
Survival	O
in	O
Response	O
to	O
M	O
-	O
CSF	O
Stimulation	O

Since	O
PKC	O
and	O
NF	O
-	O
kappaB	O
are	O
critical	O
in	O
cell	O
survival	O
[	O
37	O
]	O
,	O
[	O
38	O
]	O
,	O
we	O
hypothesized	O
that	O
M	O
-	O
CSF	O
promoted	O
cell	O
survival	O
through	O
PKC	O
in	O
human	O
MDMs	O
.	O

To	O
detect	O
apoptosis	O
,	O
the	O
expression	O
of	O
cleaved	O
caspase	B-Protein
-	I-Protein
3	I-Protein
,	O
a	O
marker	O
of	O
apoptosis	O
,	O
was	O
analyzed	O
in	O
the	O
presence	O
or	O
absence	O
of	O
M	O
-	O
CSF	O
and	O
PKC	O
inhibitors	O
.	O

In	O
MDMs	O
pretreated	O
with	O
PKC	O
inhibitors	O
(	O
Ro	O
-	O
31	O
-	O
8220	O
,	O
Go	O
-	O
6976	O
,	O
or	O
BAPTA	O
/	O
AM	O
)	O
and	O
stimulated	O
with	O
M	O
-	O
CSF	O
,	O
cleaved	O
caspase	B-Protein
-	I-Protein
3	I-Protein
was	O
elevated	O
to	O
levels	O
of	O
cells	O
treated	O
with	O
vehicle	O
alone	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
cells	O
incubated	O
with	O
M	O
-	O
CSF	O
and	O
vehicle	O
had	O
less	O
cleaved	O
caspase	B-Protein
-	I-Protein
3	I-Protein
than	O
cells	O
incubated	O
with	O
vehicle	O
alone	O
or	O
M	O
-	O
CSF	O
with	O
PKC	O
inhibitors	O
.	O

These	O
data	O
supported	O
the	O
hypothesis	O
that	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
was	O
regulated	O
by	O
conventional	O
PKCs	O
,	O
not	O
novel	O
PKCs	O
.	O

To	O
confirm	O
that	O
PKC	O
inhibition	O
decreased	O
cell	O
survival	O
,	O
cells	O
were	O
treated	O
with	O
M	O
-	O
CSF	O
in	O
the	O
absence	O
or	O
presence	O
of	O
PKC	O
inhibitors	O
and	O
then	O
also	O
examined	O
for	O
apoptosis	O
by	O
Annexin	B-Protein
V	I-Protein
/	O
PI	O
staining	O
.	O

PKC	O
inhibitors	O
in	O
the	O
presence	O
of	O
M	O
-	O
CSF	O
reduced	O
the	O
number	O
of	O
Annexin	B-Protein
V	I-Protein
/	O
PI	O
negative	O
MDMs	O
compared	O
to	O
cells	O
treated	O
with	O
M	O
-	O
CSF	O
alone	O
(	O
Figure	O
3B	O
)	O
.	O

These	O
observations	O
further	O
suggested	O
that	O
MDM	O
survival	O
is	O
promoted	O
by	O
M	O
-	O
CSF	O
and	O
critically	O
involves	O
conventional	O
PKCs	O
and	O
NF	O
-	O
kappaB	O
activity	O
.	O

M	O
-	O
CSF	O
-	O
Induces	O
PKCalpha	B-Protein
Kinase	O
Activity	O

Since	O
our	O
data	O
suggested	O
that	O
conventional	O
PKCs	O
were	O
involved	O
in	O
activating	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
M	O
-	O
CSF	O
in	O
primary	O
human	O
macrophages	O
,	O
we	O
next	O
investigated	O
whether	O
the	O
conventional	O
PKC	O
,	O
PKCalpha	B-Protein
was	O
a	O
downstream	O
target	O
of	O
M	O
-	O
CSF	O
in	O
human	O
MDMs	O
.	O

PKCalpha	O
was	O
immunoprecipitated	O
from	O
human	O
MDMs	O
at	O
the	O
indicated	O
time	O
points	O
(	O
Figure	O
4	O
)	O
,	O
and	O
then	O
a	O
PKC	O
kinase	O
assay	O
was	O
performed	O
using	O
a	O
fluorescein	O
-	O
tagged	O
peptide	O
as	O
a	O
substrate	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
(	O
upper	O
panel	O
)	O
,	O
the	O
peptide	O
substrate	O
was	O
maximally	O
phosphorylated	O
within	O
10	O
minutes	O
of	O
stimulation	O
(	O
1	O
.	O
8	O
-	O
fold	O
over	O
resting	O
cells	O
,	O
lower	O
panel	O
)	O
,	O
and	O
then	O
returned	O
to	O
basal	O
levels	O
by	O
15	O
minutes	O
.	O

This	O
effect	O
was	O
not	O
seen	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
monocytes	O
when	O
isogenic	O
antibodies	O
(	O
IgG	O
)	O
were	O
used	O
for	O
immunoprecipitation	O
.	O

Western	O
blots	O
of	O
identical	O
samples	O
using	O
an	O
antibody	O
recognizing	O
PKCalpha	O
demonstrated	O
that	O
equal	O
amounts	O
of	O
PKCalpha	O
were	O
assayed	O
(	O
Figure	O
4	O
,	O
middle	O
panel	O
)	O
.	O

M	O
-	O
CSF	O
-	O
Dependent	O
Activation	O
of	O
PKC	O
Does	O
Not	O
Regulate	O
the	O
Classical	O
NF	O
-	O
kappaB	O
p65	B-Protein
Activation	O
Pathway	O

Canonical	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
via	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-Protein
leading	O
to	O
the	O
release	O
and	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
heterodimer	O
to	O
transactivate	O
target	O
genes	O
[	O
37	O
]	O
,	O
[	O
39	O
]	O
.	O

Since	O
conventional	O
PKC	O
activity	O
was	O
important	O
in	O
regulating	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
,	O
we	O
next	O
investigated	O
whether	O
IkappaBalpha	B-Protein
degradation	O
was	O
regulated	O
by	O
PKC	O
.	O

Cells	O
were	O
treated	O
with	O
cyclohexamide	O
(	O
CHX	O
)	O
to	O
inhibit	O
protein	O
synthesis	O
of	O
IkappaBalpha	B-Protein
,	O
and	O
its	O
degradation	O
was	O
followed	O
.	O

As	O
shown	O
in	O
Figure	O
5A	O
,	O
PKC	O
inhibition	O
with	O
Ro	O
-	O
31	O
-	O
8220	O
did	O
not	O
alter	O
M	O
-	O
CSF	O
-	O
induced	O
IkappaBalpha	B-Protein
degradation	O
,	O
suggesting	O
that	O
M	O
-	O
CSF	O
-	O
induced	O
PKC	O
activity	O
augmented	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
by	O
an	O
alternative	O
pathway	O
,	O
like	O
post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
.	O

M	O
-	O
CSF	O
Induces	O
Phosphorylation	O
of	O
NF	O
-	O
kappaB	O
Ser276	O
in	O
a	O
PKC	O
-	O
dependent	O
Fashion	O

Since	O
M	O
-	O
CSF	O
did	O
not	O
regulate	O
NF	O
-	O
kappaB	O
activation	O
by	O
influencing	O
IkappaBalpha	B-Protein
,	O
we	O
next	O
sought	O
to	O
determine	O
if	O
M	O
-	O
CSF	O
affected	O
NF	O
-	O
kappaB	O
p65	B-Protein
by	O
post	O
-	O
translational	O
mechanisms	O
.	O

Thus	O
,	O
we	O
examined	O
the	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
with	O
specific	O
phospho	O
-	O
NFkappaB	O
p65	O
(	O
Ser276	O
and	O
Ser536	O
)	O
antibodies	O
.	O

M	O
-	O
CSF	O
induced	O
the	O
phosphorylation	O
of	O
Ser276	O
but	O
not	O
Ser536	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
MDMs	O
.	O

Compared	O
to	O
vehicle	O
,	O
the	O
general	O
PKC	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
reduced	O
Ser276	O
phosphorylation	O
,	O
but	O
not	O
Ser536	O
,	O
phosphorylation	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
cells	O
(	O
Figure	O
5B	O
)	O
.	O

Furthermore	O
,	O
M	O
-	O
CSF	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
residue	O
Ser276	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
was	O
also	O
PKC	O
dependent	O
(	O
Figure	O
5C	O
)	O
.	O

These	O
studies	O
suggested	O
that	O
PKC	O
(	O
s	O
)	O
regulated	O
Ser276	O
phosphorylation	O
but	O
not	O
Ser536	O
in	O
both	O
human	O
MDMs	O
and	O
mouse	O
macrophages	O
after	O
M	O
-	O
CSF	O
stimulation	O
.	O

We	O
next	O
performed	O
cellular	O
fractionation	O
to	O
identify	O
the	O
cellular	O
location	O
of	O
phosphorylated	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
Raw	O
264	O
.	O
7	O
cells	O
.	O

Non	O
-	O
phosphorylated	O
NF	O
-	O
kappaB	O
p65	B-Protein
was	O
located	O
in	O
both	O
cytosolic	O
and	O
nuclear	O
fractions	O
,	O
but	O
phosphorylated	O
Ser276	O
and	O
Ser536	O
NF	O
-	O
kappaB	O
p65	B-Protein
was	O
primarily	O
located	O
in	O
nuclear	O
fraction	O
after	O
M	O
-	O
CSF	O
stimulation	O
(	O
Figure	O
5D	O
)	O
.	O

Notably	O
,	O
constitutive	O
phosphorylation	O
of	O
Ser536	O
NF	O
-	O
kappaB	O
p65	B-Protein
was	O
found	O
in	O
these	O
cells	O
.	O

Importantly	O
,	O
Ro	O
-	O
31	O
-	O
8220	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
Ser276	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
both	O
the	O
cytosolic	O
and	O
nuclear	O
fractions	O
,	O
while	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
p65	B-Protein
Ser536	O
phosphorylation	O
was	O
present	O
in	O
the	O
nucleus	O
regardless	O
of	O
PKC	O
inhibition	O
.	O

These	O
observations	O
indicate	O
that	O
M	O
-	O
CSF	O
-	O
induced	O
Ser276	O
and	O
Ser536	O
are	O
regulated	O
differently	O
by	O
conventional	O
PKC	O
activation	O
in	O
mononuclear	O
phagocytes	O
.	O

The	O
purity	O
of	O
the	O
cytosol	O
and	O
nuclear	O
cell	O
fractions	O
was	O
confirmed	O
by	O
immunoblotting	O
with	O
GAPDH	O
and	O
Lamin	O
B	O
,	O
respectively	O
(	O
Figure	O
5D	O
)	O
.	O

M	O
-	O
CSF	O
-	O
dependent	O
PKC	O
Regulates	O
NF	O
-	O
kappaB	O
-	O
targeted	O
Genes	O

NF	O
-	O
kappaB	O
induces	O
a	O
number	O
of	O
downstream	O
genes	O
,	O
including	O
the	O
IkappaB	O
family	O
.	O

Among	O
the	O
IkappaB	O
molecules	O
,	O
IkappaBalpha	B-Protein
is	O
highly	O
induced	O
by	O
NF	O
-	O
kappaB	O
activation	O
[	O
40	O
]	O
.	O

Having	O
shown	O
that	O
PKC	O
regulated	O
NF	O
-	O
kappaB	O
activity	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
MDMs	O
,	O
we	O
next	O
determined	O
whether	O
inhibition	O
of	O
PKC	O
activity	O
decreased	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
genes	O
.	O

We	O
treated	O
both	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
with	O
the	O
PKC	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
and	O
then	O
stimulated	O
with	O
M	O
-	O
CSF	O
.	O

IkappaBalpha	B-Protein
gene	O
was	O
measured	O
by	O
qRT	O
-	O
PCR	O
.	O

As	O
shown	O
in	O
Figures	O
6A	O
and	O
6B	O
,	O
M	O
-	O
CSF	O
enhanced	O
IkappaBalpha	B-Protein
gene	O
expression	O
and	O
PKC	O
inhibition	O
by	O
Ro	O
-	O
31	O
-	O
8220	O
decreased	O
IkappaBalpha	B-Protein
gene	O
expression	O
in	O
both	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
demonstrating	O
that	O
PKC	O
affected	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
in	O
macrophages	O
.	O

To	O
further	O
define	O
the	O
role	O
of	O
PKC	O
in	O
mediating	O
human	O
MDM	O
survival	O
in	O
response	O
to	O
M	O
-	O
CSF	O
,	O
we	O
examined	O
the	O
expression	O
of	O
the	O
anti	O
-	O
apoptotic	O
gene	O
BCL	B-Protein
-	I-Protein
xL	I-Protein
,	O
which	O
is	O
also	O
regulated	O
by	O
NF	O
-	O
kappaB	O
.	O

As	O
shown	O
in	O
Figure	O
6C	O
,	O
Ro	O
-	O
31	O
-	O
8220	O
reduced	O
M	O
-	O
CSF	O
-	O
stimulated	O
BCL	B-Protein
-	I-Protein
xL	I-Protein
expression	O
compared	O
to	O
cells	O
treated	O
with	O
M	O
-	O
CSF	O
and	O
the	O
vehicle	O
control	O
DMSO	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Identification	O
of	O
PKCalpha	O
as	O
the	O
Upstream	O
Activator	O
of	O
NF	O
-	O
kappaB	O
in	O
Myeloid	O
Cells	O

Even	O
though	O
the	O
PKC	O
family	O
consists	O
of	O
10	O
members	O
,	O
finding	O
that	O
PKCalpha	B-Protein
/	O
beta	B-Protein
inhibitors	O
and	O
intracellular	O
calcium	O
inhibitors	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
,	O
suggested	O
PKCalpha	B-Protein
was	O
involved	O
in	O
NF	O
-	O
kappaB	O
activation	O
after	O
M	O
-	O
CSF	O
treatment	O
.	O

To	O
confirm	O
the	O
role	O
of	O
PKCalpha	B-Protein
in	O
NF	O
-	O
kappaB	O
activation	O
in	O
macrophages	O
,	O
constructs	O
for	O
either	O
wildtype	O
(	O
WT	O
)	O
-	O
PKCalpha	B-Protein
or	O
kinase	O
-	O
deficient	O
(	O
KD	O
)	O
-	O
PKCalpha	B-Protein
was	O
co	O
-	O
transfected	O
with	O
the	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
reporter	O
gene	O
and	O
SEAP	O
secretion	O
was	O
measured	O
.	O

As	O
shown	O
in	O
Figure	O
7A	O
,	O
MDMs	O
co	O
-	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
and	O
WT	O
-	O
PKCalpha	B-Protein
had	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
in	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
after	O
M	O
-	O
CSF	O
activation	O
compared	O
with	O
NS	O
cells	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
similar	O
to	O
M	O
-	O
CSF	O
-	O
treated	O
cells	O
expressing	O
only	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
.	O

Transfecting	O
human	O
macrophages	O
with	O
the	O
KD	O
-	O
PKCalpha	B-Protein
construct	O
significantly	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
compared	O
to	O
WT	O
-	O
PKCalpha	B-Protein
transfected	O
cells	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
.	O

Similarly	O
,	O
RAW	O
264	O
.	O
7	O
cells	O
transfected	O
with	O
WT	O
-	O
PKCalpha	B-Protein
had	O
2	O
.	O
5	O
-	O
fold	O
more	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
after	O
M	O
-	O
CSF	O
activation	O
compared	O
to	O
unstimulated	O
RAW	O
264	O
.	O
7	O
cells	O
(	O
NS	O
)	O
transfected	O
with	O
WT	O
-	O
PKCalpha	B-Protein
(	O
Figure	O
7B	O
)	O
.	O

Expression	O
of	O
the	O
KD	O
-	O
PKCalpha	B-Protein
construct	O
into	O
RAW	O
264	O
.	O
7	O
cells	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
to	O
1	O
.	O
5	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
045	O
)	O
compared	O
to	O
cells	O
transfected	O
with	O
WT	O
PKCalpha	B-Protein
.	O

Cell	O
survival	O
was	O
also	O
examined	O
in	O
MDMs	O
expressing	O
either	O
WT	O
-	O
PKCalpha	B-Protein
or	O
KD	O
-	O
PKCalpha	B-Protein
constructs	O
by	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
PI	O
staining	O
.	O

As	O
expected	O
,	O
M	O
-	O
CSF	O
increased	O
MDM	O
survival	O
as	O
measured	O
by	O
the	O
percent	O
of	O
Annexin	B-Protein
V	I-Protein
/	O
PI	O
negative	O
cells	O
.	O

Similarly	O
,	O
expression	O
of	O
WT	O
-	O
PKCalpha	B-Protein
protected	O
cells	O
from	O
apoptosis	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
KD	O
-	O
PKCalpha	B-Protein
decreased	O
M	O
-	O
CSF	O
-	O
induced	O
cell	O
survival	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
7C	O
)	O
.	O

Next	O
,	O
we	O
examined	O
the	O
effect	O
of	O
expressing	O
the	O
PKCalpha	B-Protein
constructs	O
on	O
NF	O
-	O
kappaB	O
phosphorylation	O
.	O

As	O
shown	O
in	O
Figure	O
7D	O
,	O
expression	O
of	O
KD	O
-	O
PKCalpha	B-Protein
in	O
RAW	O
264	O
.	O
7	O
cells	O
did	O
not	O
affect	O
the	O
constitutive	O
phosphorylation	O
at	O
Ser536	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
,	O
but	O
attenuated	O
the	O
phosphorylation	O
at	O
Ser276	O
.	O

Expression	O
of	O
WT	O
-	O
PKCalpha	B-Protein
did	O
not	O
effect	O
the	O
phosphorylation	O
of	O
either	O
residue	O
with	O
or	O
without	O
M	O
-	O
CSF	O
stimulation	O
.	O

These	O
observations	O
demonstrate	O
that	O
PKCalpha	B-Protein
is	O
important	O
in	O
M	O
-	O
CSF	O
-	O
regulated	O
cell	O
survival	O
and	O
NF	O
-	O
kappaB	O
activation	O
and	O
likely	O
regulated	O
through	O
phosphorylation	O
of	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
.	O

To	O
further	O
validate	O
the	O
impact	O
that	O
PKCalpha	B-Protein
played	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
,	O
we	O
next	O
employed	O
PKCalpha	B-Protein
siRNA	I-Protein
treatment	O
of	O
MDM	O
or	O
RAW	O
cells	O
.	O

A	O
pool	O
of	O
specific	O
PKCalpha	B-Protein
siRNA	I-Protein
were	O
transfected	O
into	O
MDM	O
or	O
Raw	O
264	O
.	O
7	O
cells	O
in	O
the	O
presence	O
or	O
absence	O
or	O
M	O
-	O
CSF	O
.	O

Reducing	O
native	O
PKCalpha	B-Protein
expression	O
decreased	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
both	O
MDM	O
(	O
Figure	O
7E	O
)	O
(	O
p	O
=	O
0	O
.	O
012	O
)	O
and	O
Raw	O
264	O
.	O
7	O
cells	O
(	O
Figure	O
7F	O
)	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

We	O
also	O
examined	O
cell	O
survival	O
of	O
the	O
MDMs	O
by	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
PI	O
staining	O
after	O
PKCalpha	B-Protein
siRNA	I-Protein
transfection	O
.	O

As	O
shown	O
in	O
Figure	O
7G	O
,	O
M	O
-	O
CSF	O
-	O
induced	O
MDM	O
survival	O
was	O
reduced	O
in	O
the	O
cells	O
transfected	O
with	O
PKCalpha	B-Protein
siRNA	I-Protein
compared	O
with	O
cells	O
transfected	O
with	O
control	O
siRNA	O
(	O
p	O
=	O
0	O
.	O
047	O
)	O
.	O

In	O
Figure	O
7H	O
,	O
we	O
confirmed	O
that	O
PKCalpha	B-Protein
siRNA	I-Protein
transfection	O
decreased	O
PKCalpha	B-Protein
protein	O
expression	O
in	O
both	O
MDM	O
and	O
Raw	O
264	O
.	O
7	O
cells	O
.	O

Our	O
results	O
indicated	O
that	O
PKCalpha	B-Protein
regulated	O
NF	O
-	O
kappaB	O
activation	O
and	O
M	O
-	O
CSF	O
-	O
regulated	O
cell	O
survival	O
.	O

PKC	O
is	O
Essential	O
in	O
Regulating	O
NF	O
-	O
kappaB	O
Activity	O

M	O
-	O
CSF	O
-	O
dependent	O
PKC	O
activity	O
facilitated	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
but	O
not	O
Ser536	O
.	O

To	O
confirm	O
the	O
role	O
of	O
PKC	O
and	O
p65	B-Protein
Ser276	O
phosphorylation	O
on	O
NF	O
-	O
kappaB	O
activity	O
,	O
we	O
co	O
-	O
transfected	O
the	O
NF	O
-	O
kappaB	O
-	O
SEAP	O
construct	O
with	O
either	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
constructs	O
in	O
Raw	O
264	O
.	O
7	O
cells	O
,	O
then	O
treated	O
cells	O
with	O
the	O
PKC	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
in	O
the	O
absence	O
or	O
presences	O
of	O
M	O
-	O
CSF	O
.	O

As	O
expected	O
in	O
cells	O
transfected	O
with	O
vector	O
control	O
,	O
inhibiting	O
PKC	O
reduced	O
M	O
-	O
CSF	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
activity	O
compared	O
to	O
cells	O
treated	O
with	O
M	O
-	O
CSF	O
and	O
the	O
vehicle	O
DMSO	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
(	O
Figure	O
8A	O
)	O
.	O

In	O
contrast	O
,	O
expressing	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
(	O
p65	B-Protein
WT	O
)	O
increased	O
NF	O
-	O
kappaB	O
activity	O
,	O
while	O
the	O
general	O
PKC	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
decreased	O
this	O
NF	O
-	O
kappaB	O
activity	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Notably	O
,	O
the	O
introduction	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
276	O
S	O
/	O
A	O
construct	O
significantly	O
reduced	O
NF	O
-	O
kappaB	O
activity	O
compared	O
with	O
the	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
construct	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
M	O
-	O
CSF	O
treatment	O
was	O
unable	O
to	O
overcome	O
this	O
inhibition	O
.	O

Furthermore	O
,	O
we	O
co	O
-	O
transfected	O
the	O
NF	O
-	O
kappaB	O
-	O
SEAP	O
construct	O
along	O
with	O
either	O
the	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
536S	O
/	O
A	O
constructs	O
into	O
a	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
murine	O
fibroblast	O
cell	O
line	O
and	O
measured	O
NF	O
-	O
kappaB	O
activity	O
.	O

As	O
predicted	O
,	O
expression	O
of	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
(	O
p65	B-Protein
WT	O
)	O
in	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cell	O
line	O
constitutively	O
activated	O
NF	O
-	O
kappaB	O
compared	O
to	O
cells	O
transfected	O
with	O
vector	O
control	O
without	O
any	O
stimulation	O
(	O
Figure	O
8B	O
)	O
.	O

In	O
comparison	O
,	O
transfecting	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
construct	O
reduced	O
NF	O
-	O
kappaB	O
activity	O
by	O
5	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
vs	O
.	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
)	O
,	O
while	O
expressing	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
536S	O
/	O
A	O
construct	O
increased	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
p65	B-Protein
-	O
/	O
-	O
cells	O
to	O
levels	O
similar	O
to	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
transfected	O
cells	O
.	O

Since	O
M	O
-	O
CSF	O
-	O
induced	O
PKC	O
activation	O
regulated	O
NF	O
-	O
kappaB	O
activity	O
via	O
Ser276	O
residue	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
primary	O
human	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
we	O
next	O
examined	O
if	O
this	O
occurred	O
in	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
fibroblasts	O
in	O
response	O
to	O
a	O
native	O
stimulus	O
for	O
these	O
cells	O
,	O
TNFalpha	B-Protein
.	O

NF	O
-	O
kappaB	O
activity	O
was	O
measured	O
in	O
the	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
transfected	O
cells	O
treated	O
with	O
TNFalpha	B-Protein
in	O
the	O
absence	O
or	O
presence	O
of	O
Ro	O
-	O
31	O
-	O
8220	O
(	O
Figure	O
8C	O
)	O
.	O

As	O
expected	O
,	O
TNFalpha	B-Protein
increased	O
NF	O
-	O
kappaB	O
activity	O
in	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cells	O
expressing	O
WT	O
p65	B-Protein
and	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
PKC	O
inhibitors	O
decreased	O
NF	O
-	O
kappaB	O
activity	O
to	O
the	O
non	O
-	O
stimulated	O
(	O
NS	O
)	O
level	O
(	O
p	O
=	O
0	O
.	O
007	O
)	O
.	O

Introducing	O
NF	O
-	O
kappaB	O
p65	B-Protein
276	O
S	O
/	O
A	O
constructs	O
significantly	O
reduced	O
NF	O
-	O
kappaB	O
activity	O
compared	O
with	O
the	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
construct	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Notably	O
,	O
TNFalpha	B-Protein
failed	O
to	O
increase	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cells	O
expressing	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
constructs	O
.	O

These	O
observations	O
are	O
similar	O
to	O
macrophages	O
overexpressing	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
(	O
Figure	O
8A	O
)	O
.	O

Our	O
data	O
demonstrate	O
that	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
essential	O
in	O
regulating	O
NF	O
-	O
kappaB	O
activity	O
and	O
suggests	O
that	O
PKC	O
regulates	O
NF	O
-	O
kappaB	O
activity	O
by	O
modulating	O
the	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
residue	O
.	O

NF	O
-	O
kappaB	O
transcriptional	O
activity	O
is	O
important	O
in	O
regulating	O
intracellular	O
signaling	O
,	O
stress	O
response	O
,	O
proliferation	O
,	O
survival	O
,	O
differentiation	O
and	O
inflammation	O
[	O
8	O
]	O
.	O

To	O
regulate	O
gene	O
transcription	O
,	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
heterodimers	O
translocate	O
to	O
the	O
nucleus	O
from	O
the	O
cytoplasm	O
,	O
however	O
,	O
their	B-Protein
translocation	O
is	O
not	O
sufficient	O
to	O
activate	O
gene	O
transcription	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
heterodimers	O
such	O
as	O
phosphorylation	O
or	O
acetylation	O
also	O
contributes	O
to	O
its	O
transcriptional	O
activity	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
,	O
[	O
43	O
]	O
.	O

Because	O
NF	O
-	O
kappaB	O
constitutively	O
translocates	O
to	O
the	O
nucleus	O
in	O
monocytic	O
lineage	O
[	O
13	O
]	O
and	O
activates	O
gene	O
transcription	O
and	O
survival	O
in	O
murine	O
macrophages	O
[	O
11	O
]	O
,	O
we	O
sought	O
to	O
determine	O
how	O
M	O
-	O
CSF	O
affected	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
human	O
MDMs	O
and	O
whether	O
this	O
activation	O
regulated	O
their	O
survival	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
M	O
-	O
CSF	O
stimulated	O
PKCalpha	B-Protein
kinase	O
upstream	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
primary	O
human	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

We	O
showed	O
inhibition	O
of	O
conventional	O
PKCs	O
by	O
PKC	O
inhibitors	O
,	O
kinase	O
deficient	O
PKCalpha	B-Protein
or	O
PKCalpha	B-Protein
siRNA	I-Protein
blocked	O
M	O
-	O
CSF	O
-	O
induced	O
cell	O
survival	O
and	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
.	O

This	O
block	O
correlated	O
with	O
a	O
reduction	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
.	O

Consistent	O
with	O
these	O
findings	O
the	O
dominant	B-Protein
negative	I-Protein
PKCalpha	I-Protein
constructs	O
also	O
inhibited	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
but	O
not	O
at	O
Ser536	O
resulting	O
in	O
reduced	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
and	O
M	O
-	O
CSF	O
-	O
induced	O
MDM	O
survival	O
.	O

A	O
simplified	O
proposed	O
cartoon	O
model	O
in	O
Figure	O
9	O
demonstrates	O
that	O
M	O
-	O
CSF	O
induced	O
monocytes	O
survival	O
is	O
regulated	O
by	O
activating	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
via	O
PKC	O
.	O

Finally	O
,	O
in	O
a	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
fibroblast	O
cell	O
line	O
,	O
we	O
confirmed	O
that	O
the	O
Ser276	O
residue	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
important	O
and	O
essential	O
for	O
PKC	O
modulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

More	O
compelling	O
is	O
that	O
we	O
observed	O
a	O
similar	O
regulation	O
between	O
two	O
different	O
cell	O
lineages	O
in	O
our	O
study	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
regulates	O
its	O
activating	O
or	O
repressing	O
effects	O
on	O
gene	O
expression	O
.	O

Among	O
the	O
seven	O
reported	O
putative	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
sites	O
,	O
five	O
increase	O
nuclear	O
translocation	O
,	O
DNA	O
binding	O
and	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
[	O
17	O
]	O
.	O

Similar	O
to	O
our	O
finding	O
,	O
Zhong	O
et	O
al	O
.	O
found	O
that	O
in	O
response	O
to	O
LPS	O
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
phosphorylated	O
at	O
the	O
highly	O
conserved	O
Ser276	O
residue	O
by	O
the	O
catalytic	O
subunit	O
of	O
PKA	O
[	O
16	O
]	O
.	O

In	O
addition	O
to	O
PKA	O
,	O
Ser276	O
can	O
be	O
phosphorylated	O
by	O
MSK1	B-Protein
in	O
the	O
nucleus	O
upon	O
TNFalpha	B-Protein
treatment	O
[	O
18	O
]	O
.	O

Phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser536	O
occurs	O
in	O
response	O
to	O
many	O
inflammatory	O
stimuli	O
as	O
well	O
as	O
kinases	O
,	O
IKKalpha	B-Protein
,	O
IKKbeta	B-Protein
and	O
RSK1	B-Protein
[	O
17	O
]	O
,	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

Notably	O
,	O
in	O
addition	O
to	O
phosphorylating	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
,	O
our	O
study	O
revealed	O
that	O
M	O
-	O
CSF	O
also	O
modulated	O
the	O
phosphorylation	O
of	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
at	O
Ser536	O
,	O
however	O
,	O
PKC	O
inhibitors	O
or	O
kinase	O
deficient	O
PKCalpha	B-Protein
constructs	O
did	O
not	O
affect	O
this	O
phosphorylation	O
event	O
.	O

Moreover	O
,	O
mutant	O
constructs	O
containing	O
a	O
point	O
mutation	O
at	O
Ser536	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
did	O
not	O
reduce	O
NF	O
-	O
kappaB	O
activity	O
in	O
cells	O
lacking	O
endogenous	O
NF	O
-	O
kappaB	O
p65	B-Protein
,	O
while	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
construct	O
did	O
reduce	O
NF	O
-	O
kappaB	O
activity	O
in	O
these	O
cells	O
.	O

Therefore	O
,	O
specific	O
post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
likely	O
to	O
regulate	O
transcriptional	O
activation	O
in	O
response	O
to	O
specific	O
stimuli	O
[	O
15	O
]	O
,	O
[	O
43	O
]	O
.	O

It	O
is	O
notable	O
that	O
M	O
-	O
CSF	O
activated	O
NF	O
-	O
kappaB	O
p65	B-Protein
Ser276	O
phosphorylation	O
and	O
transcriptional	O
activation	O
in	O
a	O
PKCalpha	B-Protein
-	O
dependent	O
manner	O
.	O

PKCalpha	B-Protein
is	O
a	O
member	O
of	O
the	O
conventional	O
PKC	O
family	O
of	O
protein	O
kinases	O
that	O
are	O
critical	O
for	O
cell	O
growth	O
,	O
differentiation	O
and	O
cell	O
death	O
.	O

PKCalpha	B-Protein
primarily	O
modulates	O
anti	O
-	O
apoptotic	O
and	O
proliferation	O
signals	O
following	O
cytokine	O
treatment	O
in	O
various	O
cell	O
types	O
[	O
42	O
]	O
.	O

Expression	O
of	O
PKCalpha	B-Protein
attenuates	O
apoptosis	O
in	O
many	O
different	O
cell	O
types	O
,	O
while	O
PKCalpha	B-Protein
inhibition	O
generally	O
potentiates	O
apoptosis	O
[	O
42	O
]	O
.	O

In	O
our	O
studies	O
using	O
conventional	O
PKC	O
inhibitors	O
and	O
dominant	B-Protein
negative	I-Protein
PKCalpha	I-Protein
constructs	O
,	O
PKCalpha	B-Protein
was	O
critical	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
macrophage	O
survival	O
by	O
inducing	O
Ser276	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
both	O
primary	O
human	O
MDMs	O
and	O
Raw	O
264	O
.	O
7	O
cells	O
.	O

We	O
also	O
demonstrated	O
PKC	O
inhibition	O
downregulated	O
NF	O
-	O
kappaB	O
-	O
induction	O
of	O
the	O
anti	O
-	O
apoptotic	O
gene	O
BCL	B-Protein
-	I-Protein
xL	I-Protein
.	O

Consistent	O
with	O
our	O
finding	O
,	O
others	O
reported	O
NF	O
-	O
kappaB	O
regulated	O
the	O
gene	O
expression	O
of	O
many	O
anti	O
-	O
apoptotic	O
proteins	O
including	O
other	O
BCL	O
-	O
2	O
family	O
members	O
and	O
inhibitor	O
of	O
apoptosis	O
(	O
IAP	O
)	O
proteins	O
which	O
are	O
regulators	O
of	O
apoptosis	O
and	O
function	O
upstream	O
of	O
caspases	O
[	O
44	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
phosphorylation	O
of	O
p65	B-Protein
at	O
Ser276	O
prevents	O
its	O
degradation	O
by	O
ubiquitin	B-Protein
-	O
mediated	O
proteolysis	O
and	O
promotes	O
cell	O
survival	O
in	O
HeLa	O
cells	O
[	O
24	O
]	O
.	O

In	O
addition	O
to	O
BCL	B-Protein
-	I-Protein
xL	I-Protein
expression	O
as	O
examined	O
in	O
this	O
study	O
,	O
we	O
are	O
evaluating	O
the	O
possibility	O
that	O
PKCalpha	B-Protein
-	O
regulated	O
NF	O
-	O
kappaB	O
activity	O
upregulates	O
additional	O
anti	O
-	O
apoptotic	O
genes	O
in	O
an	O
M	O
-	O
CSF	O
-	O
dependent	O
fashion	O
to	O
modulate	O
cell	O
survival	O
.	O

The	O
use	O
of	O
inhibitors	O
and	O
siRNA	O
in	O
our	O
study	O
has	O
not	O
ruled	O
out	O
that	O
other	O
conventional	O
PKCs	O
might	O
also	O
be	O
important	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
macrophage	O
survival	O
.	O

In	O
contrast	O
to	O
the	O
actions	O
of	O
PKCalpha	B-Protein
activation	O
of	O
other	O
conventional	O
PKC	O
isoforms	O
,	O
like	O
PKCbetaI	B-Protein
/	O
betaII	B-Protein
,	O
appear	O
necessary	O
for	O
macrophage	O
apoptosis	O
.	O

The	O
PKCbetaI	B-Protein
/	O
betaII	B-Protein
isoforms	O
are	O
expressed	O
in	O
apoptotic	O
U937	O
myelomonocytic	O
cells	O
[	O
45	O
]	O
.	O

The	O
human	O
myeloid	O
cell	O
line	O
HL	O
-	O
525	O
which	O
is	O
devoid	O
of	O
endogenous	O
PKCbetaII	B-Protein
is	O
resistant	O
to	O
TNFalpha	B-Protein
-	O
induced	O
apoptosis	O
[	O
46	O
]	O
.	O

Re	O
-	O
expression	O
of	O
PKCbetaII	B-Protein
in	O
HL	O
-	O
525	O
cells	O
restores	O
their	O
susceptibility	O
to	O
TNFalpha	B-Protein
-	O
induced	O
apoptosis	O
implying	O
that	O
PKCbetaII	B-Protein
is	O
pro	O
-	O
apoptotic	O
and	O
may	O
be	O
required	O
to	O
induce	O
macrophage	O
apoptosis	O
.	O

Recent	O
studies	O
demonstrated	O
that	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
can	O
be	O
regulated	O
by	O
phosphorylation	O
of	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
in	O
the	O
absence	O
of	O
IkappaBalpha	B-Protein
degradation	O
[	O
47	O
]	O
.	O

By	O
this	O
pathway	O
,	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
regulates	O
its	O
interaction	O
with	O
other	O
components	O
of	O
the	O
basal	O
transcriptional	O
machinery	O
without	O
affecting	O
its	O
capability	O
to	O
bind	O
DNA	O
[	O
21	O
]	O
.	O

Since	O
NF	O
-	O
kappaB	O
can	O
bind	O
the	O
promoters	O
of	O
numerous	O
gene	O
targets	O
,	O
post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
may	O
affect	O
its	O
interaction	O
with	O
other	O
proteins	O
,	O
refining	O
the	O
expression	O
of	O
gene	O
targets	O
.	O

We	O
did	O
not	O
find	O
that	O
PKC	O
was	O
involved	O
in	O
IkappaBalpha	B-Protein
degradation	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
nuclear	O
translocation	O
induced	O
by	O
M	O
-	O
CSF	O
,	O
but	O
that	O
M	O
-	O
CSF	O
-	O
induced	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
was	O
dramatically	O
reduced	O
by	O
the	O
conventional	O
PKC	O
inhibitor	O
and	O
kinase	O
deficient	O
PKCalpha	B-Protein
and	O
by	O
siRNA	B-Protein
towards	O
PKCalpha	B-Protein
.	O

Current	O
studies	O
are	O
underway	O
to	O
delineate	O
the	O
protein	O
complexes	O
formed	O
by	O
activated	O
NF	O
-	O
kappaB	O
and	O
other	O
transcriptional	O
co	O
-	O
activators	O
in	O
response	O
to	O
M	O
-	O
CSF	O
and	O
PKC	O
activation	O
.	O

Recently	O
studies	O
indicated	O
that	O
the	O
non	O
-	O
canonical	O
pathway	O
was	O
activated	O
during	O
human	O
monocyte	O
-	O
macrophage	O
differentiation	O
[	O
48	O
]	O
.	O

During	O
this	O
process	O
,	O
expression	O
of	O
IKKalpha	B-Protein
among	O
other	O
proteins	O
,	O
is	O
elevated	O
leading	O
to	O
increased	O
p52	B-Protein
NF	O
-	O
kappaB	O
(	O
relB	B-Protein
)	O
expression	O
through	O
partial	O
proteolytic	O
degradation	O
of	O
the	O
p100	B-Protein
NF	O
-	O
kappaB	O
protein	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
M	O
-	O
CSF	O
regulates	O
monocyte	O
survival	O
through	O
both	O
the	O
canonical	O
and	O
non	O
-	O
canonical	O
NF	O
-	O
kappaB	O
pathways	O
,	O
which	O
will	O
be	O
a	O
focus	O
in	O
future	O
research	O
.	O

We	O
previously	O
showed	O
that	O
M	O
-	O
CSF	O
reduced	O
caspase	B-Protein
-	I-Protein
3	I-Protein
and	O
-	B-Protein
9	I-Protein
activity	O
and	O
prevented	O
monocyte	O
apoptosis	O
[	O
3	O
]	O
.	O

This	O
study	O
reveals	O
that	O
treatment	O
of	O
monocytes	O
with	O
conventional	O
PKC	O
inhibitors	O
,	O
or	O
overexpression	O
of	O
kinase	O
-	O
deficient	O
PKCalpha	B-Protein
blocked	O
M	O
-	O
CSF	O
-	O
induced	O
cell	O
survival	O
.	O

Our	O
data	O
revealed	O
that	O
conventional	O
PKCs	O
are	O
upstream	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
response	O
to	O
M	O
-	O
CSF	O
and	O
mediate	O
post	O
-	O
translational	O
activation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
by	O
phosphorylating	O
Ser276	O
to	O
regulate	O
gene	O
transcription	O
and	O
cell	O
survival	O
.	O

Thus	O
,	O
our	O
observation	O
may	O
provide	O
insight	O
in	O
potential	O
therapeutic	O
targets	O
for	O
inflammatory	O
diseases	O
.	O

Materials	O

Recombinant	O
human	O
M	O
-	O
CSF	O
was	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Minneapolis	O
,	O
MN	O
)	O
.	O

Ro	O
-	O
31	O
-	O
8220	O
,	O
Go	O
-	O
6976	O
,	O
Rotterin	O
,	O
and	O
BAPTA	O
/	O
AM	O
were	O
obtained	O
from	O
Calbiochem	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Low	O
endotoxin	O
RPMI	O
and	O
X	O
-	O
vivo	O
serum	O
free	O
medium	O
were	O
obtained	O
from	O
Lonza	O
Walkersville	O
Inc	O
(	O
Walkersville	O
,	O
MD	O
)	O
.	O

Fetal	O
bovine	O
serum	O
(	O
FBS	O
,	O
certified	O
<	O
0	O
.	O
06	O
endotoxin	O
units	O
/	O
ml	O
endotoxin	O
levels	O
)	O
was	O
purchased	O
from	O
Atlanta	O
Biological	O
(	O
Lawrenceville	O
,	O
GA	O
)	O
.	O

All	O
other	O
cell	O
culture	O
reagents	O
were	O
obtained	O
through	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O

PKCalpha	O
NF	O
-	O
kappaB	O
p65	O
,	O
Lamin	O
B	O
,	O
beta	O
-	O
actin	O
,	O
and	O
GAPDH	O
antibodies	O
,	O
anti	O
-	O
mouse	O
and	O
rabbit	O
IgG	O
-	O
HRP	O
conjugated	O
antibodies	O
,	O
and	O
PKCalpha	B-Protein
siRNA	I-Protein
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

Phospho	O
-	O
NFkappaB	O
p65	O
(	O
Ser276	O
or	O
Ser536	O
)	O
antibodies	O
were	O
purchased	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Danvers	O
,	O
MA	O
)	O
.	O

DNA	O
constructs	O
pTAL	O
-	O
SEAP	O
and	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
were	O
obtained	O
from	O
Clontech	O
(	O
Mountian	O
View	O
,	O
CA	O
)	O
.	O

Expression	O
vectors	O
containing	O
CMV	O
-	O
p65	B-Protein
WT	O
,	O
CMV	O
-	O
p65	B-Protein
276S	O
/	O
A	O
and	O
CMV	O
-	O
p65	B-Protein
536S	O
/	O
A	O
were	O
cloned	O
in	O
pBa5e	O
Puro	O
vector	O
or	O
pFLAG	O
-	O
CMV	O
-	O
2	O
vector	O
as	O
described	O
previously	O
[	O
49	O
]	O
.	O

Kinase	O
deficient	O
CMV	O
-	O
PKCalpha	B-Protein
(	O
KD	O
-	O
PKCalpha	B-Protein
)	O
or	O
wild	O
type	O
pCMV	O
-	O
PKCalpha	B-Protein
(	O
WT	O
-	O
PKCalpha	B-Protein
)	O
were	O
generous	O
gifts	O
from	O
Alexandra	O
C	O
.	O
Newton	O
(	O
University	O
of	O
California	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

IkappaBalpha	B-Protein
(	O
NFKBIA	O
)	O
and	O
GAPDH	O
primers	O
for	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
were	O
obtained	O
from	O
SABiosciences	O
(	O
Frederick	O
,	O
MD	O
)	O
.	O

A	O
pool	O
of	O
mouse	O
or	O
human	O
PKCalpha	B-Protein
specific	I-Protein
siRNA	I-Protein
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
cruz	O
,	O
CA	O
)	O
.	O

Cell	O
Culture	O

The	O
murine	O
macrophage	O
cell	O
line	O
RAW	O
264	O
.	O
7	O
was	O
purchased	O
from	O
ATCC	O
(	O
Manassas	O
,	O
VA	O
)	O
.	O

RAW	O
264	O
.	O
7	O
cells	O
were	O
maintained	O
in	O
RPMI	O
supplemented	O
with	O
5	O
%	O
FBS	O
and	O
antibiotic	O
-	O
antimycotic	O
(	O
1000	O
U	O
/	O
ml	O
penicillin	O
,	O
1000	O
microg	O
/	O
ml	O
streptomycin	O
sulfate	O
,	O
and	O
250	O
ng	O
/	O
ml	O
amphotericin	O
B	O
)	O
at	O
37degreesC	O
.	O

Mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
cell	O
line	O
lacking	O
specific	O
NFkappaB	O
signaling	O
subunits	O
NF	O
-	O
kappaB	O
p65	B-Protein
(	O
p65	B-Protein
-	O
/	O
-	O
cell	O
line	O
)	O
[	O
50	O
]	O
were	O
cultured	O
in	O
DMEM	O
medium	O
supplemented	O
with	O
10	O
%	O
FBS	O
and	O
antibiotic	O
-	O
antimycotic	O
solution	O
.	O

Purification	O
of	O
Peripheral	O
Blood	O
Monocytes	O
and	O
Monocyte	O
-	O
Derived	O
Macrophages	O
(	O
MDMs	O
)	O

Monocytes	O
were	O
isolated	O
from	O
source	O
leukocyte	O
packs	O
obtained	O
from	O
the	O
American	O
Red	O
Cross	O
as	O
described	O
previously	O
[	O
51	O
]	O
.	O

Monocytes	O
used	O
in	O
real	O
time	O
PCR	O
experiments	O
and	O
transfection	O
experiments	O
were	O
purified	O
by	O
positive	O
selection	O
using	O
CD14	B-Protein
Monocyte	O
Isolation	O
Kit	O
from	O
Miltenyi	O
Biotech	O
(	O
Auburn	O
,	O
CA	O
)	O
(	O
>	O
90	O
%	O
pure	O
)	O
.	O

In	O
some	O
experiments	O
,	O
monocytes	O
were	O
isolated	O
by	O
clumping	O
method	O
(	O
70	O
%	O
pure	O
)	O
.	O

To	O
obtain	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
,	O
monocytes	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
medium	O
containing	O
10	O
%	O
FBS	O
,	O
and	O
10	O
microg	O
/	O
ml	O
polymyxin	O
B	O
and	O
20	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
.	O

Electrophoresis	O
of	O
the	O
Mobility	O
Shift	O
Analysis	O
(	O
EMSA	O
)	O

Nuclear	O
extracts	O
were	O
isolated	O
from	O
MDMs	O
by	O
using	O
a	O
nuclear	O
extraction	O
kit	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
from	O
Active	O
Motif	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O

Briefly	O
,	O
MDMs	O
were	O
lysed	O
in	O
hypotonic	O
lysis	O
buffer	O
(	O
20	O
mM	O
Hepes	O
,	O
pH	O
7	O
.	O
5	O
;	O
5	O
mM	O
NaF	O
,	O
10	O
microM	O
Na2MoO4	O
0	O
.	O
5	O
%	O
NP	O
-	O
40	O
and	O
0	O
.	O
1	O
mM	O
EDTA	O
)	O
,	O
and	O
then	O
nuclei	O
were	O
resuspended	O
in	O
lysis	O
buffer	O
supplemented	O
with	O
0	O
.	O
5	O
mM	O
DTT	O
and	O
0	O
.	O
2	O
mM	O
PMSF	O
.	O

The	O
NF	O
-	O
kappaB	O
consensus	O
oligonucleotides	O
(	O
sense	O
:	O
AGTTGAGGGGACTTTCCCAGGC	O
;	O
antisense	O
:	O
GCCTGGGAAAGTCCCCTCAACT	O
)	O
labeled	O
with	O
32P	O
by	O
T4	O
polynucleokinase	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
incubated	O
with	O
nuclear	O
extracts	O
in	O
binding	O
buffer	O
(	O
10	O
mM	O
Tris	O
pH	O
7	O
.	O
6	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
,	O
2	O
microg	O
polydI	O
-	O
dC	O
and	O
10	O
%	O
Glycerol	O
)	O
at	O
30degreesC	O
for	O
30	O
minutes	O
.	O

The	O
free	O
DNA	O
and	O
DNA	O
-	O
protein	O
mixtures	O
were	O
resolved	O
in	O
5	O
%	O
native	O
polyacrylamide	O
gels	O
in	O
0	O
.	O
5x	O
TBE	O
buffer	O
(	O
45	O
mM	O
Tris	O
,	O
45	O
mM	O
boric	O
acid	O
and	O
1	O
mM	O
EDTA	O
,	O
pH	O
8	O
.	O
3	O
)	O
by	O
electrophoresis	O
.	O

The	O
gel	O
was	O
dried	O
and	O
subjected	O
to	O
autoradiography	O
analysis	O
.	O

Transient	O
Transfection	O
of	O
RAW	O
264	O
.	O
7	O
Cells	O

RAW	O
264	O
.	O
7	O
cells	O
were	O
seeded	O
in	O
12	O
-	O
well	O
plates	O
in	O
RPMI	O
medium	O
containing	O
5	O
%	O
FBS	O
one	O
day	O
prior	O
to	O
transfection	O
,	O
Secreted	O
alkaline	O
phosphatase	O
(	O
SEAP	O
)	O
reporter	O
plasmids	O
pTAL	O
-	O
SEAP	O
or	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
were	O
transfected	O
into	O
cells	O
using	O
Qiagene	O
Effectene	O
or	O
Attractene	O
transfection	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

For	O
co	O
-	O
transfection	O
studies	O
,	O
PKCalpha	B-Protein
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
constructs	O
were	O
mixed	O
at	O
a	O
ratio	O
of	O
5	O
:	O
1	O
with	O
the	O
reporter	O
plasmid	O
.	O

For	O
siRNA	O
transfection	O
,	O
100	O
nM	O
of	O
PKCalpha	B-Protein
siRNA	I-Protein
or	O
control	O
siRNA	O
were	O
used	O
.	O

Cells	O
were	O
incubated	O
with	O
the	O
transfection	O
reagents	O
for	O
16	O
-	O
24	O
hours	O
,	O
washed	O
and	O
starved	O
in	O
RPMI	O
without	O
FBS	O
for	O
4	O
hours	O
.	O

Samples	O
were	O
then	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
for	O
4	O
hours	O
at	O
which	O
point	O
the	O
medium	O
was	O
collected	O
for	O
the	O
SEAP	O
analysis	O
.	O

For	O
inhibition	O
studies	O
,	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
inhibitors	O
for	O
30	O
minutes	O
before	O
M	O
-	O
CSF	O
treatment	O
.	O

On	O
average	O
,	O
we	O
realized	O
30	O
-	O
40	O
%	O
transfection	O
efficiency	O
as	O
confirmed	O
by	O
GFP	B-Protein
expression	O
in	O
Raw	O
264	O
.	O
7	O
cells	O
.	O

Transient	O
Transfection	O
of	O
Primary	O
Human	O
Monocytes	O

Monocytes	O
were	O
transfected	O
using	O
the	O
human	O
monocyte	O
Amaxa	O
nucleofector	O
kit	O
(	O
Lonza	O
Walkersville	O
Inc	O
,	O
Walkersville	O
,	O
MD	O
)	O
as	O
previously	O
described	O
[	O
51	O
]	O
.	O

Briefly	O
,	O
monocytes	O
were	O
resuspended	O
in	O
Amaxa	O
Nucleofactor	O
solution	O
at	O
a	O
density	O
of	O
20x106	O
cells	O
/	O
ml	O
,	O
and	O
2	O
microg	O
of	O
total	O
plasmid	O
DNA	O
100	O
nM	O
of	O
PKCalpha	B-Protein
siRNA	I-Protein
or	O
control	O
siRNA	O
was	O
added	O
and	O
transfected	O
using	O
program	O
Amaxa	O
Y	O
-	O
01	O
.	O

For	O
co	O
-	O
transfection	O
studies	O
,	O
PKCalpha	B-Protein
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
constructs	O
were	O
mixed	O
at	O
a	O
ratio	O
of	O
5	O
:	O
1	O
with	O
the	O
reporter	O
plasmid	O
.	O

Immediately	O
after	O
transfection	O
,	O
cells	O
were	O
washed	O
with	O
1	O
ml	O
of	O
RPMI	O
medium	O
containing	O
2	O
mM	O
glutamine	O
and	O
10	O
%	O
FBS	O
or	O
serum	O
free	O
LGM	O
medium	O
(	O
Lonza	O
Walkersville	O
Inc	O
.	O
)	O
then	O
plated	O
at	O
4x105	O
cells	O
/	O
well	O
in	O
24	O
-	O
well	O
plates	O
.	O

The	O
original	O
medium	O
was	O
replaced	O
by	O
serum	O
free	O
LGM	O
medium	O
without	O
or	O
with	O
M	O
-	O
CSF	O
(	O
100	O
ng	O
/	O
ml	O
)	O
one	O
hour	O
later	O
.	O

The	O
next	O
day	O
,	O
cell	O
-	O
free	O
supernatants	O
were	O
collected	O
for	O
the	O
SEAP	O
analysis	O
.	O

Cells	O
were	O
stained	O
with	O
Annexin	B-Protein
V	I-Protein
/	O
propidium	O
iodide	O
(	O
PI	O
)	O
.	O

For	O
the	O
inhibition	O
studies	O
,	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
inhibitor	O
for	O
30	O
minutes	O
in	O
X	O
-	O
vivo	O
medium	O
prior	O
to	O
the	O
addition	O
of	O
M	O
-	O
CSF	O
.	O

Secreted	O
Alkaline	O
Phosphatase	O
(	O
SEAP	O
)	O
Analysis	O

Secreted	O
alkaline	O
phosphatase	O
activity	O
was	O
analyzed	O
by	O
GreatEscape	O
SEAP	O
kit	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Briefly	O
,	O
medium	O
was	O
diluted	O
in	O
the	O
dilution	O
buffer	O
and	O
heated	O
to	O
65degreesC	O
to	O
inactivate	O
endogenous	O
phosphatases	O
then	O
incubated	O
with	O
the	O
substrate	O
for	O
30	O
minutes	O
.	O

The	O
chemiluminence	O
signal	O
was	O
recorded	O
using	O
a	O
luminometer	O
.	O

Annexin	B-Protein
V	I-Protein
/	O
PI	O
Apoptosis	O
Assay	O

Cell	O
apoptosis	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
[	O
51	O
]	O
using	O
the	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
apoptosis	O
detection	O
kit	O
(	O
BD	O
PharMingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Briefly	O
,	O
human	O
monocytes	O
(	O
5x106	O
)	O
were	O
incubated	O
with	O
inhibitors	O
for	O
30	O
minutes	O
in	O
X	O
-	O
vivo	O
medium	O
and	O
restimulated	O
with	O
100	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
overnight	O
.	O

The	O
cells	O
were	O
removed	O
from	O
the	O
culture	O
dish	O
using	O
Accutase	O
(	O
eBioscience	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
stained	O
with	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
PI	O
and	O
analyzed	O
by	O
flow	O
cytometry	O
(	O
FACSCalibur	O
;	O
BD	O
PharMingen	O
)	O
.	O

Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
PI	O
double	O
negative	O
cells	O
were	O
considered	O
non	O
-	O
apoptotic	O
cells	O
for	O
statistical	O
analysis	O
.	O

Western	O
Blot	O
Analysis	O

Cells	O
were	O
washed	O
with	O
PBS	O
and	O
resuspended	O
in	O
cell	O
lysis	O
buffer	O
.	O

(	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
incubated	O
for	O
10	O
minutes	O
on	O
ice	O
then	O
centrifuged	O
to	O
remove	O
the	O
insoluble	O
fraction	O
.	O

The	O
protein	O
concentration	O
was	O
determined	O
by	O
the	O
BCA	O
protein	O
assay	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

Cell	O
lysates	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
on	O
10	O
%	O
polyacrylamide	O
gels	O
and	O
then	O
transferred	O
onto	O
nitrocellulose	O
membranes	O
and	O
subjected	O
to	O
Western	O
blotting	O
.	O

The	O
immunoblotted	O
proteins	O
were	O
detected	O
by	O
ECL	O
reagent	O
(	O
GE	O
Healthcare	O
Bio	O
-	O
Sciences	O
Corp	O
.	O
,	O
Piscataway	O
,	O
NJ	O
)	O
.	O

Analysis	O
of	O
PKCalpha	B-Protein
Kinase	O
Activity	O

Human	O
MDMs	O
were	O
starved	O
for	O
2	O
hours	O
before	O
stimulation	O
with	O
M	O
-	O
CSF	O
(	O
0	O
-	O
60	O
minutes	O
)	O
,	O
then	O
washed	O
with	O
cold	O
PBS	O
and	O
removed	O
from	O
the	O
plates	O
.	O

The	O
cells	O
were	O
resuspended	O
in	O
lysis	O
buffer	O
(	O
20	O
mM	O
Tris	O
,	O
5	O
mM	O
MgCl2	O
,	O
1	O
mM	O
EGTA	O
,	O
20	O
mM	O
beta	O
-	O
glycerol	O
phosphate	O
,	O
1	O
mM	O
PMSF	O
2	O
microg	O
/	O
ml	O
aprotinin	O
and	O
2	O
microg	O
/	O
ml	O
leupeptin	O
,	O
pH	O
7	O
.	O
5	O
)	O
,	O
sonicated	O
and	O
centrifuged	O
to	O
obtain	O
whole	O
cell	O
lysates	O
,	O
which	O
were	O
then	O
immunoprecipitated	O
with	O
anti	O
-	O
PKCalpha	O
antibody	O
and	O
protein	O
G	O
-	O
agarose	O
(	O
Invitrogen	O
)	O
.	O

Immune	O
complexes	O
were	O
washed	O
twice	O
,	O
and	O
PKCalpha	B-Protein
activity	O
was	O
analyzed	O
by	O
non	O
-	O
radioactive	O
Peptag	O
assay	O
kit	O
(	O
Promega	O
)	O
.	O

Briefly	O
,	O
kinase	O
buffer	O
,	O
activator	O
,	O
peptide	O
protection	O
solution	O
and	O
Peptag	O
peptide	O
were	O
incubated	O
with	O
the	O
immune	O
complexes	O
at	O
30degreesC	O
for	O
30	O
minutes	O
.	O

Reactions	O
were	O
stopped	O
by	O
boiling	O
for	O
10	O
minutes	O
and	O
samples	O
were	O
separated	O
on	O
0	O
.	O
8	O
%	O
agarose	O
gel	O
.	O

Phosphorylated	O
peptide	O
migrated	O
toward	O
the	O
anode	O
(	O
+	O
)	O
,	O
while	O
non	O
-	O
phosphorylated	O
peptide	O
migrated	O
toward	O
the	O
cathode	O
(	O
-	O
)	O
.	O

Fluorescein	O
-	O
tagged	O
peptides	O
were	O
visualized	O
by	O
UV	O
light	O
.	O

RNA	O
Isolation	O
and	O
Quantitative	O
Real	O
-	O
time	O
PCR	O

MDMs	O
or	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
serum	O
-	O
starved	O
overnight	O
or	O
for	O
2	O
hours	O
,	O
respectively	O
,	O
prior	O
to	O
incubating	O
with	O
inhibitors	O
for	O
30	O
minutes	O
.	O

The	O
cells	O
were	O
restimulated	O
with	O
100	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
and	O
total	O
mRNA	O
was	O
extracted	O
from	O
cells	O
with	O
Trizol	O
(	O
Invitrogen	O
)	O
and	O
1	O
-	O
2	O
microg	O
of	O
total	O
RNA	O
was	O
used	O
to	O
synthesized	O
cDNA	O
using	O
SuperScript	O
III	O
(	O
Invitrogen	O
)	O
.	O

Quantitative	O
real	O
-	O
time	O
(	O
qRT	O
)	O
-	O
PCR	O
was	O
performed	O
using	O
SYBR	O
Green	O
Master	O
Mix	O
(	O
Applied	O
BioSystems	O
,	O
Carlsbad	O
,	O
CA	O
)	O
.	O

The	O
reactions	O
were	O
performed	O
using	O
an	O
ABI	O
PRIZM	O
7700	O
machine	O
with	O
software	O
Sequence	O
Detector	O
version	O
1	O
.	O
7	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
target	O
gene	O
values	O
were	O
normalized	O
to	O
the	O
values	O
of	O
GAPDH	O
as	O
a	O
housekeeping	O
gene	O
and	O
expressed	O
as	O
relative	O
fold	O
increase	O
2	O
(	O
-	O
deltadeltaCt	O
)	O
over	O
the	O
non	O
-	O
stimulated	O
samples	O
(	O
NS	O
)	O
.	O

Statistical	O
Analysis	O

Statistical	O
comparisons	O
were	O
performed	O
using	O
analysis	O
of	O
variance	O
testing	O
(	O
Minitab	O
software	O
,	O
State	O
Park	O
,	O
PA	O
or	O
SPSS16	O
software	O
,	O
SPSS	O
Inc	O
.	O
Chicago	O
,	O
IL	O
)	O
.	O

Statistical	O
significance	O
was	O
defined	O
as	O
p	O
<	O
=	O
0	O
.	O
05	O
.	O

Ethics	O
Statement	O

All	O
research	O
involving	O
human	O
blood	O
(	O
Buffy	O
coat	O
)	O
were	O
ordered	O
from	O
American	O
Red	O
cross	O
and	O
have	O
been	O
approved	O
by	O
the	O
Ohio	O
State	O
University	O
review	O
board	O
(	O
ARC	O
IRB	O
Protocol	O
#	O
2001	O
-	O
26	O
)	O
.	O

M	O
-	O
CSF	O
induces	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
macrophages	O
.	O

(	O
A	O
)	O
Nuclei	O
were	O
extracted	O
from	O
human	O
MDMs	O
treated	O
without	O
or	O
with	O
M	O
-	O
CSF	O
for	O
15	O
or	O
30	O
minutes	O
.	O

NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
was	O
analyzed	O
by	O
EMSA	O
Shown	O
is	O
a	O
representative	O
blot	O
from	O
three	O
independent	O
experiments	O
.	O

NS	O
:	O
non	O
-	O
stimulated	O
.	O

(	O
B	O
)	O
Human	O
MDMs	O
transiently	O
transfected	O
with	O
pTAL	O
-	O
SEAP	O
or	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
constructs	O
were	O
treated	O
with	O
M	O
-	O
CSF	O
in	O
X	O
-	O
vivo	O
medium	O
and	O
incubated	O
for	O
6	O
hours	O
before	O
the	O
collection	O
of	O
medium	O
.	O

NF	O
-	O
kappaB	O
activity	O
was	O
analyzed	O
by	O
measuring	O
the	O
amount	O
of	O
SEAP	O
secreted	O
into	O
the	O
medium	O
and	O
data	O
are	O
expressed	O
as	O
fold	O
increase	O
of	O
SEAP	O
activity	O
over	O
that	O
in	O
pTAL	O
-	O
SEAP	O
transfected	O
resting	O
cells	O
.	O

(	O
C	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
transiently	O
transfected	O
with	O
pTAL	O
-	O
SEAP	O
or	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
construct	O
.	O

Cells	O
were	O
serum	O
starved	O
for	O
4	O
hours	O
prior	O
to	O
2	O
hours	O
stimulation	O
with	O
mouse	O
recombinant	O
M	O
-	O
CSF	O
(	O
100	O
ng	O
/	O
ml	O
)	O
.	O

Culture	O
media	O
was	O
collected	O
to	O
measure	O
SEAP	O
production	O
.	O

Data	O
are	O
expressed	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
,	O
for	O
three	O
independent	O
experiments	O
.	O

Inhibition	O
of	O
PKC	O
reduces	O
NF	O
-	O
kappaB	O
activity	O
in	O
M	O
-	O
CSF	O
stimulated	O
macrophages	O
.	O

(	O
A	O
)	O
Human	O
MDMs	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
were	O
pre	O
-	O
incubated	O
with	O
inhibitors	O
;	O
Ro	O
-	O
31	O
-	O
8220	O
,	O
Go	O
-	O
6976	O
,	O
or	O
BAPTA	O
/	O
AM	O
for	O
30	O
minutes	O
prior	O
to	O
6	O
hours	O
M	O
-	O
CSF	O
stimulation	O
.	O

(	O
B	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
transfected	O
with	O
the	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
construct	O
were	O
pre	O
-	O
incubated	O
with	O
inhibitors	O
for	O
30	O
minutes	O
prior	O
to	O
2	O
hours	O
of	O
stimulation	O
with	O
mouse	O
recombinant	O
M	O
-	O
CSF	O
.	O

The	O
NF	O
-	O
kappaB	O
activity	O
was	O
analyzed	O
by	O
measuring	O
SEAP	O
production	O
in	O
the	O
medium	O
and	O
data	O
are	O
expressed	O
as	O
fold	O
increase	O
of	O
SEAP	O
activity	O
over	O
that	O
in	O
pTAL	O
-	O
SEAP	O
transfected	O
resting	O
cells	O
.	O

The	O
graph	O
represents	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
for	O
three	O
independent	O
experiments	O
.	O

*	O
The	O
p	O
-	O
values	O
of	O
cells	O
treated	O
with	O
inhibitors	O
/	O
M	O
-	O
CSF	O
compared	O
to	O
vehicle	O
/	O
M	O
-	O
CSF	O
were	O
<	O
=	O
0	O
.	O
05	O
.	O

Inhibition	O
of	O
PKC	O
or	O
NF	O
-	O
kappaB	O
induces	O
apoptosis	O
in	O
MDMs	O
.	O

(	O
A	O
)	O
MDMs	O
were	O
pre	O
-	O
incubated	O
in	O
RPMI	O
medium	O
containing	O
inhibitors	O
(	O
Ro	O
-	O
31	O
-	O
8220	O
:	O
5	O
microM	O
,	O
Go	O
-	O
6976	O
:	O
5	O
microM	O
,	O
BAPTA	O
/	O
AM	O
:	O
2	O
.	O
5	O
microM	O
)	O
for	O
30	O
minutes	O
prior	O
to	O
the	O
addition	O
of	O
M	O
-	O
CSF	O
.	O

As	O
a	O
control	O
,	O
untreated	O
cells	O
were	O
incubated	O
with	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
.	O

Cell	O
lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotted	O
with	O
antibody	O
recognizing	O
the	O
active	O
cleaved	O
form	O
of	O
caspase	O
-	O
3	O
.	O

The	O
blots	O
were	O
reblotted	O
with	O
beta	B-Protein
-	I-Protein
actin	I-Protein
that	O
served	O
as	O
a	O
loading	O
control	O
.	O

The	O
ratio	O
of	O
active	O
caspase	B-Protein
-	I-Protein
3	I-Protein
bands	O
(	O
17	O
kD	O
and	O
19	O
kD	O
)	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
control	O
was	O
determined	O
by	O
densitometry	O
analysis	O
(	O
bottom	O
panel	O
)	O
.	O

Data	O
represents	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
from	O
two	O
independent	O
donors	O
.	O

(	O
B	O
)	O
Apoptosis	O
of	O
the	O
treated	O
MDMs	O
was	O
also	O
measured	O
by	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
propidium	O
iodine	O
(	O
PI	O
)	O
staining	O
and	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

The	O
percentage	O
of	O
surviving	O
cells	O
(	O
Annexin	B-Protein
V	I-Protein
/	O
PI	O
negative	O
)	O
for	O
the	O
cells	O
treated	O
with	O
vehicle	O
/	O
M	O
-	O
CSF	O
was	O
arbitrarily	O
set	O
as	O
100	O
.	O

Data	O
shown	O
represent	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
from	O
three	O
independent	O
experiments	O
.	O

*	O
The	O
p	O
-	O
values	O
of	O
inhibitors	O
/	O
M	O
-	O
CSF	O
compared	O
to	O
vehicle	O
/	O
M	O
-	O
CSF	O
were	O
<	O
=	O
0	O
.	O
05	O
.	O

M	O
-	O
CSF	O
activates	O
PKCalpha	B-Protein
in	O
human	O
MDMs	O
.	O

MDMs	O
treated	O
with	O
M	O
-	O
CSF	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
varying	O
amounts	O
of	O
time	O
were	O
lysed	O
and	O
immunoprecipitated	O
using	O
anti	O
-	O
PKC	O
antibody	O
or	O
control	O
IgG	O
antibody	O
.	O

One	O
half	O
of	O
the	O
samples	O
was	O
used	O
to	O
analyze	O
PKC	O
kinase	O
activity	O
using	O
a	O
fluorescein	O
tagged	O
peptide	O
and	O
visualized	O
by	O
agarose	O
gel	O
electrophoresis	O
(	O
top	O
panel	O
)	O
,	O
while	O
the	O
other	O
half	O
was	O
subjected	O
to	O
Western	O
blot	O
analysis	O
to	O
confirm	O
equal	O
amounts	O
of	O
PKCalpha	B-Protein
were	O
immunoprecipitated	O
from	O
each	O
sample	O
(	O
middle	O
panel	O
)	O
.	O

The	O
kinase	O
assay	O
was	O
quantitated	O
using	O
Quantity	O
One	O
software	O
(	O
Bio	O
-	O
Rad	O
)	O
(	O
bottom	O
panel	O
)	O
.	O

Data	O
represents	O
the	O
average	O
fold	O
increase	O
of	O
PKCalpha	B-Protein
activity	O
in	O
non	O
-	O
stimulated	O
samples	O
compared	O
to	O
M	O
-	O
CSF	O
-	O
treated	O
MDM	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
for	O
three	O
independent	O
experiments	O
.	O

NS	O
:	O
non	O
-	O
stimulated	O
.	O

*	O
The	O
p	O
-	O
values	O
of	O
M	O
-	O
CSF	O
stimulated	O
compared	O
to	O
non	O
-	O
stimulated	O
were	O
<	O
=	O
0	O
.	O
05	O
.	O

M	O
-	O
CSF	O
-	O
induced	O
PKC	O
activity	O
does	O
not	O
regulate	O
IkappaBalpha	B-Protein
degradation	O
but	O
regulates	O
the	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
.	O

(	O
A	O
)	O
MDMs	O
were	O
pretreated	O
with	O
cycloheximide	O
(	O
CHX	O
)	O
in	O
the	O
absence	O
or	O
presence	O
of	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
prior	O
to	O
M	O
-	O
CSF	O
stimulation	O
for	O
the	O
indicated	O
times	O
.	O

Whole	O
cell	O
lysates	O
were	O
subjected	O
to	O
Western	O
blotting	O
with	O
anti	O
-	O
IkappaBalpha	O
antibody	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
MDMs	O
were	O
pretreated	O
with	O
either	O
vehicle	O
or	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
before	O
the	O
addition	O
of	O
M	O
-	O
CSF	O
for	O
10	O
minutes	O
.	O

Whole	O
cell	O
lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
phospho	O
-	O
Ser276	O
or	O
phospho	O
-	O
Ser536	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
was	O
detected	O
using	O
phospho	O
-	O
specific	O
antibodies	O
to	O
either	O
residue	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
.	O

(	O
C	O
)	O
Whole	O
cell	O
lysates	O
of	O
RAW	O
264	O
.	O
7	O
cells	O
treated	O
with	O
vehicle	O
control	O
or	O
Ro	O
-	O
31	O
-	O
8220	O
in	O
the	O
absence	O
or	O
presence	O
of	O
M	O
-	O
CSF	O
were	O
subjected	O
to	O
Western	O
blot	O
analysis	O
with	O
phospho	O
-	O
Ser276	O
or	O
phospho	O
-	O
Ser536	O
NF	O
-	O
kappaB	O
p65	O
antibodies	O
.	O

(	O
D	O
)	O
Cytosolic	O
and	O
nuclear	O
fractions	O
of	O
RAW	O
264	O
.	O
7	O
were	O
obtained	O
from	O
the	O
treated	O
cells	O
and	O
immunoblotted	O
for	O
phospho	O
-	O
NF	O
-	O
kappaB	O
.	O

The	O
purity	O
of	O
the	O
cytosolic	O
and	O
nuclear	O
fractions	O
was	O
confirmed	O
by	O
immunoblotting	O
with	O
GAPDH	O
and	O
Lamin	O
B	O
,	O
respectively	O
.	O

Shown	O
are	O
representative	O
blots	O
from	O
three	O
independent	O
experiments	O
.	O

Inhibition	O
of	O
M	O
-	O
CSF	O
-	O
induced	O
PKC	O
reduces	O
NF	O
-	O
kappaB	O
-	O
regulated	O
genes	O
in	O
both	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

MDMs	O
(	O
A	O
and	O
C	O
)	O
and	O
RAW	O
264	O
.	O
7	O
(	O
B	O
)	O
cells	O
were	O
pretreated	O
with	O
Ro	O
-	O
31	O
-	O
8220	O
or	O
solvent	O
control	O
DMSO	O
for	O
30	O
minutes	O
prior	O
to	O
M	O
-	O
CSF	O
stimulation	O
for	O
the	O
indicated	O
times	O
.	O

Total	O
RNA	O
was	O
isolated	O
and	O
converted	O
to	O
cDNA	O
.	O

Real	O
-	O
time	O
RT	O
PCR	O
was	O
performed	O
using	O
primers	O
for	O
IkappaBalpha	B-Protein
,	O
BCL	B-Protein
-	I-Protein
xl	I-Protein
or	O
GAPDH	O
.	O

Data	O
are	O
expressed	O
as	O
relative	O
fold	O
increase	O
of	O
IkappaBalpha	B-Protein
or	O
BCL	B-Protein
-	I-Protein
xl	I-Protein
gene	O
expression	O
upon	O
treatment	O
over	O
non	O
-	O
stimulated	O
cells	O
.	O

Data	O
represent	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
for	O
three	O
independent	O
experiments	O
.	O

PKCalpha	B-Protein
regulates	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
.	O

(	O
A	O
)	O
MDM	O
or	O
(	O
B	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
transiently	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
along	O
with	O
either	O
WT	O
-	O
PKCalpha	B-Protein
or	O
the	O
kinase	O
-	O
deficient	O
(	O
KD	O
)	O
-	O
PKCalpha	B-Protein
construct	O
at	O
a	O
1	O
:	O
5	O
ratio	O
.	O

Cells	O
were	O
serum	O
starved	O
and	O
stimulated	O
with	O
M	O
-	O
CSF	O
and	O
then	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

Data	O
is	O
from	O
of	O
three	O
independent	O
experiments	O
.	O

The	O
p	O
-	O
value	O
of	O
cells	O
transfected	O
with	O
KD	O
compared	O
to	O
those	O
transfected	O
with	O
WT	O
was	O
0	O
.	O
05	O
.	O

(	O
C	O
)	O
MDMs	O
were	O
removed	O
from	O
the	O
plate	O
using	O
accutase	O
and	O
apoptosis	O
of	O
MDMs	O
was	O
measured	O
by	O
flow	O
cytometry	O
using	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
propidium	O
iodine	O
(	O
PI	O
)	O
.	O

(	O
D	O
)	O
Whole	O
cell	O
lysates	O
from	O
the	O
transfected	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
subjected	O
to	O
Western	O
blot	O
analysis	O
with	O
phospho	O
-	O
Ser276	O
or	O
phospho	O
-	O
Ser536	O
NF	O
-	O
kappaB	O
p65	O
antibodies	O
.	O

Blots	O
were	O
immunoblotted	O
with	O
PKCalpha	B-Protein
to	O
determine	O
equal	O
protein	O
expression	O
for	O
the	O
PKCalpha	B-Protein
constructs	O
.	O
beta	B-Protein
-	I-Protein
actin	I-Protein
served	O
as	O
a	O
loading	O
control	O
.	O

Shown	O
is	O
a	O
representative	O
blot	O
from	O
three	O
independent	O
experiments	O
.	O

(	O
E	O
)	O
MDM	O
or	O
(	O
F	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
along	O
with	O
either	O
100	O
nM	O
PKCalpha	B-Protein
siRNA	I-Protein
or	O
control	O
siRNA	O
for	O
20	O
-	O
24	O
hours	O
.	O

Cells	O
were	O
serum	O
starved	O
for	O
2	O
-	O
4	O
hours	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
for	O
6	O
hours	O
for	O
MDM	O
or	O
RAW	O
264	O
.	O
7	O
for	O
2	O
hours	O
and	O
then	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

Shown	O
is	O
data	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
G	O
)	O
MDMs	O
were	O
removed	O
from	O
the	O
plate	O
using	O
accutase	O
and	O
apoptosis	O
of	O
MDMs	O
was	O
measured	O
by	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
propidium	O
iodine	O
(	O
PI	O
)	O
staining	O
and	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

(	O
H	O
)	O
Whole	O
cell	O
lysates	O
from	O
the	O
transfected	O
MDM	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
subjected	O
to	O
Western	O
blot	O
analysis	O
with	O
PKCalpha	O
antibody	O
.	O
beta	B-Protein
-	I-Protein
actin	I-Protein
served	O
as	O
a	O
loading	O
control	O
.	O

Shown	O
is	O
a	O
representative	O
blot	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

NF	O
-	O
kappaB	O
p65	B-Protein
Ser276	O
is	O
essential	O
in	O
regulating	O
NF	O
-	O
kappaB	O
activity	O
.	O

(	O
A	O
)	O
Raw	O
264	O
.	O
7	O
cell	O
line	O
was	O
transiently	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
along	O
with	O
empty	O
vector	O
or	O
plasmid	O
encoding	O
either	O
NF	O
-	O
kappaB	O
p65	B-Protein
WT	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
.	O

The	O
cells	O
were	O
transfected	O
for	O
18	O
-	O
24	O
hours	O
,	O
serum	O
starved	O
for	O
4	O
hours	O
,	O
and	O
then	O
incubated	O
with	O
10	O
microM	O
of	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
prior	O
to	O
treatment	O
with	O
100	O
ng	O
/	O
ml	O
of	O
M	O
-	O
CSF	O
for	O
2	O
hours	O
and	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

(	O
B	O
)	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cell	O
line	O
was	O
transiently	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
along	O
with	O
empty	O
vector	O
or	O
plasmid	O
encoding	O
either	O
NF	O
-	O
kappaB	O
p65	B-Protein
WT	O
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
,	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
536S	O
/	O
A	O
.	O

The	O
cells	O
were	O
cultured	O
for	O
24	O
hours	O
and	O
then	O
serum	O
starved	O
for	O
4	O
hours	O
.	O

Cells	O
were	O
then	O
incubated	O
in	O
fresh	O
DMEM	O
medium	O
for	O
2	O
hours	O
and	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

The	O
results	O
shown	O
are	O
fold	O
change	O
over	O
empty	O
vector	O
+	O
pTAL	O
-	O
SEAP	O
.	O

(	O
C	O
)	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cell	O
line	O
was	O
transiently	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
with	O
either	O
empty	O
vector	O
or	O
plasmid	O
encoding	O
either	O
NF	O
-	O
kappaB	O
p65	B-Protein
WT	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
.	O

The	O
cells	O
were	O
transfected	O
for	O
24	O
hours	O
and	O
serum	O
starved	O
for	O
4	O
hours	O
,	O
and	O
then	O
incubated	O
with	O
10	O
microM	O
of	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
prior	O
to	O
treatment	O
with	O
10	O
ng	O
/	O
ml	O
of	O
TNFalpha	B-Protein
.	O

The	O
supernatant	O
were	O
collected	O
after	O
2	O
hours	O
of	O
treatment	O
and	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

The	O
results	O
shown	O
are	O
the	O
fold	O
change	O
over	O
empty	O
vector	O
+	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
.	O

Data	O
shown	O
are	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
for	O
at	O
least	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O

Proposed	O
model	O
for	O
M	O
-	O
CSF	O
-	O
induced	O
monocyte	O
survival	O
via	O
PKC	O
regulation	O
by	O
activating	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
.	O

SHARPIN	B-Protein
Is	O
Essential	O
for	O
Cytokine	O
Production	O
,	O
NF	O
-	O
kappaB	O
Signaling	O
,	O
and	O
Induction	O
of	O
Th1	O
Differentiation	O
by	O
Dendritic	O
Cells	O

Spontaneous	O
mutations	O
of	O
the	O
Sharpin	B-Protein
(	O
SHANK	B-Protein
-	I-Protein
associated	I-Protein
RH	I-Protein
domain	I-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
,	O
other	O
aliases	O
:	O
Rbckl1	B-Protein
,	O
Sipl1	B-Protein
)	O
gene	O
in	O
mice	O
result	O
in	O
systemic	O
inflammation	O
that	O
is	O
characterized	O
by	O
chronic	O
proliferative	O
dermatitis	O
and	O
dysregulated	O
secretion	O
of	O
T	O
helper1	O
(	O
Th1	O
)	O
and	O
Th2	O
cytokines	O
.	O

The	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
this	O
inflammatory	O
phenotype	O
remain	O
elusive	O
.	O

Dendritic	O
cells	O
may	O
contribute	O
to	O
the	O
initiation	O
and	O
progression	O
of	O
the	O
phenotype	O
of	O
SHARPIN	B-Protein
-	O
deficient	O
mice	O
because	O
of	O
their	O
pivotal	O
role	O
in	O
innate	O
and	O
adaptive	O
immunity	O
.	O

Here	O
we	O
show	O
by	O
flow	O
cytometry	O
that	O
SHARPIN	B-Protein
-	O
deficiency	O
did	O
not	O
alter	O
the	O
distribution	O
of	O
different	O
DC	O
subtypes	O
in	O
the	O
spleen	O
.	O

In	O
response	O
to	O
TOLL	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	O
LPS	O
and	O
poly	O
I	O
:	O
C	O
,	O
cultured	O
bone	O
marrow	O
-	O
derived	O
dendritic	O
cells	O
(	O
BMDC	O
)	O
from	O
WT	O
and	O
mutant	O
mice	O
exhibited	O
similar	O
increases	O
in	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
CD40	B-Protein
,	O
CD80	B-Protein
,	O
and	O
CD86	B-Protein
.	O

However	O
,	O
stimulated	O
SHARPIN	B-Protein
-	O
deficient	O
BMDC	O
had	O
reduced	O
transcription	O
and	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
IL6	B-Protein
,	O
IL12P70	O
,	O
GMCSF	B-Protein
,	O
and	O
nitric	O
oxide	O
.	O

Mutant	O
BMDC	O
had	O
defective	O
activation	O
of	O
NF	O
-	O
kappaB	O
signaling	O
,	O
whereas	O
the	O
MAPK1	B-Protein
/	O
3	B-Protein
(	O
ERK1	B-Protein
/	O
2	B-Protein
)	O
and	O
MAPK11	B-Protein
/	O
12	B-Protein
/	O
13	B-Protein
/	O
14	B-Protein
(	O
p38	O
MAP	O
kinase	O
isoforms	O
)	O
and	O
TBK1	B-Protein
signaling	O
pathways	O
were	O
intact	O
.	O

A	O
mixed	O
lymphocyte	O
reaction	O
showed	O
that	O
mutant	O
BMDC	O
only	O
induced	O
a	O
weak	O
Th1	O
immune	O
response	O
but	O
stimulated	O
increased	O
Th2	O
cytokine	O
production	O
from	O
allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
.	O

In	O
conclusion	O
,	O
loss	O
of	O
Sharpin	B-Protein
in	O
mice	O
significantly	O
affects	O
the	O
immune	O
function	O
of	O
DC	O
and	O
this	O
may	O
partially	O
account	O
for	O
the	O
systemic	O
inflammation	O
and	O
Th2	O
-	O
biased	O
immune	O
response	O
.	O

SHARPIN	B-Protein
was	O
originally	O
identified	O
in	O
post	O
-	O
synaptic	O
densities	O
of	O
excitatory	O
synapses	O
in	O
the	O
brain	O
of	O
rats	O
[	O
1	O
]	O
,	O
but	O
this	O
protein	O
is	O
widely	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
[	O
2	O
]	O
.	O

Two	O
allelic	O
,	O
autosomal	O
recessive	O
mutations	O
in	O
the	O
Sharpin	B-Protein
gene	O
occurred	O
spontaneously	O
in	O
two	O
inbred	O
strains	O
of	O
mice	O
,	O
C57B	O
/	O
KaLawRij	O
-	O
Sharpincpdm	O
/	O
Sharpincpdm	O
and	O
CBy	O
.	O
Ocb3	O
/	O
Dem	O
-	O
Sharpincpdm	O
-	O
Dem	O
/	O
Sharpincpdm	O
-	O
Dem	O
,	O
resulting	O
in	O
premature	O
termination	O
of	O
mRNA	O
synthesis	O
and	O
absence	O
of	O
a	O
functional	O
protein	O
product	O
[	O
2	O
]	O
.	O

Despite	O
different	O
genetic	O
backgrounds	O
,	O
both	O
mutations	O
cause	O
similar	O
inflammatory	O
disease	O
with	O
severe	O
chronic	O
progressive	O
dermatitis	O
and	O
defective	O
development	O
of	O
secondary	O
lymphoid	O
organs	O
[	O
2	O
]	O
-	O
[	O
4	O
]	O
.	O

The	O
dermatitis	O
becomes	O
clinically	O
apparent	O
at	O
about	O
four	O
weeks	O
of	O
age	O
.	O

There	O
are	O
accumulations	O
of	O
eosinophils	O
,	O
neutrophils	O
and	O
macrophages	O
in	O
the	O
skin	O
of	O
Sharpincpdm	O
/	O
Sharpincpdm	O
mutant	O
mice	O
(	O
hereafter	O
referred	O
to	O
as	O
cpdm	O
mice	O
)	O
associated	O
with	O
increased	O
expression	O
of	O
Th2	O
cytokines	O
in	O
the	O
skin	O
and	O
in	O
the	O
supernatants	O
of	O
activated	O
splenocytes	O
[	O
5	O
]	O
.	O

The	O
mice	O
have	O
an	O
impaired	O
delayed	O
type	O
hypersensitivity	O
response	O
and	O
decreased	O
secretion	O
of	O
IFNgamma	B-Protein
[	O
5	O
]	O
,	O
indicating	O
a	O
defect	O
in	O
Th1	O
immune	O
responses	O
and	O
a	O
bias	O
towards	O
a	O
Th2	O
immune	O
response	O
.	O

Systemic	O
treatment	O
of	O
cpdm	O
mice	O
with	O
recombinant	O
IL12	O
caused	O
complete	O
remission	O
of	O
the	O
dermatitis	O
[	O
5	O
]	O
.	O

Neutralization	O
of	O
IL5	B-Protein
by	O
antibody	O
treatment	O
or	O
crosses	O
with	O
IL5	B-Protein
-	O
deficient	O
mice	O
reduced	O
the	O
number	O
of	O
circulating	O
and	O
cutaneous	O
eosinophils	O
,	O
but	O
failed	O
to	O
reduce	O
the	O
onset	O
and	O
severity	O
of	O
the	O
dermatitis	O
[	O
6	O
]	O
.	O

Recently	O
,	O
three	O
independent	O
groups	O
identified	O
SHARPIN	B-Protein
as	O
an	O
essential	O
component	O
of	O
the	O
linear	O
ubiquitin	O
chain	O
assembly	O
complex	O
(	O
LUBAC	O
)	O
that	O
regulates	O
TNFalpha	B-Protein
-	O
induced	O
canonical	O
NF	O
-	O
kappaB	O
signaling	O
[	O
7	O
]	O
-	O
[	O
9	O
]	O
.	O

SHARPIN	B-Protein
-	O
deficient	O
mouse	O
embryonic	O
fibroblast	O
(	O
MEF	O
)	O
were	O
sensitized	O
to	O
TNFalpha	B-Protein
-	O
induced	O
apoptosis	O
and	O
cell	O
death	O
was	O
implicated	O
as	O
a	O
factor	O
in	O
the	O
dermatitis	O
of	O
cpdm	O
mice	O
[	O
7	O
]	O
-	O
[	O
9	O
]	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
have	O
a	O
sentinel	O
role	O
in	O
sensing	O
pathogen	O
or	O
danger	O
signals	O
and	O
initiate	O
and	O
direct	O
activation	O
of	O
the	O
adaptive	O
immune	O
response	O
[	O
10	O
]	O
.	O

Activated	O
and	O
mature	O
DC	O
can	O
carry	O
processed	O
antigenic	O
peptides	O
,	O
migrate	O
to	O
lymphoid	O
organs	O
,	O
and	O
induce	O
T	O
-	O
cell	O
-	O
mediated	O
immune	O
responses	O
or	O
tolerance	O
.	O

DC	O
direct	O
the	O
differentiation	O
of	O
CD4	O
+	O
T	O
cells	O
,	O
and	O
hence	O
the	O
type	O
of	O
immune	O
response	O
,	O
through	O
the	O
selective	O
secretion	O
of	O
cytokines	O
.	O

We	O
hypothesized	O
that	O
defective	O
cytokine	O
secretion	O
by	O
DC	O
contributed	O
to	O
the	O
Th2	O
-	O
biased	O
inflammatory	O
phenotype	O
in	O
SHARPIN	B-Protein
-	O
deficient	O
mice	O
.	O

The	O
studies	O
reported	O
here	O
found	O
that	O
lack	O
of	O
SHARPIN	B-Protein
protein	O
in	O
BMDC	O
caused	O
defective	O
expression	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
and	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
upon	O
ligand	O
stimulation	O
.	O

The	O
ability	O
of	O
cpdm	O
BMDC	O
to	O
stimulate	O
Th1	O
cytokine	O
production	O
in	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
was	O
compromised	O
.	O

Taken	O
together	O
,	O
these	O
results	O
reveal	O
that	O
SHARPIN	B-Protein
is	O
a	O
novel	O
regulatory	O
molecule	O
in	O
DC	O
biology	O
and	O
suggest	O
that	O
the	O
dysregulated	O
function	O
of	O
SHARPIN	B-Protein
-	O
deficient	O
DC	O
plays	O
a	O
role	O
in	O
the	O
cpdm	O
phenotype	O
.	O

Characterization	O
of	O
Sharpin	B-Protein

Orthologs	O
of	O
SHARPIN	B-Protein
protein	O
are	O
found	O
in	O
various	O
species	O
,	O
including	O
human	O
,	O
mouse	O
and	O
rat	O
.	O

Motif	O
prediction	O
programming	O
,	O
using	O
COILS	O
[	O
11	O
]	O
and	O
MotifScan	O
[	O
12	O
]	O
,	O
suggests	O
that	O
SHARPIN	B-Protein
contains	O
a	O
coiled	O
-	O
coil	O
(	O
CC	O
)	O
domain	O
,	O
a	O
ubiquitin	O
-	O
like	O
(	O
UBL	O
)	O
domain	O
,	O
and	O
a	O
zinc	O
-	O
finger	O
Ran	O
-	O
binding	O
protein	O
2	O
(	O
ZFRBP	O
)	O
domain	O
.	O

These	O
functional	O
motifs	O
constitute	O
similar	O
domain	O
profiles	O
that	O
are	O
present	O
in	O
the	O
SHARPIN	B-Protein
protein	O
of	O
all	O
three	O
origins	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
suggesting	O
that	O
SHARPIN	B-Protein
exerts	O
highly	O
conserved	O
functions	O
across	O
species	O
.	O

Spontaneous	O
mutations	O
in	O
the	O
mouse	O
Sharpin	B-Protein
gene	O
results	O
in	O
a	O
complex	O
inflammatory	O
phenotype	O
characterized	O
by	O
severe	O
dermatitis	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
systemic	O
inflammation	O
and	O
an	O
enlarged	O
spleen	O
(	O
Fig	O
.	O
1C	O
)	O
caused	O
by	O
extramedullary	O
hematopoiesis	O
[	O
3	O
]	O
.	O

The	O
endogenous	O
expression	O
of	O
Sharpin	B-Protein
mRNA	O
in	O
BMDC	O
was	O
determined	O
by	O
quantitative	O
real	O
time	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
following	O
culture	O
in	O
medium	O
only	O
or	O
after	O
stimulation	O
with	O
LPS	O
.	O

Sharpin	B-Protein
mRNA	O
was	O
present	O
in	O
BMDC	O
generated	O
from	O
WT	O
mice	O
(	O
Fig	O
.	O
1D	O
)	O
and	O
its	O
level	O
was	O
modestly	O
decreased	O
by	O
LPS	O
stimulation	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
Sharpin	B-Protein
mRNA	O
(	O
6	O
-	O
7	O
-	O
fold	O
)	O
in	O
BMDC	O
generated	O
from	O
cpdm	O
mice	O
.	O

Transfection	O
of	O
Flag	O
-	O
tagged	O
Sharpin	B-Protein
in	O
fibroblasts	O
(	O
NIH3T3	O
)	O
and	O
macrophages	O
(	O
RAW264	O
.	O
7	O
)	O
indicated	O
cytoplasmic	O
localization	O
of	O
the	O
SHARPIN	B-Protein
protein	O
(	O
Fig	O
.	O
1E	O
)	O
.	O

Phenotyping	O
splenic	O
DC	O
and	O
BMDC	O
from	O
WT	O
and	O
cpdm	O
mice	O

DC	O
are	O
heterogeneous	O
and	O
can	O
be	O
categorized	O
into	O
multiple	O
subtypes	O
based	O
on	O
surface	O
markers	O
[	O
13	O
]	O
.	O

To	O
determine	O
if	O
the	O
Sharpin	B-Protein
mutation	O
affects	O
DC	O
development	O
in	O
lymphoid	O
tissues	O
,	O
mouse	O
spleens	O
were	O
examined	O
for	O
the	O
distribution	O
of	O
conventional	O
DC	O
(	O
cDC	O
;	O
CD11c	B-Protein
+	O
CD8alpha	B-Protein
+	O
and	O
CD11c	B-Protein
+	O
CD8alpha	B-Protein
-	O
)	O
[	O
13	O
]	O
and	O
plasmacytoid	O
DC	O
(	O
pDC	O
;	O
CD11c	B-Protein
-	O
PDCA	B-Protein
-	I-Protein
1	I-Protein
+	O
)	O
[	O
14	O
]	O
.	O

The	O
percentages	O
for	O
splenic	O
cDC	O
and	O
pDC	O
were	O
both	O
reduced	O
in	O
cpdm	O
mice	O
when	O
compared	O
with	O
WT	O
controls	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

However	O
,	O
when	O
gated	O
on	O
CD11c	O
+	O
cDC	O
,	O
the	O
percentages	O
of	O
CD8alpha	O
+	O
and	O
CD8alpha	O
-	O
cells	O
were	O
not	O
affected	O
by	O
SHARPIN	B-Protein
deficiency	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Since	O
the	O
spleen	O
of	O
cpdm	O
mice	O
is	O
markedly	O
enlarged	O
and	O
contains	O
three	O
times	O
as	O
many	O
cells	O
(	O
Fig	O
.	O
1C	O
)	O
,	O
the	O
different	O
percentages	O
of	O
splenic	O
cDC	O
and	O
pDC	O
between	O
WT	O
and	O
mutant	O
mice	O
reflect	O
the	O
increased	O
number	O
of	O
total	O
spleen	O
cells	O
rather	O
than	O
a	O
reduction	O
in	O
cDC	O
and	O
pDC	O
numbers	O
.	O

These	O
data	O
indicate	O
that	O
the	O
Sharpin	B-Protein
mutation	O
does	O
not	O
affect	O
the	O
distribution	O
of	O
the	O
examined	O
DC	O
subsets	O
in	O
the	O
spleen	O
.	O

BMDC	O
from	O
in	O
vitro	O
cultures	O
functionally	O
resemble	O
non	O
-	O
lymphoid	O
tissue	O
DC	O
and	O
monocyte	O
-	O
derived	O
inflammatory	O
DC	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

The	O
yields	O
of	O
BMDC	O
from	O
WT	O
and	O
cpdm	O
mice	O
were	O
similar	O
.	O

BMDC	O
were	O
CD11c	B-Protein
+	O
and	O
MHC	O
II	O
+	O
with	O
low	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
CD40	B-Protein
,	O
CD80	B-Protein
,	O
and	O
CD86	B-Protein
.	O

The	O
TLR3	B-Protein
ligand	O
poly	O
I	O
:	O
C	O
and	O
the	O
TLR4	B-Protein
ligand	O
LPS	O
each	O
activate	O
overlapping	O
but	O
different	O
signaling	O
pathways	O
and	O
were	O
used	O
to	O
induce	O
DC	O
maturation	O
[	O
17	O
]	O
,	O
[	O
18	O
]	O
.	O

Incubation	O
with	O
the	O
TLR	O
agonists	O
for	O
24	O
hours	O
resulted	O
in	O
increased	O
expression	O
of	O
CD40	B-Protein
,	O
CD80	B-Protein
,	O
and	O
CD86	B-Protein
on	O
BMDC	O
;	O
however	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
expression	O
levels	O
of	O
these	O
markers	O
between	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Thus	O
,	O
SHARPIN	B-Protein
deficiency	O
did	O
not	O
influence	O
the	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
by	O
BMDC	O
.	O

Production	O
of	O
proinflammatory	O
mediators	O
by	O
cpdm	O
BMDC	O
is	O
impaired	O

Incubation	O
with	O
LPS	O
or	O
poly	O
I	O
:	O
C	O
resulted	O
in	O
secretion	O
of	O
IL6	B-Protein
,	O
IL12P70	O
,	O
and	O
GMCSF	B-Protein
from	O
both	O
WT	O
and	O
cpdm	O
BMDC	O
;	O
however	O
,	O
BMDC	O
from	O
cpdm	O
mice	O
produced	O
significantly	O
less	O
of	O
all	O
three	O
cytokines	O
compared	O
with	O
WT	O
BMDC	O
(	O
Fig	O
.	O
3A	O
-	O
C	O
,	O
E	O
-	O
F	O
)	O
.	O

The	O
amount	O
of	O
nitric	O
oxide	O
generated	O
by	O
mutant	O
BMDC	O
was	O
also	O
significantly	O
reduced	O
compared	O
with	O
WT	O
cells	O
(	O
Fig	O
.	O
3D	O
)	O
,	O
indicating	O
severely	O
disrupted	O
production	O
of	O
proinflammatory	O
mediators	O
from	O
Sharpin	B-Protein
-	O
deficient	O
BMDC	O
.	O

In	O
vivo	O
complementation	O
with	O
a	O
Sharpin	B-Protein
gene	O
-	O
containing	O
BAC	O
reversed	O
the	O
phenotype	O
of	O
the	O
mutant	O
mice	O
[	O
2	O
]	O
,	O
and	O
BMDC	O
generated	O
from	O
these	O
rescued	O
mice	O
secreted	O
significantly	O
more	O
IL12P70	O
than	O
BMDC	O
from	O
cpdm	O
mice	O
(	O
Fig	O
.	O
3G	O
)	O
,	O
supporting	O
a	O
necessary	O
role	O
of	O
SHARPIN	B-Protein
for	O
the	O
production	O
of	O
IL12P70	O
.	O

In	O
addition	O
,	O
the	O
transcript	O
levels	O
of	O
the	O
inflammatory	O
cytokines	O
Il6	B-Protein
,	O
Il12p40	B-Protein
,	O
Gmcsf	B-Protein
,	O
and	O
Ifnb	B-Protein
were	O
examined	O
,	O
and	O
these	O
were	O
all	O
significantly	O
reduced	O
in	O
stimulated	O
cpdm	O
BMDC	O
when	O
compared	O
with	O
WT	O
controls	O
(	O
Fig	O
.	O
4	O
)	O
.	O

Impaired	O
cytokine	O
production	O
by	O
cpdm	O
BMDC	O
is	O
correlated	O
with	O
selective	O
defects	O
in	O
NF	O
-	O
kappaB	O
signaling	O

There	O
are	O
a	O
number	O
of	O
possible	O
explanations	O
for	O
the	O
defective	O
cytokine	O
secretion	O
in	O
stimulated	O
cpdm	O
BMDC	O
,	O
including	O
1	O
)	O
reduced	O
surface	O
expression	O
of	O
the	O
LPS	O
receptor	O
complex	O
,	O
2	O
)	O
increased	O
production	O
of	O
anti	O
-	O
inflammatory	O
mediators	O
,	O
3	O
)	O
increased	O
expression	O
of	O
negative	O
regulators	O
of	O
TLR	O
pathways	O
,	O
and	O
4	O
)	O
impaired	O
TLR	O
-	O
induced	O
signaling	O
activation	O
.	O

We	O
determined	O
the	O
surface	O
expression	O
of	O
the	O
LPS	O
receptor	O
complex	O
that	O
comprises	O
TLR4	B-Protein
,	O
the	O
accessory	O
proteins	O
CD14	B-Protein
and	O
myeloid	B-Protein
differentiation	I-Protein
factor	I-Protein
2	I-Protein
(	O
MD2	B-Protein
/	O
LY96	B-Protein
)	O
[	O
19	O
]	O
.	O

Flow	O
cytometric	O
analysis	O
shows	O
that	O
the	O
expression	O
levels	O
of	O
CD14	B-Protein
and	O
TLR4	B-Protein
/	O
MD2	B-Protein
between	O
WT	O
and	O
cpdm	O
BMDC	O
were	O
similar	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

We	O
then	O
quantified	O
the	O
secretion	O
of	O
the	O
suppressive	O
cytokines	O
IL10	B-Protein
that	O
can	O
inhibit	O
IL12	O
secretion	O
in	O
an	O
autocrine	O
manner	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

The	O
supernatants	O
from	O
LPS	O
-	O
stimulated	O
cpdm	O
BMDC	O
contained	O
significantly	O
lower	O
levels	O
of	O
IL10	B-Protein
than	O
stimulated	O
WT	O
BMDC	O
(	O
Fig	O
.	O
5B	O
)	O
,	O
suggesting	O
that	O
IL10	B-Protein
was	O
not	O
responsible	O
for	O
decreased	O
secretion	O
of	O
IL12P70	O
by	O
cpdm	O
BMDC	O
.	O

Increased	O
expression	O
of	O
a	O
negative	O
regulator	O
of	O
TLR	O
signaling	O
such	O
as	O
A20	B-Protein
[	O
22	O
]	O
may	O
also	O
suppress	O
cytokine	O
secretion	O
.	O

However	O
,	O
the	O
transcript	O
level	O
of	O
A20	B-Protein
was	O
lower	O
in	O
LPS	O
-	O
activated	O
cpdm	O
BMDC	O
than	O
WT	O
controls	O
(	O
Fig	O
.	O
5C	O
)	O
,	O
thereby	O
ruling	O
out	O
overexpression	O
of	O
A20	B-Protein
as	O
a	O
factor	O
in	O
the	O
reduced	O
cytokine	O
production	O
.	O

The	O
transcription	O
of	O
TLR3	B-Protein
/	O
4	B-Protein
-	O
induced	O
proinflammatory	O
intermediates	O
is	O
tightly	O
regulated	O
by	O
cellular	O
signaling	O
pathways	O
,	O
in	O
particular	O
NF	O
-	O
kappaB	O
,	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
and	O
MAPK	O
[	O
23	O
]	O
-	O
[	O
27	O
]	O
.	O

We	O
next	O
determined	O
if	O
disrupted	O
NF	O
-	O
kappaB	O
,	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
and	O
/	O
or	O
MAPK	O
signaling	O
may	O
underlie	O
the	O
impaired	O
cytokine	O
production	O
from	O
stimulated	O
Sharpin	B-Protein
-	O
deficient	O
BMDC	O
.	O

Stimulus	O
-	O
induced	O
phosphorylation	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK1	B-Protein
/	O
2	B-Protein
)	O
is	O
an	O
essential	O
step	O
in	O
NF	O
-	O
kappaB	O
signaling	O
,	O
allowing	O
phosphorylation	O
and	O
proteasome	O
-	O
mediated	O
degradation	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
IkappaBalpha	B-Protein
to	O
release	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
into	O
the	O
nucleus	O
.	O

The	O
amount	O
of	O
phosphorylated	O
IKK1	B-Protein
/	O
2	B-Protein
(	O
p	O
-	O
IKK1	B-Protein
/	O
2	B-Protein
)	O
and	O
IkappaBalpha	B-Protein
(	O
p	O
-	O
IkappaBalpha	B-Protein
)	O
following	O
incubation	O
with	O
LPS	O
or	O
poly	O
I	O
:	O
C	O
was	O
severely	O
decreased	O
in	O
cpdm	O
BMDC	O
as	O
compared	O
with	O
WT	O
controls	O
(	O
Fig	O
.	O
6	O
)	O
.	O

The	O
cpdm	O
BMDC	O
exhibited	O
similar	O
levels	O
of	O
TBK1	B-Protein
,	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
and	O
p38	O
phosphorylation	O
to	O
those	O
of	O
WT	O
cells	O
(	O
Fig	O
.	O
6	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
absence	O
of	O
functional	O
SHARPIN	B-Protein
decreased	O
NF	O
-	O
kappaB	O
activation	O
but	O
did	O
not	O
affect	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
and	O
p38	O
signaling	O
in	O
BMDC	O
.	O

Th2	O
-	O
biased	O
immunogenicity	O
of	O
stimulated	O
cpdm	O
BMDC	O

The	O
defective	O
IL12	O
production	O
(	O
Fig	O
.	O
3A	O
)	O
and	O
Th2	O
-	O
dominant	O
cytokine	O
profile	O
in	O
cpdm	O
mice	O
[	O
5	O
]	O
suggest	O
that	O
the	O
absence	O
of	O
SHARPIN	B-Protein
affects	O
the	O
ability	O
of	O
cpdm	O
BMDC	O
to	O
induce	O
T	O
cell	O
differentiation	O
into	O
effector	O
cells	O
.	O

Co	O
-	O
culture	O
of	O
allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
with	O
WT	O
BMDC	O
stimulated	O
with	O
LPS	O
or	O
poly	O
I	O
:	O
C	O
elicited	O
robust	O
IFNgamma	B-Protein
production	O
,	O
whereas	O
the	O
concentration	O
of	O
IFNgamma	B-Protein
in	O
cpdm	O
BMDC	O
-	O
T	O
cell	O
cultures	O
was	O
significantly	O
lower	O
after	O
LPS	O
stimulation	O
(	O
Fig	O
.	O
7A	O
)	O
,	O
indicating	O
impaired	O
Th1	O
-	O
polarizing	O
abilities	O
of	O
cpdm	O
BMDC	O
.	O

In	O
addition	O
to	O
TLR3	B-Protein
/	O
4	B-Protein
agonists	O
,	O
the	O
TLR2	B-Protein
ligand	O
Pam3CYS	B-Protein
was	O
used	O
since	O
it	O
has	O
been	O
shown	O
to	O
induce	O
both	O
Th1	O
and	O
Th2	O
responses	O
[	O
28	O
]	O
-	O
[	O
30	O
]	O
.	O

Pam3CYS	B-Protein
-	O
matured	O
WT	O
BMDC	O
induced	O
robust	O
IFNgamma	B-Protein
production	O
at	O
a	O
significantly	O
higher	O
level	O
than	O
cpdm	O
BMDC	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

The	O
reduced	O
Th1	O
differentiation	O
following	O
Pam3CYS	B-Protein
stimulation	O
is	O
consistent	O
with	O
the	O
recent	O
report	O
of	O
decreased	O
IL12	O
production	O
in	O
cpdm	O
macrophages	O
following	O
TLR2	B-Protein
stimulation	O
[	O
31	O
]	O
.	O

In	O
contrast	O
,	O
more	O
Th2	O
-	O
specific	O
IL4	B-Protein
cytokine	O
was	O
produced	O
in	O
the	O
cpdm	O
BMDC	O
co	O
-	O
cultures	O
than	O
the	O
WT	O
control	O
(	O
Fig	O
.	O
7B	O
)	O
,	O
suggesting	O
Th2	O
-	O
skewed	O
immunogenicity	O
of	O
cpdm	O
BMDC	O
.	O

The	O
production	O
of	O
Th17	O
-	O
specific	O
cytokine	O
IL17A	B-Protein
following	O
LPS	O
stimulation	O
of	O
dendritic	O
cells	O
was	O
similar	O
between	O
stimulated	O
WT	O
and	O
cpdm	O
BMDC	O
cocultures	O
(	O
data	O
not	O
shown	O
)	O
.	O

Despite	O
the	O
distinct	O
Th1	O
-	O
and	O
Th2	O
-	O
stimulating	O
abilities	O
of	O
WT	O
and	O
cpdm	O
BMDC	O
,	O
they	O
were	O
equally	O
effective	O
in	O
IL2	B-Protein
production	O
from	O
BMDC	O
-	O
T	O
cell	O
co	O
-	O
cultures	O
except	O
for	O
poly	O
I	O
:	O
C	O
stimulation	O
where	O
WT	O
BMDC	O
induced	O
more	O
IL2	B-Protein
than	O
cpdm	O
BMDC	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

The	O
Th2	O
-	O
biased	O
stimulating	O
capability	O
of	O
cpdm	O
BMDC	O
when	O
co	O
-	O
cultured	O
with	O
allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
is	O
consistent	O
with	O
the	O
Th2	O
-	O
dominant	O
cytokine	O
phenotype	O
observed	O
in	O
cpdm	O
mice	O
.	O

The	O
present	O
report	O
showed	O
that	O
null	O
mutations	O
of	O
the	O
mouse	O
Sharpin	B-Protein
gene	O
did	O
not	O
affect	O
the	O
steady	O
-	O
state	O
distribution	O
of	O
splenic	O
DC	O
subsets	O
nor	O
the	O
development	O
and	O
phenotype	O
of	O
BMDC	O
.	O

However	O
,	O
loss	O
of	O
SHARPIN	B-Protein
significantly	O
diminished	O
the	O
capacity	O
of	O
BMDC	O
to	O
secrete	O
inflammatory	O
cytokines	O
and	O
nitric	O
oxide	O
.	O

The	O
attenuated	O
cytokine	O
production	O
was	O
not	O
due	O
to	O
the	O
presence	O
of	O
anti	O
-	O
inflammatory	O
inhibitors	O
,	O
and	O
can	O
be	O
largely	O
explained	O
by	O
selective	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Stimulated	O
cpdm	O
BMDC	O
exhibited	O
Th2	O
-	O
biased	O
T	O
cell	O
-	O
polarizing	O
capabilities	O
,	O
consistent	O
with	O
the	O
Th2	O
cytokine	O
-	O
dominant	O
phenotype	O
in	O
cpdm	O
mice	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
an	O
indispensible	O
role	O
of	O
SHARPIN	B-Protein
in	O
regulating	O
DC	O
immunological	O
functions	O
,	O
disruption	O
of	O
which	O
may	O
contribute	O
to	O
the	O
development	O
of	O
immune	O
diseases	O
.	O

Since	O
WT	O
and	O
cpdm	O
mice	O
are	O
both	O
specific	O
pathogen	O
-	O
free	O
,	O
the	O
nature	O
of	O
the	O
trigger	O
of	O
the	O
severe	O
inflammation	O
in	O
cpdm	O
mice	O
is	O
not	O
obvious	O
.	O

One	O
such	O
initiating	O
factor	O
could	O
be	O
endogenous	O
apoptotic	O
and	O
/	O
or	O
necrotic	O
cells	O
that	O
can	O
release	O
danger	O
-	O
associated	O
molecular	O
patterns	O
(	O
DAMPs	O
)	O
to	O
launch	O
and	O
amplify	O
an	O
inflammatory	O
response	O
[	O
32	O
]	O
.	O

Such	O
'	O
sterile	O
'	O
inflammation	O
could	O
be	O
initiated	O
and	O
take	O
place	O
in	O
all	O
organs	O
and	O
tissues	O
affected	O
in	O
cpdm	O
mice	O
,	O
thus	O
causing	O
multi	O
-	O
organ	O
inflammatory	O
disorders	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
several	O
recent	O
studies	O
.	O

Fibroblasts	O
of	O
cpdm	O
mice	O
are	O
highly	O
sensitive	O
to	O
TNFalpha	B-Protein
-	O
induced	O
cell	O
death	O
and	O
the	O
cpdm	O
phenotype	O
can	O
be	O
partially	O
rescued	O
by	O
deletion	O
of	O
TNF	B-Protein
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
suggesting	O
that	O
deficiency	O
of	O
SHARPIN	B-Protein
compromises	O
the	O
anti	O
-	O
apoptotic	O
mechanisms	O
in	O
cpdm	O
mice	O
resulting	O
in	O
cell	O
death	O
-	O
induced	O
inflammatory	O
disease	O
.	O

Apoptosis	O
of	O
keratinocytes	O
is	O
a	O
prominent	O
feature	O
of	O
the	O
skin	O
lesions	O
in	O
cpdm	O
mice	O
[	O
33	O
]	O
and	O
this	O
is	O
mediated	O
by	O
caspase	O
-	O
dependent	O
mitochondrial	O
pathways	O
[	O
34	O
]	O
.	O

These	O
induced	O
and	O
/	O
or	O
intrinsic	O
apoptotic	O
cells	O
can	O
release	O
various	O
types	O
of	O
DAMPs	O
that	O
exert	O
their	O
pro	O
-	O
inflammatory	O
properties	O
by	O
activating	O
DC	O
through	O
pattern	O
recognition	O
receptors	O
[	O
32	O
]	O
,	O
[	O
35	O
]	O
,	O
such	O
as	O
HMGB1	B-Protein
recognized	O
by	O
TLR2	B-Protein
/	O
4	B-Protein
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

Consistent	O
with	O
the	O
impaired	O
Th1	O
immune	O
response	O
in	O
cpdm	O
mice	O
[	O
5	O
]	O
,	O
stimulated	O
BMDC	O
weakly	O
polarized	O
Th1	O
differentiation	O
,	O
but	O
strongly	O
supported	O
the	O
development	O
of	O
Th2	O
effector	O
cells	O
.	O

Combined	O
with	O
the	O
dramatic	O
effect	O
of	O
IL12	O
treatment	O
on	O
the	O
phenotype	O
of	O
these	O
mice	O
[	O
5	O
]	O
,	O
this	O
suggests	O
that	O
the	O
Th2	O
-	O
biased	O
systemic	O
inflammation	O
in	O
cpdm	O
mice	O
is	O
caused	O
by	O
reduced	O
IL12P70	O
production	O
from	O
DC	O
.	O

The	O
importance	O
of	O
IL12P70	O
in	O
regulating	O
Th1	O
and	O
Th2	O
immune	O
responses	O
in	O
mice	O
was	O
clearly	O
demonstrated	O
in	O
IL12P35	B-Protein
-	O
and	O
IL12P40	B-Protein
-	O
deficient	O
mice	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
and	O
through	O
clinical	O
studies	O
in	O
human	O
patients	O
[	O
40	O
]	O
-	O
[	O
42	O
]	O
.	O

NF	O
-	O
kappaB	O
,	O
TBK	O
/	O
IRF3	B-Protein
,	O
and	O
MAPK	O
signaling	O
are	O
important	O
pathways	O
activated	O
by	O
LPS	O
or	O
poly	O
I	O
:	O
C	O
and	O
disruption	O
of	O
either	O
pathway	O
may	O
lead	O
to	O
decreased	O
cytokine	O
expression	O
.	O

NF	O
-	O
kappaB	O
activation	O
was	O
selectively	O
inhibited	O
in	O
LPS	O
and	O
poly	O
I	O
:	O
C	O
stimulated	O
cpdm	O
BMDC	O
compared	O
to	O
wild	O
type	O
,	O
while	O
activation	O
of	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
or	O
p38	O
was	O
not	O
,	O
indicating	O
that	O
disrupted	O
NF	O
-	O
kappaB	O
signaling	O
in	O
cpdm	O
DC	O
is	O
responsible	O
for	O
the	O
defective	O
cytokine	O
expression	O
.	O

These	O
results	O
seem	O
to	O
contradict	O
a	O
recent	O
study	O
that	O
found	O
increased	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
IL1	O
transcription	O
in	O
cpdm	O
mice	O
[	O
43	O
]	O
.	O

This	O
difference	O
can	O
probably	O
be	O
attributed	O
to	O
the	O
different	O
cells	O
and	O
tissues	O
used	O
in	O
these	O
studies	O
,	O
and	O
may	O
point	O
to	O
cell	O
-	O
and	O
tissue	O
-	O
type	O
specific	O
functions	O
of	O
SHARPIN	B-Protein
.	O

This	O
is	O
consistent	O
with	O
recent	O
reports	O
of	O
tissue	O
-	O
specific	O
effects	O
of	O
NF	O
-	O
kappaB	O
signaling	O
[	O
44	O
]	O
.	O

Ubiquitous	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
removing	O
inhibitors	O
such	O
as	O
A20	B-Protein
and	O
ITCH	B-Protein
through	O
genetic	O
manipulation	O
results	O
in	O
widespread	O
inflammation	O
,	O
consistent	O
with	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

However	O
,	O
selective	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
parenchymal	O
cells	O
of	O
the	O
skin	O
,	O
liver	O
,	O
and	O
intestine	O
results	O
in	O
chronic	O
inflammation	O
driven	O
by	O
NF	O
-	O
kappaB	O
competent	O
leukocytes	O
[	O
47	O
]	O
-	O
[	O
50	O
]	O
.	O

This	O
indicates	O
that	O
a	O
balance	O
between	O
the	O
pro	O
-	O
inflammatory	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
leukocytes	O
and	O
the	O
anti	O
-	O
inflammatory	O
role	O
in	O
parenchymal	O
cells	O
is	O
critical	O
in	O
the	O
maintenance	O
of	O
tissue	O
homeostasis	O
.	O

Experiments	O
with	O
mice	O
with	O
cell	O
-	O
and	O
tissue	O
-	O
specific	O
deletion	O
of	O
Sharpin	B-Protein
,	O
currently	O
under	O
way	O
,	O
will	O
help	O
to	O
elucidate	O
the	O
role	O
of	O
SHARPIN	B-Protein
in	O
inflammation	O
.	O

Despite	O
defective	O
NF	O
-	O
kappaB	O
activation	O
in	O
the	O
absence	O
of	O
Sharpin	B-Protein
expression	O
,	O
there	O
was	O
no	O
significant	O
change	O
in	O
splenic	O
DC	O
populations	O
or	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
on	O
BMDC	O
.	O

Different	O
NF	O
-	O
kappaB	O
subunits	O
involved	O
in	O
the	O
canonical	O
and	O
non	O
-	O
canonical	O
branches	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
have	O
distinct	O
functions	O
to	O
control	O
specific	O
aspects	O
of	O
DC	O
development	O
and	O
function	O
[	O
51	O
]	O
,	O
[	O
52	O
]	O
.	O

The	O
non	O
-	O
canonical	O
pathway	O
(	O
p100	B-Protein
processing	O
to	O
produce	O
p52	B-Protein
)	O
appears	O
to	O
be	O
intact	O
in	O
SHARPIN	B-Protein
-	O
deficient	O
cells	O
[	O
7	O
]	O
,	O
[	O
9	O
]	O
suggesting	O
that	O
the	O
NF	O
-	O
kappaB	O
heterodimer	O
p52	B-Protein
/	O
RELB	B-Protein
is	O
sufficient	O
to	O
maintain	O
the	O
normal	O
regulation	O
of	O
DC	O
homeostasis	O
and	O
maturation	O
.	O

The	O
molecular	O
basis	O
by	O
which	O
the	O
Sharpin	B-Protein
mutation	O
causes	O
reduced	O
NF	O
-	O
kappaB	O
activation	O
in	O
BMDC	O
remains	O
to	O
be	O
determined	O
.	O

LPS	O
and	O
poly	O
I	O
:	O
C	O
used	O
here	O
are	O
well	O
-	O
defined	O
ligands	O
that	O
specifically	O
engage	O
TLR4	B-Protein
and	O
TLR3	B-Protein
,	O
respectively	O
.	O

The	O
expression	O
profile	O
of	O
surface	O
TLR4	O
complexes	O
is	O
similar	O
between	O
WT	O
and	O
cpdm	O
BMDC	O
suggesting	O
that	O
defective	O
NF	O
-	O
kappaB	O
activation	O
is	O
not	O
a	O
result	O
of	O
differential	O
TLR	O
expression	O
on	O
target	O
cells	O
.	O

LPS	O
engages	O
TLR4	B-Protein
to	O
activate	O
MYD88	B-Protein
-	O
dependent	O
and	O
TRIF	B-Protein
-	O
dependent	O
pathways	O
,	O
whereas	O
TLR3	B-Protein
stimulated	O
by	O
poly	O
I	O
:	O
C	O
only	O
triggers	O
TRIF	B-Protein
-	O
dependent	O
signaling	O
[	O
53	O
]	O
.	O

The	O
defective	O
NF	O
-	O
kappaB	O
activation	O
by	O
both	O
stimuli	O
suggests	O
that	O
the	O
Sharpin	B-Protein
mutation	O
interferes	O
with	O
the	O
protein	O
adaptors	O
or	O
kinases	O
shared	O
by	O
both	O
signaling	O
pathways	O
,	O
such	O
as	O
RIP1	B-Protein
and	O
TRAF6	B-Protein
[	O
18	O
]	O
.	O

Recent	O
studies	O
demonstrated	O
that	O
SHARPIN	B-Protein
interacts	O
with	O
HOIP	B-Protein
to	O
form	O
LUBAC	O
that	O
exerts	O
its	O
linear	O
-	O
ubiquitin	O
-	O
chain	O
-	O
ligase	O
activity	O
on	O
NF	O
-	O
kappaB	O
signaling	O
players	O
RIP1	B-Protein
and	O
NEMO	B-Protein
[	O
7	O
]	O
,	O
an	O
essential	O
step	O
for	O
intact	O
TNFalpha	B-Protein
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
.	O

The	O
Sharpin	B-Protein
null	O
mutation	O
disrupts	O
the	O
ubiquitylation	O
process	O
and	O
abrogates	O
the	O
TNFalpha	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
.	O

Since	O
TNFR	O
and	O
TLR	O
partially	O
share	O
their	O
downstream	O
signaling	O
cascades	O
,	O
a	O
similar	O
ubiquitin	O
-	O
mediated	O
regulation	O
may	O
hold	O
true	O
for	O
SHARPIN	B-Protein
in	O
LPS	O
-	O
and	O
poly	O
I	O
:	O
C	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
summary	O
,	O
the	O
present	O
study	O
identified	O
an	O
indispensible	O
role	O
of	O
SHARPIN	B-Protein
in	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
and	O
TLR	O
-	O
induced	O
NF	O
-	O
kappaB	O
signaling	O
.	O

The	O
impaired	O
Th1	O
-	O
stimulating	O
ability	O
of	O
Sharpin	B-Protein
-	O
deficient	O
DC	O
may	O
account	O
for	O
the	O
Th2	O
-	O
dominant	O
inflammatory	O
phenotype	O
of	O
cpdm	O
mice	O
.	O

The	O
balance	O
between	O
Th1	O
and	O
Th2	O
differentiation	O
is	O
critical	O
for	O
immune	O
homeostasis	O
.	O

A	O
better	O
understanding	O
of	O
how	O
such	O
balance	O
is	O
maintained	O
will	O
help	O
design	O
cytokine	O
treatment	O
for	O
human	O
diseases	O
with	O
Th2	O
-	O
biased	O
cytokine	O
secretion	O
similar	O
to	O
the	O
mouse	O
cpdm	O
,	O
such	O
as	O
allergies	O
and	O
hypereosinophilic	O
syndromes	O
.	O

Ethics	O
Statement	O

All	O
mouse	O
work	O
was	O
carried	O
out	O
in	O
strict	O
accordance	O
with	O
protocols	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committees	O
.	O

Mice	O

Specific	O
-	O
pathogen	O
free	O
colonies	O
of	O
C57BL	O
/	O
KaLawRij	O
-	O
Sharpincpdm	O
/	O
RijSunJ	O
(	O
JR	O
#	O
7599	O
)	O
and	O
WT	O
mice	O
were	O
obtained	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
ME	O
)	O
and	O
were	O
maintained	O
in	O
a	O
barrier	O
facility	O
.	O

Normal	O
littermate	O
controls	O
were	O
either	O
+	O
/	O
+	O
or	O
+	O
/	O
Sharpincpdm	O
.	O

These	O
control	O
animals	O
were	O
phenotypically	O
indistinguishable	O
and	O
are	O
referred	O
to	O
as	O
WT	O
.	O

Sex	O
-	O
matched	O
WT	O
and	O
mutant	O
mice	O
were	O
used	O
at	O
6	O
-	O
10	O
weeks	O
of	O
age	O
.	O

For	O
some	O
experiments	O
,	O
cpdm	O
mice	O
were	O
crossed	O
with	O
transgenic	O
mice	O
with	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
containing	O
the	O
Sharpin	B-Protein
gene	O
(	O
FVB	O
/	O
NJ	O
-	O
Tg	O
(	O
RP24	O
-	O
173I23	O
)	O
1Sun	O
/	O
Sun	O
,	O
JR	O
#	O
8279	O
)	O
.	O

These	O
mice	O
were	O
backcrossed	O
onto	O
the	O
C57BL	O
/	O
KaLawRij	O
-	O
Sharpincpdm	O
/	O
RijSunJ	O
background	O
and	O
N4	O
mice	O
were	O
used	O
in	O
the	O
experiments	O
reported	O
here	O
.	O

All	O
mouse	O
work	O
was	O
carried	O
out	O
in	O
strict	O
accordance	O
with	O
the	O
approved	O
protocols	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O

Constructs	O
and	O
transfection	O

The	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
of	O
the	O
mouse	O
Sharpin	B-Protein
gene	O
was	O
cloned	O
and	O
amplified	O
from	O
RAW264	O
.	O
7	O
RNA	O
extracts	O
.	O

The	O
primer	O
sequences	O
were	O
forward	O
,	O
5	O
'	O
-	O
CC	O
ATG	O
GCG	O
ATG	O
TCG	O
CCG	O
CCC	O
GCC	O
GGC	O
GGT	O
;	O
reverse	O
,	O
5	O
'	O
-	O
AAG	O
CTT	O
CTA	O
GGT	O
GGA	O
AGC	O
TGC	O
AGC	O
AAG	O
A	O
.	O

The	O
Sharpin	B-Protein
cDNA	O
was	O
cloned	O
into	O
expression	O
vector	O
pFLAG	O
-	O
CMV	O
-	O
2	O
.	O

Murine	O
fibroblasts	O
and	O
macrophages	O
were	O
were	O
used	O
to	O
express	O
recombinant	O
SHARPIN	B-Protein
protein	O
.	O

Cells	O
(	O
2x104	O
)	O
were	O
seeded	O
in	O
96	O
-	O
well	O
treated	O
plates	O
the	O
day	O
before	O
transfection	O
.	O

After	O
overnight	O
incubation	O
,	O
200	O
ng	O
pFLAG	O
-	O
SHARPIN	B-Protein
plasmids	O
were	O
transfected	O
with	O
0	O
.	O
5	O
ul	O
Lipofectamine	O
2000	O
.	O

24	O
hours	O
later	O
,	O
cells	O
were	O
incubated	O
with	O
fresh	O
culture	O
medium	O
.	O

After	O
another	O
24	O
hours	O
,	O
cells	O
were	O
lysed	O
to	O
confirm	O
the	O
FLAG	O
-	O
SHARPIN	B-Protein
expression	O
by	O
immunoblots	O
with	O
anti	O
-	O
FLAG	O
.	O

Cells	O
with	O
no	O
transfection	O
and	O
transfected	O
with	O
empty	O
vector	O
pFLAG	O
-	O
CMV	O
-	O
2	O
were	O
used	O
as	O
negative	O
control	O
in	O
all	O
transfection	O
experiments	O
.	O

Generation	O
of	O
BMDC	O

BMDC	O
were	O
developed	O
as	O
previously	O
reported	O
[	O
54	O
]	O
,	O
[	O
55	O
]	O
.	O

Cells	O
were	O
collected	O
after	O
10	O
-	O
12	O
days	O
of	O
culture	O
.	O

The	O
cell	O
yield	O
was	O
2	O
-	O
3x107	O
cells	O
/	O
mouse	O
with	O
80	O
-	O
95	O
%	O
BMDC	O
.	O

Phenotype	O
of	O
BMDC	O
and	O
splenic	O
DC	O
subsets	O

The	O
phenotype	O
of	O
BMDC	O
was	O
determined	O
before	O
and	O
after	O
24	O
hour	O
culture	O
in	O
the	O
presence	O
of	O
100	O
ng	O
/	O
mL	O
LPS	O
.	O

The	O
cells	O
were	O
incubated	O
in	O
PBS	O
with	O
0	O
.	O
1	O
%	O
NaN3	O
,	O
1	O
%	O
BSA	O
and	O
10	O
%	O
normal	O
rabbit	O
serum	O
for	O
20	O
minutes	O
on	O
ice	O
,	O
washed	O
and	O
incubated	O
for	O
30	O
minutes	O
on	O
ice	O
with	O
Alex	O
Fluor	O
-	O
labeled	O
anti	O
-	O
CD11c	O
(	O
MCD11C20	O
,	O
CALTAG	O
)	O
in	O
combination	O
with	O
PE	O
-	O
anti	O
-	O
CD40	O
(	O
3	O
/	O
23	O
,	O
BD	O
Biosciences	O
)	O
,	O
PE	O
-	O
anti	O
-	O
CD80	O
(	O
16	O
-	O
10A1	O
,	O
eBioscience	O
)	O
,	O
PE	O
-	O
anti	O
-	O
CD86	O
(	O
P03	O
.	O
1	O
,	O
eBioscience	O
)	O
,	O
PE	O
-	O
anti	O
-	O
CD14	O
(	O
Sa2	O
.	O
8	O
,	O
eBioscience	O
)	O
and	O
biotinylated	O
anti	O
-	O
TLR4	O
(	O
BioLegend	O
)	O
.	O

The	O
cells	O
incubated	O
with	O
biotinylated	O
anti	O
-	O
TLR4	O
/	O
MD	O
-	O
2	O
were	O
washed	O
twice	O
and	O
incubated	O
for	O
30	O
minutes	O
on	O
ice	O
with	O
avidin	O
-	O
PE	O
.	O

To	O
isolate	O
splenic	O
DC	O
,	O
spleens	O
were	O
collagenase	O
digested	O
and	O
subject	O
to	O
Percoll	O
gradient	O
centrifugation	O
.	O

The	O
bands	O
at	O
the	O
35	O
-	O
55	O
%	O
interface	O
were	O
collected	O
to	O
stain	O
with	O
PE	O
-	O
anti	O
-	O
CD11c	O
(	O
HL3	O
,	O
BioLegend	O
)	O
,	O
APC	O
-	O
anti	O
-	O
PDCA	O
-	O
1	O
(	O
927	O
,	O
BioLegend	O
)	O
and	O
FITC	O
-	O
anti	O
-	O
CD8alpha	O
(	O
53	O
-	O
6	O
.	O
7	O
,	O
BD	O
BioScience	O
)	O
.	O

The	O
cells	O
were	O
washed	O
twice	O
,	O
fixed	O
in	O
2	O
%	O
paraformaldehyde	O
,	O
and	O
stored	O
at	O
4degreesC	O
until	O
analysis	O
.	O

Flow	O
cytometry	O
was	O
performed	O
in	O
an	O
Excel	O
(	O
Coulter	O
)	O
instrument	O
.	O

Dead	O
cells	O
were	O
omitted	O
from	O
the	O
analysis	O
by	O
gating	O
on	O
forward	O
and	O
90degrees	O
light	O
scatter	O
,	O
and	O
10	O
,	O
000	O
cells	O
were	O
analyzed	O
by	O
FlowJo	O
software	O
.	O

BMDC	O
-	O
T	O
cell	O
in	O
vitro	O
interaction	O

WT	O
and	O
cpdm	O
BMDC	O
(	O
5x104	O
)	O
were	O
stimulated	O
with	O
medium	O
,	O
1	O
microg	O
/	O
mL	O
LPS	O
,	O
25	O
microg	O
/	O
mL	O
and	O
5	O
microg	O
/	O
mL	O
Pam3CYS	O
.	O

24	O
hours	O
later	O
,	O
cells	O
were	O
collected	O
and	O
washed	O
with	O
PBS	O
.	O

Allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
were	O
isolated	O
from	O
spleens	O
of	O
BALB	O
/	O
c	O
mice	O
by	O
negative	O
selection	O
kit	O
(	O
Invitrogen	O
)	O
and	O
were	O
then	O
added	O
at	O
2	O
.	O
5x105	O
and	O
co	O
-	O
cultured	O
with	O
activated	O
BMDC	O
.	O

After	O
5	O
days	O
,	O
supernatant	O
was	O
collected	O
and	O
the	O
secretion	O
of	O
IFNgamma	B-Protein
,	O
IL4	B-Protein
,	O
IL2	B-Protein
,	O
and	O
IL17A	B-Protein
measured	O
by	O
ELISA	O
.	O

Negative	O
controls	O
are	O
1	O
)	O
stimulated	O
BMDC	O
without	O
co	O
-	O
culture	O
with	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
;	O
2	O
)	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
without	O
co	O
-	O
culture	O
with	O
stimulated	O
BMDC	O
.	O

Both	O
negative	O
controls	O
show	O
no	O
production	O
of	O
aforementioned	O
cytokines	O
.	O

RNA	O
expression	O
by	O
BMDC	O

BMDC	O
were	O
cultured	O
at	O
106	O
cells	O
/	O
mL	O
in	O
10	O
mL	O
of	O
RPMI	O
-	O
1640	O
complete	O
medium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
100	O
ng	O
/	O
mL	O
LPS	O
or	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
.	O

After	O
1	O
and	O
2	O
hours	O
,	O
RNA	O
was	O
isolated	O
with	O
TRI	O
-	O
reagent	O
(	O
Sigma	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
expression	O
of	O
Il6	B-Protein
,	O
Il12p40	B-Protein
,	O
Gmcsf	B-Protein
,	O
and	O
Sharpin	B-Protein
mRNA	O
was	O
determined	O
by	O
qRT	O
-	O
PCR	O
.	O

Primers	O
and	O
probes	O
were	O
purchased	O
from	O
Applied	O
Biosystems	O
.	O

Reverse	O
transcription	O
was	O
performed	O
at	O
42degreesC	O
for	O
60	O
minutes	O
with	O
the	O
final	O
denaturation	O
step	O
at	O
90degreesC	O
for	O
5	O
minutes	O
in	O
30	O
microl	O
containing	O
0	O
.	O
5	O
microg	O
of	O
total	O
RNA	O
.	O

dNTPs	O
,	O
oligo	O
(	O
dT	O
)	O
15	O
primer	O
,	O
recombinant	O
RNasin	O
Ribonuclease	O
Inhibitor	O
,	O
and	O
M	B-Protein
-	I-Protein
MLV	I-Protein
Reverse	I-Protein
Transcriptase	I-Protein
(	O
all	O
from	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Reverse	O
transcription	O
was	O
done	O
in	O
a	O
PTC	O
-	O
200	O
Peltier	O
Thermal	O
Cycler	O
(	O
MJ	O
Research	O
,	O
Watertown	O
,	O
MA	O
)	O
.	O

qRT	O
-	O
PCR	O
was	O
performed	O
in	O
ABI	O
Prism	O
7700	O
Sequence	O
Detection	O
System	O
with	O
TaqMan	O
(	O
R	O
)	O
Gene	O
Expression	O
Assays	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
for	O
mouse	O
Actb	B-Protein
,	O
IL6	B-Protein
,	O
IL12p40	B-Protein
,	O
Ifnbeta	B-Protein
,	O
Gmcsf	B-Protein
,	O
and	O
Sharpin	B-Protein
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
endogenous	O
standard	O
for	O
normalization	O
of	O
the	O
target	O
gene	O
was	O
beta	B-Protein
-	I-Protein
actin	I-Protein
.	O

Relative	O
gene	O
expression	O
was	O
calculated	O
using	O
the	O
2	O
-	O
deltadeltaCt	O
method	O
[	O
56	O
]	O
.	O

In	O
vitro	O
cytokine	O
secretion	O
by	O
BMDC	O

The	O
BMDC	O
were	O
cultured	O
in	O
triplicate	O
wells	O
of	O
24	O
-	O
well	O
or	O
96	O
-	O
well	O
plates	O
at	O
106	O
or	O
105	O
cells	O
/	O
mL	O
,	O
respectively	O
,	O
in	O
RPMI	O
-	O
1640	O
complete	O
medium	O
.	O

The	O
cells	O
were	O
washed	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
mL	O
LPS	O
or	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
.	O

After	O
24	O
hours	O
,	O
supernatants	O
were	O
harvested	O
for	O
ELISA	O
analysis	O
.	O

The	O
presence	O
of	O
nitrite	O
in	O
the	O
supernatants	O
was	O
determined	O
using	O
the	O
Griess	O
reagent	O
.	O

Immunofluorescence	O

Fibroblast	O
and	O
macrophage	O
cells	O
were	O
transfected	O
with	O
pFLAG	O
-	O
SHARPIN	B-Protein
.	O

48	O
hours	O
later	O
,	O
cells	O
were	O
washed	O
briefly	O
with	O
PBS	O
,	O
then	O
fixed	O
in	O
cold	O
methanol	O
at	O
-	O
20degreesC	O
for	O
10	O
minutes	O
and	O
cold	O
acetone	O
at	O
-	O
20degreesC	O
for	O
1	O
minute	O
.	O

Incubate	O
cells	O
with	O
PBS	O
+	O
1	O
%	O
BSA	O
for	O
15	O
minutes	O
to	O
block	O
non	O
-	O
specific	O
binding	O
.	O

Fixed	O
cells	O
were	O
then	O
incubated	O
with	O
anti	O
-	O
FLAG	O
(	O
1	O
:	O
100	O
)	O
as	O
the	O
primary	O
antibody	O
at	O
room	O
temperature	O
for	O
1	O
hour	O
,	O
followed	O
by	O
three	O
5	O
-	O
minute	O
washes	O
.	O

Cells	O
were	O
further	O
incubated	O
with	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
-	O
FITC	O
(	O
1	O
:	O
100	O
)	O
as	O
the	O
secondary	O
antibody	O
at	O
room	O
temperature	O
for	O
30	O
minutes	O
,	O
followed	O
by	O
three	O
5	O
-	O
minute	O
washes	O
.	O

Cells	O
were	O
then	O
examined	O
using	O
inverse	O
fluorescence	O
microscope	O
.	O

Immunoblots	O

After	O
adding	O
stimulating	O
ligands	O
,	O
100	O
ng	O
/	O
mL	O
LPS	O
or	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
,	O
BMDC	O
were	O
collected	O
and	O
lysed	O
at	O
0	O
-	O
,	O
15	O
-	O
,	O
30	O
-	O
,	O
and	O
60	O
-	O
minute	O
time	O
points	O
.	O

Immunoblots	O
were	O
performed	O
with	O
antibodies	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
against	O
p	O
-	O
IKK1	B-Protein
/	O
2	B-Protein
(	O
#	O
2697	O
)	O
,	O
p	O
-	O
IkappaBalpha	B-Protein
(	O
#	O
9246	O
)	O
,	O
IkappaBalpha	B-Protein
(	O
#	O
4814	O
)	O
,	O
p	O
-	O
TBK1	B-Protein
(	O
#	O
5483	O
)	O
,	O
p	O
-	O
p38	O
(	O
#	O
9216	O
)	O
,	O
p38	O
(	O
#	O
9212	O
)	O
,	O
p	O
-	O
ERK1	B-Protein
/	O
2	B-Protein
(	O
#	O
4376	O
)	O
,	O
and	O
ERK1	B-Protein
/	O
2	B-Protein
(	O
#	O
4695	O
)	O
.	O

Beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
sc	O
-	O
47778	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
was	O
used	O
as	O
loading	O
control	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O

The	O
statistical	O
significance	O
of	O
differences	O
of	O
means	O
between	O
experimental	O
groups	O
was	O
determined	O
by	O
Students	O
'	O
t	O
-	O
test	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
features	O
of	O
SHARPIN	B-Protein
.	O

(	O
A	O
)	O
COILS	O
and	O
MotifScan	O
programs	O
were	O
used	O
to	O
predict	O
the	O
presence	O
of	O
CC	O
(	O
coiled	O
-	O
coil	O
)	O
domain	O
,	O
UBL	O
(	O
ubiquitin	O
-	O
like	O
)	O
domain	O
and	O
ZFRBP	O
(	O
zinc	O
-	O
finger	O
Ran	O
-	O
Binding	O
protein	O
2	O
)	O
domain	O
which	O
form	O
similar	O
motif	O
patterns	O
in	O
the	O
SHARPIN	B-Protein
protein	O
of	O
human	O
,	O
mouse	O
and	O
rat	O
origins	O
.	O

(	O
B	O
)	O
Eight	O
week	O
-	O
old	O
females	O
of	O
WT	O
and	O
cpdm	O
mice	O
.	O

The	O
mutant	O
mice	O
(	O
above	O
)	O
develop	O
progressive	O
skin	O
inflammation	O
starting	O
at	O
about	O
four	O
weeks	O
.	O

(	O
C	O
)	O
Extramedullary	O
hematopoiesis	O
causes	O
marked	O
enlargement	O
of	O
the	O
spleen	O
of	O
cpdm	O
mice	O
.	O

(	O
D	O
)	O
BMDC	O
were	O
incubated	O
in	O
the	O
absence	O
or	O
presence	O
of	O
100	O
ng	O
/	O
ml	O
LPS	O
for	O
4	O
hours	O
.	O

The	O
mRNA	O
level	O
of	O
Sharpin	B-Protein
was	O
measured	O
by	O
qRT	O
-	O
PCR	O
and	O
presented	O
relative	O
to	O
the	O
mRNA	O
expression	O
in	O
non	O
-	O
stimulated	O
WT	O
BMDC	O
.	O

Bars	O
represent	O
the	O
mean	O
+	O
/	O
-	O
s	O
.	O
d	O
.	O
of	O
3	O
mice	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
P	O
<	O
0	O
.	O
001	O
.	O

(	O
E	O
)	O
Fibroblast	O
(	O
NIH3T3	O
)	O
and	O
macrophages	O
(	O
RAW264	O
.	O
7	O
)	O
cells	O
were	O
transfected	O
with	O
the	O
expression	O
plasmid	O
pFLAG	O
-	O
SHARPIN	B-Protein
.	O

After	O
48	O
hours	O
,	O
cells	O
were	O
fixed	O
and	O
probed	O
with	O
anti	O
-	O
FLAG	O
and	O
FITC	O
-	O
conjugated	O
secondary	O
antibody	O
.	O

Nuclei	O
were	O
stained	O
with	O
DAPI	O
.	O

In	O
both	O
transfected	O
cell	O
lines	O
,	O
FLAG	O
-	O
SHARPIN	B-Protein
was	O
found	O
to	O
be	O
cytoplasm	O
-	O
localized	O
.	O

Effect	O
of	O
Sharpin	B-Protein
mutation	O
on	O
DC	O
subpopulations	O
and	O
maturation	O
.	O

(	O
A	O
)	O
Spleens	O
from	O
WT	O
and	O
cpdm	O
mice	O
were	O
isolated	O
and	O
subject	O
to	O
collagenase	O
and	O
DNase	O
digestion	O
.	O

The	O
obtained	O
splenic	O
homogenates	O
were	O
centrifuged	O
over	O
a	O
Percoll	O
gradient	O
(	O
35	O
%	O
and	O
55	O
%	O
density	O
)	O
for	O
15	O
minutes	O
.	O

The	O
bands	O
at	O
the	O
35	O
%	O
-	O
medium	O
and	O
the	O
35	O
-	O
55	O
%	O
interface	O
were	O
pooled	O
,	O
washed	O
and	O
stained	O
with	O
a	O
combination	O
of	O
various	O
antibodies	O
to	O
stain	O
different	O
DC	O
subsets	O
,	O
conventional	O
CD11c	O
+	O
CD8alpha	O
+	O
,	O
CD11c	O
+	O
CD8alpha	O
-	O
and	O
plasmacytoid	O
DC	O
(	O
CD11c	O
-	O
PDCA	O
-	O
1	O
+	O
)	O
.	O
The	O
top	O
panels	O
were	O
gated	O
on	O
FSChiSSClo	O
cells	O
to	O
show	O
separate	O
populations	O
of	O
CD11c	O
+	O
PDCA	O
-	O
1	O
-	O
and	O
CD11c	O
-	O
PDCA	O
-	O
1	O
+	O
cells	O
.	O

Further	O
gating	O
on	O
the	O
CD11c	O
+	O
PDCA	O
-	O
1	O
-	O
subpopulation	O
gave	O
the	O
bottom	O
panel	O
that	O
showed	O
two	O
distinct	O
pools	O
of	O
CD11c	O
+	O
CD8alpha	O
+	O
and	O
CD11c	O
+	O
CD8alpha	O
-	O
cells	O
.	O

Percentages	O
were	O
calculated	O
based	O
on	O
the	O
parental	O
population	O
and	O
were	O
additionally	O
shown	O
as	O
bar	O
graphs	O
(	O
n	O
=	O
2	O
)	O
(	O
B	O
)	O
.	O

(	O
C	O
)	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
)	O
cells	O
were	O
stimulated	O
with	O
medium	O
,	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
for	O
24	O
hours	O
.	O

The	O
cells	O
were	O
labeled	O
with	O
PE	O
-	O
labeled	O
anti	O
-	O
CD40	O
,	O
anti	O
-	O
CD80	O
,	O
and	O
anti	O
-	O
CD86	O
,	O
and	O
subjected	O
to	O
flow	O
cytometry	O
analysis	O
.	O

The	O
populations	O
shown	O
in	O
histograms	O
were	O
gated	O
on	O
CD11c	O
+	O
cells	O
.	O

Unstained	O
cells	O
served	O
as	O
negative	O
controls	O
.	O

Results	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O

Defective	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
from	O
stimulated	O
cpdm	O
BMDC	O
.	O

(	O
A	O
-	O
D	O
)	O
Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
1x105	O
cells	O
in	O
0	O
.	O
1	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
medium	O
,	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
for	O
24	O
hours	O
.	O

Supernatants	O
were	O
collected	O
for	O
ELISA	O
of	O
IL12P70	O
,	O
IL6	B-Protein
,	O
and	O
GMCSF	B-Protein
,	O
and	O
for	O
quantification	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O

(	O
E	O
-	O
F	O
)	O
Gradient	O
numbers	O
(	O
1x104	O
,	O
2x104	O
,	O
and	O
4x104	O
cells	O
in	O
0	O
.	O
1	O
mL	O
complete	O
medium	O
)	O
of	O
BMDC	O
were	O
used	O
for100	O
ng	O
/	O
mL	O
LPS	O
stimulation	O
.	O

After	O
24	O
hours	O
,	O
the	O
amounts	O
of	O
IL12P70	O
and	O
IL6	B-Protein
from	O
the	O
supernatant	O
were	O
measured	O
.	O

(	O
G	O
)	O
The	O
cpdm	O
mice	O
rescued	O
by	O
Sharpin	B-Protein
-	O
containing	O
BAC	O
had	O
complete	O
remission	O
of	O
the	O
inflammatory	O
phenotype	O
[	O
2	O
]	O
.	O

BMDC	O
developed	O
from	O
cpdm	O
and	O
rescued	O
cpdm	O
mice	O
were	O
plated	O
(	O
1x106	O
cells	O
in	O
0	O
.	O
3	O
mL	O
)	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
mL	O
LPS	O
.	O

After	O
24	O
hours	O
,	O
supernatants	O
were	O
collected	O
for	O
analysis	O
of	O
IL12P70	O
production	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

*	O
P	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
P	O
<	O
0	O
.	O
005	O
.	O

Decreased	O
mRNA	O
levels	O
of	O
inflammatory	O
cytokines	O
from	O
cpdm	O
BMDC	O
.	O

Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
cells	O
in	O
0	O
.	O
2	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
(	O
A	O
,	O
C	O
,	O
E	O
,	O
G	O
)	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
(	O
B	O
,	O
D	O
,	O
F	O
,	O
H	O
)	O
.	O

At	O
0	O
,	O
1	O
and	O
2	O
hours	O
,	O
total	O
RNA	O
was	O
extracted	O
and	O
subject	O
to	O
qRT	O
-	O
PCR	O
to	O
measure	O
the	O
expression	O
of	O
Il12p40	B-Protein
(	O
A	O
,	O
B	O
)	O
,	O
Il6	B-Protein
(	O
C	O
,	O
D	O
)	O
,	O
Gmcsf	B-Protein
(	O
E	O
,	O
F	O
)	O
,	O
and	O
Ifnb	B-Protein
(	O
G	O
,	O
H	O
)	O
mRNA	O
.	O

Bars	O
represent	O
mean	O
+	O
/	O
-	O
SD	O
.	O

Data	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O

Normal	O
TLR4	B-Protein
and	O
MD2	B-Protein
expression	O
and	O
decreased	O
IL10	B-Protein
secretion	O
and	O
A20	B-Protein
expression	O
by	O
cpdm	O
BMDC	O
.	O

(	O
A	O
)	O
Unstimulated	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
)	O
were	O
labeled	O
with	O
PE	O
-	O
labeled	O
anti	O
-	O
TLR4	O
/	O
MD2	O
or	O
anti	O
-	O
CD14	O
and	O
then	O
subject	O
to	O
flow	O
cytometry	O
analysis	O
.	O

Unstained	O
cells	O
serve	O
as	O
negative	O
controls	O
.	O

(	O
B	O
)	O
Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
1x105	O
cells	O
in	O
0	O
.	O
1	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
medium	O
,	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
for	O
24	O
hours	O
.	O

Supernatants	O
were	O
collected	O
for	O
ELISA	O
of	O
IL10	B-Protein
.	O

(	O
C	O
)	O
Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
cells	O
in	O
0	O
.	O
2	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
.	O

At	O
0	O
,	O
1	O
,	O
and	O
2	O
hours	O
,	O
total	O
RNA	O
was	O
extracted	O
and	O
subject	O
to	O
qRT	O
-	O
PCR	O
to	O
measure	O
the	O
production	O
of	O
A20	B-Protein
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
signaling	O
in	O
cpdm	O
BMDC	O
.	O

WT	O
and	O
cpdm	O
BMDC	O
(	O
2x106	O
cells	O
in	O
0	O
.	O
5	O
mL	O
complete	O
medium	O
)	O
were	O
stimulated	O
with	O
100	O
ng	O
/	O
mL	O
LPS	O
(	O
A	O
)	O
or	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
(	O
B	O
)	O
.	O

At	O
0	O
,	O
15	O
,	O
30	O
,	O
and	O
60	O
minutes	O
,	O
whole	O
-	O
cell	O
lysates	O
were	O
obtained	O
and	O
subject	O
to	O
immunoblots	O
with	O
antibodies	O
against	O
proteins	O
involved	O
in	O
NF	O
-	O
kappaB	O
,	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
and	O
p38	O
signaling	O
pathways	O
.	O

Beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
used	O
as	O
loading	O
control	O
.	O

(	O
C	O
)	O
Cellular	O
levels	O
of	O
p	O
-	O
IKK1	B-Protein
/	O
2	B-Protein
and	O
p	O
-	O
IkappaBalpha	B-Protein
in	O
LPS	O
-	O
or	O
poly	O
I	O
:	O
C	O
-	O
stimulated	O
BMDC	O
were	O
quantitated	O
with	O
ImageJ	O
(	O
NIH	O
)	O
and	O
presented	O
as	O
trend	O
lines	O
.	O

Results	O
are	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
.	O

Stimulated	O
cpdm	O
BMDC	O
induced	O
Th2	O
-	O
biased	O
cytokine	O
production	O
from	O
naive	O
CD4	O
+	O
T	O
cells	O
.	O

WT	O
and	O
cpdm	O
BMDC	O
(	O
5x104	O
cells	O
in	O
0	O
.	O
1	O
mL	O
complete	O
medium	O
;	O
MHC	O
haplotype	O
:	O
H	O
-	O
2b	O
)	O
were	O
incubated	O
with	O
medium	O
,	O
100	O
ng	O
/	O
mL	O
LPS	O
,	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
or	O
5	O
microg	O
/	O
mL	O
Pam3CYS	O
.	O

After	O
24	O
hours	O
,	O
cells	O
were	O
washed	O
with	O
PBS	O
and	O
incubated	O
with	O
freshly	O
isolated	O
allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
(	O
2	O
.	O
5x105	O
cells	O
in	O
0	O
.	O
1	O
mL	O
complete	O
medium	O
;	O
MHC	O
haplotype	O
:	O
H	O
-	O
2d	O
)	O
.	O

After	O
5	O
days	O
,	O
supernatants	O
were	O
collected	O
and	O
the	O
secretion	O
of	O
IFNgamma	B-Protein
,	O
IL4	B-Protein
,	O
and	O
IL2	B-Protein
were	O
measured	O
by	O
ELISA	O
.	O

Negative	O
controls	O
are	O
1	O
)	O
stimulated	O
BMDC	O
without	O
co	O
-	O
culture	O
with	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
;	O
2	O
)	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
without	O
co	O
-	O
culture	O
with	O
stimulated	O
BMDC	O
.	O

Samples	O
from	O
both	O
negative	O
controls	O
had	O
no	O
detectable	O
production	O
of	O
the	O
aforementioned	O
cytokines	O
(	O
not	O
shown	O
)	O
.	O

Results	O
are	O
analyzed	O
based	O
on	O
2	O
-	O
4	O
mice	O
per	O
group	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
.	O

